var images_info;if (!images_info) images_info =[]; images_info["115"]={"115000":{"type":"graphic_table","displayName":"Dermoscopic features of various scalp and hair disorders","title":"Dermoscopic features of various scalp and hair disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dermoscopic features of various scalp and hair disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup class=\"null\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Follicular ostia</td> <td class=\"subtitle1\">Perifollicular skin</td> <td class=\"subtitle1\">Vascular pattern</td> <td class=\"subtitle1\">Hair shafts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Nonscarring alopecias</td> </tr> <tr> <td class=\"indent1\">Androgenetic alopecia</td> <td>Increased number of single-hair follicles, yellow dots</td> <td>Peripilar sign</td> <td>Increased number of arborizing vessels commonly seen since concomitant seborrheic dermatitis is common</td> <td> <p>Hair diameter variability*</p> Short, thin, regrowing hairs (&#60;0.03 mm diameter)</td> </tr> <tr> <td class=\"indent1\">Alopecia areata</td> <td>Black dots, yellow dots<sup>&#182;</sup>, increased number of regularly distributed, pinpoint white dots (pigmented scalp)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Exclamation point hairs<sup>&#916;</sup>, broken hairs, circle hairs, coudability<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Telogen effluvium</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Short, regrowing hairs of normal (&#62;0.03 mm) thickness</td> </tr> <tr> <td class=\"indent1\">Traction alopecia</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>The alopecic patch has few terminal hairs but retains vellus hairs, hair casts along the hair shafts at the periphery of the patch<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trichotillomania</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Broken hairs of varying length, flame hairs<sup>&#165;</sup>, question mark hairs<sup>&#135;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cicatricial alopecias</td> </tr> <tr> <td class=\"indent1\">Central centrifugal cicatricial alopecia</td> <td>Irregular distribution of pinpoint white dots</td> <td>Peripilar gray-white halo, white patches</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Discoid lupus erythematosus</td> <td>Follicular keratotic plugs, red dots, blue-gray dots in speckled pattern</td> <td>Loss of pigment network (in highly pigmented scalp)</td> <td>Enlarged, branching, tortuous vessels</td> <td>Peripilar casts</td> </tr> <tr> <td class=\"indent1\">Dissecting cellulitis of the scalp</td> <td>Black dots, yellow dots, follicular keratotic plugging, regrowing hairs, loss of follicular ostia in persistent disease</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Folliculitis decalvans</td> <td>Hair tufting</td> <td>Severe scaling, pustules, crusts</td> <td>Twisted red loops</td> <td>Thick, peripilar casts</td> </tr> <tr> <td class=\"indent1\">Frontal fibrosing alopecia</td> <td> <p>The cicatricial band shows loss of follicular ostia</p> The new hairline shows reduction of follicular ostia and few, occasional black dots</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Absence of vellus hairs at frontal hairline, peripilar casts, pili torti, broken hairs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lichen planopilaris</td> <td>Loss of follicular ostia, blue-gray dots in target pattern (highly pigmented scalp)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Peripilar casts, pili torti, broken hairs</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Inflammatory scalp disorders</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> <td>&nbsp;</td> <td>Interfollicular, whitish scales, follicular ostia might not be visible</td> <td>Red dots at low magnification, twisted capillary loops at high magnification (&#8805;40x)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Seborrheic dermatitis</td> <td>&nbsp;</td> <td>Yellow/white scales</td> <td>Increased number of arborizing vessels</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Infectious and parasitic disorders</td> </tr> <tr> <td class=\"indent1\">Pediculosis capitis</td> <td>&nbsp;</td> <td>Lice</td> <td>&nbsp;</td> <td>Nits</td> </tr> <tr> <td class=\"indent1\">Piedra, black</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Dark nodules surrounding hair shafts</td> </tr> <tr> <td class=\"indent1\">Piedra, white</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Yellow or beige nodules or sheaths around hair shafts</td> </tr> <tr> <td class=\"indent1\">Tinea capitis</td> <td>Black dots</td> <td>Diffuse scale, pustules</td> <td>&nbsp;</td> <td>Broken hairs, comma hairs, corkscrew hairs</td> </tr> <tr> <td class=\"indent1\">Trichomycosis axillaris</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Yellow concretions surrounding hair shafts</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Hair diameter variability –&nbsp;Terminal hair shafts of varying diameter.<br />¶ Yellow dots are not visible in children as sebaceous glands are not active. Yellow dots are rare in the highly pigmented scalp.<br />Δ Exclamation point hairs –&nbsp;Broken hairs with a dark, thick tip.<br /><FONT class=lozenge>◊</FONT> Coudability hairs –&nbsp;Hairs of normal length that are tapered at the proximal end.<br />§ Hair casts in traction alopecia correspond to detached root sheaths.<br />¥ Flame hairs –&nbsp;Short, broken hairs with wavy configuration at distal end.<br />‡ Question mark hairs –&nbsp;Short hair with a coiled tip.</div><div id=\"graphicVersion\">Graphic 115000 Version 1.0</div></div></div>"},"115001":{"type":"graphic_table","displayName":"Stress echocardiogram risk stratification in adults","title":"Stress echocardiogram risk stratification in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stress echocardiogram risk stratification in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">High risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Severe resting LV dysfunction (EF &#60;35%) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Extensive new rest wall motion abnormality (&#8805;5 of 16 segments of LV) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Moderate-sized rest wall motion abnormality (3 to 4 segments) with remote ischemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Echocardiographic wall motion abnormality (&#62;3 segments) developing at low ischemic threshold (dobutamine dose &#8804;10 micrograms/kg/minute or a heart rate &#60;120 beats/minute) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stress echocardiographic evidence of extensive ischemia (4 to 5 segments of LV) or ischemia in multiple coronary territories or peak wall motion score &#62;1.7 </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Severe exercise LV dysfunction (exercise EF &#60;35%) or decrease in global LV contractility from rest to stress due to ischemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Dilatation of the LV cavity with stress with associated ischemic wall motion abnormalities </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Intermediate risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mild to moderate resting LV dysfunction (EF 35 to 49%) with no ischemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Moderate-sized resting wall motion abnormality (3 to 4 segments) with no ischemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Limited resting wall motion abnormality (&#8804;2 segments) with limited (&#8804;2 segments) peri-infarction ischemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Normal resting wall motion with limited ischemia (&#8804;2 segments) at high stress level </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Low risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Normal resting wall motion with no ischemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Limited resting wall motion abnormality (&#8804;2 segments) with no ischemia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LV: left ventricular; EF: ejection fraction.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33:2092.</LI>&#xD;&#xA;<LI>Yao SS, Bangalore S, Chaudhry FA. Prognostic implications of stress echocardiography and impact on patient outcomes: an effective gatekeeper for coronary angiography and revascularization. J Am Soc Echocardiogr 2010; 23:832.</LI></OL></div><div id=\"graphicVersion\">Graphic 115001 Version 3.0</div></div></div>"},"115002":{"type":"graphic_table","displayName":"Recommendations stress testing in specific populations post-ACS","title":"Recommendations for stress testing in specific populations post-ACS<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for stress testing in specific populations post-ACS<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Recommendations</td> </tr> <tr> <td>Culprit vessel revascularized with angiographic disease of uncertain functional significance in one or more remaining vessels</td> <td>SPECT or PET perfusion imaging or stress echocardiography</td> </tr> <tr> <td>NSTEACS patients with unexplained dyspnea, mitral regurgitation, or mild to moderate aortic stenosis</td> <td>Exercise echocardiography with Doppler imaging</td> </tr> <tr> <td>LV systolic dysfunction and/or large infarct territory with question of viability</td> <td>Dobutamine echocardiography, SPECT, PET, or MRI with viability protocol</td> </tr> <tr> <td>Higher-risk patients undergoing predischarge testing early after infarction</td> <td>Vasodilator SPECT or PET imaging</td> </tr> <tr> <td>Low-risk subjects in whom the diagnosis of ACS is uncertain or with biomarker elevation likely not due to ACS</td> <td>SPECT or PET perfusion imaging or stress echocardiography</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; SPECT: single-proton emission computed tomography; PET: positron emission tomography; NSTEACS: non-ST elevation acute coronary syndrome;&nbsp;LV: left ventricular; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Pi&eacute;rard LA, Lancellotti P. The role of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med 2004; 351:1627.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115002 Version 2.0</div></div></div>"},"115003":{"type":"graphic_table","displayName":"Treadmill ECG risk stratification","title":"Treadmill ECG risk stratification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treadmill ECG risk stratification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">High risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>High-risk Duke treadmill score (&#60;&ndash;11) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Exercise-induced ST elevation without diagnostic Q waves (except for leads V1 or aVR) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Excessive ST-segment depression (&#62;2 mm) which persists into recovery </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Drop in systolic blood pressure&nbsp;&#62;10 mmHg from baseline despite an increase in workload </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sustained ventricular tachycardia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Intermediate risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Intermediate risk treadmill score (&ndash;11 to +5) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>ST depression (&#60;2 mm) at peak stress with normalization in early recovery </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Low risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Low risk treadmill score (&#62;+5) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Adapted from: Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33:2092.</div><div id=\"graphicVersion\">Graphic 115003 Version 2.0</div></div></div>"},"115004":{"type":"graphic_table","displayName":"Radionuclide myocardial perfusion imaging risk stratification","title":"Radionuclide myocardial perfusion imaging risk stratification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radionuclide myocardial perfusion imaging risk stratification</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">High risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Severe LV dysfunction (EF &#60;35%) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stress-induced large perfusion defect (particularly if anterior) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Stress-induced multiple perfusion defects of moderate size (&#62;10% total reversible myocardium) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Large fixed defect with LV dilation or increased lung uptake (thallium-201) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (thallium-201) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Intermediate risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mild to moderate resting LV dysfunction (EF 35 to 49%) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Moderate stress-induced perfusion defect without LV dilation or increased lung uptake </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Low risk</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Normal LV systolic function </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Normal or small myocardial perfusion defect at rest or with stress </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LV: left ventricular; EF: ejection fraction.</div><div class=\"graphic_reference\">Adapted from: Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999; 33:2092.</div><div id=\"graphicVersion\">Graphic 115004 Version 2.0</div></div></div>"},"115012":{"type":"graphic_figure","displayName":"ERCP in patients with Roux-en-Y anatomy","title":"ERCP in patients with Roux-en-Y anatomy","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">ERCP in patients with Roux-en-Y anatomy</div><div class=\"cntnt\"><img style=\"width:529px; height:703px;\" src=\"images/GAST/115012_ERCPinpatientswithRouxenYanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Approach to ERCP&nbsp;in patients with Roux-en-Y anatomy.&nbsp;Panel&nbsp;A shows the laparoscopic-assisted, transgastric&nbsp;approach with the trocar seen entering the stomach. Gastric access can be achieved through multiple methods; see the UpToDate topic&nbsp;\"ERCP in patients with Roux-en-Y anatomy\" for details. Panel B shows the transoral endoscopic approach.</div><div class=\"graphic_footnotes\">ERCP: Endoscopic retrograde cholangiopancreatography. </div><div id=\"graphicVersion\">Graphic 115012 Version 2.0</div></div></div>"},"115015":{"type":"graphic_algorithm","displayName":"Management of arthritis in patients with IBD","title":"Systemic medical management of peripheral and axial arthritis in patients with inflammatory bowel disease*<SUP>¶</SUP><SUP>Δ</SUP>","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Systemic medical management of peripheral and axial arthritis in patients with inflammatory bowel disease*<SUP>¶</SUP><SUP>Δ</SUP></div><div class=\"cntnt\"><img style=\"width:592px; height:989px;\" src=\"images/RHEUM/115015_MgmtarthritispatientsIBD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease; GI: gastrointestinal; NSAID: nonsteroidal antiinflammatory drug; mab: monoclonal antibody; TNF: tumor necrosis factor; IL: interleukin.<br />* Refer to UpToDate topic on treatment of arthritis associated with inflammatory bowel disease.<br />¶ Patients should be treated in collaboration with the patient's gastroenterologist.<br />Δ Intraarticular glucocorticoid injection is a potential added treatment option in a patient with a small number of affected joints.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topics on the management of ulcerative colitis and Crohn disease in adults.<br />§ Patients with axial disease should receive physical therapy for back exercise program.<br />¥ Refer to UpToDate topic on treatment of arthritis associated with inflammatory bowel disease for drug and dosing regimens.<br />‡ NSAIDs should not be administered for peripheral arthritis without excluding septic arthritis as the cause of joint inflammation (refer to UpToDate topic on septic arthritis in adults).<br />† Symptoms and signs of peripheral arthritis and inflammatory back pain and stiffness are well controlled.</div><div id=\"graphicVersion\">Graphic 115015 Version 1.0</div></div></div>"},"115017":{"type":"graphic_table","displayName":"Polysomnographic variables and cardiac structure of children","title":"Polysomnographic variables and cardiac structure of children with primary snoring and children with obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Polysomnographic variables and cardiac structure of children with primary snoring and children with obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Primary snoring</td> <td class=\"subtitle1\">OSA</td> </tr> <tr class=\"divider_bottom\"> <td><strong>n</strong></td> <td class=\"centered\">19</td> <td class=\"centered\">28</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Polysomnographic variables</td> </tr> <tr> <td class=\"indent1\">AHI</td> <td class=\"centered\">0.15 &#177; 0.31</td> <td class=\"centered\">18.2 &#177; 21.0*</td> </tr> <tr> <td class=\"indent1\">Desaturation index</td> <td class=\"centered\">1.07 &#177; 1.96</td> <td class=\"centered\">13.6 &#177; 17.3*</td> </tr> <tr> <td class=\"indent1\">Lowest O<sub>2</sub> saturation</td> <td class=\"centered\">93.4 &#177; 2.6</td> <td class=\"centered\">73.6 &#177; 19*</td> </tr> <tr> <td class=\"indent1\">Maximum ETCO<sub>2</sub> (mmHg)</td> <td class=\"centered\">49.5 &#177; 3.6</td> <td class=\"centered\">55.3 &#177; 9.1<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Arousal index</td> <td class=\"centered\">9.25 &#177; 3.6</td> <td class=\"centered\">16.8 &#177; 11<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiac structure</td> </tr> <tr> <td class=\"indent1\">Left ventricular mass index (g/ht<sup>2.7</sup>)</td> <td class=\"centered\">30.1 &#177; 6.5</td> <td class=\"centered\">36.8 &#177; 10.8<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Relative wall thickness</td> <td class=\"centered\">0.28 &#177; 0.05</td> <td class=\"centered\">0.346 &#177; 0.07<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">RV dimension adjusted for body surface area (cm/m)</td> <td class=\"centered\">1.43 &#177; 0.45</td> <td class=\"centered\">1.52 &#177; 0.52</td> </tr> <tr> <td class=\"indent1\">RV dimension adjusted for height (cm/m)</td> <td class=\"centered\">1.21 &#177; 0.26</td> <td class=\"centered\">1.39 &#177; 0.34</td> </tr> <tr> <td class=\"indent1\">Number of subjects with RV dimension above the 95th percentile, n (%)</td> <td class=\"centered\">5 (26)</td> <td class=\"centered\">14 (50)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All data displayed as mean ± SD (standard deviations) unless otherwise specified.</div><div class=\"graphic_footnotes\">AHI: apnea-hypopnea index; ETCO<sub>2</sub>: end-tidal CO<sub>2</sub>; ht: height in meters; OSA: obstructive sleep apnea; RV: right ventricle.<br />* p value &lt;0.001.<br />&para; p = 0.002 to 0.005.<br />&Delta; p = 0.012.<br /><span class=\"lozenge\">&loz;</span> p = 0.001.</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2017 American Thoracic Society. From: Amin RS, Kimball TR, Bean JA, et al. Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med 2002; 165:1395-9. The <em>American Journal of Respiratory and Critical Care Medicine</em> is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 115017 Version 1.0</div></div></div>"},"115021":{"type":"graphic_figure","displayName":"Vaginal ring","title":"Contraceptive vaginal ring","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Contraceptive vaginal ring</div><div class=\"cntnt\"><img style=\"width:756px; height:310px;\" src=\"images/PEDS/115021_Vaginal_ring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ring stays inside the vagina for three weeks at a time. It delivers hormones into the body that help prevent pregnancy.</div><div class=\"graphic_reference\">Reproduced with permission from: <A href=\"http://www.nuvaring.com/\" target=_blank>www.nuvaring.com</A>. Copyright © 2004 Organon USA.</div><div id=\"graphicVersion\">Graphic 115021 Version 1.0</div></div></div>"},"115022":{"type":"graphic_table","displayName":"Medical instability in patients with anorexia nervosa","title":"Medical instability in patients with anorexia nervosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical instability&nbsp;in patients with anorexia nervosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">Medical instability is characterized by one or more of the following:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pulse &#60;40 beats/minute </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Blood pressure &#60;80/60 mmHg </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Orthostatic increase in pulse (&#62;20 beats/minute) or decrease in systolic blood pressure (&#62;20 mmHg) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cardiac dysrhythmia (eg, QTc &#62;0.499 msec), or any rhythm other than normal sinus rhythm or sinus bradycardia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cardiovascular, hepatic, or renal compromise requiring medical stabilization </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Marked dehydration </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Serious medical complication of malnutrition (eg, electrolyte imbalance, hypoglycemia, or syncope) </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Body mass index &#60;15 kg/m<sup>2</sup> or ideal body weight &#60;70% </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 115022 Version 1.0</div></div></div>"},"115023":{"type":"graphic_table","displayName":"WHO 2016 classification of non-germ cell tumors of the testis","title":"World Health Organization (WHO) 2016 classification of non-germ cell tumors of the testis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization (WHO) 2016 classification of non-germ cell tumors of the testis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Sex cord-stromal tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Pure tumors</td> </tr> <tr> <td class=\"indent2\">Leydig cell tumors</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Malignant Leydig cell tumor</li> </ul> </td> </tr> <tr> <td class=\"indent2\">Sertoli cell tumor</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Malignant Sertoli cell tumor</li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Large-cell calcifying Sertoli cell tumor</li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Intratubular large-cell hyalinizing Sertoli cell tumor</li> </ul> </td> </tr> <tr> <td class=\"indent2\">Granulosa cell tumor</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Adult granulosa cell tumor</li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Juvenile granulosa cell tumor</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Tumors in the fibroma-thecoma group</td> </tr> <tr> <td class=\"subtitle2_single\">Mixed and unclassified sex cord-stromal tumors</td> </tr> <tr> <td class=\"indent2\">Mixed sex cord-stromal tumor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Unclassified sex cord-stromal tumor</td> </tr> <tr> <td class=\"subtitle1_single\">Tumor containing both germ cell and sex cord-stromal elements</td> </tr> <tr> <td class=\"subtitle2_single\">Gonadoblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous tumors of the testis</td> </tr> <tr> <td class=\"subtitle2_single\">Ovarian epithelial-type tumors</td> </tr> <tr> <td class=\"indent2\">Serous cystadenoma</td> </tr> <tr> <td class=\"indent2\">Serous tumor of borderline malignancy</td> </tr> <tr> <td class=\"indent2\">Serous cystadenocarcinoma</td> </tr> <tr> <td class=\"indent2\">Mucinous cystadenoma</td> </tr> <tr> <td class=\"indent2\">Mucinous borderline tumor</td> </tr> <tr> <td class=\"indent2\">Mucinous cystadenocarcinoma</td> </tr> <tr> <td class=\"indent2\">Endometrioid adenocarcinoma</td> </tr> <tr> <td class=\"indent2\">Clear cell adenocarcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Brenner tumor</td> </tr> <tr> <td class=\"subtitle2_single\">Juvenile xanthogranuloma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_single\">Haemangioma</td> </tr> <tr> <td class=\"subtitle1_single\">Haematolymphoid tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Diffuse large B-cell lymphoma</td> </tr> <tr> <td class=\"subtitle2_single\">Follicular lymphoma, NOS</td> </tr> <tr> <td class=\"subtitle2_single\">Extranodal NK/T-cell lymphoma, nasal-type</td> </tr> <tr> <td class=\"subtitle2_single\">Plasmacytoma</td> </tr> <tr> <td class=\"subtitle2_single\">Myeloid sarcoma</td> </tr> <tr> <td style=\"padding-left:1.5em;\"><strong>Rosai-Dorfman disease</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NOS: not otherwise specified.</div><div class=\"graphic_reference\">Reprinted&nbsp;from:&nbsp;Moch H, Humphrey PE, Ulbright TM, Reuter VE. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th ed, World Health Organization, p. 186.&nbsp;Copyright © 2016. Available from: <A spellcheck=true href=\"http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&amp;codcol=70&amp;codcch=4008\" target=_blank>http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&amp;codcol=70&amp;codcch=4008</A> (accessed on September 29, 2016). Adapted with permission.</div><div id=\"graphicVersion\">Graphic 115023 Version 1.0</div></div></div>"},"115024":{"type":"graphic_picture","displayName":"Eumycetoma: Black grain","title":"Eumycetoma: Black grain","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Eumycetoma: Black grain</div><div class=\"cntnt\"><img style=\"width:576px; height:469px;\" src=\"images/ID/115024_EumycetomaBlackgrain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Black grain from a draining fistula.</div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD, and Claudia Banda, MD.</div><div id=\"graphicVersion\">Graphic 115024 Version 1.0</div></div></div>"},"115026":{"type":"graphic_table","displayName":"Rapid MRSA assays","title":"Performance of molecular assays for rapid detection of MRSA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Performance of molecular assays for rapid detection of MRSA</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Assay</td> <td class=\"subtitle1\">Target(s)</td> <td class=\"subtitle1\">Specimen</td> <td class=\"subtitle1\">&nbsp;Prevalence (%)</td> <td class=\"subtitle1\">Sensitivity (%)</td> <td class=\"subtitle1\">Specificity (%)</td> <td class=\"subtitle1\">Positive predictive value (%)</td> <td class=\"subtitle1\">Negative predictive value (%)</td> <td class=\"subtitle1\">Reference, year</td> </tr> <tr> <td>BD MAX MRSA assay - first generation</td> <td>SCC<em>mec</em> at orfX junction</td> <td> <p>Nasal swab (91%)</p> <p>Other (9%)</p> </td> <td class=\"centered\">4.1</td> <td class=\"centered\">93.9</td> <td class=\"centered\">99.2</td> <td class=\"centered\">83.8</td> <td class=\"centered\">99.7</td> <td>[1], 2012</td> </tr> <tr> <td>BD MAX Staph SR assay - second generation</td> <td>SCC<em>mec</em> right extremity junction, thermostable nuclease (<em>nuc</em>), <em>mecA</em>, <em>mecC</em></td> <td>Blood culture</td> <td class=\"centered\">10.4</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td>[2], 2015</td> </tr> <tr class=\"divider_bottom\"> <td>BD MAX MRSA XT - third generation</td> <td><em>mecA</em>, <em>mecC</em>, SCC<em>mec</em>-orfX junction</td> <td>Nasal swab</td> <td class=\"centered\">10<span class=\"centered\"></span></td> <td class=\"centered\">66.7</td> <td class=\"centered\">97.1</td> <td class=\"centered\">72.7</td> <td class=\"centered\">97.2</td> <td>[3], 2015</td> </tr> <tr> <td>Xpert SA nasal complete - second generation</td> <td>Staphylococcal protein A gene (<em>spa</em>), <em>mecA</em>, SCC<em>mec</em>-orfX junction</td> <td>Nasal swab</td> <td class=\"centered\">8.7</td> <td class=\"centered\">89.3</td> <td class=\"centered\">97.9</td> <td class=\"centered\">79.8</td> <td class=\"centered\">99</td> <td>[4], 2014</td> </tr> <tr> <td>Xpert MRSA/SA BC - second generation</td> <td>Staphylococcal protein A gene (<em>spa</em>), <em>mecA</em>, SCC<em>mec</em>-orfX junction </td> <td>Blood culture (pediatric)</td> <td class=\"centered\">7.3</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td>[5], 2011</td> </tr> <tr> <td>Xpert MRSA/SA SSTI - second generation</td> <td>Staphylococcal protein A gene (<em>spa</em>), <em>mecA</em>, SCC<em>mec</em>-orfX junction </td> <td>Wound swab</td> <td class=\"centered\">30</td> <td class=\"centered\">97.1&nbsp;</td> <td class=\"centered\">96.2&nbsp;</td> <td class=\"centered\">91.9&nbsp;</td> <td class=\"centered\">98.7&nbsp;</td> <td>[6], 2009</td> </tr> <tr> <td>Xpert MRSA/SA SSTI - second generation</td> <td>Staphylococcal protein A gene (<em>spa</em>), <em>mecA</em>, SCC<em>mec</em>-orfX junction </td> <td>Blood culture</td> <td class=\"centered\">14</td> <td class=\"centered\">98.3</td> <td class=\"centered\">99.4&nbsp;</td> <td class=\"centered\">96.6</td> <td class=\"centered\">99.7</td> <td>[6], 2009</td> </tr> <tr class=\"divider_bottom\"> <td>Xpert MRSA/SA BC - third generation</td> <td>Staphylococcal protein A gene (<em>spa</em>), <em>mecA</em>, <em>mecC</em>, SCC<em>mec</em>-orfX junction</td> <td>Nasal swab</td> <td class=\"centered\">10</td> <td class=\"centered\">91.7</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td>[3], 2015</td> </tr> <tr> <td>LightCycler MRSA Advanced Test</td> <td>Insertion site SCC<em>mec</em> at orfX junction</td> <td>Nasal swab</td> <td class=\"centered\">6.8</td> <td class=\"centered\">98.3</td> <td class=\"centered\">98.9</td> <td class=\"centered\">86.7</td> <td class=\"centered\">99.9</td> <td>[7], 2015</td> </tr> <tr> <td>Xpert MRSA Assay</td> <td>Not stated</td> <td>Nasal swab</td> <td class=\"centered\">5.4</td> <td class=\"centered\">95.7</td> <td class=\"centered\">98.8</td> <td class=\"centered\">82.7</td> <td class=\"centered\">99.7</td> <td>[7], 2015</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Dalpke AH, Hofko M, Zimmermann S. Comparison of the BD Max methicillin-resistant Staphylococcus aureus (MRSA) assay and the BD GeneOhm MRSA achromopeptidase assay with direct- and enriched-culture techniques using clinical specimens for detection of MRSA. J Clin Microbiol 2012; 50:3365.</LI>&#xD;&#xA;<LI>Ellem JA, Olma T, O'Sullivan MV. Rapid Detection of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus directly from positive blood cultures by use of the BD Max StaphSR assay. J Clin Microbiol 2015; 53:3900. </LI>&#xD;&#xA;<LI>Lepainteur M, Delattre S, Cozza S, Lawrence C, Roux AL, Rottman M. Comparative evaluation of two PCR-based methods for detection of methicillin-resistant Staphylococcus aureus (MRSA): Xpert MRSA Gen 3 and BD-Max MRSA XT. J Clin Microbiol 2015; 53:1955. </LI>&#xD;&#xA;<LI>Patel PA, Schora DM, Peterson KE, Grayes A, Boehm S, Peterson LR. Performance of the Cepheid Xpert SA nasal complete PCR assay compared to culture for detection of methicillin-sensitive and methicillin-resistant Staphylococcus aureus colonization. Diagn Microbiol Infect Dis 2014; 80:32. </LI>&#xD;&#xA;<LI>Spencer DH, Sellenriek P, Burnham CA. Validation and implementation of the GeneXpert MRSA/SA blood culture assay in a pediatric setting. Am J Clin Pathol 2011; 136:690. </LI>&#xD;&#xA;<LI>Wolk DM, Struelens MJ, Pancholi P, et al. Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol 2009; 47:823. </LI>&#xD;&#xA;<LI>Patel PA, Robicsek A, Grayes A, Schora DM, Peterson KE, Wright MO, et al. Evaluation of multiple real-time PCR tests on nasal samples in a large MRSA surveillance program. Am J Clin Pathol 2015; 143:652. </LI></OL></div><div id=\"graphicVersion\">Graphic 115026 Version 2.0</div></div></div>"},"115031":{"type":"graphic_picture","displayName":"Seborrheic dermatitis dark skin 5","title":"Seborrheic dermatitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis of the scalp</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115031_Seborrheicdrmattsdrkskn5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Widespread, scaly plaques involving the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115031 Version 1.0</div></div></div>"},"115032":{"type":"graphic_diagnosticimage","displayName":"Calcific tendinopathy of shoulder in resorptive phase","title":"Plain radiograph of calcific tendinopathy of the shoulder in the resorptive phase","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of calcific tendinopathy of the shoulder in the resorptive phase</div><div class=\"cntnt\"><img style=\"width:504px; height:751px;\" src=\"images/SM/115032_Clcfctndpthyshldrstgphs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;plain radiograph above shows calcific deposits (arrows)&nbsp;in the shoulder. The deposits have a fluffy appearance with poorly defined limits suggesting the patient's calcific tendinopathy is in the resorptive phase.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 115032 Version 4.0</div></div></div>"},"115034":{"type":"graphic_diagnosticimage","displayName":"Insertional calcific tendinopathy of the shoulder","title":"Plain radiograph of insertional calcific tendinopathy of the shoulder","html":"<div class=\"graphic\"><div style=\"width: 709px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of insertional calcific tendinopathy of the shoulder</div><div class=\"cntnt\"><img style=\"width:689px; height:751px;\" src=\"images/SM/115034_Insrtlclcfctndnpthyshldr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this plain radiograph, the calcific deposits are seen as discrete linear lesions at the tendon insertion, suggesting insertional tendinopathy.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 115034 Version 1.0</div></div></div>"},"115036":{"type":"graphic_diagnosticimage","displayName":"Calcific tendinopathy of shoulder in resting (chronic) phase","title":"Plain radiograph of calcific tendinopathy of the shoulder in the resting (chronic) phase","html":"<div class=\"graphic\"><div style=\"width: 672px\" class=\"figure\"><div class=\"ttl\">Plain radiograph of calcific tendinopathy of the shoulder in the resting (chronic) phase</div><div class=\"cntnt\"><img style=\"width:652px; height:753px;\" src=\"images/SM/115036_Clcfctndpthyshldrsptvps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph of the shoulder shows calcific deposits (arrow)&nbsp;in the region of the supraspinatus tendon. The deposit is dense and homogeneous with well-defined limits suggesting the tendinopathy is in the resting phase.</div><div class=\"graphic_reference\">Courtesy of Tore Prestgaard, MD.</div><div id=\"graphicVersion\">Graphic 115036 Version 3.0</div></div></div>"},"115039":{"type":"graphic_table","displayName":"JVS patency definitions hemodialysis access intervention","title":"JVS patency definitions following hemodialysis access intervention<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">JVS patency definitions following hemodialysis access intervention<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Primary patency</td> </tr> <tr class=\"divider_bottom\"> <td>Interval from the time of access placement until any intervention* designed to maintain or reestablish patency, access thrombosis, or the time of measurement of patency.</td> </tr> <tr> <td class=\"subtitle1_single\">Assisted primary patency</td> </tr> <tr class=\"divider_bottom\"> <td>Interval from the time of access placement until access thrombosis or the time of measurement of patency, including intervening manipulations (surgical or endovascular interventions*) designed to maintain the functionality of a patent access<sup>&#182;</sup>.</td> </tr> <tr> <td class=\"subtitle1_left\">Secondary patency (cumulative patency)</td> </tr> <tr class=\"divider_bottom\"> <td>Interval from the time of access placement until access abandonment, thrombosis, or the time of patency measurement including intervening manipulations (surgical or endovascular interventions*) designed to reestablish functionality in thrombosed access.</td> </tr> <tr> <td class=\"subtitle1_left\">Post-intervention* primary patency</td> </tr> <tr class=\"divider_bottom\"> <td>Interval from the time of any surgical or endovascular intervention* until thrombosis or the time of measurement of patency.</td> </tr> <tr> <td class=\"subtitle1_left\">Post-intervention* assisted primary patency</td> </tr> <tr class=\"divider_bottom\"> <td>Interval from the time of intervention* until first access thrombosis or the time of patency measurement, including all intervening similar manipulations (surgical or endovascular interventions) designed to maintain the functionality of the access. Of note, patency ends for a particular intervention if another method is used to maintain patency.</td> </tr> <tr> <td class=\"subtitle1_left\">Post-intervention* secondary patency (cumulative patency)</td> </tr> <tr> <td>Interval from the time of intervention* until access abandonment or the time of patency measurement, including similar intervening manipulations (surgical or endovascular interventions) designed to reestablish functionality in thrombosed access.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">JVS: Journal of Vascular Surgery. <br />* Intervention: Any surgical or endovascular manipulation of the access to maintain or reestablish its functionality. <br />&para; The number of interventions* can be represented numerically in between brackets after the actual patency of an access (ie, assisted primary patency of 18 months [2]). This indicates that the access has been functional for 18 months but needed two interventions* to maintain its functionality.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35:603.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115039 Version 1.0</div></div></div>"},"115041":{"type":"graphic_picture","displayName":"Surgical wound hematoma","title":"Surgical wound hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical wound hematoma</div><div class=\"cntnt\"><img style=\"width:360px; height:257px;\" src=\"images/DERM/115041_Surgicalwoundhematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoma formation over the left forehead after Mohs surgery.</div><div id=\"graphicVersion\">Graphic 115041 Version 1.0</div></div></div>"},"115042":{"type":"graphic_picture","displayName":"Surgical wound hematoma 2","title":"Surgical wound hematoma​","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Surgical wound hematoma​</div><div class=\"cntnt\"><img style=\"width:692px; height:465px;\" src=\"images/DERM/115042_Surgicalwoundhematoma2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hematoma with surrounding ecchymoses. Hematomas of this size often require drainage to ensure proper wound healing.</div><div id=\"graphicVersion\">Graphic 115042 Version 1.0</div></div></div>"},"115045":{"type":"graphic_picture","displayName":"Surgical wound dehiscence","title":"Surgical wound dehiscence","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical wound dehiscence</div><div class=\"cntnt\"><img style=\"width:378px; height:529px;\" src=\"images/DERM/115045_Surgicalwounddehiscence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A wound that has undergone dehiscence, likely secondary to being in a high-tension location.</div><div id=\"graphicVersion\">Graphic 115045 Version 1.0</div></div></div>"},"115054":{"type":"graphic_table","displayName":"Consensus classification of pediatric Behçet's syndrome","title":"Consensus classification of pediatric Behçet's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consensus classification of pediatric Beh&ccedil;et's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Value/item</td> </tr> <tr> <td>Recurrent oral aphthosis</td> <td>At least three attacks/year</td> <td class=\"centered\">1</td> </tr> <tr> <td>Genital ulceration or aphthosis</td> <td>Typically with scar</td> <td class=\"centered\">1</td> </tr> <tr> <td>Skin involvement</td> <td>Necrotic folliculitis, acneiform lesions, erythema nodosum</td> <td class=\"centered\">1</td> </tr> <tr> <td>Ocular involvement</td> <td>Anterior uveitis, posterior uveitis, retinal vasculitis</td> <td class=\"centered\">1</td> </tr> <tr> <td>Neurologic signs</td> <td>With the exception of isolated headaches</td> <td class=\"centered\">1</td> </tr> <tr> <td>Vascular signs</td> <td>Venous thrombosis, arterial thrombosis, arterial aneurysm</td> <td class=\"centered\">1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Three of six items are required to classify a patient as having pediatric Beh&ccedil;et's syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Kon&eacute;-Paut I, Shahram F, Darce-Bello M, et al. Consensus classification criteria for paediatric Beh&ccedil;et's disease from a prospective observational cohort: PEDBD. Ann Rheum Dis 2016; 75:958-64. Copyright &copy; 2016 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 115054 Version 1.0</div></div></div>"},"115055":{"type":"graphic_algorithm","displayName":"CTS treatment","title":"Treatment of carpal tunnel syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of carpal tunnel syndrome</div><div class=\"cntnt\"><img style=\"width:344px; height:485px;\" src=\"images/NEURO/115055_CTStreatment.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CTS: carpal tunnel syndrome; EDX: electrodiagnostic; ADLs: activities of daily living.<br />* CTS during pregnancy can be treated with wrist splinting and usually resolves gradually after delivery.<br />&para;&#xD;&#xA;<ul>&#xD;&#xA;    <li><strong>Mild CTS</strong>: Numbness, tingling, or discomfort in median nerve distribution, but no sensory loss or weakness, symptoms do not disrupt sleep, and no difficulty with hand function or ADLs.</li>&#xD;&#xA;    <li><strong>Moderate CTS</strong>: Sensory loss in median distribution, symptoms (sensory loss or pain) interfere slightly with hand function but patient is able to perform all ADLs; nocturnal symptoms may occasionally but not routinely disrupt sleep.</li>&#xD;&#xA;    <li><strong>Severe CTS</strong>: Weakness in median distribution, or symptoms disrupt one or more ADLs, or nocturnal symptoms routinely disrupt sleep.</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; Effective nonsurgical treatment options for short-term improvement include splinting, glucocorticoids injections, and oral glucocorticoids. Combined therapy may be more effective than the use of any single modality.</div><div id=\"graphicVersion\">Graphic 115055 Version 1.0</div></div></div>"},"115056":{"type":"graphic_algorithm","displayName":"Approach premenopausal woman hirsutism","title":"Approach to the premenopausal woman with hirsutism","html":"<div class=\"graphic\"><div style=\"width: 758px\" class=\"figure\"><div class=\"ttl\">Approach to the premenopausal woman with hirsutism</div><div class=\"cntnt\"><img style=\"width:738px; height:825px;\" src=\"images/ENDO/115056_Appr_prmenopsl_wmn_hirsutsm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for women with hirsutism without evidence of virilization or rare endocrine disorders such as Cushing's syndrome.</div><div class=\"graphic_footnotes\">OCs: oral estrogen-progestin contraceptives; T: testosterone; 17-OHP: 17-hydroxyprogesterone; hCG: human chorionic gonadotropin; PRL: prolactin; TSH: thyroid-stimulating hormone; FSH: follicle-stimulating hormone; PCOS: polycystic ovary syndrome; IH: idiopathic hirsutism; NCCAH: nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency; ACTH: corticotropin.<br />* Hirsutism should be distinguished from 1) hypertrichosis (generalized excessive hair growth [vellus] that may be hereditary or result from certain medications [eg, phenytoin], not caused by excess androgen) and 2) \"unwanted hair\" - light, unpigmented facial hair that the patient finds bothersome. Signs of virilization include balding, lowering of the voice, and clitoromegaly.<br />¶ Criteria for diagnosis of PCOS include two of three of the following: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Clinical or biochemical evidence of hyperandrogenism</LI>&#xD;&#xA;<LI>Oligomenorrhea</LI>&#xD;&#xA;<LI>Polycystic ovaries on pelvic ultrasound</LI></OL>&nbsp;&nbsp; In addition, other endocrine disorders that cause hirsutism and/or oligomenorrhea must be ruled out.<br />Δ Idiopathic hirsutism is hirsutism without hyperandrogenemia or other signs or symptoms indicative of a hyperandrogenic endocrine disorder.<br /><FONT class=lozenge>◊</FONT> 8 AM serum 17-OHP: Measure at 8 AM on a random day if amenorrhea or infrequent menses; otherwise, day 3 of a menstrual cycle.</div><div id=\"graphicVersion\">Graphic 115056 Version 1.0</div></div></div>"},"115057":{"type":"graphic_table","displayName":"Severity of CTS","title":"Grading the severity of carpal tunnel syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading the severity of carpal tunnel syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical symptom grading</td> </tr> <tr> <td class=\"subtitle2_single\">Mild CTS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Numbness, tingling, or discomfort in median nerve distribution, and </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>No sensory loss or weakness, and </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>CTS symptoms do not disrupt sleep, and </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>No difficulty with hand function or ADLs </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Moderate CTS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sensory loss in median distribution, or </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>CTS symptoms (sensory loss or pain) interfere slightly with hand function but patient is able to perform all ADLs, or </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Nocturnal symptoms may occasionally but not routinely disrupt sleep </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Severe CTS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Weakness in the median distribution, or </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>CTS symptoms disrupt one or more ADLs; patient is unable to carry out all previous activities, or </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Nocturnal symptoms routinely disrupt sleep </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">EDX classification<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Mild CTS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Prolonged (relative or absolute) sensory latencies, and </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Normal motor studies, and </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>No evidence for axon loss </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Moderate CTS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Abnormal median sensory latencies as noted for mild CTS, and </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Relative or absolute prolongation of median motor distal latency, and </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>No evidence of axon loss </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Severe CTS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Any of the aforementioned NCS abnormalities with evidence of axon loss as defined by any of the following: </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <ul> <li>An absent or low-amplitude SNAP or mixed NAP </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <ul> <li>A low-amplitude or absent thenar CMAP </li> </ul> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <ul> <li>A needle EMG with fibrillation potentials or motor unit potential changes (large amplitude, long-duration motor unit potentials, or excessive polyphasics) </li> </ul> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTS: carpal tunnel syndrome; ADLs: activities of daily living; EDX: electrodiagnostic; NCS: nerve conduction studies; NAP: nerve action potential; SNAP: sensory nerve action potential; CMAP: compound muscle action potential; EMG: electromyography.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Werner RA, Andary M. Electrodiagnostic evaluation of carpal tunnel syndrome. Muscle Nerve 2011; 44:597.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115057 Version 1.0</div></div></div>"},"115060":{"type":"graphic_table","displayName":"Diseases in Latin America and Caribbean","title":"Diseases potentially acquired by travel to Latin America and the Caribbean","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases potentially acquired by travel to Latin America and the Caribbean</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Arthropod-borne diseases</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Dengue fever</td> </tr> <tr> <td class=\"indent1\">Chikungunya</td> </tr> <tr> <td class=\"indent1\">Zika virus</td> </tr> <tr> <td class=\"indent1\">Yellow fever</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Chagas disease</td> </tr> <tr> <td class=\"indent1\">Rocky Mountain spotted fever (and other rickettsioses)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ehrlichiosis</td> </tr> <tr> <td class=\"subtitle1_single\">Food-borne and water-borne diseases</td> </tr> <tr> <td class=\"indent1\">Travelers' diarrhea</td> </tr> <tr> <td class=\"indent1\">Enteric fever (typhoid and paratyphoid fever)</td> </tr> <tr> <td class=\"indent1\">Hepatitis A</td> </tr> <tr> <td class=\"indent1\">Cholera</td> </tr> <tr> <td class=\"indent1\">Giardiasis</td> </tr> <tr> <td class=\"indent1\">Cyclosporiasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Leptospirosis</td> </tr> <tr> <td class=\"subtitle1_single\">Other infections</td> </tr> <tr> <td class=\"indent1\">Fungal infections</td> </tr> <tr> <td class=\"indent1\">Hantavirus</td> </tr> <tr> <td class=\"indent1\">Myiasis</td> </tr> <tr> <td class=\"indent1\">Melioidosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 115060 Version 1.0</div></div></div>"},"115061":{"type":"graphic_table","displayName":"Liver abscess characteristics","title":"Characteristics of liver abscess*<SUP>[1-3]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of liver abscess*<SUP>[1-3]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Findings suggestive of pyogenic liver abscess</td> <td class=\"subtitle1\">Findings suggestive of amebic liver abscess</td> </tr> <tr> <td><strong>Age</strong></td> <td>Older adults</td> <td>Younger adults</td> </tr> <tr> <td><strong>Gender distribution</strong></td> <td>Both men and women affected</td> <td>Usually men affected</td> </tr> <tr> <td><strong>Left shift on white blood cell count</strong></td> <td>Often present</td> <td>Usually absent</td> </tr> <tr> <td><strong>Serum bilirubin concentration</strong></td> <td>Often elevated</td> <td>Usually normal</td> </tr> <tr> <td><strong>History</strong></td> <td> <p>Prior history of gallstones</p> <p>Diabetes mellitus</p> </td> <td>Exposure to resource-limited settings</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Clinical findings alone cannot distinguish between pyogenic and amebic liver abscess; however, certain clinical features can raise suspicion of one over the other.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Cosme A, Ojeda E, Zamarreño I, Bujanda L, et al. Pyogenic versus amoebic liver abscesses. A comparative clinical study in a series of 58 patients. Rev Esp Enferm Dig 2010; 102:90.</LI>&#xD;&#xA;<LI>Abbas MT, Khan FY, Muhsin SA, et al. Epidemiology, Clinical Features and Outcome of Liver Abscess: A single Reference Center Experience in Qatar. Oman Med J 2014; 29:260.</LI>&#xD;&#xA;<LI>Barnes PF, De Cock KM, Reynolds TN, Ralls PW. A comparison of amebic and pyogenic abscess of the liver. Medicine (Baltimore) 1987; 66:472.</LI></OL></div><div id=\"graphicVersion\">Graphic 115061 Version 3.0</div></div></div>"},"115065":{"type":"graphic_figure","displayName":"Knee OA PI","title":"Knee osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Knee osteoarthritis</div><div class=\"cntnt\"><img style=\"width:575px; height:348px;\" src=\"images/RHEUM/115065_KneeOAPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a normal knee joint next to a knee joint with osteoarthritis (OA). In the OA joint, the cartilage covering the ends of the bones roughens and becomes thin, while the bone underneath the cartilage grows thicker. Bony growths called \"osteophytes\" can form. The space between the bones also becomes narrower.</div><div id=\"graphicVersion\">Graphic 115065 Version 2.0</div></div></div>"},"115067":{"type":"graphic_waveform","displayName":"Polysomnogram in a child with severe OSA","title":"Polysomnogram in a child with severe obstructive sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Polysomnogram in a child with severe obstructive sleep apnea</div><div class=\"cntnt\"><img style=\"width:797px; height:527px;\" src=\"images/SLEEP/115067_PolysomnogrmsevrOSAchild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epoch from a polysomnogram for a child with severe obstructive sleep apnea (OSA), with a 12.1-second obstructive apnea, identified by flattening of the nasal airflow (thermal sensor airflow). Note the slowing of the heart rate (\"ECG\" leads) and dipping in blood pressure during the event. This is quickly followed by a transient increase in the heart rate and blood pressure once the obstruction is no longer present on the nasal airflow.</div><div class=\"graphic_footnotes\">EOG: electrooculogram; EEG: electroencephalogram; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 115067 Version 1.0</div></div></div>"},"115069":{"type":"graphic_figure","displayName":"Protocol dipyridamole stress Tc99m SPECT","title":"Protocol dipyridamole stress Tc99m SPECT*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Protocol dipyridamole stress Tc99m SPECT*<SUP>¶</SUP></div><div class=\"cntnt\"><img style=\"width:466px; height:217px;\" src=\"images/CARD/115069_Protcldipyridamolestress.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SPECT: single photon emission computed tomography; IV: intravenous.<br />* Low level exercise is optional throughout.<br />¶ Imaging should occur 15 to 45 minutes after protocol.</div><div id=\"graphicVersion\">Graphic 115069 Version 1.0</div></div></div>"},"115070":{"type":"graphic_figure","displayName":"Protocol regadenoson stress Tc99m SPECT","title":"Protocol regadenoson stress Tc99m SPECT*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div style=\"width: 647px\" class=\"figure\"><div class=\"ttl\">Protocol regadenoson stress Tc99m SPECT*<SUP>¶</SUP></div><div class=\"cntnt\"><img style=\"width:627px; height:217px;\" src=\"images/CARD/115070_Protocolregadenosonstress.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SPECT: single photon emission computed tomography.<br />* Low level exercise is optional throughout.<br />¶ Imaging should occur 15 to 45 minutes after protocol.</div><div id=\"graphicVersion\">Graphic 115070 Version 1.0</div></div></div>"},"115071":{"type":"graphic_algorithm","displayName":"Evaluation and management of acute proctitis in MSM","title":"Evaluation and management of acute proctitis in men who have sex with men<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div style=\"width: 844px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of acute proctitis in men who have sex with men<sup>[1,2]</sup></div><div class=\"cntnt\"><img style=\"width:824px; height:754px;\" src=\"images/PC/115071_EvalmgmtacuteprocttsMSM.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; HIV: human immunodeficiency virus; HCV: hepatitis C virus;&nbsp;LGV: lymphogranuloma venereum; NAAT: nucleic acid amplification test; PCR: polymerase chain reaction; RPR: rapid plasma reagin.<br />* Diagnostic tests for sexually transmitted infections include anal swabs for gonorrhea (NAAT or culture), chlamydia (NAAT), herpes simplex virus (PCR or culture); and peripheral blood for syphilis serology (RPR). If the chlamydia NAAT is positive, LGV PCR should be performed if available.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</li>&#xD;&#xA;    <li>Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Available at: <a href=\"https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0</a> (Accessed on October 10, 2017).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115071 Version 1.0</div></div></div>"},"115073":{"type":"graphic_figure","displayName":"Umbilical vein catheterization","title":"Umbilical vein catheterization","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Umbilical vein catheterization</div><div class=\"cntnt\"><img style=\"width:540px; height:627px;\" src=\"images/EM/115073_Umbilicalveincatheterization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The steps for passage of an umbilical vein catheter (UVC)&nbsp;are as follows:<br /><br />A.&nbsp;After preparing the stump with antiseptic solution,&nbsp;place umbilical tie firmly around the base of the umbilicus with a half knot that will control bleeding from the stump but permit passage of the UVC. Cut the residual umbilical cord about 2 cm above the skin.<br />B. Locate the umbilical vein (thin-walled, typically cephalad in the 12 o’clock position, and, in newborns, bleeds after cutting). For patients undergoing resuscitation outside of the delivery room, identify and remove any blood clot from the umbilical vein using a small, curved hemostat. <br />B and C. While holding the base of the umbilicus with the non-dominant hand, insert the pre-flushed UVC into the vein approximately 3 to 5 cm in a full-term infant (2 to 4 cm in a premature infant) and check for blood return. <br />D. Once blood return is confirmed, secure the catheter manually or with adhesive tape and administer medications. Because emergency UVCs can frequently become misplaced during resuscitation, check for blood return prior to each use.<br /><br />For further information, refer to UpToDate topics on vascular access for pediatric resuscitation and other pediatric emergencies.</div><div id=\"graphicVersion\">Graphic 115073 Version 1.0</div></div></div>"},"115080":{"type":"graphic_algorithm","displayName":"ED patient with chief complaint of vaginal bleeding","title":"Emergency department patient with chief complaint of vaginal bleeding","html":"<div class=\"graphic\"><div style=\"width: 877px\" class=\"figure\"><div class=\"ttl\">Emergency department patient with chief complaint of vaginal bleeding</div><div class=\"cntnt\"><img style=\"width:857px; height:722px;\" src=\"images/EM/115080_EDvaginalbleeding.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GA: gauge; IV: intravenous; HCG: human chronic gonadotropin; OB: obstetrics; GYN: gynecology; US: ultrasound; IUP: intrauterine pregnancy; PUL: pregnancy of unknown location.<br />* Iron supplementation may be indicated for some anemic patients. Patients requiring a transfusion require an expeditious workup to determine the cause, and close follow-up. Refer to specific UpToDate topics covering causes of vaginal bleeding.</div><div id=\"graphicVersion\">Graphic 115080 Version 1.0</div></div></div>"},"115084":{"type":"graphic_movie","displayName":"Robotic surgical correction of UPJ obstruction","title":"Video showing robotic correction of congenital ureteropelvic junction obstruction","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Video showing robotic correction of congenital ureteropelvic junction obstruction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PEDS/115084_RobosurgUPJobstrctnvid.mp4\" style=\"width:704px;height:416px\"></div><img style=\"width:756px; height:626px;\" src=\"images/PEDS/115084_RobosurgUPJobstrctnimg.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 115084 Version 1.0</div></div></div>"},"115090":{"type":"graphic_figure","displayName":"Anatomy of central lymphatic circulation view","title":"Anatomy of central lymphatic circulation view","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Anatomy of central lymphatic circulation view</div><div class=\"cntnt\"><img style=\"width:529px; height:582px;\" src=\"images/PULM/115090_Anatomyofcentrallymphaticcirculationview.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">a: artery; v: vein.</div><div class=\"graphic_reference\">Modified from: Brotons ML, Bolca C, Fréchette E, Deslauriers J. Anatomy and physiology of the thoracic lymphatic system. Thorac Surg Clin 2012; 22:139.</div><div id=\"graphicVersion\">Graphic 115090 Version 1.0</div></div></div>"},"115091":{"type":"graphic_diagnosticimage","displayName":"Tracheal aspiration","title":"Computed tomographic image of tracheal aspiration","html":"<div class=\"graphic\"><div style=\"width: 717px\" class=\"figure\"><div class=\"ttl\">Computed tomographic image of tracheal aspiration</div><div class=\"cntnt\"><img style=\"width:697px; height:759px;\" src=\"images/PULM/115091_Trachealaspiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with aspiration pneumonia. Axial computed tomographic (CT) scan (A) shows food and secretions in the tracheal lumen forming a gas-liquid level (arrow). Coronal CT view in the same patient (B) shows secretions and food in the superior aspect of the trachea (dashed arrow) and bibasal streaky opacities and consolidation in both lower lobes consistent with aspiration pneumonia (C).</div><div id=\"graphicVersion\">Graphic 115091 Version 1.0</div></div></div>"},"115092":{"type":"graphic_diagnosticimage","displayName":"Tracheal stenosis I","title":"Computed tomography of neoplastic tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Computed tomography of neoplastic tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:761px; height:338px;\" src=\"images/PULM/115092_TrachealstenosisI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cavitating squamous cell carcinoma in the right upper lobe with adjacent mediastinal invasion. Axial computed tomographic (CT) scan (A) shows severe circumferential tracheal stenosis (arrow) due to extrinsic neoplastic compression as well as marked narrowing of the superior vena cava (dashed arrow). Coronal CT chest in the same patient (B) confirms severe circumferential stenosis of the intrathoracic trachea (arrows).</div><div id=\"graphicVersion\">Graphic 115092 Version 1.0</div></div></div>"},"115093":{"type":"graphic_diagnosticimage","displayName":"Tracheomegaly","title":"Tracheomegaly","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Tracheomegaly</div><div class=\"cntnt\"><img style=\"width:752px; height:725px;\" src=\"images/PULM/115093_Tracheomegaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracheomegaly in patient with mixed connective tissue disease. Axial computed tomographic scan (CT) scan shows dilated trachea with a transverse diameter of 30 mm and concurrent esophageal dilation (arrow).</div><div id=\"graphicVersion\">Graphic 115093 Version 1.0</div></div></div>"},"115094":{"type":"graphic_diagnosticimage","displayName":"Tracheal stenosis II","title":"Computed tomography of post intubation tracheal stenosis","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Computed tomography of post intubation tracheal stenosis</div><div class=\"cntnt\"><img style=\"width:758px; height:431px;\" src=\"images/PULM/115094_TrachealstenosisII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postintubation tracheal stenosis. Axial computed tomographic scan (CT) scan (A) shows focal severe narrowing of the upper trachea with tracheal wall thickening. Coronal CT (B) in the same patient shows focal narrowing in the upper half of the trachea (arrows).</div><div id=\"graphicVersion\">Graphic 115094 Version 1.0</div></div></div>"},"115095":{"type":"graphic_diagnosticimage","displayName":"Tracheal diverticulum II","title":"Computed tomography of tracheal diverticulum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomography of tracheal diverticulum</div><div class=\"cntnt\"><img style=\"width:409px; height:760px;\" src=\"images/PULM/115095_TrachealdiverticulumII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tracheal diverticulum at the level of the thoracic inlet. Axial computed tomographic (CT) scan (A) shows a pocket of gas projecting posteriorly and to the right of the tracheal lumen (arrow). Sagittal CT (B) in the same patient demonstrates the diverticulum posterior to the tracheal lumen (dashed arrow).</div><div id=\"graphicVersion\">Graphic 115095 Version 1.0</div></div></div>"},"115096":{"type":"graphic_figure","displayName":"Weight loss 12 mos FDA-approved drugs","title":"Weight loss at 12 months for FDA-approved drugs","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Weight loss at 12 months for FDA-approved drugs</div><div class=\"cntnt\"><img style=\"width:655px; height:487px;\" src=\"images/PC/115096_Wghtloss12mFDAaprvdrg.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of George A Bray, MD.<br />Data from: Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016; 315:2424. doi: 10.1001/jama.2016.7602</div><div id=\"graphicVersion\">Graphic 115096 Version 1.0</div></div></div>"},"115102":{"type":"graphic_movie","displayName":"Thoracoscopic biopsy","title":"Thoracoscopic biopsy of tumor on parietal pleura","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic biopsy of tumor on parietal pleura</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/115102_BiopsyIvid.mp4\" style=\"width:224px;height:176px\"></div><img style=\"width:350px; height:240px;\" src=\"images/PULM/115102_BiopsyIimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows a thoracoscopic biopsy of a tumor lesion affecting the parietal pleura. The biopsy motion in this case is a direct \"grab-and-pull\" process performed under direct visualization.</div><div id=\"graphicVersion\">Graphic 115102 Version 1.0</div></div></div>"},"115103":{"type":"graphic_movie","displayName":"Thorcoscopic biopsy II","title":"Thoracoscopic biopsy of mesothelioma deposit on parietal pleura","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracoscopic biopsy of mesothelioma deposit on parietal pleura</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/115103_BiopsyIIvid.mp4\" style=\"width:224px;height:176px\"></div><img style=\"width:350px; height:240px;\" src=\"images/PULM/115103_BiopsyIIimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video shows a thoracoscopic biopsy of a mesothelioma deposit affecting the parietal pleura. The biopsy motion in this case is a direct \"tearing\" process performed under direct visualization.</div><div id=\"graphicVersion\">Graphic 115103 Version 1.0</div></div></div>"},"115104":{"type":"graphic_figure","displayName":"HFNC and nasopharyngeal pressure","title":"Effect of high flow nasal oxygen on nasopharyngeal pressure","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Effect of high flow nasal oxygen on nasopharyngeal pressure</div><div class=\"cntnt\"><img style=\"width:672px; height:385px;\" src=\"images/PULM/115104_HFNC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is nasopharyngeal pressure as a function of increasing oxygen flow. As the flow rate is increased, nasopharyngeal pressure rises, and peaks mid to late expiration.</div><div class=\"graphic_reference\">Republished with permission of: Daedalus Enterprises for the American Association for Respiratory Therapy, Parke RL, McGuinness SP. Pressures delivered by nasal high flow oxygen during all phases of the respiratory cycle. Respir Care 2013; 58(10):1621. Permission conveyed through Copyright Clearance Center, Inc. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 115104 Version 1.0</div></div></div>"},"115105":{"type":"graphic_table","displayName":"Mechanisms and benefits of HFNC","title":"Mechanisms and benefits of oxygen delivered via high flow nasal cannula","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mechanisms and benefits of oxygen delivered via high flow nasal cannula</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Physiologic and clinical benefit</td> </tr> <tr> <td>Small, pliable nasal prongs</td> <td> <ul> <li>Enhanced patient comfort </li> </ul> </td> </tr> <tr> <td>Heat and humidification</td> <td> <ul> <li>Facilitates removal of airway secretions </li> <li>Avoids airway dessication and epithelial injury </li> <li>Decreased work of breathing </li> <li>Enhances patient comfort </li> </ul> </td> </tr> <tr> <td>Washout of nasopharyngeal deadspace</td> <td> <ul> <li>Improved ventilation and oxygen delivery </li> </ul> </td> </tr> <tr> <td>Positive end-expiratory (PEEP) effect</td> <td> <ul> <li>Unload auto-PEEP (if present) </li> <li>Decrease work of breathing </li> <li>Enhance oxygenation </li> </ul> </td> </tr> <tr> <td>High nasal flow rate</td> <td> <ul> <li>Reliable delivery of fraction of inspired oxygen (FiO<sub>2</sub>) </li> <li>Improved breathing pattern (eg, increased tidal volume, decreased respiratory rate) </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 115105 Version 1.0</div></div></div>"},"115106":{"type":"graphic_figure","displayName":"SLE virus disease cases reported by state, 2004 to 2015","title":"St. Louis encephalitis virus neuroinvasive disease cases reported by state, 2004 to 2015","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">St. Louis encephalitis virus neuroinvasive disease cases reported by state, 2004 to 2015</div><div class=\"cntnt\"><img style=\"width:565px; height:376px;\" src=\"images/ID/115106_SLEcasesstate20042015.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This map shows the geographic distribution of St. Louis encephalitis cases in the United States reported to the Centers for Disease Control and Prevention, 2004 to 2015.</div><div class=\"graphic_reference\">Adapted from: Saint Louis Encephalitis: Epidemiology &amp; Geographic Distribution. Centers for Disease Control and Prevention 2015. Available at: <A href=\"https://www.cdc.gov/sle/technical/epi.html\" target=_blank>https://www.cdc.gov/sle/technical/epi.html</A> (Accessed on September 28, 2017). Data updated with reported numbers from 2014 and 2015.</div><div id=\"graphicVersion\">Graphic 115106 Version 1.0</div></div></div>"},"115107":{"type":"graphic_diagnosticimage","displayName":"Right middle lobe atelectasis I","title":"Computed tomography of right middle lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Computed tomography of right middle lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:528px; height:762px;\" src=\"images/PULM/115107_RghtmddlelbatelectasisI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) axial view (A) showing right middle lobe atelectasis forming the so-called ice cream cone sign as it abuts on the cardiac structures (arrow). Coronal CT in the same patient (B) shows the same right middle lobe atelectasis (arrow).</div><div id=\"graphicVersion\">Graphic 115107 Version 1.0</div></div></div>"},"115108":{"type":"graphic_diagnosticimage","displayName":"Right middle lobe atelectasis II","title":"Computed tomography of right middle lobe atelectasis and bronchiectasis (Lady Windermere syndrome)","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Computed tomography of right middle lobe atelectasis and bronchiectasis (Lady Windermere syndrome)</div><div class=\"cntnt\"><img style=\"width:754px; height:490px;\" src=\"images/PULM/115108_RghtmddllbatelectasisII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomography showing right middle lobe atelectasis and bronchiectasis in the right middle lobe, lingula, and superior segment of the left lower lobe, in a patient with atypical mycobacterial infection, the so-called Lady Windermere syndrome.</div><div id=\"graphicVersion\">Graphic 115108 Version 1.0</div></div></div>"},"115109":{"type":"graphic_diagnosticimage","displayName":"Right middle lobe atelectasis III","title":"Computed tomography of right middle lobe atelectasis due to lung cancer","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Computed tomography of right middle lobe atelectasis due to lung cancer</div><div class=\"cntnt\"><img style=\"width:753px; height:593px;\" src=\"images/PULM/115109_RghtmdllbatelectasisIII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial computed tomographic (CT) scan shows a convex lateral contour to the atelectatic lobe (arrow). A small right pleural effusion is also visible.</div><div id=\"graphicVersion\">Graphic 115109 Version 1.0</div></div></div>"},"115110":{"type":"graphic_diagnosticimage","displayName":"Right middle lobe atelectasis IV","title":"Atypical right middle lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Atypical right middle lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:487px; height:763px;\" src=\"images/PULM/115110_RghtmddllbatelectasisIV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical right middle lobe atelectasis after right upper lobe lobectomy. Frontal chest bedside postoperative radiograph (A) shows the displaced atelectatic right middle lobe mimicking a collapsed right upper lobe (arrow). Contrast-enhanced axial computed tomography scan in the same patient (B) shows the postoperative cephalad displacement of the atelectatic right middle lobe (arrow).</div><div id=\"graphicVersion\">Graphic 115110 Version 1.0</div></div></div>"},"115111":{"type":"graphic_diagnosticimage","displayName":"Right upper and lower lobe atelectasis","title":"Computed tomography of right upper and lower lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Computed tomography of right upper and lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:753px; height:653px;\" src=\"images/PULM/115111_Rghtupprlwrleatelectass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced coronal computed tomography showing passive atelectasis of the right upper and right lower lobes due to a large right pleural effusion. The collapsed lobes are medially displaced (arrows), separated by the right major fissure which contains pleural fluid as well (thick arrow).</div><div id=\"graphicVersion\">Graphic 115111 Version 1.0</div></div></div>"},"115112":{"type":"graphic_diagnosticimage","displayName":"Pericardial fat pad","title":"Pericardial fat pad mimicking atelectasis","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Pericardial fat pad mimicking atelectasis</div><div class=\"cntnt\"><img style=\"width:493px; height:762px;\" src=\"images/PULM/115112_Pericardialfatpad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal chest radiograph (A) showing large left pericardial fat pad that mimics lingular atelectasis (arrow). Axial computed tomographic scan (B) showing that the presumed lingular opacification is caused by a large left pericardial fat pad (arrow).</div><div id=\"graphicVersion\">Graphic 115112 Version 1.0</div></div></div>"},"115113":{"type":"graphic_diagnosticimage","displayName":"Left lower lobe atelectasis I","title":"Left lower lobe atelectasis due to elevation of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Left lower lobe atelectasis due to elevation of the diaphragm</div><div class=\"cntnt\"><img style=\"width:760px; height:665px;\" src=\"images/PULM/115113_LeftlowlobeatelectasisI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph (A) of compressive atelectasis of the left lower lobe due to marked elevation of the left hemidiaphragm (arrow). Axial (B) and coronal (C, D) computed tomographic (CT) scan in the same patient displays the compressive atelectasis of the left lower lobe in the basal segments (dashed arrows).</div><div id=\"graphicVersion\">Graphic 115113 Version 1.0</div></div></div>"},"115114":{"type":"graphic_diagnosticimage","displayName":"Left lower lobe atelectasis II","title":"Left lower lobe atelectasis due to pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Left lower lobe atelectasis due to pleural effusion</div><div class=\"cntnt\"><img style=\"width:754px; height:476px;\" src=\"images/PULM/115114_LeftlwlobeatelectasisII.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left lower lobe compressive atelectasis of the basal segments due to a left pleural effusion that resulted after esophageal perforation during endoscopy. Axial computed tomography (CT) scan shows the collapsed basal segments of the left lower lobe (arrow) with accompanying pneumomediastinum (dashed arrow) and extravasation of water-soluble contrast material after an esophagram (thick arrow).</div><div id=\"graphicVersion\">Graphic 115114 Version 1.0</div></div></div>"},"115116":{"type":"graphic_table","displayName":"Maternal and fetal outcome estimates","title":"Maternal and fetal outcome estimates (%) for women with mechanical heart valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Maternal and fetal outcome estimates (%) for women with mechanical heart valves</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Anticoagulation regimen during pregnancy</td> <td class=\"subtitle1\" colspan=\"2\">Maternal outcomes</td> <td class=\"subtitle1\" rowspan=\"2\">Fetal/neonatal anticoagulant-related adverse events</td> <td class=\"subtitle1\" rowspan=\"2\">Livebirth rate</td> </tr> <tr> <td class=\"subtitle2\">Maternal mortality</td> <td class=\"subtitle2\">Thromboembolism</td> </tr> <tr> <td>Vitamin K antagonist<br /> (INR target 2.5 to 3.5)</td> <td>0.9 (0.1, 1.6)</td> <td>2.7 (1.4, 4.0)</td> <td>2.0 (0.3, 3.7)*</td> <td>64.5 (48.8, 80.2)</td> </tr> <tr> <td>Sequential treatment</td> <td>2.0 (0.8, 3.1)</td> <td>5.8 (3.8, 7.7)</td> <td>1.4 (0.3, 2.5)<sup>&#182;</sup></td> <td>79.9 (74.3, 85.6)</td> </tr> <tr> <td>LMWH only<br /> (aPTT 1.5 to 2.5 &times; control)</td> <td>2.9 (0.2, 5.7)</td> <td>8.7 (3.9, 13.4)</td> <td>0</td> <td>92.0 (86.1, 98.0)</td> </tr> <tr> <td>UFH only</td> <td>3.4 (0, 7.7)</td> <td>11.2 (2.8, 19.6)</td> <td>7.6 (0.1, 15.0)<sup>&#182;</sup></td> <td>69.5 (37.8, 100)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Estimates are presented as proportions per 100 affected pregnancies with 95% confidence intervals.</div><div class=\"graphic_footnotes\">INR: international normalized ratio; LMWH: low molecular weight heparin; aPTT: activated partial thromboplastin time; UFH: unfractionated heparin.<br />* Of these, 0.8% (0.0, 1.7) represent embryopathy and 2.1% (0.1, 4.1) represent fetopathy.<br />&para; All cases represent fetopathy.</div><div class=\"graphic_reference\">Modified from: D'Souza R, Ostro J, Shah PS, et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur Heart J 2017; 38(19):1509-1516, by permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright &copy; 2017 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 115116 Version 1.0</div></div></div>"},"115123":{"type":"graphic_picture","displayName":"Dermoscopy of androgenetic alopecia - single follicular units","title":"Dermoscopy of androgenetic alopecia","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of androgenetic alopecia</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115123_Drmscpyandrgntcalpcsngl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular ostia containing only a single hair shaft.</div><div id=\"graphicVersion\">Graphic 115123 Version 1.0</div></div></div>"},"115124":{"type":"graphic_picture","displayName":"Dermoscopy of terminal and vellus hairs","title":"Dermoscopy of terminal and vellus hairs","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of terminal and vellus hairs</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115124_Drmscpyterminlvellushair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vellus hairs (bottom portion of photograph) are shorter and thinner than terminal hairs (top portion of photograph).</div><div id=\"graphicVersion\">Graphic 115124 Version 1.0</div></div></div>"},"115125":{"type":"graphic_picture","displayName":"Dermoscopy of discoid lupus erythematosus - blue-gray dots","title":"Dermoscopy of discoid lupus erythematosus on the scalp","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of discoid lupus erythematosus on the scalp</div><div class=\"cntnt\"><img style=\"width:753px; height:564px;\" src=\"images/DERM/115125_Dydscdlprytmtsblgryds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple blue-gray dots (arrow) in a speckled pattern.</div><div id=\"graphicVersion\">Graphic 115125 Version 1.0</div></div></div>"},"115127":{"type":"graphic_picture","displayName":"Dermoscopy of scalp psoriasis scale","title":"Dermoscopy of scalp psoriasis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of scalp psoriasis</div><div class=\"cntnt\"><img style=\"width:756px; height:566px;\" src=\"images/DERM/115127_Drmscpyscalppsoriasisscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White scale and twisted capillaries.</div><div id=\"graphicVersion\">Graphic 115127 Version 1.0</div></div></div>"},"115128":{"type":"graphic_picture","displayName":"Dermoscopy of scalp seborrheic dermatitis","title":"Dermoscopy of seborrheic dermatitis on the scalp","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of seborrheic dermatitis on the scalp</div><div class=\"cntnt\"><img style=\"width:756px; height:566px;\" src=\"images/DERM/115128_Drmscpyscalpsbrrhcdrmtts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow and white scale and arborizing vessels.</div><div id=\"graphicVersion\">Graphic 115128 Version 1.0</div></div></div>"},"115131":{"type":"graphic_picture","displayName":"Dermoscopy of the scalp white patches","title":"Dermoscopy of the scalp","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of the scalp</div><div class=\"cntnt\"><img style=\"width:538px; height:718px;\" src=\"images/DERM/115131_Drmscpyscalpwhitepatches.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White patches (arrow) in a patient with cicatricial alopecia.</div><div id=\"graphicVersion\">Graphic 115131 Version 1.0</div></div></div>"},"115132":{"type":"graphic_picture","displayName":"Dermoscopy of alopecia areata circle hairs","title":"Dermoscopy of alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of alopecia areata</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115132_Drmscpyalpcareatacrclhr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple short, thin hairs forming circles (circle hairs).</div><div id=\"graphicVersion\">Graphic 115132 Version 1.0</div></div></div>"},"115133":{"type":"graphic_picture","displayName":"Dermoscopy of pediculosis capitis nonviable nit","title":"Dermoscopy of pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115133_Drmscpypdclsscptsnvblnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nonviable nits (empty louse egg cases) attached to hair shafts.</div><div id=\"graphicVersion\">Graphic 115133 Version 1.0</div></div></div>"},"115136":{"type":"graphic_picture","displayName":"Dermoscopy of hair pseudocast","title":"Dermoscopy of hair pseudocast","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of hair pseudocast</div><div class=\"cntnt\"><img style=\"width:756px; height:562px;\" src=\"images/DERM/115136_Dermoscopyhairpseudocast.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregularly shaped, white concretion surrounding hair shaft.</div><div id=\"graphicVersion\">Graphic 115136 Version 1.0</div></div></div>"},"115137":{"type":"graphic_picture","displayName":"Dermoscopy of trichoptilosis","title":"Dermoscopy of trichoptilosis (hair split ends)","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of trichoptilosis (hair split ends)</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115137_Dermoscopytrichoptilosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal splitting of distal hair shaft (center of photograph).</div><div id=\"graphicVersion\">Graphic 115137 Version 1.0</div></div></div>"},"115138":{"type":"graphic_picture","displayName":"Dermoscopy of trichorrhexis nodosa","title":"Dermoscopy of trichorrhexis nodosa","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of trichorrhexis nodosa</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115138_Drmscpytrichorrhexsnodosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple fractured hair shafts.</div><div id=\"graphicVersion\">Graphic 115138 Version 1.0</div></div></div>"},"115140":{"type":"graphic_picture","displayName":"Dermoscopy of monilethrix","title":"Dermoscopy of monilethrix","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of monilethrix</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115140_Dermoscopymonilethrix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Regularly spaced beading of hair shafts.</div><div id=\"graphicVersion\">Graphic 115140 Version 1.0</div></div></div>"},"115141":{"type":"graphic_picture","displayName":"Dermoscopy of pili torti in lichen planopilaris","title":"Dermoscopy of pili torti","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of pili torti</div><div class=\"cntnt\"><img style=\"width:716px; height:536px;\" src=\"images/DERM/115141_Dmspypilitrtlchnplnplrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Presence of irregular torsions along the shaft.</div><div id=\"graphicVersion\">Graphic 115141 Version 1.0</div></div></div>"},"115142":{"type":"graphic_picture","displayName":"Dermoscopy of pili annulati","title":"Dermoscopy of pili annulati","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of pili annulati</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115142_Dermoscopypiliannulati.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alternating white bands (air-filled cavities) within hair shafts.</div><div id=\"graphicVersion\">Graphic 115142 Version 1.0</div></div></div>"},"115144":{"type":"graphic_picture","displayName":"Dermoscopy of trichomycosis","title":"Dermoscopy of trichomycosis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Dermoscopy of trichomycosis</div><div class=\"cntnt\"><img style=\"width:756px; height:567px;\" src=\"images/DERM/115144_Dermoscopytrichomycosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellow concretions on hair shafts.</div><div id=\"graphicVersion\">Graphic 115144 Version 1.0</div></div></div>"},"115147":{"type":"graphic_algorithm","displayName":"VUR grades I to II","title":"Children with mild (grade I or II) VUR*","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Children with mild (grade I or II) VUR*</div><div class=\"cntnt\"><img style=\"width:518px; height:1116px;\" src=\"images/PEDS/115147_VURgradesIII.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VUR: vesicoureteral reflux; UTI: urinary tract infection.<br />* This algorithm reflects the management of grades I to II VUR based on the approach of the authors for the UpToDate topic on management of VUR. Of note, the potential benefits of circumcision are discussed with the family for any uncircumcised boy with VUR. Refer to topic on the risk and benefits of neonatal circumcision. Details for VUR grading can be found in the UpToDate&nbsp;topic on presentation, diagnosis, and clinical course of primary VUR.<br />¶ Details on antibiotic prophylaxis for VUR and surgical options are presented in the UpToDate topic on management of VUR.<br />Δ Follow-up care includes mandatory urine cultures and urinalysis whenever there are urinary symptoms suggestive of UTI or unexplained fever. Monitoring of VUR is done by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC) and is typically performed in our practice every 18 to 24 months. In addition, DMSA (dimercaptosuccinic acid) renal scans are obtained in cases with breakthrough UTI.<br /><FONT class=lozenge>◊</FONT> Details on the management measures for bladder and bowel dysfunction are presented in the UpToDate topics on bladder dysfunction and chronic functional constipation and fecal incontinence, and follow-up.<br />§ Surgery is considered based on family preference, due to persistent VUR and the need for monitoring by imaging, breakthrough UTI, noncompliance with medical management, significant adverse effects of prophylactic antibiotics, and development of a new renal scar. Details on management decisions regarding surgical correction and continuation and discontinuation of prophylactic antibiotics are presented in the UpToDate topic on management of VUR.</div><div id=\"graphicVersion\">Graphic 115147 Version 1.0</div></div></div>"},"115149":{"type":"graphic_algorithm","displayName":"VUR grades III to V","title":"Children with moderate to severe (grades III to V) VUR*","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Children with moderate to severe (grades III to V) VUR*</div><div class=\"cntnt\"><img style=\"width:708px; height:1028px;\" src=\"images/PEDS/115149_VURgradesIIIV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VUR: vesicoureteral reflux; UTI: urinary tract infection.<br />* This algorithm reflects the management of grades III to V VUR based on the approach of the authors of the UpToDate topic on management of VUR. Details for VUR grading can be found in the UpToDate topic on presentation, diagnosis, and clinical course of primary VUR.<br />¶ Details on antibiotic prophylaxis for VUR and surgical options are presented in the UpToDate topic on management of VUR. Surgery is considered for persistent grade IV and V VUR that is unlikely to resolve, breakthrough UTI, noncompliance with medical management, new renal scarring, and significant adverse effects of prophylactic antibiotics.<br />Δ Details on the management measures for bladder and bowel dysfunction are presented in the UpToDate topics on bladder dysfunction and chronic functional constipation and fecal incontinence, and follow-up.<br /><FONT class=lozenge>◊</FONT> Follow-up care includes mandatory urine cultures and urinalysis whenever there are urinary symptoms suggestive of UTI or unexplained fever. Monitoring of VUR is done by either contrast voiding cystourethrogram (VCUG) or radionuclide cystogram (RNC) and is typically performed in our practice every 18 to 24 months. DMSA (dimercaptosuccinic acid) renal scan may be obtained (refer to topic&nbsp;on management of VUR for further details).</div><div id=\"graphicVersion\">Graphic 115149 Version 1.0</div></div></div>"},"115150":{"type":"graphic_algorithm","displayName":"Emergency vascular access for newborns (<10 days of age)","title":"Emergency vascular access during resuscitation of newborns (<10 days of age)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Emergency vascular access during resuscitation of newborns (&lt;10 days of age)</div><div class=\"cntnt\"><img style=\"width:289px; height:377px;\" src=\"images/EM/115150_Vasclracsrscttnnwbrn10d.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For further information on how to perform vascular (venous) access in newborn infants, refer to UpToDate topics on vascular (venous) access for pediatric resuscitation and intraosseous infusion.</div><div class=\"graphic_footnotes\">* If peripheral veins can be reliably seen or palpated, insert two of the largest intravenous (IV) catheters that can be reliably placed (typically, 24 gauge IV in newborns younger than 10 days of age). Potential sites include the upper and lower extremities, the scalp, and the external jugular vein. Refer to UpToDate topics on vascular (venous) access for pediatric resuscitation and other pediatric emergencies.<br />&para; The proximal tibia site is preferred unless otherwise contraindicated (eg, fractured bone or vascular interruption of the extremity).<br />&Delta; For providers experienced with the technique, umbilical vein catheterization may be the preferred initial access.<br /><span class=\"lozenge\">&loz;</span> Typical site is the saphenous vein.</div><div id=\"graphicVersion\">Graphic 115150 Version 2.0</div></div></div>"},"115154":{"type":"graphic_figure","displayName":"Origin and course of the phrenic nerve in the neck","title":"Origin and course of the phrenic nerve in the neck","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Origin and course of the phrenic nerve in the neck</div><div class=\"cntnt\"><img style=\"width:533px; height:385px;\" src=\"images/SURG/115154_Originandcourseofphrenicnerveintheneck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The phrenic nerve arises from the third through fifth cervical roots, traveling along the anterior scalene muscle and passing anterior to&nbsp;the subclavian artery and vein before it enters the mediastinum. </div><div id=\"graphicVersion\">Graphic 115154 Version 1.0</div></div></div>"},"115164":{"type":"graphic_table","displayName":"Gene sequencing thoracic aortic aneurysm","title":"Gene sequencing thoracic aortic aneurysm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gene sequencing thoracic aortic aneurysm</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene</td> </tr> <tr> <td>MFS</td> <td> <ul> <li><em>FBN1</em> </li> </ul> </td> </tr> <tr> <td>LDS</td> <td> <ul> <li><em>TGFBR1</em> &ndash; TGF-beta receptor 1 </li> <li><em>TGFBR2</em> &ndash; TGF-beta receptor 2 </li> <li><em>SMAD3</em> &ndash; SMAD family member 3 </li> <li><em>TGFB2</em> &ndash; TGF-beta 2 ligand </li> <li><em>TGFB3</em> &ndash; TGF-beta 3 ligand </li> </ul> </td> </tr> <tr> <td>vEDS</td> <td> <ul> <li><em>COL3A1</em> &ndash; Type III procollagen </li> </ul> </td> </tr> <tr> <td>FTAAD</td> <td> <ul> <li><em>ACTA2</em> &ndash; Smooth muscle alpha-2-actin </li> <li><em>MYH11</em> &ndash; Smooth muscle myosin heavy chain </li> <li><em>TGFBR2</em> &ndash; TGF-beta receptor 2 </li> <li><em>MYLK</em> &ndash; Myosin light chain kinase </li> <li><em>PRKG1</em> &ndash; Type I cGMP-dependent protein kinase regulating smooth muscle cell relaxation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MFS: Marfan syndrome; LDS: Loeys-Dietz syndrome; vEDS: vascular Ehlers-Danlos syndrome; FTAAD: familial thoracic aortic aneurysm and dissection; cGMP: cyclic guanosine monophosphate.</div><div class=\"graphic_reference\">Adapted from: Goyal A, Keramati AR, Czarny MJ, et al. The genetics of aortopathies in clinical cardiology. Clin Med Insights Cardiol 2017; 11:1.</div><div id=\"graphicVersion\">Graphic 115164 Version 1.0</div></div></div>"},"115176":{"type":"graphic_diagnosticimage","displayName":"Upper extremity deep vein thrombosis in adolescent","title":"Upper extremity deep vein thrombosis in adolescent","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Upper extremity deep vein thrombosis in adolescent</div><div class=\"cntnt\"><img style=\"width:756px; height:452px;\" src=\"images/SURG/115176_UpprextrmtyDVTadlscnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper extremity venogram shows complete occlusion of the right subclavian vein (thick arrow) with some collateral vessel formation (arrow).</div><div class=\"graphic_reference\">From: Chu AS, Harkness J, Witmer CM. Spontaneous subclavian vein thrombosis in a healthy adolescent cheerleader: A case of Paget-Schroetter syndrome. Pediatr Emerg Care 2017; 33:e92. DOI: <A href=\"http://journals.lww.com/pec-online/Abstract/2017/10000/Spontaneous_Subclavian_Vein_Thrombosis_in_a.17.aspx\" target=_blank>10.1097/PEC.0000000000000646</A>. Copyright © 2017 Wolters Kluwer Health. Reproduced with permission. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115176 Version 1.0</div></div></div>"},"115181":{"type":"graphic_picture","displayName":"Inflammation of vulvovaginal candidiasis","title":"Inflammation of vulvovaginal candidiasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammation of vulvovaginal candidiasis</div><div class=\"cntnt\"><img style=\"width:432px; height:315px;\" src=\"images/OBGYN/115181_Inflvulvovaginalcandidias.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thick white discharge, labial erythema, and edema can be present in women with vulvovaginal candidiasis.</div><div class=\"graphic_reference\">From: Williams Gynecology, 3rd ed, Hoffman BL, Schorge JO, Bradshaw KD, et al (Eds), McGraw Hill Education, New York 2016. p.61. Reproduced with permission from Dr. William Griffith.</div><div id=\"graphicVersion\">Graphic 115181 Version 1.0</div></div></div>"},"115184":{"type":"graphic_algorithm","displayName":"ITP algorithm","title":"Our approach to the initial treatment of pediatric patients with newly diagnosed ITP based on severity of bleeding symptoms and other risk factors*","html":"<div class=\"graphic\"><div style=\"width: 1136px\" class=\"figure\"><div class=\"ttl\">Our approach to the initial treatment of pediatric patients with newly diagnosed ITP based on severity of bleeding symptoms and other risk factors*</div><div class=\"cntnt\"><img style=\"width:1116px; height:636px;\" src=\"images/PEDS/115184_ITPalgorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content on ITP in children. Refer to UpToDate topics on the management of ITP in children for additional details of our approach to treatment and the overall efficacy of these treatments.</div><div class=\"graphic_footnotes\">ITP: immune thrombocytopenia; PLT: platelet; IV: intravenous; IVIG: intravenous immune globulin; anti-D: anti-D immune globulin (also known as anti-Rho immune globulin); NSAIDS: nonsteroidal anti-inflammatory drugs; Rh: Rhesus; DAT: direct antiglobulin test.<br />* This algorithm applies to pediatric patients with newly diagnosed ITP (ie, within three months from diagnosis). For details on the management of persistent ITP (ongoing ITP between 3 and 12 months from the initial diagnosis) and chronic ITP (ie, ITP lasting &gt;12 months), refer to separate UpToDate content on these issues.<br />&para; Anti-D may be used instead of or in addition to IVIG in Rh-positive, DAT-negative, non-splenectomized patients. Anti-D should not be given if the patient's DAT status is unknown, which is often the case in emergency situations. If DAT is negative and Rh positive, our practice is to include anti-D as part of combination therapy in patients with life-threatening bleeding. We believe that IV anti-D can be a useful component of therapy, even in splenectomized patients despite its relative lack of efficacy when used as the sole agent in these patients. Other experts may not use anti-D in this setting. In nonemergency situations, anti-D is generally used as an alternative to IVIG rather than an additive therapy.<br />&Delta; Additional interventions that have been used in patients with severe or life-threatening bleeding, but for which evidence is generally lacking, include: recombinant human factor VIIa, vincristine, adjunctive antifibrinolytic agents (eg, epsilon aminocaproic acid or tranexamic acid), and emergency splenectomy. For patients with severe menorrhagia, hormonal therapy may be warranted. In addition, we often administer a high dose of a thrombopoietin receptor agonist (eg, romiplostim) in patients with severe bleeding. This practice is not standardized. PLT transfusions are generally reserved for patients with active life-threatening bleeding. However, PLT transfusions may be necessary for patients with non-life-threatening bleeding who require surgery and for those who do not achieve an adequate response with other treatments (eg, if the response is too slow or if the PLT count does not increase to an acceptable level). Refer to separate UpToDate content on ITP for additional details regarding these therapies.<br /><span class=\"lozenge\">&loz;</span> For severe bleeding that is not life-threatening (gastrointestinal bleeding without hemodynamic instability, pulmonary hemorrhage without cardiopulmonary compromise, severe prolonged epistaxis, muscle or joint hemorrhage), the components of treatment are similar to those used for life-threatening bleeding; however, rather than giving all three agents (IVIG, IV anti-D, and methylprednisolone) for up to four days, a measured approach using only one or two of these agents for fewer days may be sufficient. The choice of agents can be guided by the patient's previous treatment response if such experience exists. The choice and duration of therapy also depends upon the response to treatment.<br />&sect; Target platelet counts for surgeries and invasive procedures are higher than thresholds to prevent spontaneous bleeding and depend on the nature of the procedure. Threshold platelet counts are approximations and have not been substantiated in prospective studies. Refer to UpToDate content on ITP and platelet transfusion therapy for further details.<br />&yen; For children with substantially impaired quality of life due to symptoms (especially fatigue) or anxiety about bleeding risks, pharmacologic therapy may be a reasonable option (after discussing with the patient and/or caregivers and carefully weighing the potential risks and benefits).<br />&Dagger; IVIG and anti-D are our preferred agents for most patients deemed to be at moderate to high risk of bleeding in whom a rapid rise in platelet count is desired. In addition, in our practice, we typically treat these patients concomitantly with a single dose of high-dose methylprednisolone to augment the platelet response and ameliorate the side effects of IVIG and anti-D. This practice is not standardized and other experts do not advocate treating with methylprednisolone. Glucocorticoids alone are a reasonable alternative in this setting; however, glucocorticoids generally have more delayed onset compared with IVIG. Refer to UpToDate content on management of ITP in children for further details.<br />&dagger; Oral glucocorticoids are our preferred agents for most patients with moderate risk of bleeding who do not require a rapid rise in platelet count. IVIG and anti-D are reasonable alternatives. Refer to UpToDate content on management of ITP in children for further details.</div><div id=\"graphicVersion\">Graphic 115184 Version 1.0</div></div></div>"},"115194":{"type":"graphic_figure","displayName":"Spectrum of CSLD in children","title":"Spectrum of chronic endobronchial suppurative disease in children","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Spectrum of chronic endobronchial suppurative disease in children</div><div class=\"cntnt\"><img style=\"width:597px; height:543px;\" src=\"images/PEDS/115194_ExERASpthwygynclgcsrgry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this pathobiologic model, protracted bacterial bronchitis (PBB), chronic suppurative lung disease (CSLD), and radiographic-confirmed bronchiectasis likely represent a spectrum of disease, with similar underlying mechanisms of airway neutrophilia, endobronchial bacterial infection, and impaired mucociliary clearance. If PBB is untreated, it is likely that some (but not all) children will progress to develop CSLD. Some will ultimately develop bronchiectasis, which is initially reversible but may become irreversible. There is some overlap between these entities.</div><div class=\"graphic_reference\">Modified from: Chang AB, Upham JW, Masters IB, et al. Protracted bacterial bronchitis: The last decade and the road ahead. Pediatr Pulmonol 2016; 51:225. <A spellcheck=true href=\"http://onlinelibrary.wiley.com/wol1/doi/10.1002/ppul.23351/abstract\" target=_blank>http://onlinelibrary.wiley.com/wol1/doi/10.1002/ppul.23351/abstract</A>. Copyright © 2016 Wiley Periodicals. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A spellcheck=true href=\"mailto:permissions@wiley.com\">permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A spellcheck=true href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 115194 Version 1.0</div></div></div>"},"115195":{"type":"graphic_algorithm","displayName":"Approach to the evaluation and management of dyspepsia in adults","title":"Approach to the evaluation and management of dyspepsia in adults","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Approach to the evaluation and management of dyspepsia in adults</div><div class=\"cntnt\"><img style=\"width:570px; height:1171px;\" src=\"images/GAST/115195_Aprevlmgmtdyspepsiaadlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\"><em>H. pylori</em>: <em>Helicobacter pylori</em>.<br />* Gastric mucosal biopsies should be obtained at the time of upper gastrointestinal endoscopy to rule out infection with <em>H. pylori</em>.<br />&para; Additional evaluation may be required based on symptoms (eg, abdominal imaging in patients with concurrent jaundice or pain suggestive of a biliary/pancreatic source).<br />&Delta; Refer to UpToDate topic reviews.<br /><span class=\"lozenge\">&loz;</span> Patients with continued symptoms of dyspepsia for three months with symptom onset at least six months before diagnosis and no evidence of structural disease to explain the symptoms should be diagnosed and treated as functional dyspepsia.<br />&sect; Eradication of <em>H. pylori</em> infection can be confirmed with a urea breath test, stool antigen testing, or upper endoscopy-based testing performed 4 weeks after completion of antibiotic therapy. The choice of test depends on the need for an upper endoscopy (eg, follow-up of bleeding peptic ulcer) and local availability. <em>H. pylori</em> serology should not be used to confirm eradication of <em>H. pylori</em>. Refer to UpToDate topic on diagnostic tests for <em>H. pylori</em>.<br />&yen; Allow 8 to 12 weeks before reassessing symptomatic response.<br />&Dagger; For patients with a partial clinical response to a proton pump inhibitor, a tricyclic antidepressant can be initiated as combination therapy with a proton pump inhibitor.</div><div id=\"graphicVersion\">Graphic 115195 Version 1.0</div></div></div>"},"115197":{"type":"graphic_algorithm","displayName":"Management of gastric MZL","title":"Management of gastric marginal zone lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of gastric marginal zone lymphoma</div><div class=\"cntnt\"><img style=\"width:399px; height:795px;\" src=\"images/HEME/115197_ManagementgastricMZL.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MZL: marginal zone lymphoma; CR: complete response; RT: radiation therapy; GI: gastrointestinal.<br />* Localized (stage IE or II) disease includes a single primary lesion or multiple, noncontiguous lesions confined to the GI tract that may have nodal involvement.<br />¶ Tumor biopsy should be tested for <EM>Helicobacter pylori</EM>. If <EM>H. pylori</EM> is negative by histopathology, evaluate with noninvasive testing (stool antigen test or urea breath test).<br />Δ Four weeks after the completion of <EM>H. pylori</EM> eradication therapy, testing should be performed to confirm eradication of infection. Up to 20% of patients will require a second <EM>H. pylori</EM> eradication regimen to fully eliminate the infection. We offer up to three eradication regimens before pursuing alternative therapies.<br /><FONT class=lozenge>◊</FONT> We typically perform endoscopy with biopsies every three months until a histologic complete response (CR) is attained, and then perform endoscopy every six months for at least the first two years and then suggest endoscopy every 18 months and as clinically indicated. Surveillance can stop in asymptomatic patients once two sequential endoscopies show no abnormalities on biopsy. Surveillance endoscopy evaluates for recurrence and for gastric adenocarcinoma; surveillance is especially important for those with persistent chronic gastritis that may have components of gastric atrophy or gastric/intestinal metaplasia.<br />§ The systemic therapies used for MZL include single agent rituximab and the combination of rituximab and chemotherapy (eg, bendamustine rituximab). These therapies are not curative, but may control symptoms and prolong survival.</div><div id=\"graphicVersion\">Graphic 115197 Version 1.0</div></div></div>"},"115217":{"type":"graphic_table","displayName":"Adjusted survival by treatment modality and year of ESRD onset","title":"Adjusted survival (%) by treatment modality and incident cohort year (year of ESRD onset)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjusted survival (%) by treatment modality and incident cohort year (year of ESRD onset)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">3 months</td> <td class=\"subtitle1\">12 months</td> <td class=\"subtitle1\">24 months</td> <td class=\"subtitle1\">36 months</td> <td class=\"subtitle1\">60 months</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Hemodialysis</td> </tr> <tr> <td class=\"indent1\">2001</td> <td class=\"centered\">91.0</td> <td class=\"centered\">74.8</td> <td class=\"centered\">61.4</td> <td class=\"centered\">50.8</td> <td class=\"centered\">35.6</td> </tr> <tr> <td class=\"indent1\">2003</td> <td class=\"centered\">91.0</td> <td class=\"centered\">74.8</td> <td class=\"centered\">61.8</td> <td class=\"centered\">51.4</td> <td class=\"centered\">36.5</td> </tr> <tr> <td class=\"indent1\">2005</td> <td class=\"centered\">91.2</td> <td class=\"centered\">75.4</td> <td class=\"centered\">62.7</td> <td class=\"centered\">52.9</td> <td class=\"centered\">38.5</td> </tr> <tr> <td class=\"indent1\">2007</td> <td class=\"centered\">91.5</td> <td class=\"centered\">76.3</td> <td class=\"centered\">64.1</td> <td class=\"centered\">54.6</td> <td class=\"centered\">39.9</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2009</td> <td class=\"centered\">91.7</td> <td class=\"centered\">77.4</td> <td class=\"centered\">65.6</td> <td class=\"centered\">56.1</td> <td class=\"centered\">41.5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Peritoneal dialysis</td> </tr> <tr> <td class=\"indent1\">2001</td> <td class=\"centered\">95.5</td> <td class=\"centered\">82.1</td> <td class=\"centered\">67.3</td> <td class=\"centered\">55.4</td> <td class=\"centered\">39.4</td> </tr> <tr> <td class=\"indent1\">2003</td> <td class=\"centered\">96.3</td> <td class=\"centered\">83.9</td> <td class=\"centered\">69.0</td> <td class=\"centered\">57.7</td> <td class=\"centered\">42.9</td> </tr> <tr> <td class=\"indent1\">2005</td> <td class=\"centered\">96.4</td> <td class=\"centered\">85.6</td> <td class=\"centered\">72.3</td> <td class=\"centered\">61.6</td> <td class=\"centered\">45.7</td> </tr> <tr> <td class=\"indent1\">2007</td> <td class=\"centered\">96.9</td> <td class=\"centered\">87.5</td> <td class=\"centered\">74.8</td> <td class=\"centered\">64.6</td> <td class=\"centered\">49.0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2009</td> <td class=\"centered\">97.3</td> <td class=\"centered\">87.8</td> <td class=\"centered\">76.5</td> <td class=\"centered\">66.5</td> <td class=\"centered\">51.4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Deceased-donor transplant</td> </tr> <tr> <td class=\"indent1\">2001</td> <td class=\"centered\">94.9</td> <td class=\"centered\">89.4</td> <td class=\"centered\">83.2</td> <td class=\"centered\">77.8</td> <td class=\"centered\">66.1</td> </tr> <tr> <td class=\"indent1\">2003</td> <td class=\"centered\">95.7</td> <td class=\"centered\">90.0</td> <td class=\"centered\">84.6</td> <td class=\"centered\">79.5</td> <td class=\"centered\">69.2</td> </tr> <tr> <td class=\"indent1\">2005</td> <td class=\"centered\">95.6</td> <td class=\"centered\">89.9</td> <td class=\"centered\">85.1</td> <td class=\"centered\">80.5</td> <td class=\"centered\">71.3</td> </tr> <tr> <td class=\"indent1\">2007</td> <td class=\"centered\">96.7</td> <td class=\"centered\">92.3</td> <td class=\"centered\">88.1</td> <td class=\"centered\">83.7</td> <td class=\"centered\">73.3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">2009</td> <td class=\"centered\">96.8</td> <td class=\"centered\">92.3</td> <td class=\"centered\">88.5</td> <td class=\"centered\">84.3</td> <td class=\"centered\">75.7</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Living-donor transplant</td> </tr> <tr> <td class=\"indent1\">2001</td> <td class=\"centered\">97.3</td> <td class=\"centered\">93.6</td> <td class=\"centered\">89.6</td> <td class=\"centered\">85.5</td> <td class=\"centered\">76.0</td> </tr> <tr> <td class=\"indent1\">2003</td> <td class=\"centered\">98.1</td> <td class=\"centered\">95.6</td> <td class=\"centered\">91.9</td> <td class=\"centered\">87.8</td> <td class=\"centered\">79.3</td> </tr> <tr> <td class=\"indent1\">2005</td> <td class=\"centered\">98.2</td> <td class=\"centered\">95.3</td> <td class=\"centered\">92.0</td> <td class=\"centered\">88.7</td> <td class=\"centered\">81.0</td> </tr> <tr> <td class=\"indent1\">2007</td> <td class=\"centered\">99.1</td> <td class=\"centered\">97.2</td> <td class=\"centered\">94.8</td> <td class=\"centered\">91.9</td> <td class=\"centered\">85.1</td> </tr> <tr> <td class=\"indent1\">2009</td> <td class=\"centered\">98.9</td> <td class=\"centered\">97.1</td> <td class=\"centered\">94.5</td> <td class=\"centered\">91.4</td> <td class=\"centered\">84.6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Adjusted survival probabilities, from day 1, in the ESRD population. Reference population: incident ESRD patients, 2011. Adjusted for age, sex, race, Hispanic ethnicity, and primary diagnosis.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reproduced from: United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016. The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.</div><div id=\"graphicVersion\">Graphic 115217 Version 1.0</div></div></div>"},"115221":{"type":"graphic_table","displayName":"Diet and fluid recommendations in SBS","title":"Diet and fluid recommendations in short bowel syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diet and fluid recommendations in short bowel syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Colon present</td> <td class=\"subtitle1\">Colon absent</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Carbohydrate</strong></td> <td>50 to 60% of caloric intake</td> <td>40 to 50% of caloric intake</td> </tr> <tr class=\"divider_bottom\"> <td>Complex carbohydrates</td> <td>Complex carbohydrates</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Fat</strong></td> <td>20 to 30% of caloric intake</td> <td>30 to 40% of caloric intake</td> </tr> <tr> <td>Ensure adequate essential fats</td> <td>Ensure adequate essential fats</td> </tr> <tr class=\"divider_bottom\"> <td>MCT/LCT</td> <td>LCT</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Protein</strong></td> <td>20 to 30% of caloric intake</td> <td>20 to 30% of caloric intake</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Fiber</strong></td> <td>Net secretors</td> <td>Net secretors</td> </tr> <tr class=\"divider_bottom\"> <td>Soluble</td> <td>Soluble</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Oxalate</strong></td> <td>Restrict</td> <td>No restriction needed</td> </tr> <tr> <td rowspan=\"2\"><strong>Fluids</strong></td> <td>ORS and/or hypotonic</td> <td>ORS</td> </tr> <tr> <td>Avoid hyperosmolar</td> <td>Avoid hyperosmolar</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCT: medium-chain triglycerides; LCT: long-chain triglycerides; ORS: oral rehydration solution.</div><div id=\"graphicVersion\">Graphic 115221 Version 1.0</div></div></div>"},"115224":{"type":"graphic_figure","displayName":"Chronic dialysis risk associated with AKI and dialysis","title":"Risk of chronic dialysis in association with acute kidney injury and dialysis during index hospitalization","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Risk of chronic dialysis in association with acute kidney injury and dialysis during index hospitalization</div><div class=\"cntnt\"><img style=\"width:797px; height:669px;\" src=\"images/NEPH/115224_ChrondialysrskAKIdialys.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier curves showing cumulative risk of (A) chronic dialysis and (B) all-cause mortality among patients with dialysis-requiring AKI (thin line) and patients without AKI (thick line).</div><div class=\"graphic_footnotes\">AKI: acute kidney injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Wald R, Quinn RR, Luo J, et al. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 2009; 302:1179. Copyright &copy; 2009 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115224 Version 1.0</div></div></div>"},"115225":{"type":"graphic_table","displayName":"Complications of acute bacterial rhinosinusitis","title":"Complications of acute bacterial rhinosinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of acute bacterial rhinosinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Complication</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Imaging evaluation*</td> </tr> <tr class=\"divider_bottom\"> <td>Preseptal cellulitis</td> <td>Ocular pain, eyelid swelling, and erythema</td> <td>Clinical diagnosis (imaging usually not needed unless there is concern for orbital cellulitis)</td> </tr> <tr class=\"divider_bottom\"> <td>Orbital cellulitis</td> <td>Ocular pain, eyelid swelling, and erythema plus pain with eye movements, proptosis, or visual changes suggesting involvement of the orbital tissue</td> <td>CT with contrast or MRI without and with contrast of the head, including the orbit and paranasal sinuses</td> </tr> <tr class=\"divider_bottom\"> <td>Subperiosteal abscess</td> <td>Displacement of the globe, in addition to symptoms of orbital cellulitis</td> <td>MRI without and with contrast of the head, orbit, and paranasal sinuses</td> </tr> <tr class=\"divider_bottom\"> <td>Intracranial abscess</td> <td>Headache with or without altered mental status, fever, or nausea/vomiting</td> <td>CT with contrast or MRI without and with contrast of the head and paranasal sinuses</td> </tr> <tr class=\"divider_bottom\"> <td>Meningitis</td> <td>Fever, neck stiffness, and/or altered mental status</td> <td>CT of the head without contrast may be indicated prior to lumbar puncture<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Septic cavernous sinus thrombosis</td> <td>Cranial nerve palsies (CN III, IV, VI) with or without headache and fever</td> <td>MRI without and with contrast of the head and paranasal sinuses. MR venography either without or with contrast.</td> </tr> <tr> <td>Osteomyelitis</td> <td>Dull pain at involved site often with overlying tenderness, erythema, or swelling</td> <td>CT with contrast or MRI without and with contrast of the head and paranasal sinuses</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging.<br />* Patient contraindications, severity of illness, available imaging modalities, and local expertise should also be taken into account when selecting an imaging approach.<br />&para; Refer to UpToDate content on clinical features and diagnosis of acute bacterial meningitis.</div><div id=\"graphicVersion\">Graphic 115225 Version 2.0</div></div></div>"},"115226":{"type":"graphic_table","displayName":"Tachycardia detection evidence","title":"Tachycardia detection evidence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tachycardia detection evidence</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Participants (n)</td> <td class=\"subtitle1\">Short detection controls</td> <td class=\"subtitle1\">Prolonged detection intervention</td> <td class=\"subtitle1\">Findings</td> </tr> <tr> <td>PREPARE</td> <td> <p>1391 Nonrandomized</p> Primary prevention</td> <td> <p>12 of 16 (58%) beats</p> 18 of 24 (42%)&nbsp; beats</td> <td>30 of 40 beats</td> <td>Reduction in inappropriate shocks (SVT), avoidable shocks (VT), and \"morbidity index\"</td> </tr> <tr> <td>RELEVANT</td> <td> <p>324 Nonrandomized</p> Primary prevention</td> <td>12 of 16 beats</td> <td>30 of 40 beats</td> <td>Reduction in inappropriate shocks (SVT), avoidable shocks (VT), and HF hospitalizations</td> </tr> <tr> <td>MADIT-RIT</td> <td> <p>1500 Randomized</p> Primary prevention</td> <td> <p>2.5 seconds (170 to 199 bpm)</p> 1 second (&#8805;200 bpm)</td> <td> <p>60 seconds (170 to 199 bpm)</p> <p>12 seconds (200 to 249 bpm)</p> 2.5 seconds (&#8805;250 bpm)</td> <td>Reduction in first inappropriate therapy, first appropriate therapy, appropriate ATP, and inappropriate ATP; improved survival</td> </tr> <tr> <td>ADVANCE-III</td> <td> <p>1902 Randomized</p> Primary and secondary prevention</td> <td>18 of 24 beats</td> <td>30 of 40 beats</td> <td>Reduction in overall therapies, inappropriate shocks, and all-cause hospitalizations</td> </tr> <tr> <td>PROVIDE</td> <td> <p>1670 Randomized</p> Primary prevention</td> <td>12 beats</td> <td> <p>25 beats (180 to 214 bpm)</p> <p>18 beats (214 to 250 bpm)</p> 12 beats (&#62;250 bpm)</td> <td>Reduction in all-cause shock rate; improved survival</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVT: supraventricular tachycardia; VT: ventricular tachycardia; HF: heart failure; bpm: beats per minute; ATP: antitachycardia pacing.</div><div class=\"graphic_reference\">Reproduced from: Wilkoff BL, Fauchier L, Stiles MK, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. Heart Rhythm 2016; 13:e50. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115226 Version 1.0</div></div></div>"},"115227":{"type":"graphic_diagnosticimage","displayName":"Ovarian vein thrombophlebitis","title":"Ovarian vein thrombophlebitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ovarian vein thrombophlebitis</div><div class=\"cntnt\"><img style=\"width:428px; height:352px;\" src=\"images/ID/115227_Ovarianvnthrombophlebitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial contrast-enhanced computed tomography (CT) image of the abdomen in a 22-year-old woman who presented with postpartum fever shows an expansile thrombus in the right ovarian vein (arrow), with thickening and enhancement of the venous wall and perivenous inflammation.</div><div class=\"graphic_reference\">Reproduced with permission from: Plowman RS, Javidan-Nejad C, Raptis CA, et al. Imaging of Pregnancy-related Vascular Complications. <em>RadioGraphics</em> 2017; 37:1270-1289.</div><div id=\"graphicVersion\">Graphic 115227 Version 1.0</div></div></div>"},"115232":{"type":"graphic_picture","displayName":"Noncaseating granulomas in sarcoidosis","title":"Noncaseating granulomas in pulmonary sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Noncaseating granulomas in pulmonary sarcoidosis</div><div class=\"cntnt\"><img style=\"width:557px; height:763px;\" src=\"images/PULM/115232_Noncaseatggrnlmssarcoidss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low-power view shows extensive infiltration by noncaseating granulomas distributed along the pleura, interlobular septa, and bronchovascular bundles.<br />(B) Accumulation of T-lymphocytes, macrophages, epithelioid cells, and multinucleated giant cells organized into discrete structures (granulomas).</div><div id=\"graphicVersion\">Graphic 115232 Version 1.0</div></div></div>"},"115237":{"type":"graphic_table","displayName":"Variables and cut-off values used for risk stratification","title":"Variables and cut-off values used for risk stratification","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Variables and cut-off values used for risk stratification</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Low risk</td> <td class=\"subtitle1\">Intermediate risk</td> <td class=\"subtitle1\">High risk</td> </tr> <tr> <td><strong>WHO FC</strong></td> <td class=\"centered\">I/II</td> <td class=\"centered\">III</td> <td class=\"centered\">IV</td> </tr> <tr> <td><strong>Six-minute walking distance</strong> (m)</td> <td class=\"centered\">&#62;440</td> <td class=\"centered\">165 to 440</td> <td class=\"centered\">&#60;165</td> </tr> <tr> <td><strong>BNP</strong> (ng<span class=\"small\">&#8226;</span>L<sup>-1</sup>)</td> <td class=\"centered\">&#60;50</td> <td class=\"centered\">50 to 300</td> <td class=\"centered\">&#62;300</td> </tr> <tr> <td><strong>NT-proBNP</strong> (ng<span class=\"small\">&#8226;</span>L<sup>-1</sup>)</td> <td class=\"centered\">&#60;300</td> <td class=\"centered\">300 to 1400</td> <td class=\"centered\">&#62;1400</td> </tr> <tr> <td><strong>Right atrial pressure</strong> (mmHg)</td> <td class=\"centered\">&#60;8</td> <td class=\"centered\">8 to 14</td> <td class=\"centered\">&#62;14</td> </tr> <tr> <td><strong>Cardiac index</strong> (L<span class=\"small\">&#8226;</span>minute<sup>&ndash;1</sup><span class=\"small\">&#8226;</span>m<sup>&ndash;2</sup>)</td> <td class=\"centered\">&#8805;2.5</td> <td class=\"centered\">2.0 to 2.4</td> <td class=\"centered\">&#60;2.0</td> </tr> <tr> <td><strong>SvO<sub>2</sub></strong> (%)</td> <td class=\"centered\">&#62;65</td> <td class=\"centered\">60 to 65</td> <td class=\"centered\">&#60;60</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO FC: World Health Organization functional class; BNP: brain natriuretic peptide; NT-proBNP: N-terminal fragment of pro-brain natriuretic peptide; SvO<SUB>2</SUB>: mixed venous oxygen saturation.</div><div class=\"graphic_reference\">Reproduced with permission from the &copy;ERS 2017. European Respiratory Journal Aug 2017, 50 (2) 1700740; DOI: 10.1183/13993003.00740-2017.</div><div id=\"graphicVersion\">Graphic 115237 Version 1.0</div></div></div>"},"115264":{"type":"graphic_diagnosticimage","displayName":"Grade I renal contusion","title":"Grade I renal contusion","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">Grade I renal contusion</div><div class=\"cntnt\"><img style=\"width:752px; height:554px;\" src=\"images/SURG/115264_GradeIrenalcontusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcapsular hematoma (grade I) in a 40-year-old man who had sustained blunt abdominal trauma. Contrast-enhanced helical CT scan demonstrates a subcapsular fluid collection (dashed arrows) flattening the posterolateral contour of the left kidney. There is minimal cortical laceration (arrowhead). Note also the subcutaneous emphysema in the left side of the back (arrow). A chest tube had been inserted for a left pneumothorax (not shown).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Kawashima A, Sandler CM, Corl FM, et al. Imaging of renal trauma: A comprehensive review. Radiographics 2001; 21:557-574. Copyright &copy; 2001 The Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 115264 Version 1.0</div></div></div>"},"115265":{"type":"graphic_diagnosticimage","displayName":"Grade II renal laceration","title":"Grade II renal laceration","html":"<div class=\"graphic\"><div style=\"width: 773px\" class=\"figure\"><div class=\"ttl\">Grade II renal laceration</div><div class=\"cntnt\"><img style=\"width:753px; height:471px;\" src=\"images/SURG/115265_GradeIIrenallaceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simple renal laceration (grade II) in a 30-year-old woman who had sustained blunt abdominal trauma. Contrast-enhanced multidetector helical CT scan reveals a small, hypoattenuating laceration crossing the interpolar region of the left kidney (arrow) associated with a limited perinephric hematoma. A hepatic laceration (dashed arrow) and hemoperitoneum in the Morrison pouch (arrowheads) are also seen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Kawashima A, Sandler CM, Corl FM, et al. Imaging of renal trauma: A comprehensive review. Radiographics 2001; 21:557-574. Copyright &copy; 2001 The Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 115265 Version 1.0</div></div></div>"},"115267":{"type":"graphic_table","displayName":"Necrotizing fasciitis versus pyoderma gangrenosum","title":"Clinical features of necrotizing fasciitis and pyoderma gangrenosum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of necrotizing fasciitis and pyoderma gangrenosum</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Necrotizing fasciitis</td> <td class=\"subtitle1\">Pyoderma gangrenosum</td> </tr> <tr> <td>No association with inflammatory bowel disease</td> <td>Strong link with inflammatory bowel disease</td> </tr> <tr> <td>Rapid progression</td> <td>Slower progression within days</td> </tr> <tr> <td>Can resemble cellulitis in early stage</td> <td>Does not resemble cellulitis</td> </tr> <tr> <td>Violaceous ulcer edge not a typical feature</td> <td>Violaceous ulcer edge is typical</td> </tr> <tr> <td>Septic picture can develop</td> <td>Unlikely to develop sepsis</td> </tr> <tr> <td>Likely to require intensive care</td> <td>Unlikely to require intensive care</td> </tr> <tr> <td>Responds to surgery</td> <td>Worsens with surgery</td> </tr> <tr> <td>Lack of resistance to blunt dissection of fascial planes</td> <td>Fascial planes have normal resistance to dissection</td> </tr> <tr> <td>Worsens with immunosuppressive therapy</td> <td>Responds to immunosuppressive therapy</td> </tr> <tr> <td>Should respond to antibiotics and surgery</td> <td>No response to antibiotics and worsens with surgery</td> </tr> <tr> <td>Usually positive blood and tissue cultures</td> <td>Usually negative blood and tissue cultures</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Bisarya K, Azzopardi S, Lye G, Drew PJ. Necrotizing fasciitis versus pyoderma gangrenosum: Securing the correct diagnosis! A case report and literature review. Eplasty 2011; 11:e24.</div><div id=\"graphicVersion\">Graphic 115267 Version 1.0</div></div></div>"},"115268":{"type":"graphic_figure","displayName":"Classical four stages of ECG evolution in acute pericarditis","title":"Classical four stages of ECG evolution in acute pericarditis","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Classical four stages of ECG evolution in acute pericarditis</div><div class=\"cntnt\"><img style=\"width:766px; height:235px;\" src=\"images/CARD/115268_Cl4sECGevoacuteprcrdts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage I: diffuse ST elevation with PR depression<br />Stage II: normalization of ST and PR segments<br />Stage III: diffuse deep T-wave inversions<br />Stage IV: normalization of the ECG</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">From: Myopericardial Diseases, Diagnosis: History, Physical Examination and ECG, 2016, p. 22, Imazio M, &copy; Springer International Publishing Switzerland 2016. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 115268 Version 1.0</div></div></div>"},"115269":{"type":"graphic_diagnosticimage","displayName":"Pericardial edema and LGE by CMR","title":"Pericardial edema and LGE by CMR","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Pericardial edema and LGE by CMR</div><div class=\"cntnt\"><img style=\"width:757px; height:378px;\" src=\"images/CARD/115269_PericardialedemaLGECMR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pericardial edema.<br />(B) Pericardial LGE.</div><div class=\"graphic_footnotes\">LGE: late gadolinium enhancement; CMR: cardiac magnetic resonance.</div><div class=\"graphic_reference\">From: Myopericardial Diseases, Multimodality Imaging of Pericardial/Myopericardial Diseases, 2016, p. 33, Imazio M, &copy; Springer International Publishing Switzerland 2016. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 115269 Version 1.0</div></div></div>"},"115271":{"type":"graphic_figure","displayName":"Sites for manual aortic compression for control of PPH","title":"Potential sites for manual aortic compression at laparotomy for control of postpartum hemorrhage. ","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Potential&nbsp;sites&nbsp;for manual aortic compression at laparotomy for control of postpartum hemorrhage. </div><div class=\"cntnt\"><img style=\"width:473px; height:548px;\" src=\"images/OBGYN/115271_Postpartumhemorrhagevascularanatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">If there is an imminent threat of exsanguination (ie, within a few minutes), the surgeon should compress the aorta against the vertebrae a few centimeters superior to the sacral promontory; the bifurcation into the common iliac arteries is just distal to this point. Alternatively, the aorta can be compressed just below the renal arteries, which will minimize collateral flow to the uterus from the ovarian and inferior mesenteric arteries. Compression at either site will slow the volume of bleeding and will afford a better opportunity for finding and controlling the source of hemorrhage.&nbsp;Compression just above the bifurcation&nbsp;may be&nbsp;easier to accomplish, but is less effective than below the renal arteries&nbsp;because of the extensive collateral blood supply to the uterus. <br /><br />​An intraaortic balloon catheter&nbsp;is another option.&nbsp;The balloon is positioned below the renal arteries and above the ovarian and inferior mesenteric arteries and then inflated,&nbsp;which should lead to a substantial reduction in uterine blood flow. The balloon must be deflated intermittently to prevent ischemic limb and colon complications.</div><div id=\"graphicVersion\">Graphic 115271 Version 1.0</div></div></div>"},"115272":{"type":"graphic_picture","displayName":"Fumarate hydratase-deficient uterine leiomyoma","title":"Uterine leiomyoma variants: Fumarate hydratase-deficient smooth muscle neoplasm is HLRCC (Reed syndrome)","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Uterine leiomyoma variants: Fumarate hydratase-deficient smooth muscle neoplasm is HLRCC (Reed syndrome)</div><div class=\"cntnt\"><img style=\"width:763px; height:573px;\" src=\"images/OBGYN/115272_Fmrthydrtsdfctutrnlmyma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Uterine smooth muscle neoplasms in women with HLRCC, also referred to as Reed syndrome, are fumarate hydratase-deficient.<br />(A) Intermediate magnification reveals uniformly atypical nuclei of moderately increased size, decreased elongation, and increased hyperchromasia.<br />(B) Prominent red or orange nucleoli with distinct perinucleolar chromatin clearing in scattered nuclei (arrow) is evident at higher magnification.<br />(C) Careful inspection also reveals glassy eosinophilic inclusions (dashed arrow) within the cytoplasm of neoplastic smooth muscle cells throughout the tumor.<br />(D) The normal immunohistochemical staining pattern for fumarate hydratase expressed in smooth muscle cells consists of multiple granules within the cytoplasm, reflecting mitochondrial subcellular localization. In HLRCC, the staining pattern is lost, unmasking the counterstain. Normal endothelial (shown) and vascular smooth muscle cells (not shown), however, retained their cytoplasmic fumarate hydratase staining, which serves as an internal control.</div><div class=\"graphic_footnotes\">HLRCC: hereditary leiomyomatosis and renal cell carcinoma syndrome.</div><div id=\"graphicVersion\">Graphic 115272 Version 1.0</div></div></div>"},"115273":{"type":"graphic_figure","displayName":"Markers of risk for one-year post-transplant mortality","title":"Independent categorical markers of decreased or increased risk for one-year post-transplant mortality","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Independent categorical markers of decreased or increased risk for one-year post-transplant mortality</div><div class=\"cntnt\"><img style=\"width:762px; height:688px;\" src=\"images/CARD/115273_Mrkrsk1yrpsttrnpltmrt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multivariate analysis of data from the Registry of the International Society for Heart and Lung Transplantation identified several categorical risk factors for one-year post-transplant mortality among over 10,000 adult heart transplant recipients between 2010 and June 2015.</div><div class=\"graphic_footnotes\">LCL: lower confidence limit; UCL: upper confidence limit; HLA: human leukocyte antigen; MCS: mechanical circulatory support; VAD: ventricular assist device; IV: intravenous; CABG: coronary artery bypass graft; RCM: restrictive cardiomyopathy; NICM: nonischemic cardiomyopathy; TAH: total artificial heart; RETX: Retransplant; CHD: congenital heart disease; CI: confidence interval.</div><div class=\"graphic_reference\">Reproduced from: Lund LH, Khush KK, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant 2017; 36:1037. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115273 Version 1.0</div></div></div>"},"115276":{"type":"graphic_figure","displayName":"Time to appearance of nivolumab-related adverse events","title":"Time to appearance of nivolumab-related adverse events (AEs)","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Time to appearance of nivolumab-related adverse events (AEs)</div><div class=\"cntnt\"><img style=\"width:579px; height:391px;\" src=\"images/ONC/115276_TmapprncnivolumbrltdAEs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Time to onset and resolution of treatment-related select AEs of any grade, with or without use of immune-modulating agents. Circles represent medians, and bars indicate ranges. The treatment population included those in phase III trials (n = 474). For time to onset, number and percent indicate AE incidence.</div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">From: Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2017; 35:785. Reprinted with permission © 2017 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 115276 Version 1.0</div></div></div>"},"115280":{"type":"graphic_algorithm","displayName":"Algorithm for disposition of adults who present with anorexia","title":"Algorithm for disposition of medically stable adults who initially present with anorexia nervosa*","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">Algorithm for disposition of medically stable adults who initially present with anorexia nervosa*</div><div class=\"cntnt\"><img style=\"width:668px; height:776px;\" src=\"images/PSYCH/115280_Algdsptnadltprsntanrxia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* For a definition of medical stability in anorexia nervosa, refer to UpToDate topic on evaluating patients with anorexia nervosa for medical complications. Patients with a body mass index &lt;15 kg/m<SUP>2</SUP> should generally initiate treatment as an inpatient rather than in partial hospital or outpatient clinic. Treatment may be less effective if higher levels of care are postponed until patients manifest more severe symptoms, and refeeding in these circumstances is associated with greater risks.<br />¶ Symptoms of suicidal ideation and behavior typically supersede symptoms of anorexia nervosa in determining the level of care. Refer to UpToDate topic on suicidal ideation and behavior in adults for assessing suicidality and determining level of care.<br />Δ Refer to UpToDate topic on clinical manifestations, assessment, and diagnosis of anorexia nervosa. As an example, one symptom is restricted energy intake leading to low body weight. Mild to moderate low body weight is a body mass index of 16 to 18.4 kg/m<SUP>2</SUP>. A severely low body weight is a body mass index &lt;16 kg/m<SUP>2</SUP>.<br /><FONT class=“lozenge”>◊</FONT> Refer to UpToDate topic on clinical manifestations, assessment, and diagnosis of anorexia nervosa for common comorbid psychopathology. As an example, severe major depression is characterized by a score on the 9-item Patient Health Questionnaire ≥20. <br />§ Generally inpatient hospitalization is required. However, if both a comprehensive partial hospital program devoted to eating disorders and adequate family resources to provide consistent supervision at other times are both available, partial hospital can be sufficient.<br />\u2028¥ If family and friends provide supervision rather than clinicians, family and friends need to be consistently available.<br />\u2028‡ Generally partial hospital is required. However, if adequate family resources are available to provide consistent supervision, outpatient care can be sufficient.</div><div id=\"graphicVersion\">Graphic 115280 Version 2.0</div></div></div>"},"115284":{"type":"graphic_picture","displayName":"Bronchoscopy in protracted bacterial bronchitis","title":"Bronchoscopy in a child with protracted bacterial bronchitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopy in a child with protracted bacterial bronchitis</div><div class=\"cntnt\"><img style=\"width:351px; height:940px;\" src=\"images/PEDS/115284_BronchoscopyPBB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchoscopy in a child with protracted bacterial bronchitis (PBB) reveals mucopurulent secretions in the bronchi.</div><div class=\"graphic_reference\">Courtesy of Drs. Julie Marchant and Anne Chang.</div><div id=\"graphicVersion\">Graphic 115284 Version 1.0</div></div></div>"},"115285":{"type":"graphic_table","displayName":"ECG features of acute pericarditis versus acute MI","title":"Electrocardiogram features of acute pericarditis versus acute myocardial infarction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electrocardiogram features of acute pericarditis versus acute myocardial infarction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33.33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">ECG features</td> <td class=\"subtitle1\">Findings in acute pericarditis</td> <td class=\"subtitle1\">Findings in acute MI</td> </tr> <tr> <td>ST segment elevation morphology</td> <td> <ul> <li>ST segment elevation begins at J point, rarely exceeds 5 mm, normal concavity</li> </ul> </td> <td> <ul> <li>ST segment elevation begins at J point, often exceeds 5 mm in height, abnormal concavity (convex or \"dome-shaped\")</li> </ul> </td> </tr> <tr> <td>ST segment elevation distribution</td> <td> <ul> <li>Widespread ST segment elevation in most/all leads</li> <li>Typically most prominent in inferolateral leads</li> </ul> </td> <td> <ul> <li>Anatomical groupings of leads show ST segment elevation, which corresponds to vascular territory of infarction</li> </ul> </td> </tr> <tr> <td>Reciprocal ST segment changes</td> <td> <ul> <li>Usually not seen</li> </ul> </td> <td> <ul> <li>ST segment depressions usually seen in reciprocal leads</li> </ul> </td> </tr> <tr> <td>Concurrent ST elevation and T wave inversion</td> <td> <ul> <li>Unusual unless concomitant myocarditis</li> </ul> </td> <td> <ul> <li>Common</li> </ul> </td> </tr> <tr> <td>PR segment changes</td> <td> <ul> <li>PR elevation in aVR and PR depression in most/all other leads</li> </ul> </td> <td> <ul> <li>Rare</li> </ul> </td> </tr> <tr> <td>Other ECG findings <ul class=\"decimal_heading\"> <li>Hyperacute T waves</li> <li>Q waves</li> <li>QT prolongation</li> </ul> </td> <td> <ul> <li>Rare; if seen, due to fusion of elevated ST segment and T wave</li> <li>Not usually new from acute pericarditis</li> <li>Unusual</li> </ul> </td> <td> <ul> <li>Commonly seen at onset of acute infarction/ischemia</li> <li>Seen late in course of MI due to transmural injury</li> <li>Can be seen</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; MI: myocardial infarction.</div><div id=\"graphicVersion\">Graphic 115285 Version 1.0</div></div></div>"},"115288":{"type":"graphic_figure","displayName":"Variations TRAb in Graves' hyperthyroidism","title":"Variations in TSH-receptor antibodies in Graves' hyperthyroidism after radioiodine, surgery, or medical therapy","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Variations in TSH-receptor antibodies in Graves' hyperthyroidism after radioiodine, surgery, or medical therapy</div><div class=\"cntnt\"><img style=\"width:570px; height:443px;\" src=\"images/ENDO/115288_VrtnsTRAbGravshyperthyrd.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Variations in TRAbs in serum after randomly assigning patients with Graves' hyperthyroidism to radioiodine (n = 36; radioiodine was only given to patients ≥35 years of age), surgery (n = 47), or medical therapy (n = 48). In all groups, patients were kept euthyroid by the addition of levothyroxine therapy as appropriate. Medical therapy was given for 18 months. The values for the patients who needed a treatment other than the randomized are omitted beyond the time the change occurred. Values are mean±SEM. The upper normal reference for the TRAb assay was 10%, as indicated by the straight dashed line. Values before therapy were not different between groups. After therapy, all values were significantly higher for the radioiodine group when compared with values for the medical or surgical therapy groups (p&lt;0.01).</div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; TRAb: TSH-receptor antibodies; 125-I: iodine-125; SEM: standard error of mean.</div><div class=\"graphic_reference\">Reproduced with permission from: Laurberg P, Wallin G, Tallstedt L, et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. Eur J Endocrinol 2008; 158:69. Copyright © 2008 BioScientifica Ltd.</div><div id=\"graphicVersion\">Graphic 115288 Version 1.0</div></div></div>"},"115289":{"type":"graphic_diagnosticimage","displayName":"CT scan with contrast in a 14-year-old adolescent with VHL","title":"CT scan with contrast in a 14-year-old adolescent with von Hippel Lindau syndrome","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">CT scan with contrast in a 14-year-old adolescent with von Hippel Lindau syndrome</div><div class=\"cntnt\"><img style=\"width:492px; height:721px;\" src=\"images/PEDS/115289_CTcontrastadolescentVHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan with contrast in a 14-year-old adolescent with von Hippel Lindau syndrome. The axial image (A) and coronal image (B) show large, hyperenhancing rounded masses (thick arrows) arising from both adrenal glands. The largest lesion on the right adrenal gland measured 5.8 cm CC × 3.8 cm TRV × 3.0 cm AP. The less enhancement seen centrally is typical of pheochromocytoma. The multicentric nature of the disease is best seen in the left adrenal gland on the coronal image (thin arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography; CC: craniocaudal; TRV: transverse; AP: anteroposterior.</div><div id=\"graphicVersion\">Graphic 115289 Version 1.0</div></div></div>"},"115294":{"type":"graphic_table","displayName":"Conditions with high ferritin","title":"Conditions associated with increased serum ferritin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with increased serum ferritin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition (examples)</td> <td class=\"subtitle1\">Pattern</td> <td class=\"subtitle1\">Management implications</td> </tr> <tr> <td> <p>Iron overload</p> <ul> <li>Hereditary hemochromatosis </li> <li>Transfusional iron overload </li> <li>Ineffective erythropoiesis (eg, thalassemia) </li> </ul> </td> <td> <p>Progressive/cumulative increase in ferritin over time, eventually causing organ damage if not treated. TSAT will be high (typical value &#62;45%).</p> &nbsp;</td> <td>Close monitoring with iron removal once there is evidence of excess tissue deposition (eg, from MRI) or the ferritin level exceeds a certain threshold (eg, &#62;1000 ng/mL). Phlebotomy is often used in individuals without anemia; iron chelation is used for individuals with anemia.</td> </tr> <tr> <td> <p>Massive cell/tissue death</p> <ul> <li>HLH </li> <li>Cancer </li> <li>Liver failure </li> </ul> </td> <td>Rapid rise in ferritin to very high levels (eg, &#62;3000 ng/mL), usually in the setting of acute illness with immune dysregulation. TSAT will not be increased (typical value &#60;45%).</td> <td>Aggressive therapy for the underlying condition is usually indicated. Ferritin level may be a useful marker of disease activity.</td> </tr> <tr> <td> <p>Inflammatory block</p> <ul> <li>Anemia of chronic inflammation/ACD (eg, diabetes, cancer, chronic infection, autoimmune disorders) </li> <li>Anemia of renal failure </li> <li>Chronic liver disease </li> </ul> </td> <td>Chronic, modest increase in ferritin (approximately two to three times normal). Ferritin is an acute phase reactant. TSAT will not be increased (typical value &#60;45%).</td> <td>May be helpful in distinguishing ACD from iron deficiency, but ferritin by itself is a poor indicator of iron stores in the setting of chronic inflammation. A search for the cause may be indicated if not immediately apparent (eg, infection). Therapy is directed to the underlying condition.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Ferritin is a marker of iron stores, but it may also be elevated as an acute phase reactant or due to massive cell and tissue death, especially in the liver and in the setting of hemophagocytosis. The absolute ferritin level cannot be interpreted in isolation and should not be the sole basis for treatment decisions. The pattern of ferritin increase (progressive, acute/marked increase, or chronic mild elevation) as well as the patient's underlying condition must be incorporated in the evaluation.</div><div class=\"graphic_footnotes\">TSAT: transferrin saturation; MRI: magnetic resonance imaging; HLH: hemophagocytic lymphohistiocytosis; ACD: anemia of chronic disease.</div><div id=\"graphicVersion\">Graphic 115294 Version 1.0</div></div></div>"},"115298":{"type":"graphic_algorithm","displayName":"Estimate of drug dose in CRRT","title":"Adjusting maintenance drug dose for continuous renal replacement therapy*","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">Adjusting maintenance drug dose for continuous renal replacement therapy*</div><div class=\"cntnt\"><img style=\"width:601px; height:662px;\" src=\"images/NEPH/115298_EstimatedrugdoseCRRT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prior to adjusting drug dose, determine its percentage protein binding. These data may be found in many clinical references, including Lexicomp under \"Pharmacodynamics/kinetics.\" If the patient has urine output &gt;20 mL/hour, obtain 24-hour urine creatinine and urea for measurement of residual renal function.</div><div class=\"graphic_footnotes\">CRRT: continuous renal replacement therapy.<br />* This algorithm addresses only the modification of maintenance drug dose with respect to CRRT. Refer to UpToDate topic on drug removal in CRRT for a discussion of determining the optimal loading dose. Patients may require additional dose modifications based on hepatic dysfunction or other comorbidities. This algorithm is only useful for drugs &lt;2000 daltons. It is difficult to predict clearance for drugs between 2000 and 15,000 daltons. However, few drugs fall into this size range; insulin is one such drug at 5805 daltons but is dosed to target effects. There is little if any clearance of drugs &gt;15,000 daltons; most drugs this size are biological agents, such as monoclonal antibodies and soluble receptor antagonists that are dosed to target effects or given as a single dose.<br />&para; Drugs that are primarily cleared by hepatic or gastrointestinal metabolism and do not have significant pharmacologically active metabolites that are excreted by the kidney do not have to be adjusted for reduced renal function or CRRT clearance.<br />&Delta; Refer to UpToDate topic on drug removal in CRRT for the calculation of residual renal function in mL/minute.</div><div id=\"graphicVersion\">Graphic 115298 Version 1.0</div></div></div>"},"115299":{"type":"graphic_picture","displayName":"Cold sore","title":"Cold sores (fever blisters)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cold sores (fever blisters)</div><div class=\"cntnt\"><img style=\"width:396px; height:228px;\" src=\"images/PEDS/115299_Coldsore.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cold sores are caused by reactivation of the herpes simplex virus. They are characterized by a vesicular eruption on the skin adjacent to the lips; the vesicles rupture to form ulcers and crusts that heal without scarring.</div><div class=\"graphic_reference\">Reproduced with permission from: Neville B, et al: Color Atlas of Clinical Oral Pathology. Philadelphia: Lea &amp; Febiger, 1991. Copyright © 1991 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 115299 Version 1.0</div></div></div>"},"115301":{"type":"graphic_algorithm","displayName":"Approach to the diagnosis of membranous nephropathy","title":"Approach to the diagnosis of membranous nephropathy","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of membranous nephropathy</div><div class=\"cntnt\"><img style=\"width:624px; height:1036px;\" src=\"images/NEPH/115301_Aprdxmembranousnephrpthy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MN: membranous nephropathy; ANA: anti-nuclear antibodies; anti-dsDNA: anti-double-stranded DNA; HIV: human immunodeficiency virus; SFLC: serum free light chain; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; ELISA: enzyme-linked immunosorbent assay; PLA2R: phospholipase A2 receptor; Ig: immunoglobulin; THSD7A: thrombospondin type-1 domain-containing 7A.<br />* Membranous nephropathy should be suspected in all adult patients who present with features of the nephrotic syndrome, such as unexplained proteinuria and edema or weight gain.<br />¶ In patients at high risk for lung malignancy (eg, history of smoking or asbestos exposure), computed tomography (CT) of the chest should be performed.<br />Δ Evidence of secondary disease includes the following: positive testing for ANA and anti-dsDNA, hepatitis B or C, or HIV; low serum complement levels; abnormal SFLCs or SPEP; or radiographic findings consistent with sarcoidosis.<br /><FONT class=lozenge>◊</FONT> If a kidney biopsy cannot be performed (due to patient preference, lack of availability, or contraindication to biopsy), serum anti-PLA2R antibody testing can be repeated in three to four months since some patients with an initially negative serum antibody test may have delayed seroconversion. If repeat serum anti-PLA2R testing is negative, a kidney biopsy should be performed, if possible.<br />§ Aggressive screening for cancer consists of more frequent age- and risk-appropriate screening for malignancy for a period of 5 to 10 years after the diagnosis of MN.</div><div id=\"graphicVersion\">Graphic 115301 Version 1.0</div></div></div>"},"115302":{"type":"graphic_table","displayName":"Elements of the health care transition","title":"Six core elements of the health care transition 2.0","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Six core elements of the health care transition 2.0</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Transitioning youth to adult health care providers (pediatric, family medicine, and med-peds providers)</td> <td class=\"subtitle1\">Transitioning to an adult approach to health care without changing providers (family medicine and med-peds providers)</td> <td class=\"subtitle1\">Integrating young adults into adult health care (internal medicine, family medicine, and med-peds providers)</td> </tr> <tr> <td class=\"subtitle2_left\">1. Transition policy</td> <td class=\"subtitle2_left\">1. Transition policy</td> <td class=\"subtitle2_left\">1. Young adult transition and care policy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Develop a transition policy/statement with input from youth and families that describes the practice's approach to transition, including privacy and consent information. </li> <li>Educate all staff about the practice's approach to transition, the policy/statement, the six core elements, and distinct roles of the youth, family, and pediatric and adult health care team in the transition process, taking into account cultural preferences. </li> <li>Post policy and share/discuss with youth and families, beginning at age 12 to 14, and regularly review as part of ongoing care. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Develop a transition policy/statement with input from youth/young adults and families that describes the practice's approach to transitioning to an adult approach to care at 18, including privacy and consent information. </li> <li>Educate all staff about the practice's approach to transition, the policy/statement, the six core elements, and distinct roles of the youth, family, and health care team in the transition process, taking into account cultural preferences. </li> <li>Post policy and share/discuss with youth and families, beginning at age 12 to 14, and regularly review as part of ongoing care. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Develop a transition policy/statement with input from young adults that describes the practice's approach to accepting and partnering with new young adults, including privacy and consent information. </li> <li>Educate all staff about the practice's approach to transition, the policy/statement, the six core elements, and distinct roles of the young adult, family, and pediatric and adult health care team in the transition process, taking into account cultural preferences. </li> <li>Post policy and share/discuss with young adults at first visit and regularly review as part of ongoing care. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">2. Transition tracking and monitoring</td> <td class=\"subtitle2_left\">2. Transition tracking and monitoring</td> <td class=\"subtitle2_left\">2. Young adult tracking and monitoring</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Establish criteria and process for identifying transitioning youth and enter their data into a registry. </li> <li>Utilize individual flow sheet or registry to track youth's transition progress with the six core elements. </li> <li>Incorporate the six core elements into clinical care process, using&nbsp;the electronic health record&nbsp;if possible. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Establish criteria and process for identifying transitioning youth/young adults and enter their data into a registry. </li> <li>Utilize individual flow sheet or registry to track youth/young adults' transition progress with the six core elements. </li> <li>Incorporate the six core elements into clinical care process, using&nbsp;the electronic health record&nbsp;if possible. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Establish criteria and process for identifying transitioning young adults until age 26 and enter their data into a registry. </li> <li>Utilize individual flow sheet or registry to track young adults' completion of the six core elements. </li> <li>Incorporate the six core elements into clinical care process, using&nbsp;the electronic health record&nbsp;if possible. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">3. Transition readiness</td> <td class=\"subtitle2_left\">3. Transition readiness</td> <td class=\"subtitle2_left\">3. Transition readiness/orientation to adult practice</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Conduct regular transition readiness assessments, beginning at age 14, to identify and discuss with youth and parent/caregiver their needs and goals in self-care. </li> <li>Jointly develop goals and prioritized actions with youth and parent/caregiver, and document regularly in a plan of care. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Conduct regular transition readiness assessments, beginning at age 14, to identify and discuss with youth and parent/caregiver their needs and goals in self-care. </li> <li>Jointly develop goals and prioritized actions with youth and parent/caregiver, and document regularly in a plan of care. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Identify and list adult providers within your practice interested in caring for young adults. </li> <li>Establish a process to welcome and orient new young adults into practice, including a description of available services. </li> <li>Provide youth-friendly online or written information about the practice and offer a \"get-acquainted\" appointment, if feasible. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">4. Transition planning</td> <td class=\"subtitle2_left\">4. Transition planning/integration into adult approach to care</td> <td class=\"subtitle2_left\">4. Transition planning/integration into adult practice</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Develop and regularly update the plan of care, including readiness assessment findings, goals and prioritized actions, medical summary and emergency care plan, and, if needed, a condition fact sheet and legal documents. </li> <li>Prepare youth and parent/caregiver for adult approach to care at age 18, including legal changes in decision-making and privacy and consent, self-advocacy, and access to information. </li> <li>Determine level of need for decision-making supports for youth with intellectual challenges and make referrals to legal resources. </li> <li>Plan with youth/parent/caregiver for optimal timing of transfer. If both primary and subspecialty care are involved, discuss optimal timing for each. </li> <li>Obtain consent from youth/guardian for release of medical information. </li> <li>Assist youth in identifying an adult provider and communicate with selected provider about pending transfer of care. </li> <li>Provide linkages to insurance resources, self-care management information, and culturally appropriate community supports. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Develop and regularly update a plan of care, including readiness assessment findings, goals and prioritized actions, medical summary and emergency care plan, and, if needed, legal documents. </li> <li>Prepare youth and parent/caregiver for adult approach to care at age 18, including legal changes in decision-making and privacy and consent, self-advocacy, and access to information. </li> <li>Determine need for decision-making supports for youth with intellectual challenges and make referrals to legal resources. </li> <li>Plan with youth and parent/caregiver for optimal timing of transfer from pediatric to adult specialty care </li> <li>Obtain consent from youth/guardian for release of medical information. </li> <li>Provide linkages to insurance resources, self-care management information, and culturally appropriate community supports. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Communicate with young adult's pediatric provider(s) and arrange for consultation assistance, if needed. </li> <li>Prior to first visit, ensure receipt of transfer package (final transition readiness assessment, plan of care with transition goals and pending actions, medical summary and emergency care plan, and, if needed, legal documents, condition fact sheet, and additional provider records). </li> <li>Make pre-visit appointment reminder call welcoming new young adult and identifying any special needs and preferences. </li> <li>Provide linkages to insurance resources, self-care management information, and culturally appropriate community supports. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">5. Transfer of care</td> <td class=\"subtitle2_left\">5. Transfer to adult approach to care</td> <td class=\"subtitle2_left\">5. Transfer of care/initial visit</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Confirm date of first adult provider appointment. </li> <li>Transfer young adult when his/her condition is stable. </li> <li>Complete transfer package, including final transition readiness assessment, plan of care with transition goals and pending actions, medical summary and emergency care plan, and, if needed, legal documents, condition fact sheet, and additional provider records. </li> <li>Prepare letter with transfer package, send to adult practice, and confirm adult practice's receipt of transfer package. </li> <li>Confirm with adult provider the pediatric provider's responsibility for care until young adult is seen in adult setting. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Address any concerns that young adult has about transferring to adult approach to care. Clarify adult approach to care, including shared decision-making, privacy and consent, access to information, adherence to care, and preferred methods of communication, including attending to health literacy needs. </li> <li>Conduct self-care assessment (transition readiness assessment) if not recently completed and discuss needed self-care skills. </li> <li>Review young adult's health priorities as part of ongoing plan of care. </li> <li>Continue to update and share portable medical summary and emergency care plan. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Prepare for initial visit by reviewing transfer package with appropriate team members. </li> <li>Address any concerns that young adult has about transferring to adult approach to care. Clarify approach to adult care, including shared decision-making, privacy and consent, access to information, adherence to care, and preferred methods of communication, including attending to health literacy needs. </li> <li>Conduct self-care assessment (transition readiness assessment) if not recently completed and discuss the young adult's needs and goals in self-care. </li> <li>Review young adult's health priorities as part of their plan of care. </li> <li>Update and share portable medical summary and emergency care plan. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">6. Transfer completion</td> <td class=\"subtitle2_left\">6. Transfer completion/ongoing care</td> <td class=\"subtitle2_left\">6. Transfer completion/ongoing care</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Contact young adult and parent/caregiver three to six months after last pediatric visit to confirm transfer of responsibilities to adult practice and elicit feedback on experience with transition process. </li> <li>Communicate with adult practice confirming completion of transfer and offer consultation assistance, as needed. </li> <li>Build ongoing and collaborative partnerships with adult primary and specialty care providers. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Assist young adult to connect with adult specialists and other support services, as needed. </li> <li>Continue with ongoing care management tailored to each young adult. </li> <li>Elicit feedback from young adult to assess experience with adult health care. </li> <li>Build ongoing and collaborative partnerships with specialty care providers. </li> </ul> </td> <td class=\"indent1\"> <ul> <li>Communicate with pediatric practice confirming transfer into adult practice and consult with pediatric provider(s), as needed. </li> <li>Assist young adult to connect with adult specialists and other support services, as needed. </li> <li>Continue with ongoing care management tailored to each young adult. </li> <li>Elicit feedback from young adult to assess experience with adult health care. </li> <li>Build ongoing and collaborative partnerships with pediatric primary and specialty care providers. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The six core elements of health care transition 2.0&nbsp;table is&nbsp;intended for use by pediatric, family medicine, med-peds, and internal medicine practices to assist youth and young adults as they transition to adult-centered care. These elements&nbsp;are aligned with the AAP/AAFP/ACP clinical report on transition<SUP>[1]</SUP>. Sample clinical tools and measurement resources are available for quality improvement purposes at <A href=\"http://www.gottransition.org/\" target=_blank>www.GotTransition.org</A>.</div><div class=\"graphic_footnotes\">Med-peds: combined internal medicine and pediatrics practice; AAP: American Academy of Pediatrics; AAFP: American Academy of Family Physicians; ACP: American College of Physicians.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians, et al. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics 2011; 128:182.</LI></OL>Reproduced with permission from: Got Transition/Center for Health Care Transition Improvement. Six Core Elements of Health Care Transition 2.0 (Side-by-Side Version). Available at: <A href=\"http://www.gottransition.org/resourceGet.cfm?id=206\" target=_blank>http://www.gottransition.org/resourceGet.cfm?id=206</A> (Accessed on October 20, 2017). Copyright © 2014 Got Transition.</div><div id=\"graphicVersion\">Graphic 115302 Version 1.0</div></div></div>"},"115303":{"type":"graphic_figure","displayName":"Anatomy of the salivary glands and ducts","title":"Anatomy of the salivary glands and ducts ","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Anatomy of the salivary glands and ducts </div><div class=\"cntnt\"><img style=\"width:538px; height:471px;\" src=\"images/PC/115303_Anatomyofthesalivaryglandsandducts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three major salivary glands are the parotid, submandibular, and sublingual glands. Stensen's duct drains the parotid gland opposite the upper second molar. Wharton's duct drains the submandibular and some of the sublingual glands into the floor of the mouth near the frenulum of the tongue.</div><div id=\"graphicVersion\">Graphic 115303 Version 1.0</div></div></div>"},"115304":{"type":"graphic_figure","displayName":"Salivary gland massage","title":"Salivary gland massage","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Salivary gland massage</div><div class=\"cntnt\"><img style=\"width:452px; height:645px;\" src=\"images/PC/115304_Salivaryglandmassage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To perform salivary gland massage, place two fingers over the gland and sweep&nbsp;them along the course&nbsp;of the salivary gland duct, applying gentle pressure.&nbsp;In the case of the parotid gland (A), start at the angle of the jaw and move forward, toward the mouth at the level of the upper jaw.&nbsp;In the case of the submandibular gland (B), start under the jaw and move forward, toward the front of the jaw.</div><div class=\"graphic_reference\">Modified from: Sjögren's Syndrome Foundation. Patient education sheet: How to massage salivary glands. Available at <A spellcheck=true href=\"https://www.sjogrens.org/files/brochures/Salivary_Glands_Massage.pdf\" target=_blank>https://www.sjogrens.org/files/brochures/Salivary_Glands_Massage.pdf</A> (Accessed on November 17, 2017).</div><div id=\"graphicVersion\">Graphic 115304 Version 3.0</div></div></div>"},"115305":{"type":"graphic_table","displayName":"Diagnostic testing diaphragm paralysis","title":"Diagnostic testing diaphragm paralysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic testing diaphragm paralysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Sniff test</td> </tr> <tr> <td class=\"indent1\">Required to confirm paralysis*</td> </tr> <tr> <td class=\"indent1\">May be difficult to diagnose bilateral paralysis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Can demonstrate paresis, paralysis, or paradoxical movement</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary spirometry</td> </tr> <tr> <td class=\"indent1\">Unilateral: Mild-to-moderate restrictive deficit, or sometimes normal in spite of symptoms</td> </tr> <tr> <td class=\"indent1\">Bilateral: Moderate-to-severe restrictive deficit</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mixed deficit if comorbid conditions are present</td> </tr> <tr> <td class=\"subtitle1_single\">Electrodiagnostics</td> </tr> <tr> <td class=\"indent1\">Phrenic nerve conduction studies quantitate the neural and motor deficits and compare value obtained (right and left) to standard values</td> </tr> <tr> <td class=\"indent1\">Diaphragm electromyography to assess whether there is preservation of VMUs to determine feasibility of reinnervation</td> </tr> <tr> <td class=\"indent1\">Most important for surgical decision making</td> </tr> <tr> <td class=\"indent1\">Used to rule out polyneuropathy and systemic neurodegenerative conditions<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Technically demanding; availability limited due to lack of skilled technicians with significant experience in phrenic nerve and diaphragm testing</td> </tr> <tr> <td class=\"subtitle1_single\">MR imaging cervical spine</td> </tr> <tr> <td class=\"indent1\">Obtain when there is suspected or known history of cervical spine disease<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Findings useful to determine need for referral to spine surgeon</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Does not show peripheral cervical root or phrenic nerve compression</td> </tr> <tr> <td class=\"subtitle1_single\">CT neck and chest</td> </tr> <tr> <td class=\"indent1\">Obtain when there is suspected or known history of organic pathology in neck or chest, or prior surgical intervention</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Not necessary to confirm paralysis</td> </tr> <tr> <td class=\"subtitle1_single\">Polysomnography</td> </tr> <tr> <td class=\"indent1\">Used to confirm if there is sleep-disordered breathing<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Assists in determining utility of BiPAP or CPAP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VMUs: voluntary motor units; MR: magnetic resonance; CT: computed tomography; BiPAP: bilevel positive airway pressure; CPAP: continuous positive airway pressure.<br />* A static chest radiograph showing diaphragm elevation is suspicious but not confirmatory for making the diagnosis.<br />¶ Eg, amyotrophic lateral sclerosis, multiple sclerosis, spinal muscular atrophy.<br />Δ Cervical spondylosis, herniated disc, degenerative spine disease, and/or radiculopathy.<br /><FONT class=lozenge>◊</FONT> Frequently associated with diaphragm paralysis.</div><div id=\"graphicVersion\">Graphic 115305 Version 1.0</div></div></div>"},"115308":{"type":"graphic_table","displayName":"CVD risk scores","title":"Cardiovascular disease risk scores","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular disease risk scores</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk score (year)</td> <td class=\"subtitle1\">Variables included</td> <td class=\"subtitle1\">Key variables excluded</td> <td class=\"subtitle1\">Endpoint assessed</td> </tr> <tr class=\"divider_bottom\"> <td>Framingham risk score (1998)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Total or LDL cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Diabetes mellitus (yes or no) </li> <li>Current smoking (yes or no) </li> </ul> </td> <td> <ul> <li>Blood pressure treatment (yes or no) </li> <li>Family history of CVD (yes or no) </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Unstable angina </li> <li>Stable angina </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Adult Treatment Panel (ATP III) hard CHD risk score (2002)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Current smoking (yes or no) </li> </ul> </td> <td> <ul> <li>Diabetes mellitus (yes or no) </li> <li>Family history of CVD (yes or no) </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>SCORE CVD death risk score (2003)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Current smoking (yes or no) </li> <li>Region of Europe (high risk or low risk region) </li> </ul> </td> <td> <ul> <li>Blood pressure treatment (yes or no) </li> <li>Diabetes mellitus (yes or no) </li> <li>Family history of CVD (yes or no) </li> </ul> </td> <td> <ul> <li>CVD death (including CHD, arrhythmia, heart failure, stroke, aortic aneurysm, and peripheral vascular disease) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>QRISK and QRISK2 risk calculators (2007)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Current smoking (yes or no) </li> <li>Family history of CVD in first degree relative aged &#60;60 years (yes or no) </li> <li>Region of United Kingdom (score based on levels of unemployment, overcrowding, car ownership, home ownership) </li> <li>Body mass index (kg/m<sup>2</sup>) </li> </ul> </td> <td> <ul> <li>Diabetes mellitus (yes or no) </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Coronary insufficiency or angina </li> <li>Coronary revascularization </li> <li>Fatal or nonfatal stroke </li> <li>Transient ischemic attack </li> <li>Intermittent claudication </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Reynolds CVD risk score (2007/2008)</td> <td> <ul> <li>Age </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Diabetes mellitus assessed by hemoglobin A1c (percent)* </li> <li>Current smoking (yes or no) </li> <li>Parental history of MI before age 60 years (yes or no) </li> <li>Serum hs-CRP (mg/L) </li> </ul> </td> <td> <ul> <li>Diabetes mellitus (yes or no)* </li> <li>Blood pressure treatment (yes or no) </li> </ul> </td> <td> <ul> <li>Cardiovascular death </li> <li>Nonfatal MI </li> <li>Nonfatal stroke </li> <li>Coronary revascularization </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Framingham general CVD risk score (2008)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Diabetes mellitus (yes or no) </li> <li>Current smoking (yes or no) </li> </ul> </td> <td> <ul> <li>Family history of CVD (yes or no) </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Coronary insufficiency or angina </li> <li>Fatal or nonfatal ischemic or hemorrhagic stroke </li> <li>Transient ischemic attack </li> <li>Intermittent claudication </li> <li>Heart failure</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>ACC/AHA pooled cohort hard CVD risk calculator (2013)</td> <td> <ul> <li>Age (validated only in patients 40 to 79 years of age) </li> <li>Gender </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Diabetes mellitus (yes or no) </li> <li>Current smoking (yes or no) </li> </ul> </td> <td> <ul> <li>Family history of CVD (yes or no) </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Fatal stroke </li> <li>Nonfatal stroke </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>JBS3 risk score (2014)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Ethnicity </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Diabetes mellitus (yes or no) </li> <li>Current smoking (yes or no) </li> <li>Family history of CVD in first degree relative aged &#60;60 years (yes or no) </li> <li>Chronic kidney disease </li> <li>Atrial fibrillation </li> <li>Rheumatoid arthritis </li> <li>Region of United Kingdom (score based on levels of unemployment, overcrowding, car ownership, home ownership) </li> <li>Body mass index (kg/m<sup>2</sup>) </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Coronary insufficiency or angina </li> <li>Coronary revascularization </li> <li>Fatal or nonfatal stroke </li> <li>Transient ischemic attack </li> <li>Intermittent claudication </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>MESA risk score (2015)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Ethnicity (non-Hispanic white, Chinese American, African American, Hispanic) </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Lipid lowering treatment (yes or no) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Diabetes mellitus (yes or no) </li> <li>Current smoking (yes or no) </li> <li>Family history of MI at any age (yes or no) </li> <li>Coronary artery calcium score </li> </ul> </td> <td> <ul> <li>Family history of CVD other than MI </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Resuscitated cardiac arrest </li> <li>Coronary revascularization in patient with angina </li> </ul> </td> </tr> <tr> <td>China-PAR risk predictor (2016)</td> <td> <ul> <li>Age </li> <li>Gender </li> <li>Total cholesterol (mg/dL) </li> <li>HDL cholesterol (mg/dL) </li> <li>Lipid lowering treatment (yes or no) </li> <li>Systolic blood pressure (mmHg) </li> <li>Blood pressure treatment (yes or no) </li> <li>Diabetes mellitus (yes or no) </li> <li>Current smoking (yes or no) </li> <li>Waist circumference (cm) </li> <li>Geographic region (northern or southern China) </li> <li>Urbanization (yes or no, only in males) </li> <li>Family history of ASCVD (yes or no, only in males) </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>CHD death </li> <li>Nonfatal MI </li> <li>Fatal or nonfatal stroke </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LDL: low density lipoprotein; HDL: high density lipoprotein; CVD: cardiovascular disease; CHD: coronary heart disease; MI: myocardial infarction; hs-CRP: high sensitivity C-reactive protein; ASCVD: atherosclerotic cardiovascular disease.<br />* Diabetes mellitus, as assessed by hemoglobin A1c, was included in the Reynolds risk score for women but NOT included for men.</div><div id=\"graphicVersion\">Graphic 115308 Version 1.0</div></div></div>"},"115328":{"type":"graphic_algorithm","displayName":"Hematuria evaluation in living kidney donor candidates","title":"Sequential evaluation of hematuria in living kidney donor candidates*","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Sequential evaluation of hematuria in living kidney donor candidates*</div><div class=\"cntnt\"><img style=\"width:551px; height:608px;\" src=\"images/NEPH/115328_Hemtrevllvgkdnydnrcndt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In general, lower-risk and less expensive tests should be performed first, and, at each step, additional testing should only be performed if necessary to determine candidacy for kidney donation.</div><div class=\"graphic_footnotes\">* Hematuria is defined as more than 2 to 5 red blood cells/high power field on two to three separate occasions and is unrelated to exercise, trauma, sexual activity, or menstruation.<br />¶ Some clinicians also perform urologic evaluation if the candidate is younger than 35 years but has a significant smoking history or other risk factors for malignancy. However, there are no data that suggest a benefit of screening by cystoscopy among donor candidates &lt;35 years.<br />Δ In general, a kidney biopsy is recommended at this stage. However, some clinicians will defer the biopsy if both the donor candidate and potential recipient wish to proceed without it.</div><div class=\"graphic_reference\">Adapted from Lentine KL, Kasiske BL, Levey AS, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation 2017; 101:S1.</div><div id=\"graphicVersion\">Graphic 115328 Version 1.0</div></div></div>"},"115329":{"type":"graphic_table","displayName":"Conditions increased prevalence PCOS","title":"Conditions associated with an increased prevalence of PCOS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with an increased prevalence of PCOS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Oligoovulatory infertility </li> </ul> </td> </tr> <tr> <td> <ul> <li>Obesity </li> </ul> </td> </tr> <tr> <td> <ul> <li>Diabetes mellitus (type 1, type 2, gestational) </li> </ul> </td> </tr> <tr> <td> <ul> <li>History of premature adrenarche </li> </ul> </td> </tr> <tr> <td> <ul> <li>First-degree relatives with PCOS </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ethnicity (Mexican American, Australian aborigines) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Drugs (valproate) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCOS: polycystic ovary syndrome.</div><div id=\"graphicVersion\">Graphic 115329 Version 1.0</div></div></div>"},"115330":{"type":"graphic_picture","displayName":"Classical facial findings in beta thalassemia","title":"Classical facial findings (chipmunk facies) in beta thalassemia","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Classical facial findings (chipmunk facies) in beta thalassemia</div><div class=\"cntnt\"><img style=\"width:567px; height:753px;\" src=\"images/HEME/115330_Classicalchipmunkfacies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classical facial findings in beta thalassemia major and occasionally in beta thalassemia intermedia (referred to as \"chipmunk facies\") include frontal bossing, maxillary expansion, saddle nose, and depressed cranial vault. These and other skeletal changes are&nbsp;associated with&nbsp;extramedullary hematopoiesis. They occasionally occur in other conditions associated with extramedullary hematopoiesis such as other hereditary hemolytic anemias. Refer to UpToDate for more information about the&nbsp;clinical manifestations and diagnosis&nbsp;of thalassemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Singh A, Varma S. &beta;-thalassaemia intermedia masquerading as &beta;-thalassaemia major. BMJ Case Rep 2014. Copyright &copy; 2014 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 115330 Version 1.0</div></div></div>"},"115333":{"type":"graphic_algorithm","displayName":"Management of acute appendicitis in adults","title":"Management of acute appendicitis in adults","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Management of acute appendicitis in adults</div><div class=\"cntnt\"><img style=\"width:756px; height:407px;\" src=\"images/SURG/115333_Mgmtacuteappendicitsadlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Perforated appendicitis, also referred to as complicated appendicitis, is characterized by a palpable mass in the right lower quadrant on physical examination or by a phlegmon (inflammatory mass) or abscess on imaging studies. Nonperforated appendicitis, also referred to as simple or uncomplicated appendicitis, does not have any clinical or radiologic signs of perforation.<br />¶ The choice of antibiotics varies by clinical situations and is constantly evolving. Refer to related topics in UpToDate for information on antibiotic selection.<br />Δ Immediate appendectomy, as opposed to interval appendectomy, should be performed within 12 hours of decision to operate, except in the case of unstable/septic patient or the presence of free perforation or generalized perforation, where surgery should be performed emergently.<br /><FONT class=lozenge>◊</FONT> Immediate appendectomy is an alternative option for patients with an appendiceal abscess, especially if the abscess is not amenable to percutaneous drainage.</div><div id=\"graphicVersion\">Graphic 115333 Version 1.0</div></div></div>"},"115334":{"type":"graphic_algorithm","displayName":"Initial management of FL in adults","title":"Initial management of follicular lymphoma in adults","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Initial management of follicular lymphoma in adults</div><div class=\"cntnt\"><img style=\"width:539px; height:677px;\" src=\"images/HEME/115334_InitialmgmtFLadults.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FL: follicular lymphoma; CT: computed tomography; PET/CT: positron emission tomography/computed tomography; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; FDG: fludeoxyglucose.<br />* FL is graded on a scale from 1 to 3 according to the number of centroblasts per high powered field. Grade 3 FL has been subdivided for investigational purposes into grade 3a, in which centrocytes are present, and grade 3b, in which there are solid sheets of centroblasts.<br />¶ Features of aggressive clinical presentations include lymph nodes enlarging over weeks to months, systemic B symptoms (eg, fever, weight loss, drenching night sweats), elevated lactate dehydrogenase.<br />Δ A contrast-enhanced CT scan of the chest, abdomen, and pelvis should be performed. While some clinicians routinely include the neck in the CT scan, we typically only include it if lymph nodes in the neck are palpable on physical examination. For patients with limited stage disease, we suggest obtaining a combined FDG-PET/CT as a measure of disease activity. FL is considered a typically FDG-avid tumor such that involved areas should show activity on PET scan.<br />​<FONT class=lozenge>◊</FONT> The decision to use single agent rituximab versus bendamustine plus rituximab depends on the aggressiveness of the tumor and the patient's physical status/comorbidities that may impact his/her ability to tolerate bendamustine. Bendamustine plus rituximab is preferred for fit patients with highly symptomatic disease. In contrast, single agent rituximab is preferred for patients with comorbid conditions that make them poor candidates for chemotherapy and for those with a low tumor burden and/or disease progressing slowly over years. There is a paucity of data regarding the use of bendamustine plus rituximab in patients with the more aggressive histologic grade 3a disease; R-CHOP may be preferred in this setting for fit patients with clinically aggressive disease.<br />§ While we prefer to observe these patients, initial treatment with rituximab alone is an acceptable option for patients seeking immediate treatment, although this approach has not been associated with a survival advantage. In the small subset of patients with coexisting hepatitis C virus infection, treatment directed at hepatitis C may result in regression of FL. </div><div id=\"graphicVersion\">Graphic 115334 Version 1.0</div></div></div>"},"115336":{"type":"graphic_algorithm","displayName":"Initial treatment of acute TCMR of the renal allograft","title":"Initial treatment of acute T cell-mediated rejection of the renal allograft","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Initial treatment of acute T cell-mediated rejection of the renal allograft</div><div class=\"cntnt\"><img style=\"width:615px; height:832px;\" src=\"images/NEPH/115336_TrtmntTCMRrenlallgrft.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">rATG: rabbit antithymocyte globulin; WBC: white blood cell; IV: intravenous.<br />* Treatment of mixed acute rejection involves treatment of both T cell-mediated rejection and acute antibody-mediated rejection. Refer to UpToDate topics on treatment of antibody-mediated rejection.<br />¶ Augmentation of immunosuppression depends upon the patient's regimen: &#xD;&#xA;<UL>&#xD;&#xA;<LI>In patients who are being administered triple immunosuppressive therapy, we switch to mycophenolate (if they are on azathioprine) or tacrolimus (if they are on cyclosporine).</LI>&#xD;&#xA;<LI>In patients who develop acute rejection while on triple therapy with tacrolimus, mycophenolate, and prednisone, we continue these agents at higher doses, if possible. We typically start by targeting higher levels of tacrolimus (ie, 5 to 7 ng/mL).</LI>&#xD;&#xA;<LI>In patients who are receiving dual therapy (calcineurin inhibitor and antimetabolite without prednisone) at the time of rejection, we initiate long-term prednisone at 5 mg once daily.</LI></UL>Δ Methylprednisolone is typically administered as 3 to 5 mg/kg IV daily for three to five doses (maximum daily dose of 500 mg).<br /><FONT class=lozenge>◊</FONT> In patients with Banff grade IB rejection and few or no chronic histologic lesions who present less than one year posttransplant, rATG can be given as an alternative to pulse glucocorticoids.<br />§ Alemtuzumab is administered as a single IV dose of 30 mg.<br />¥ rATG is administered daily as 1.5 to 3 mg/kg per dose for a total dose of 5 to 10 mg/kg.</div><div id=\"graphicVersion\">Graphic 115336 Version 1.0</div></div></div>"},"115337":{"type":"graphic_table","displayName":"Thalassemia syndromes","title":"Classical thalassemia syndromes (genotypes and laboratory findings)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classical thalassemia syndromes (genotypes and laboratory findings)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Genotype&nbsp;</td> <td class=\"subtitle1\">Typical findings on CBC</td> <td class=\"subtitle1\">Hemoglobin analysis (HPLC or electrophoresis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Alpha thalassemias (reduction in alpha globin chains)</td> </tr> <tr> <td>Hydrops fetalis with Hb Barts</td> <td>(<span style=\"font-size: 13px; font-family: Symbol;\">-&nbsp;</span><span style=\"font-size: 13px; font-family: Symbol;\">- </span>/&nbsp;<span style=\"font-size: 13px; font-family: Symbol;\">-&nbsp;</span><span style=\"font-size: 13px; font-family: Symbol;\">- </span>)</td> <td>Severe microcytic anemia with hydrops fetalis; usually fatal in utero</td> <td>Hb Barts (&#947; globin tetramers); Hb Portland (embryonic hemoglobin); no HbF, HbA, or HbA<sub>2</sub></td> </tr> <tr> <td>HbH disease&nbsp;</td> <td> <p>(&#945;<span style=\"font-size: 13px; font-family: Symbol;\"> - / - -)</span></p> <p>&nbsp; or</p> <p>(&#945;<sup>t</sup>&nbsp;<span style=\"font-size: 13px; font-family: Symbol;\">- </span>/&nbsp;<span style=\"font-size: 13px; font-family: Symbol;\">-&nbsp;</span><span style=\"font-size: 13px; font-family: Symbol;\">-</span>)*</p> </td> <td>Moderate microcytic anemia</td> <td>HbH (up to 30%); HbA<sub>2 </sub>(up to 4%)</td> </tr> <tr> <td>Minor</td> <td> <p>(&#945;<span style=\"font-size: 13px; font-family: Symbol;\"> </span><span style=\"font-size: 13px; font-family: Symbol;\">- </span>/&#945;<span style=\"font-size: 13px; font-family: Symbol;\"> </span><span style=\"font-size: 13px; font-family: Symbol;\">- </span>)</p> <p>&nbsp; or</p> <p>(&#945;&nbsp;&#945; /<span style=\"font-size: 13px; font-family: Symbol;\">-&nbsp;<span style=\"font-size: 13px; font-family: Symbol;\">-</span></span>)</p> </td> <td>Mild microcytic anemia</td> <td>Hb Barts (3 to 8%)</td> </tr> <tr> <td>Silent carrier</td> <td>(&#945;&nbsp;&#945; /&#945; <span style=\"font-size: 13px; font-family: Symbol;\">-</span>)</td> <td>Normal hemoglobin, normal MCV</td> <td>Normal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Beta thalassemias (reduction in beta globin chains)<sup>&#182;</sup></td> </tr> <tr> <td>Major (transfusion-dependent)</td> <td> <p>&#946;<sup>0</sup> / &#946;<sup>0</sup></p> <p>&nbsp; or</p> <p>&#946;<sup>0</sup> / &#946;<sup>+</sup>&nbsp;</p> </td> <td>Severe microcytic anemia with target cells (typical Hb 3 to 4 g/dL)</td> <td>HbA<sub>2 </sub>(5% or more); HbF (up to 95%); no HbA</td> </tr> <tr> <td>Intermedia (non-transfusion-dependent)</td> <td>&#946;<sup>+</sup>&nbsp;/ &#946;<sup>+</sup></td> <td>Moderate microcytic anemia</td> <td>HbA<sub>2</sub> (4% or more); HbF (up to 50%)</td> </tr> <tr> <td>Minor (also called trait or carrier)</td> <td> <p>&#946; / &#946;<sup>0</sup></p> <p>&nbsp; or</p> <p>&#946; / &#946;<sup>+</sup></p> </td> <td>Mild microcytic anemia</td> <td>HbA<sub>2</sub> (4% or more); HbF (up to 5%)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><FONT style='FONT-SIZE: 11pt; LINE-HEIGHT: 107%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: \"Times New Roman\"; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA' face='\"Calibri\",sans-serif'>This table lists classical thalassemia syndromes; numerous other combinations and phenotypes are possible. Refer to UpToDate topics on thalassemia genetics, pathophysiology, and diagnosis for more details.</FONT></div><div class=\"graphic_footnotes\">CBC: complete blood count; HPLC: high-performance liquid chromatography; Hb: hemoglobin; HbF: fetal hemoglobin; HbA: adult hemoglobin; MCV: mean corpuscular volume.<br />* The \"t\" stands for a mutant alpha globin such as Hb constant spring (eg, α<SUP>cs</SUP>&nbsp;– / – –).<br />¶ β<SUP>0</SUP> refers to no beta globin production; β<SUP innerHtml>+</SUP> refers to decreased beta globin production; HbE is a β<SUP innerHtml>+</SUP> mutation.</div><div class=\"graphic_reference\">Prepared with data from: Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. Int J Lab Hematol 2016; 38 Suppl 1:32.</div><div id=\"graphicVersion\">Graphic 115337 Version 3.0</div></div></div>"},"115338":{"type":"graphic_table","displayName":"Hematologic changes of pregnancy by trimester","title":"Hematologic changes of pregnancy by trimester","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hematologic changes of pregnancy by trimester</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Nonpregnant*</td> <td class=\"subtitle1\">First trimester</td> <td class=\"subtitle1\">Second trimester</td> <td class=\"subtitle1\">Third trimester</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Hematology</td> </tr> <tr> <td class=\"indent1\">Erythropoietin<sup>&#182;</sup> (units/L)</td> <td class=\"centered\">4 to 27</td> <td class=\"centered\">12 to 25</td> <td class=\"centered\">8 to 67</td> <td class=\"centered\">14 to 222</td> <td>1 to 3</td> </tr> <tr> <td class=\"indent1\">Ferritin<sup>&#182;</sup> (ng/mL)</td> <td class=\"centered\">10 to 150<sup>&#916;</sup></td> <td class=\"centered\">6 to 130</td> <td class=\"centered\">2 to 230</td> <td class=\"centered\">10 to 116</td> <td>1 to 8</td> </tr> <tr> <td class=\"indent1\">Folate, red blood cell (ng/mL)</td> <td class=\"centered\">150 to 450</td> <td class=\"centered\">137 to 589</td> <td class=\"centered\">94 to 828</td> <td class=\"centered\">109 to 663</td> <td>6, 9, 10</td> </tr> <tr> <td class=\"indent1\">Folate, serum (ng/mL)</td> <td class=\"centered\">5.4 to 18.0</td> <td class=\"centered\">2.6 to 15.0</td> <td class=\"centered\">0.8 to 24.0</td> <td class=\"centered\">1.4 to 20.7</td> <td>1, 6, 9 to 13</td> </tr> <tr> <td class=\"indent1\">Haptoglobin (mg/mL)</td> <td class=\"centered\">25 to 250</td> <td class=\"centered\">130 +/- 43</td> <td class=\"centered\">115 +/- 50</td> <td class=\"centered\">135 +/- 65</td> <td>31</td> </tr> <tr> <td class=\"indent1\">Hemoglobin<sup>&#182;</sup> (g/dL)</td> <td class=\"centered\">12.0 to 15.8<sup>&#916;</sup></td> <td class=\"centered\">11.0 to 13.9</td> <td class=\"centered\">10.6 to 14.8</td> <td class=\"centered\">9.5 to 15.0</td> <td>2, 3, 6, 7, 13, 32</td> </tr> <tr> <td class=\"indent1\">Hematocrit<sup>&#182;</sup> (%)</td> <td class=\"centered\">35.4 to 44.4</td> <td class=\"centered\">33.0 to 41.0</td> <td class=\"centered\">32.0 to 39.0</td> <td class=\"centered\">30.0 to 40.0</td> <td>1, 2, 5, 6, 13 to 15, 32</td> </tr> <tr> <td class=\"indent1\">Iron, total binding capacity<sup>&#182;</sup> (mcg/dL)</td> <td class=\"centered\">251 to 406</td> <td class=\"centered\">278 to 403</td> <td class=\"centered\">Not reported</td> <td class=\"centered\">359 to 609</td> <td>7</td> </tr> <tr> <td class=\"indent1\">Iron, serum<sup>&#182;</sup> (mcg/dL)</td> <td class=\"centered\">41 to 141</td> <td class=\"centered\">72 to 143</td> <td class=\"centered\">44 to 178</td> <td class=\"centered\">30 to 193</td> <td>2, 7</td> </tr> <tr> <td class=\"indent1\">Mean corpuscular hemoglobin (pg/cell)</td> <td class=\"centered\">27 to 32</td> <td class=\"centered\">30 to 32</td> <td class=\"centered\">30 to 33</td> <td class=\"centered\">29 to 32</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Mean corpuscular volume (xm<sup>3</sup>)</td> <td class=\"centered\">79 to 93</td> <td class=\"centered\">81 to 96</td> <td class=\"centered\">82 to 97</td> <td class=\"centered\">81 to 99</td> <td>5, 6, 13, 14</td> </tr> <tr> <td class=\"indent1\">Platelet (x10<sup>9</sup>/L)</td> <td class=\"centered\">165 to 415</td> <td class=\"centered\">174 to 391</td> <td class=\"centered\">155 to 409</td> <td class=\"centered\">146 to 429</td> <td>5, 6, 14, 16, 17</td> </tr> <tr> <td class=\"indent1\">Mean platelet volume (mcm<sup>3</sup>)</td> <td class=\"centered\">6.4 to 11.0</td> <td class=\"centered\">7.7 to 10.3</td> <td class=\"centered\">7.8 to 10.2</td> <td class=\"centered\">8.2 to 10.4</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Red blood cell count (x10<sup>6</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">4.00 to 5.20<sup>&#916;</sup></td> <td class=\"centered\">3.42 to 4.55</td> <td class=\"centered\">2.81 to 4.49</td> <td class=\"centered\">2.71 to 4.43</td> <td>5, 6, 13, 14</td> </tr> <tr> <td class=\"indent1\">Red cell distribution width (%)</td> <td class=\"centered\">&#60;14.5</td> <td class=\"centered\">12.5 to 14.1</td> <td class=\"centered\">13.4 to 13.6</td> <td class=\"centered\">12.7 to 15.3</td> <td>5</td> </tr> <tr> <td class=\"indent1\">White blood cell count (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">3.5 to 9.1</td> <td class=\"centered\">5.7 to 13.6</td> <td class=\"centered\">5.6 to 14.8</td> <td class=\"centered\">5.9 to 16.9</td> <td>5, 6, 13, 14, 18</td> </tr> <tr> <td class=\"indent2\">Neutrophils (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">1.4 to 4.6</td> <td class=\"centered\">3.6 to 10.1</td> <td class=\"centered\">3.8 to 12.3</td> <td class=\"centered\">3.9 to 13.1</td> <td>5, 14, 16, 18</td> </tr> <tr> <td class=\"indent2\">Lymphocytes (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">0.7 to 4.6</td> <td class=\"centered\">1.1 to 3.6</td> <td class=\"centered\">0.9 to 3.9</td> <td class=\"centered\">1.0 to 3.6</td> <td>5, 14, 16, 18</td> </tr> <tr> <td class=\"indent2\">Monocytes (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">0.1 to 0.7</td> <td class=\"centered\">0.1 to 1.1</td> <td class=\"centered\">0.1 to 1.1</td> <td class=\"centered\">0.1 to 1.4</td> <td>5, 14, 18</td> </tr> <tr> <td class=\"indent2\">Eosinophils (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">0.0 to 0.6</td> <td class=\"centered\">0.0 to 0.6</td> <td class=\"centered\">0.0 to 0.6</td> <td class=\"centered\">0.0 to 0.6</td> <td>14, 18</td> </tr> <tr> <td class=\"indent2\">Basophils (x10<sup>3</sup>/mm<sup>3</sup>)</td> <td class=\"centered\">0.0 to 0.2</td> <td class=\"centered\">0.0 to 0.1</td> <td class=\"centered\">0.0 to 0.1</td> <td class=\"centered\">0.0 to 0.1</td> <td>14, 18</td> </tr> <tr> <td class=\"indent1\">Transferrin (mg/dL)</td> <td class=\"centered\">200 to 400</td> <td class=\"centered\">254 to 344</td> <td class=\"centered\">220 to 441</td> <td class=\"centered\">288 to 530</td> <td>4, 5</td> </tr> <tr> <td class=\"indent1\">Transferrin, saturation without iron (%)</td> <td class=\"centered\">22 to 46<sup>&#182;</sup></td> <td class=\"centered\">Not reported</td> <td class=\"centered\">10 to 44</td> <td class=\"centered\">5 to 37</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Transferrin, saturation with iron (%)</td> <td class=\"centered\">22 to 46<sup>&#182;</sup></td> <td class=\"centered\">Not reported</td> <td class=\"centered\">18 to 92</td> <td class=\"centered\">9 to 98</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Coagulation</td> </tr> <tr> <td class=\"indent1\">Antithrombin, functional (%)</td> <td class=\"centered\">70 to 130</td> <td class=\"centered\">89 to 114</td> <td class=\"centered\">78 to 126</td> <td class=\"centered\">82 to 116</td> <td>17, 19, 20</td> </tr> <tr> <td class=\"indent1\">D to dimer (mcg/mL)</td> <td class=\"centered\">0.22 to 0.74</td> <td class=\"centered\">0.05 to 0.95</td> <td class=\"centered\">0.32 to 1.29</td> <td class=\"centered\">0.13 to 1.70</td> <td>17, 20 to 24, 30</td> </tr> <tr> <td class=\"indent1\">Factor V (%)</td> <td class=\"centered\">50 to 150</td> <td class=\"centered\">75 to 95</td> <td class=\"centered\">72 to 96</td> <td class=\"centered\">60 to 88</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Factor VII (%)</td> <td class=\"centered\">50 to 150</td> <td class=\"centered\">100 to 146</td> <td class=\"centered\">95 to 153</td> <td class=\"centered\">149 to 211</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Factor VIII (%)</td> <td class=\"centered\">50 to 150</td> <td class=\"centered\">90 to 210</td> <td class=\"centered\">97 to 312</td> <td class=\"centered\">143 to 353</td> <td>17, 25</td> </tr> <tr> <td class=\"indent1\">Factor IX (%)</td> <td class=\"centered\">50 to 150</td> <td class=\"centered\">103 to 172</td> <td class=\"centered\">154 to 217</td> <td class=\"centered\">164 to 235</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Factor XI (%)</td> <td class=\"centered\">50 to 150</td> <td class=\"centered\">80 to 127</td> <td class=\"centered\">82 to 144</td> <td class=\"centered\">65 to 123</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Factor XII (%)</td> <td class=\"centered\">50 to 150</td> <td class=\"centered\">78 to 124</td> <td class=\"centered\">90 to 151</td> <td class=\"centered\">129 to 194</td> <td>17</td> </tr> <tr> <td class=\"indent1\">Fibrinogen (mg/dL)</td> <td class=\"centered\">211 to 496</td> <td class=\"centered\">244 to 510</td> <td class=\"centered\">291 to 538</td> <td class=\"centered\">301 to 696</td> <td>5, 17, 20, 21, 23, 24, 30</td> </tr> <tr> <td class=\"indent1\">Homocysteine (mmol/L)</td> <td class=\"centered\">4.4 to 10.8</td> <td class=\"centered\">3.34 to 11.00</td> <td class=\"centered\">2.0 to 26.9</td> <td class=\"centered\">3.2 to 21.4</td> <td>6, 9, 10 to 12</td> </tr> <tr> <td class=\"indent1\">International normalized ratio</td> <td class=\"centered\">0.90 to 1.04<sup>&#9674;</sup></td> <td class=\"centered\">0.86 to 1.08</td> <td class=\"centered\">0.83 to 1.02</td> <td class=\"centered\">0.80 to 1.09</td> <td>19, 24</td> </tr> <tr> <td class=\"indent1\">Partial thromboplastin time, activated (seconds)</td> <td class=\"centered\">26.3 to 39.4</td> <td class=\"centered\">23.0 to 38.9</td> <td class=\"centered\">22.9 to 38.1</td> <td class=\"centered\">22.6 to 35.0</td> <td>5, 17, 19, 24</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator inhibitor to 1 (PAI to 1) antigen (pg/mL)</td> <td class=\"centered\">17.3 &#177; 5.7</td> <td class=\"centered\">17.7 &#177; 1.9</td> <td class=\"centered\">Not reported</td> <td class=\"centered\">66.4 &#177; 4.9</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Plasminogen activator inhibitor to 1 (PAI to 1) activity (arbitrary units)</td> <td class=\"centered\">9.3 &#177; 1.9</td> <td class=\"centered\">9.0 &#177; 0.8</td> <td class=\"centered\">Not reported</td> <td class=\"centered\">31.4 &#177; 3.0</td> <td>30</td> </tr> <tr> <td class=\"indent1\">Prothrombin time (seconds)</td> <td class=\"centered\">12.7 to 15.4</td> <td class=\"centered\">9.7 to 13.5</td> <td class=\"centered\">9.5 to 13.4</td> <td class=\"centered\">9.6 to 12.9</td> <td>5, 17, 24</td> </tr> <tr> <td class=\"indent1\">Protein C, functional (%)</td> <td class=\"centered\">70 to 130</td> <td class=\"centered\">78 to 121</td> <td class=\"centered\">83 to 133</td> <td class=\"centered\">67 to 135</td> <td>19, 25, 26</td> </tr> <tr> <td class=\"indent1\">Protein S, total (%)</td> <td class=\"centered\">70 to 140</td> <td class=\"centered\">39 to 105</td> <td class=\"centered\">27 to 101</td> <td class=\"centered\">33 to 101</td> <td>17, 25, 26</td> </tr> <tr> <td class=\"indent1\">Protein S, free (%)</td> <td class=\"centered\">70 to 140</td> <td class=\"centered\">34 to 133</td> <td class=\"centered\">19 to 113</td> <td class=\"centered\">20 to 65</td> <td>25, 26</td> </tr> <tr> <td class=\"indent1\">Protein S, functional activity (%)</td> <td class=\"centered\">65 to 140</td> <td class=\"centered\">57 to 95</td> <td class=\"centered\">42 to 68</td> <td class=\"centered\">16 to 42</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Tissue plasminogen activator (ng/mL)</td> <td class=\"centered\">1.6 to 13.0<sup>&#167;</sup></td> <td class=\"centered\">1.8 to 6.0</td> <td class=\"centered\">2.36 to 6.60</td> <td class=\"centered\">3.34 to 9.20</td> <td>17, 19, 30</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tissue plasminogen activator inhibitor-1 (ng/mL)</td> <td class=\"centered\">4 to 43</td> <td class=\"centered\">16 to 33</td> <td class=\"centered\">36 to 55</td> <td class=\"centered\">67 to 92</td> <td>17</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">von Willebrand measurements</td> </tr> <tr> <td class=\"indent1\">von Willebrand factor antigen (%)</td> <td class=\"centered\">75 to 125</td> <td class=\"centered\">62 to 318</td> <td class=\"centered\">90 to 247</td> <td class=\"centered\">84 to 422</td> <td>20, 27, 28</td> </tr> <tr> <td class=\"indent1\">ADAMTS-13, von Willebrand cleaving protease</td> <td class=\"centered\">40 to 170<sup>&#165;</sup></td> <td class=\"centered\">40 to 160</td> <td class=\"centered\">22 to 135</td> <td class=\"centered\">38 to 105</td> <td>20, 28</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Unless otherwise specified, all normal reference values are from the seventeenth edition of Harrison's Principles of Internal Medicine<SUP>[29]</SUP>.<br />¶ Range includes references with and without iron supplementation.<br />Δ Normal reference range is specific range for females.<br /><FONT class=lozenge>◊</FONT> Reference values are from Cerneca et al: Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis<SUP>[19]</SUP>.<br />§ References values are from Cerneca et al and Choi et al: Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy<SUP>[17,19]</SUP>.<br />¥ Reference values are from Mannuci et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor<SUP>[28]</SUP>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Beguin Y, Lipscei G, Thoumsin H, Fillet G. Blunted erythropoietin production and decreased erythropoiesis in early pregnancy. Blood 1991; 78:89.</LI>&#xD;&#xA;<LI>Bianco I, Mastropietro F, D'Asero C, et al. Serum levels of erythropoietin and soluble transferrin receptor during pregnancy in non-β-thalassemic and β-thalassemic women. Haematologica 2000; 85:902.</LI>&#xD;&#xA;<LI>Milman N, Graudal N, Nielsen OJ, Agger AO. Serum erythropoietin during normal pregnancy: Relationship to hemoglobin and iron status markers and impact of iron supplementation in a longitudinal, placebo-controlled study on 118 women. Int J Hematol 1997; 66:159.</LI>&#xD;&#xA;<LI>Larsson A, Palm M, Hansson LO, Axelsson O. Reference values for clinical chemistry tests during normal pregnancy. BJOG 2008; 115:874.</LI>&#xD;&#xA;<LI>Lockitch G. Handbook of Diagnostic Biochemistry and Hematology in Normal Pregnancy. CRC Press, Boca Raton, FL, 1993.</LI>&#xD;&#xA;<LI>Milman N, Bergholt T, Byg KE, et al. Reference intervals for haematological variables during normal pregnancy and postpartum in 434 healthy Danish women. Eur J Haematol 2007; 79:39.</LI>&#xD;&#xA;<LI>Romslo I, Haram K, Sagen N, Augensen K. Iron requirement in normal pregnancy as assessed by serum ferritin, serum transferring saturation and erythrocyte protoporphyrin determinations. Br J Obstet Gynaecol 1983; 90:101.</LI>&#xD;&#xA;<LI>van Buul EJ, Steegers EA, Jongsma HW, et al. Haematological and biochemical profile of uncomplicated pregnancy in nulliparous women; a longitudinal study. Neth J Med 1995; 46:73.</LI>&#xD;&#xA;<LI>Milman N, Byg KE, Hvas AM, et al. Erythrocyte folate, plasma folate and plasma homocysteine during normal pregnancy and postpartum: A longitudinal study comprising 404 Danish women. Eur J Haematol 2006; 76:200.</LI>&#xD;&#xA;<LI>Walker MC, Smith GN, Perkins SL, et al. Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999; 180:660.</LI>&#xD;&#xA;<LI>López-Quesada E, Vilaseca MA, Lailla JM. Plasma total homocysteine in uncomplicated pregnancy and in preeclampsia. Eur J Obstet Gynecol Reprod Biol 2003; 108:45.</LI>&#xD;&#xA;<LI>Ozerol E, Ozerol I, Gökdeniz R, et al. Effect of smoking on serum concentrations of total homocysteine, folate, vitamin B12, and nitric oxide in pregnancy: A preliminary study. Fetal Diagn Ther 2004; 19:145.</LI>&#xD;&#xA;<LI>Qvist I, Abdulla M, Jägerstad M, Svensson S. Iron, zinc and folate status during pregnancy and two months after delivery. Acta Obstet Gynecol Scand 1986; 65:15.</LI>&#xD;&#xA;<LI>Balloch AJ, Cauchi MN. Reference ranges for haematology parameters in pregnancy derived from patient populations. Clin Lab Haematol 1993; 15:7.</LI>&#xD;&#xA;<LI>Singh HJ, Mohammad NH, Nila A. Serum calcium and parathormone during normal pregnancy in Malay women. J Matern Fetal Med 1999; 8:95.</LI>&#xD;&#xA;<LI>Karim SA, Khurshid M, Rizvi JH, et al. Platelets and leucocyte counts in pregnancy. J Pak Med Assoc 1992; 42:86.</LI>&#xD;&#xA;<LI>Choi JW, Pai SH. Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Ann Hematol 2002; 81:611.</LI>&#xD;&#xA;<LI>Belo L, Santos-Silva A, Rocha S, et al.&nbsp;Fluctuations in C-reactive protein concentration and neutrophil activation during normal human pregnancy. Eur J Obstet Gynecol Reprod Biol 2005; 123:46.</LI>&#xD;&#xA;<LI>Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73:31.</LI>&#xD;&#xA;<LI>Lattuada A, Rossi E, Calzarossa C, et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88:1029.</LI>&#xD;&#xA;<LI>Francalanci I, Comeglio P, Liotta AA, et al. D-Dimer concentrations during normal pregnancy, as measured by ELISA. Thromb Res 1995; 78:399.</LI>&#xD;&#xA;<LI>Kline JA, Williams GW, Hernandez-Nino J. D-Dimer concentrations in normal pregnancy: New diagnostic thresholds are needed. Clin Chem 2005; 51:825.</LI>&#xD;&#xA;<LI>Morse M. Establishing a normal range for D-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis. J Thromb Haemost 2004; 2:1202.</LI>&#xD;&#xA;<LI>Liu XH, Jiang YM, Shi H, et al. Prospective, sequential, longitudinal study of coagulation changes during pregnancy in Chinese women. Int J Gynaecol Obstet 2009; 105:240.</LI>&#xD;&#xA;<LI>Lefkowitz JB, Clarke SH, Barbour LA. Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol 1996; 175:657.</LI>&#xD;&#xA;<LI>Faught W, Garner P, Jones G, Ivey B. Changes in protein C and protein S levels in normal pregnancy. Am J Obstet Gynecol 1995; 172:147.</LI>&#xD;&#xA;<LI>Wickström K, Edelstam G, Löwbeer CH, et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64:31.</LI>&#xD;&#xA;<LI>Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730.</LI>&#xD;&#xA;<LI>Kratz A, Pesce MA, Basner RC, Einstein AJ. Appendix: Laboratory values of clinical importance. In: Harrison's Principles of Internal Medicine, 18th ed, Longo DL, Fauci AS, Kasper DL, et al (Eds), McGraw-Hill, New York 2012.</LI>&#xD;&#xA;<LI>Hale SA, Sobel B, Benvenuto A, et al. Coagulation and fibrinolytic system protein profiles in women with normal pregnancies and pregnancies complicated by hypertension. Pregnancy Hypertens 2012; 2:152.</LI>&#xD;&#xA;<LI>Haram K, Augensen K, Elsayed S. Serum protein pattern in normal pregnancy with special reference to acute-phase reactants. Br J Obstet Gynaecol 1983; 90:139.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency anemia in the United States. MMWR Recomm Rep 1998; 47:1.</LI></OL></div><div id=\"graphicVersion\">Graphic 115338 Version 1.0</div></div></div>"},"115340":{"type":"graphic_algorithm","displayName":"Administration of bright light therapy for winter depression","title":"Administration of bright light therapy with a 10,000 lux fluorescent light box for winter depression (seasonal affective disorder)*","html":"<div class=\"graphic\"><div style=\"width: 673px\" class=\"figure\"><div class=\"ttl\">Administration of bright light therapy with a 10,000 lux fluorescent light box for winter depression (seasonal affective disorder)*</div><div class=\"cntnt\"><img style=\"width:653px; height:778px;\" src=\"images/PSYCH/115340_Brghtlghtthrpywntrdprsn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">*Refer to UpToDate topic on treating seasonal affective disorder for recommendations about the positioning of the light box, as well as the concomitant use of dawn simulation.<br />¶ Throughout the algorithm, response is defined as reduction of baseline symptoms ≥50%.<br />Δ Although components of this algorithm has been used in studies of bright light therapy, no studies have compared the efficacy of a fixed dose of 30 minutes per day with an increasing dose.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topic on treating seasonal affective disorder for evaluating patients for exclusive use of evening bright light therapy.</div><div id=\"graphicVersion\">Graphic 115340 Version 1.0</div></div></div>"},"115342":{"type":"graphic_table","displayName":"Etiologies of generalized hyperhidrosis in palliative care","title":"Most common potential etiologies of generalized hyperhidrosis and night sweats in palliative care populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Most common potential etiologies of generalized hyperhidrosis and night sweats in palliative care populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine disturbances</td> </tr> <tr> <td class=\"indent1\">Diabetes insipidus (rare)</td> </tr> <tr> <td class=\"indent1\">Estrogen deficiency</td> </tr> <tr> <td class=\"indent1\">Androgen deficiency</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Endocrine dysfunction caused by cancer-related treatments</td> </tr> <tr> <td class=\"subtitle1_single\">Neurological disorders</td> </tr> <tr> <td class=\"indent1\">Autonomic neuropathy</td> </tr> <tr> <td class=\"indent1\">Cerebral and brainstem lesions (tumors, infarctions, or hemorrhages)</td> </tr> <tr> <td class=\"indent1\">Spinal injuries or lesions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parkinsonism</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancies</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma and non-Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Solid tumors, typically advanced disease, liver metastasis (germ cell, medullary thyroid cancer, prostate renal cell)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Carcinoid syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Antidepressants (selective serotonin reuptake inhibitors [SSRIs], bupropion)</td> </tr> <tr> <td class=\"indent1\">Hormone therapies (selective estrogen receptor modulators, aromatase inhibitors, gonadotropin-releasing hormone [GnRH] agonists, flutamide)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Opioids</td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size: 14px;\"><strong>Intoxication/withdrawal from alcohol or other substances, including opioids</strong></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 115342 Version 1.0</div></div></div>"},"115344":{"type":"graphic_table","displayName":"NCI CTCAE v5 hyperhidrosis","title":"NCI CTCAE v5.0 hyperhidrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hyperhidrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Hyperhidrosis</td> <td>Limited to one site (palms, soles, or axillae); self-care interventions</td> <td>Involving &#62;1 site; patient seeks medical intervention; associated with psychosocial impact</td> <td>Associated with electrolyte/hemodynamic imbalance</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hyperhidrosis is a disorder characterized by excessive perspiration (sweating).</div><div class=\"graphic_footnotes\">NCI CTCAE: National Institutes of Health Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 115344 Version 4.0</div></div></div>"},"115345":{"type":"graphic_table","displayName":"RBC membrane/cytoskeletal components","title":"RBC membrane/cytoskeletal components","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">RBC membrane/cytoskeletal components</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Component</td> <td class=\"subtitle1\">Function</td> <td class=\"subtitle1\">Clinical relevance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Lipids</td> </tr> <tr> <td class=\"indent1\">PC</td> <td>Major component of the outer membrane leaflet</td> <td>Rare cases of hemolytic anemia with high PC</td> </tr> <tr> <td class=\"indent1\">SM</td> <td>Major component of the outer membrane leaflet</td> <td>Not described</td> </tr> <tr> <td class=\"indent1\">PE</td> <td>Major component of the inner membrane leaflet</td> <td>Not described</td> </tr> <tr> <td class=\"indent1\">PS</td> <td>Major component of the inner membrane leaflet</td> <td>Exposure on the outer membrane leaflet results in phagocytosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cholesterol</td> <td>Regulates the \"flippase\" that controls membrane asymmetry</td> <td>Increased in liver disease, creating target cells and spur cells</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Integral membrane proteins</td> </tr> <tr> <td class=\"indent1\">Band 3 (AE1)</td> <td> <p>Anion exchange (bicarbonate for chloride)</p> <p>Links membrane to underlying cytoskeleton</p> Carries blood groups I, Diego</td> <td> <p>Hereditary spherocytosis (HS)</p> <p>Southeast Asian ovalocytosis (SAO)</p> <p>Cryohydrocytosis (a subtype of hereditary stomatocytosis [HSt])</p> Distal renal tubular acidosis</td> </tr> <tr> <td class=\"indent1\">Glycophorin C</td> <td> <p>Negative charge reduces RBC-RBC and RBC-vascular endothelial&nbsp;interactions</p> <p>Links membrane to underlying cytoskeleton</p> Carries blood groups MN, S, Gerbich</td> <td>Malaria resistance</td> </tr> <tr> <td class=\"indent1\">Aquaphorin-1</td> <td>Water transport</td> <td>Mild anemia due to deficiency</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Glut-1</td> <td>Glucose transport</td> <td>Mild anemia due to deficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Outer membrane proteins</td> </tr> <tr> <td class=\"indent1\">Spectrin</td> <td>Major structural protein that creates hexagonal array</td> <td>HS</td> </tr> <tr> <td class=\"indent1\">Ankyrin</td> <td>Mechanically couples spectrin to band 3</td> <td>HS</td> </tr> <tr> <td class=\"indent1\">Band 4.2</td> <td>Strengthens ankyrin-band 3 interaction</td> <td>HS</td> </tr> <tr> <td class=\"indent1\">Actin</td> <td>Principal protein component of the junctional complex</td> <td>Not described</td> </tr> <tr> <td class=\"indent1\">Protein 4.1</td> <td>Stabilizes spectrin-actin interaction</td> <td>HS/hereditary elliptocytosis (HE)</td> </tr> <tr> <td class=\"indent1\">Adducin</td> <td>Stabilizes spectrin-band 3 and spectrin-actin interactions</td> <td>Not described</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Numerous additional lipids and proteins are present at lower abundance. Refer to UpToDate topic on the RBC membrane and topics on specific hemolytic anemias for more details.</div><div class=\"graphic_footnotes\">PC: phosphatidylcholine; SM: sphingomyelin; PE: phosphatidylethanolamine; PS: phosphatidylserine; AE1: anion exchanger 1; HS: hereditary spherocytosis; SAO: Southeast Asian ovalocytosis; HSt: hereditary stomatocytosis; RBCs: red blood cells; HE: hereditary elliptocytosis.</div><div id=\"graphicVersion\">Graphic 115345 Version 1.0</div></div></div>"},"115346":{"type":"graphic_algorithm","displayName":"Approach to agitation in patients with dementia","title":"Approach to agitation in patients with dementia","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Approach to agitation in patients with dementia</div><div class=\"cntnt\"><img style=\"width:490px; height:951px;\" src=\"images/NEURO/115346_Apprchagitationdementia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; SSRI: selective serotonin reuptake inhibitor.<br />* Pharmacologic options for agitation include antipsychotic drugs, citalopram, and dextromethorphan-quinidine. Atypical antipsychotics may be most appropriate for prominent and distressing hallucinations or delusions. Antipsychotic drug treatment should be maintained only if benefits are apparent, and discontinuation should be attempted at regular intervals, weighing the risk of relapse versus the risk of adverse effects from continued treatment. Refer to UpToDate topics on management of neuropsychiatric symptoms of dementia for more details.</div><div id=\"graphicVersion\">Graphic 115346 Version 1.0</div></div></div>"},"115352":{"type":"graphic_table","displayName":"Transition action plan","title":"Action plan for the transition from pediatric to adult care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Action plan for the transition from pediatric to adult care</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Typical age</td> <td class=\"subtitle1\">Typical age-appropriate actions</td> </tr> <tr> <td>12 to 13 years</td> <td>Discuss transition policy and provide information</td> </tr> <tr> <td>14 to 15 years</td> <td>Initiate transition plan that includes assessment of patient readiness</td> </tr> <tr> <td>16 to 17 years</td> <td>Review and update transition plan and prepare for adult care</td> </tr> <tr> <td>18 years or older</td> <td>Implement adult care model, transfer medical records, and provide direct communication about special medical care needs</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Readiness of the patient must be assessed, and stages of the transition should be based on readiness, not a prespecified age. Actions are typically done sequentially (ie, ensure that the previous action is complete before proceeding to the next action). Special health care needs are incorporated at all stages of management. Refer to UpToDate for additional details.</div><div class=\"graphic_reference\">Adapted from: Cooley WC, Sagerman PJ, American Academy of Pediatrics, et al. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics 2011; 128:182.</div><div id=\"graphicVersion\">Graphic 115352 Version 1.0</div></div></div>"},"115353":{"type":"graphic_figure","displayName":"Frequency of adverse effects from blood transfusion","title":"Frequency of adverse effects from RBC transfusion placed in context relative to the risks of other hazards","html":"<div class=\"graphic\"><div style=\"width: 703px\" class=\"figure\"><div class=\"ttl\">Frequency of adverse effects&nbsp;from RBC transfusion placed in context relative to the risks of other hazards</div><div class=\"cntnt\"><img style=\"width:683px; height:521px;\" src=\"images/HEME/115353_Rkbldtrnfncmpdcrplcsh.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Risk is depicted on a logarithmic scale. Shaded bars represent the risk of the adverse event per RBC unit transfused, and unshaded bars represent the risk for fatality per person per year for various life events. Refer to the source document for additional details of these risk calculations. Refer to UpToDate for discussions of factors that impact these transfusion-associated&nbsp;risks, and our approaches to evaluating their&nbsp;presence,&nbsp;reducing their frequency, and treating them when they occur.</div><div class=\"graphic_footnotes\">RBC: red blood cell; HIV: human immunodeficiency virus; HCV: hepatitis C virus; HBV: hepatitis B virus; TRALI: transfusion-related acute lung injury; TACO: transfusion-associated circulatory overload.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495.</LI>&#xD;&#xA;<LI>Zou S, Stramer SL, Notari EP, et al. Current incidence and risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 49:1609.</LI>&#xD;&#xA;<LI>Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: Incidence and risk factors. Blood 2012; 119:1757.</LI>&#xD;&#xA;<LI>US Department of Health and Human Services. The 2009 national blood collection and utilization survey report. US Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, DC 2011.</LI>&#xD;&#xA;<LI>Use of blood products for elective surgery in 43 European hospitals. The Sanguis Study Group. Transfus Med 1994; 4:251.</LI>&#xD;&#xA;<LI>Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010; 304:1568.</LI>&#xD;&#xA;<LI>Murphy MF, Wallington TB, Kelsey P, et al. Guidelines for the clinical use of red cell transfusions. Br J Haematol 2001; 113:24.</LI>&#xD;&#xA;<LI>National Health and Medical Research Council/Australasian Society of Blood Transfusion. Clinical practice guidelines: Appropriate use of red blood cells. National Health and Medical Research Council/Australasian Society of Blood Transfusion, Sydney 2001.</LI>&#xD;&#xA;<LI>Li G, Rachmale S, Kojicic M, et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51:338.</LI>&#xD;&#xA;<LI>Popovsky MA, Audet AM, Andrzejewski C Jr. Transfusion-associated circulatory overload in orthopedic surgery patients: A multi-institutional study. Immunohematology 1996; 12:87.</LI>&#xD;&#xA;<LI>Bierbaum BE, Callaghan JJ, Galante JO, et al. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81:2.</LI>&#xD;&#xA;<LI>Linden JV, Tourault MA, Scribner CL. Decrease in frequency of transfusion fatalities. Transfusion 1997; 37:243.</LI>&#xD;&#xA;<LI>Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: An analysis of 10 years' experience. Transfusion 2000; 40:1207.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: Annual summary for fiscal year 2010. US Food and Drug Administration, Silver Spring, MD 2011.</LI>&#xD;&#xA;<LI>Federowicz I, Barrett BB, Andersen JW, et al. Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996; 36:21.</LI>&#xD;&#xA;<LI>Kohn L. To err is human: An interview with the Institute of Medicine's Linda Kohn. Jt Comm J Qual Improv 2000; 26:227.</LI>&#xD;&#xA;<LI>Minino AM, Murphy SL, Xu J, Kochanek, KD. Deaths: Final data for 2008. National Center for Health Statistics, Hyattsville, MD 2011.</LI>&#xD;&#xA;<LI><A href=\"http://www.lightningsafety.com/nlsi_lls/fatalities_us.html\" target=_blank>www.lightningsafety.com/nlsi_lls/fatalities_us.html</A> (Accessed on March 12, 2012).</LI>&#xD;&#xA;<LI><A href=\"http://www.planecrashinfo.com/cause.htm\" target=_blank>www.planecrashinfo.com/cause.htm</A> (Accessed on March 12, 2012).</LI>&#xD;&#xA;<LI><FONT color=black>Dzik WH. Emily Cooley Lecture 2002: Transfusion safety in the hospital. Transfusion 2003; 43:1190.</FONT></LI></OL>&#xD;&#xA;<P><FONT color=black>From <EM>Annals of Internal Medicine</EM>, Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: A clinical practice guideline from the AABB*. Ann Intern Med 2012; 157(1):49-58. Copyright © 2012 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</FONT></div><div id=\"graphicVersion\">Graphic 115353 Version 1.0</div></div></div>"},"115355":{"type":"graphic_figure","displayName":"Algorithm consensus standards ECG interpretation in athletes","title":"Algorithm showing international consensus standards ECG interpretation in athletes and need for subsequent evaluation","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Algorithm showing international consensus standards ECG interpretation in athletes and need for subsequent evaluation</div><div class=\"cntnt\"><img style=\"width:565px; height:395px;\" src=\"images/CARD/115355_IntrntlstnddECGintrpath.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; LVH: left ventricular hypertrophy; RVH: right ventricular hypertrophy; RBBB: right bundle branch block; AV: atrioventricular; LBBB: left bundle branch block; bpm: beats per minute; PVC: premature ventricular contraction; SCD: sudden cardiac death.</div><div class=\"graphic_reference\">Reproduced with permission from: Drezner JA, Sharma S, Baggish A, et al. International criteria for electrocardiographic interpretation in athletes. Br J Sports Med 2017; 51:704. Copyright © 2017 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 115355 Version 1.0</div></div></div>"},"115358":{"type":"graphic_table","displayName":"Example of an expanded carrier screening panel","title":"Example of an expanded carrier screening panel*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of an expanded carrier screening panel*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Carrier frequency<br /> in general population</td> <td class=\"subtitle1\">Carrier frequency<br /> in specific ethnic groups</td> </tr> <tr class=\"divider_bottom\"> <td>Alpha-thalassemia</td> <td>Unknown</td> <td> <p>African (particularly sub-Saharan): 1 in 3</p> <p>Mediterranean: 1 in 30</p> Southeast Asian and Middle Eastern: 1 in 20 </td> </tr> <tr class=\"divider_bottom\"> <td>Beta-thalassemia</td> <td>Unknown</td> <td> <p>African American: &#60;1 in 8</p> <p>Ashkenazi Jewish: Varied</p> <p>Asian: 1 in 20</p> Mediterranean: 1 in 7</td> </tr> <tr class=\"divider_bottom\"> <td>Bloom syndrome</td> <td>&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 100</td> </tr> <tr class=\"divider_bottom\"> <td>Canavan disease</td> <td>&#60;1 in 150</td> <td>Ashkenazi Jewish: 1 in 41</td> </tr> <tr class=\"divider_bottom\"> <td>Cystic fibrosis</td> <td>Unknown</td> <td> <p>African American: 1 in 61</p> <p>Asian: 1 in 94</p> <p>Ashkenazi Jewish: 1 in 24</p> <p>Caucasian: 1 in 25</p> Hispanic: 1 in 58</td> </tr> <tr class=\"divider_bottom\"> <td>Familial dysautonomia</td> <td>&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 31</td> </tr> <tr class=\"divider_bottom\"> <td>Familial hyperinsulinism</td> <td>&#60;1 in 150</td> <td>Ashkenazi Jewish: 1 in 52</td> </tr> <tr class=\"divider_bottom\"> <td>Fanconi anemia C</td> <td>&#60;1 in 790</td> <td>Ashkenazi Jewish: 1 in 89</td> </tr> <tr class=\"divider_bottom\"> <td>Fragile X syndrome<sup>&#182;</sup></td> <td>1 in 259</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Galactosemia</td> <td>1 in 87</td> <td>Ashkenazi Jewish: 1 in 127</td> </tr> <tr class=\"divider_bottom\"> <td>Gaucher disease</td> <td>&#60;1 in 100</td> <td>Ashkenazi Jewish: 1 in 15</td> </tr> <tr class=\"divider_bottom\"> <td>Glycogen storage disease type 1A</td> <td>&#60;1 in 150</td> <td>Ashkenazi Jewish: 1 in 71</td> </tr> <tr class=\"divider_bottom\"> <td>Joubert syndrome</td> <td>&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 92</td> </tr> <tr class=\"divider_bottom\"> <td>Medium-chain acyl-CoA dehydrogenase deficiency</td> <td>Unknown</td> <td>Caucasian: 1 in 50</td> </tr> <tr class=\"divider_bottom\"> <td>Maple syrup urine disease types 1A and 1B</td> <td>1 in 240</td> <td> <p>Ashkenazi Jewish: 1 in 81 (type IB)</p> Mennonite: 1 in 10 (type 1A-<em>BCKDHA</em> p.Y438N)</td> </tr> <tr class=\"divider_bottom\"> <td>Mucolipidosis IV</td> <td>&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 96</td> </tr> <tr class=\"divider_bottom\"> <td>Niemann&ndash;Pick disease type A</td> <td>&#60;1 in 500</td> <td>Ashkenazi Jewish: 1 in 90</td> </tr> <tr class=\"divider_bottom\"> <td>Phenylketonuria</td> <td>Unknown</td> <td> <p>Caucasian: 1 in 50</p> Irish: 1 in 34</td> </tr> <tr class=\"divider_bottom\"> <td>Sickle cell anemia</td> <td>Unknown</td> <td>African American: 1 in 10</td> </tr> <tr class=\"divider_bottom\"> <td>Smith-Lemli-Opitz syndrome</td> <td>Unknown</td> <td>Caucasian: 1 in 70</td> </tr> <tr class=\"divider_bottom\"> <td>Spinal muscular atrophy</td> <td>Unknown</td> <td> <p>African American: 1 in 66</p> <p>Asian: 1 in 53</p> <p>Ashkenazi Jewish: 1 in 41</p> <p>Caucasian: 1 in 35</p> Hispanic: 1 in 117</td> </tr> <tr> <td>Tay Sachs disease<sup>&#916;</sup></td> <td>1 in 300</td> <td> <p>Ashkenazi Jewish: 1 in 30</p> French Canadian and Cajun: 1 in 30</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Conditions reasonable for inclusion in an expanded carrier screening panel as of 2016. After counseling regarding screening options, obstetrician-gynecologists or other health care providers and patients may elect to screen for fewer or more conditions than those listed here. The availability of expanded carrier screening does not preclude the appropriateness of ethnic-based screening or screening based on family history. Conditions were selected on the basis of the benefits of detection, the accuracy of current screening methods, and the following consensus-determined criteria: have a carrier frequency of 1 in 100 or greater, have a well-defined phenotype, have a detrimental effect on quality of life, cause cognitive or physical impairment, require surgical or medical intervention, or have an onset early in life. Additionally, screened conditions should be able to be diagnosed prenatally and may afford opportunities for antenatal intervention to improve perinatal outcomes, changes to delivery management to optimize newborn and infant outcomes, and education of the parents about special care needs after birth.<br />¶ Included on this list despite a carrier frequency lower than 1 in 100 because, as an X-linked syndrome, fragile X syndrome is more prevalent than other conditions.<br />Δ DNA testing alone will miss up to 10% of carriers of Tay Sachs disease, especially in lower-risk groups; therefore, enzyme-based testing may be a more appropriate choice for some patients.</div><div class=\"graphic_reference\">Reprinted with permission from Carrier screening in the age of genomic medicine. Committee opinion no. 690. American College of Obstetricians and Gynecologists Committee on Genetics. Obstet Gynecol 2017:129:e35-e40.</div><div id=\"graphicVersion\">Graphic 115358 Version 1.0</div></div></div>"},"115359":{"type":"graphic_table","displayName":"Causes of splenomegaly in children","title":"Causes of splenomegaly in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of splenomegaly in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>Initial evaluation</strong> of the child with unexplained splenomegaly includes: <ul class=\"decimal_heading\"> <li>History and physical examination </li> <li>Complete blood count including platelet count and differential </li> <li>Reticulocyte count </li> <li>Review of the peripheral blood smear </li> <li>Liver function tests </li> <li>EBV and CMV serologies </li> <li>Chest radiograph </li> <li>Abdominal ultrasound </li> </ul> <br /> In most cases, a likely diagnosis (or diagnostic category) can be arrived at based upon the findings of these tests. Additional testing may be needed to establish the specific diagnosis. </td> </tr> <tr> <td class=\"subtitle1\">Diagnostic category</td> <td class=\"subtitle1\">Suggestive findings</td> <td class=\"subtitle1\">Additional evaluation*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Infectious mononucleosis</strong></td> <td> <ul> <li>Fever, pharyngitis, fatigue, and lymphadenopathy </li> <li>Lymphocytosis and atypical lymphocytes on peripheral blood smear </li> </ul> </td> <td> <ul> <li>Diagnosis is made with EBV and CMV serologies and/or heterophile antibody testing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Systemic infection</strong> <ul class=\"decimal_heading\"> <li>Tuberculosis </li> <li>Infective endocarditis </li> <li>Malaria </li> <li>HIV </li> <li>Cat scratch disease </li> <li>Babesiosis </li> </ul> </td> <td> <ul> <li>Persistent fevers, weight loss, malaise, lymphadenopathy </li> <li>Travel to an endemic region (malaria, tuberculosis, babesiosis) </li> <li>HIV risk factors (unprotected sex, IV drug use) </li> <li>Cat scratch (<em>Bartonella</em>) </li> <li>Tick bite (babesiosis) </li> </ul> </td> <td> <ul> <li>Testing is guided by clinical findings and may include: <ul> <li>TST to evaluate for TB </li> <li>Serial blood cultures to evaluate for IE </li> <li>Malaria blood smear (if relevant exposure) </li> <li>HIV testing (if there are relevant risk factors) </li> <li><em>Bartonella</em> titers (if relevant exposure) </li> <li>Blood smear and/or PCR for babesiosis (if relevant exposure) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hematologic malignancy</strong> <ul class=\"decimal_heading\"> <li>Acute lymphoblastic leukemia </li> <li>Acute myelogenous leukemia </li> </ul> </td> <td> <ul> <li>Persistent fevers, anorexia, weight loss, decreased activity level, bone pain, and/or easy bruising </li> <li>Cytopenias (neutropenia, anemia, and/or thrombocytopenia) </li> <li>Abnormal immature cells (blasts) in the peripheral blood </li> </ul> </td> <td> <ul> <li>Bone marrow aspiration/biopsy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lymphoproliferative diseases</strong> <ul class=\"decimal_heading\"> <li>Lymphoma </li> <li>Langerhans cell histiocytosis </li> <li>Hematophagocytic lymphohistiocytosis </li> <li>Autoimmune lymphoproliferative syndrome </li> <li>Castleman's disease and POEMS syndrome </li> </ul> </td> <td> <ul> <li>Lymphadenopathy (particularly if lymph nodes are massively enlarged and/or rapidly increasing in size) </li> <li>Chest radiograph findings of hilar adenopathy or mediastinal mass </li> </ul> </td> <td> <ul> <li>Contrast-enhanced CT of the chest and abdomen </li> <li>Lymph node biopsy </li> <li>Bone marrow biopsy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hemolytic anemias</strong> <ul class=\"decimal_heading\"> <li>RBC membrane defects </li> <li>RBC enzyme defects </li> <li>Hemoglobinopathies </li> <li>Autoimmune hemolytic anemia </li> <li>Other acquired hemolytic anemias </li> </ul> </td> <td> <ul> <li>Low hemoglobin, unconjugated hyperbilirubinemia, and reticulocytosis </li> <li>Clues on the peripheral blood smear include polychromasia and spherocytes </li> <li>Certain congenial RBC disorders may have specific findings on the blood smear (eg, elliptocytes, xerocytes, sickle cells) </li> </ul> </td> <td> <ul> <li>Serum markers of hemolysis (LDH, free hemoglobin, haptoglobin) </li> <li>Testing for specific causes of hemolytic anemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Liver disease</strong> <ul class=\"decimal_heading\"> <li>Biliary atresia </li> <li>Viral hepatitis </li> <li>Wilson's disease </li> <li>Other metabolic liver disease (eg, galactosemia) </li> <li>Primary sclerosing cholangitis </li> <li>Alpha-1-antitrypsin deficiency </li> <li>Alagille syndrome </li> <li>Cystic fibrosis </li> </ul> </td> <td> <ul> <li>Jaundice, hepatomegaly, firm liver edge, ascites, and/or spider angiomata </li> <li>Abnormal liver function tests </li> <li>Abnormal findings on abdominal imaging (eg, focal or diffuse liver abnormalities; slow or reversed portal blood flow suggestive of portal hypertension) </li> </ul> </td> <td> <ul> <li>Testing for specific causes of pediatric liver disease </li> <li>Liver biopsy may be warranted in some cases </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Portal vein thrombosis</strong> </td> <td> <ul> <li>Patients may have abdominal pain or may be asymptomatic </li> <li>Underlying risk factor for thrombosis (eg, invasive catheter [UVC], liver disease, malignancy, inherited thrombophilia, antiphospholipid antibodies) </li> <li>Abnormal abdominal ultrasound (ie, filling defect or absence of flow Doppler images) </li> </ul> </td> <td> <ul> <li>Diagnosis is made with Doppler ultrasound </li> <li>Additional evaluation may be warranted to determine cause of thrombus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autoimmune disease</strong> <ul class=\"decimal_heading\"> <li>SLE </li> <li>JRA </li> </ul> </td> <td> <ul> <li>Rashes and/or joint swelling </li> <li>Laboratory findings include nonspecific markers of inflammation (eg, leukocytosis, elevated ESR or CRP) </li> </ul> </td> <td> <ul> <li>Antinuclear antibody titers are obtained as a screening test </li> <li>Further evaluation is based on the clinical findings </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Primary immunodeficiency</strong> <ul class=\"decimal_heading\"> <li>Common variable immunodeficiency </li> </ul> </td> <td> <ul> <li>History of recurrent infections and/or failure to thrive </li> <li>Lymphopenia may be noted on CBC </li> </ul> </td> <td> <ul> <li>Diagnosis is based on immunoglobulin levels and antibody function studies (ie, vaccine response) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Storage disorders</strong> <ul class=\"decimal_heading\"> <li>Gaucher disease </li> <li>Niemann-Pick disease </li> <li>Mucopolysaccharidoses </li> <li>Other lysosomal storage disorders </li> </ul> </td> <td> <ul> <li>Other organ involvement (eg, hepatomegaly, skeletal abnormalities, neurologic involvement) </li> <li>Plain radiographs may show bone abnormalities </li> <li>Focal splenic masses may be noted on abdominal ultrasound </li> </ul> </td> <td> <ul> <li>Diagnosis is confirmed by testing for specific enzyme deficiencies and/or genetic mutations </li> </ul> </td> </tr> <tr> <td><strong>Space-occupying lesions</strong> <ul class=\"decimal_heading\"> <li>Hemangioma </li> <li>Hamartoma </li> <li>Cysts </li> <li>Intracapsular hematoma (trauma) </li> </ul> </td> <td> <ul> <li>Hemangiomas: <ul> <li>Skin hemangiomas may be noted </li> </ul> </li> <li>Cysts and hamartomas: <ul> <li>Most are asymptomatic </li> <li>May be noted as incidental findings on abdominal imaging studies obtained for other reasons </li> </ul> </li> <li>Intracapsular hematoma: <ul> <li>In most cases, there is a clear preceding history of substantial blunt abdominal trauma </li> <li>Relatively minor trauma can cause splenic rupture in children with underlying splenomegaly due to another etiology (eg, mononucleosis) </li> </ul> </li> </ul> </td> <td> <ul> <li>Additional imaging studies (eg, CT or MRI) may be warranted </li> <li>Diagnosis is based on imaging findings </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBV: Epstein-Barr virus; CMV: cytomegalovirus; HIV: human immunodeficiency virus; IV: intravenous; TST: tuberculin skin test; TB: tuberculosis; IE: infective endocarditis; PCR: polymerase chain reaction; POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes; CT: computed tomography; RBC: red blood cell; LDH: lactate dehydrogenase; UVC: umbilical venous catheter; SLE: systemic lupus erythematosus; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; CBC: complete blood count; JRA: juvenile rheumatoid arthritis; MRI: magnetic resonance imaging.<br />* For detailed discussion of the diagnostic approach to these conditions, refer to separate UpToDate content on the specific disorder(s).</div><div id=\"graphicVersion\">Graphic 115359 Version 1.0</div></div></div>"},"115370":{"type":"graphic_table","displayName":"Microtia syndromes","title":"Genetic disorders and syndromes associated with microtia<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic disorders and syndromes associated with microtia<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Gene(s) involved</td> <td class=\"subtitle1\">Inheritance pattern</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/200110\" target=\"_blank\">Ablepharon-macrostomia syndrome</a></td> <td><em>TWIST2</em></td> <td>AD</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/201750\" target=\"_blank\">Antley-Bixler syndrome</a></td> <td><em>POR</em>, <em>FGFR2</em></td> <td>AR</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/602483\" target=\"_blank\">Auriculocondylar syndrome</a></td> <td><em>GNAI3</em>, <em>PLCB4</em>, <em>EDN1</em></td> <td>AD, AR</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/113620\" target=\"_blank\">Branchiooculofacial syndrome</a></td> <td><em>TFAP2A</em></td> <td>AD</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/602588\" target=\"_blank\">Branchiootic syndrome</a>, <a href=\"https://www.omim.org/entry/166780\" target=\"_blank\">otofaciocervical syndrome</a></td> <td><em>EYA1</em>, <em>SIX1</em>, <em>SIX5</em></td> <td>AD</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/214800\" target=\"_blank\">CHARGE syndrome</a></td> <td><em>CHD7</em></td> <td>AD</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/610706\" target=\"_blank\">Congenital deafness, with inner ear agenesis, microtia, and microdontia</a></td> <td><em>FGF3</em></td> <td>AR</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/616854\" target=\"_blank\">Even-plus syndrome</a></td> <td><em>HSPA9</em></td> <td>AR</td> </tr> <tr> <td><a href=\"https://www.omim.org/entry/164210\" target=\"_blank\">Hemifacial microsomia</a> (Goldenhar syndrome)</td> <td>Variable</td> <td>Sporadic, AD</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/118100\" target=\"_blank\">Klippel-Feil syndrome</a></td> <td><em>GDF6</em></td> <td>AD</td> </tr> <tr> <td colspan=\"3\">Mandibulofacial dysostosis (MFD):</td> </tr> <tr> <td class=\"indent1\"><a href=\"https://www.omim.org/entry/154500\" target=\"_blank\">Treacher Collins syndrome</a></td> <td><em>TCOF1</em></td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><a href=\"https://www.omim.org/entry/610536\" target=\"_blank\">MFD, guion-almeida type</a></td> <td><em>EFTUD2</em></td> <td>AD</td> </tr> <tr> <td class=\"indent1\"><a href=\"https://www.omim.org/entry/616367\" target=\"_blank\">Mandibulofacial dysostosis with alopecia</a></td> <td><em>EDNRA</em></td> <td>AD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><a href=\"https://www.omim.org/entry/300946\" target=\"_blank\">Diamond-Blackfan anemia with MFD</a></td> <td><em>TSR2</em>, <em>RPS26</em>, <em>RPS28</em></td> <td>XLR, AD</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/224690\" target=\"_blank\">Meier-Gorlin syndrome</a></td> <td><em>ORC1</em>, <em>ORC4</em>, <em>ORC6</em>, <em>CDT1</em>, <em>CDC6</em>, <em>CDC45L</em>, <em>GMNN</em></td> <td>AR</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/612290\" target=\"_blank\">Microtia, hearing impairment, and cleft palate</a></td> <td><em>HOXA2</em></td> <td>AD, AR</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/612109\" target=\"_blank\">Oculoauricular syndrome</a></td> <td><em>HMX1</em></td> <td>AR</td> </tr> <tr class=\"divider_bottom\"> <td><a href=\"https://www.omim.org/entry/107480\" target=\"_blank\">Townes-Brocks syndrome</a></td> <td><em>SALL1</em>, <em>DACT1</em></td> <td>AD</td> </tr> <tr> <td><a href=\"https://www.omim.org/entry/615546\" target=\"_blank\">Van Maldergem syndrome</a></td> <td><em>FAT4</em></td> <td>AR</td> </tr> <tr> <td><a href=\"https://www.omim.org/entry/236670\" target=\"_blank\">Walker-Warburg syndrome</a></td> <td><em>POMT1</em></td> <td>AR</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AD: autosomal dominant; AR: autosomal recessive; XLR: X-linked recessive.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Bartel-Friedrich S. Congenital Auricular Malformations: Description of Anomalies and Syndromes. Facial Plast Surg 2015; 32:567.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115370 Version 1.0</div></div></div>"},"115378":{"type":"graphic_diagnosticimage","displayName":"Juxtacortical hemorrhage in CVT","title":"Small nontraumatic juxtacortical hemorrhage associated with cerebral venous thrombosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small nontraumatic juxtacortical hemorrhage associated with cerebral venous thrombosis</div><div class=\"cntnt\"><img style=\"width:269px; height:350px;\" src=\"images/NEURO/115378_JuxtacorticalhemorrhgeCVT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A noncontrast head CT scan shows a small juxtacortical hemorrhage, which is a characteristic feature of CVT, particularly with thrombosis of the superior sagittal sinus.</div><div class=\"graphic_footnotes\">CT: computed tomography; CVT: cerebral venous thrombosis.</div><div class=\"graphic_reference\">Patr&iacute;cia Canh&atilde;o, MD, PhD.</div><div id=\"graphicVersion\">Graphic 115378 Version 1.0</div></div></div>"},"115385":{"type":"graphic_figure","displayName":"Ultrasound guided infraclavicular brachial plexus block","title":"Ultrasound guided infraclavicular brachial plexus block","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Ultrasound guided infraclavicular brachial plexus block</div><div class=\"cntnt\"><img style=\"width:533px; height:506px;\" src=\"images/ANEST/115385_Ultrasoundguidedinfraclavicularbrachialplexusblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound transducer is placed in the parasagittal plane below the clavicle, just medial to the coracoid process, as shown by the rectangle in this graphic. The needle is inserted in-plane with the transducer, as shown by the red dot,&nbsp;in&nbsp;a cephalad to caudad trajectory. For further details, refer to UpToDate content on ultrasound guided infraclavicular block.</div><div id=\"graphicVersion\">Graphic 115385 Version 1.0</div></div></div>"},"115386":{"type":"graphic_figure","displayName":"Nerve stimulator guided infraclavicular brachial plexus block","title":"Nerve stimulator guided infraclavicular brachial plexus block","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Nerve stimulator guided infraclavicular brachial plexus block</div><div class=\"cntnt\"><img style=\"width:533px; height:506px;\" src=\"images/ANEST/115386_Nervestimulatorguidedinfraclavicularbrachialplexusblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The needle is inserted vertically two centimeters medial and two centimeters caudad to the tip of the coracoid process, as shown by the red dot in this graphic. For further details, refer to UpToDate content on nerve stimulator guided infraclavicular block.</div><div id=\"graphicVersion\">Graphic 115386 Version 1.0</div></div></div>"},"115400":{"type":"graphic_table","displayName":"Exercise recommendations to lower blood pressure","title":"Exercise recommendations to lower blood pressure from professional committees and organizations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Exercise recommendations to lower blood pressure from professional committees and organizations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">The FITT of the Ex R<sub>x</sub></td> <td class=\"subtitle1\" colspan=\"6\">Professional committee/organization</td> </tr> <tr> <td class=\"subtitle2\">JNC 8<sup>[1]</sup> and AHA/ACC Lifestyle Work Group<sup>[2]</sup></td> <td class=\"subtitle2\">JNC 7<sup>[3]</sup></td> <td class=\"subtitle2\">AHA<sup>[4]</sup></td> <td class=\"subtitle2\">ACSM<sup>[5]</sup></td> <td class=\"subtitle2\">ESH/ESC<sup>[6]</sup></td> <td class=\"subtitle2\">CHEP<sup>[7]</sup></td> </tr> <tr> <td><strong>F</strong>requency<br /> (how often?)</td> <td> <p>3 to 4 sessions/week</p> &#8805;12 weeks</td> <td>Most days of the week</td> <td>Most days of the week</td> <td>Most, preferably all, days of the week</td> <td>5 to 7 days/week</td> <td>4 to 7 days/week in addition to habitual daily activity</td> </tr> <tr> <td><strong>I</strong>ntensity<br /> (how hard?)</td> <td>Moderate to vigorous*</td> <td>None specified</td> <td>Moderate to high, &#62;40 to 60% of maximum</td> <td>Moderate 40 to &#60;60% of VO<sub>2reserve</sub></td> <td>Moderate*</td> <td>Moderate*</td> </tr> <tr> <td><strong>T</strong>ime<br /> (how long?)</td> <td>40 minutes/session</td> <td>&#8805;30 minutes/day</td> <td>150 minutes/week</td> <td>30 to 60 minutes continuous or accumulated in bouts &#8805;10 minutes each</td> <td>&#8805;30 minutes/day</td> <td>Accumulation of 30 to 60 minutes/day</td> </tr> <tr> <td><strong>T</strong>ype<br /> (what kind?)<br /> Primary</td> <td>Aerobic</td> <td>Aerobic</td> <td>Aerobic</td> <td>Aerobic</td> <td>Aerobic</td> <td>Dynamic exercise (aerobic)</td> </tr> <tr> <td>Evidence rating</td> <td> <p>\"High\"<sup>&#182;</sup><sup>&#916;</sup></p> <p>Grade B<sup>&#182;</sup><sup>&#916;</sup></p> Class IIa level of evidence A<sup>&#9674;</sup></td> <td>&nbsp;</td> <td>Class 1 level of evidence A<sup>&#9674;</sup></td> <td>Evidence category A,<sup>&#167;</sup><sup>&#165;</sup> evidence category B<sup>&#167;</sup><sup>&#165;</sup></td> <td>Class 1 level of evidence A-B<sup>&#135;</sup></td> <td>Grade D<sup>&#134;,</sup>**</td> </tr> <tr> <td>Adjuvant</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Dynamic RT</td> <td> <p>Dynamic RT</p> <p>2 to 3 days/week</p> <p>Moderate 60 to 80%</p> 1-RM, 8 to 12 repetitions</td> <td> <p>Dynamic RT</p> 2 to 3 days/week</td> <td>Dynamic, isometric, or handgrip RT</td> </tr> <tr> <td>Evidence rating</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Class IIa level of evidence B<sup>&#9674;</sup></td> <td>Evidence category B<sup>&#167;,</sup><sup>&#182;&#182;</sup></td> <td>&nbsp;</td> <td>Grade D<sup>&#134;</sup></td> </tr> <tr> <td>BP&nbsp;reduction<br /> (mmHg)</td> <td>1 to 5</td> <td>4 to 9</td> <td>&nbsp;</td> <td>5 to 7 among those with hypertension</td> <td>2 to 3 overall; 5 to 7 among those with hypertension</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FITT: Frequency, Intensity, Time, and Type of the exercise prescription; Ex R<SUB>x</SUB>: exercise prescription; JNC 8: Eighth Joint National Committee; AHA: American Heart Association; ACC: American College of Cardiology; JNC 7: Seventh Joint National Committee; ACSM: American College of Sports Medicine; ESH: European Society of Hypertension; ESC: European Society of Cardiology; CHEP: Canadian Hypertension Education Program; VO<SUB>2reserve</SUB>: oxygen uptake reserve; RT: resistance training; 1-RM: one repetition maximum; BP: blood pressure; NHLBI: National Heart, Lung, and Blood Institute.<br />* Moderate intensity is defined as 40 to &lt;60% VO<SUB>2reserve</SUB> or an intensity that causes noticeable increases in heart rate and breathing; vigorous or high intensity is defined as ≥60% VO<SUB>2reserve</SUB> or an intensity that causes substantial increases in heart rate and breathing.<br />¶ The NHLBI<SUP>[2]</SUP> rating system grades the strength of the evidence (Evidence Statement) and the strength of the recommendation(s) (Evidence Recommendation); adapted from the US Preventive Services Task Force.<SUP>[8]</SUP><br />Δ The Lifestyle Work Group rated the Evidence Statement for aerobic exercise to lower blood pressure as \"high\"<SUP innerHtml>†</SUP>; the Evidence Recommendation for the Ex R<SUB>x</SUB> (or FITT) to lower blood pressure was rated grade B<SUP>¶</SUP> or \"moderate\"; corresponding to class IIa level of evidence A<SUP>◊</SUP>.<br /><FONT class=lozenge>◊</FONT> Classification of recommendations and level of evidence per AHA guideline criteria.<SUP>[4,9,10]</SUP><br />§ NHLBI grading of evidence.<SUP>[11]</SUP><br />¥ The strength of evidence was rated: Evidence category B<SUP>§</SUP> for the immediate effects of aerobic exercise or postexercise hypotension; evidence category A<SUP>§</SUP> for aerobic exercise to lower blood pressure; evidence category B<SUP>§</SUP> for the recommended aerobic Ex R<SUB>x</SUB> (or FITT) to lower blood pressure.<br />‡ ESC recommendations.<SUP>[12]</SUP><br />† CHEP graded recommendations by the underlying evidence<SUP>[13]</SUP> using grade A (strongest evidence, based on high-quality studies) to grade D (weakest evidence, based on low-power imprecise studies or expert opinion alone).<br />** CHEP assigned grade D<SUP>†</SUP> to \"higher intensity exercise is not more effective.\"<br />¶¶ The strength of evidence was rated evidence category C<SUP>‡</SUP> for the immediate effects of dynamic resistance exercise or postexercise hypotension.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears in JAMA 2014; 311:1809]. JAMA 2014; 311:507.</li>&#xD;&#xA;    <li>Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol 2014; 63:3027]. J Am Coll Cardiol 2014; 63:2960.</li>&#xD;&#xA;    <li>Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA 2003; 290:197]. JAMA 2003; 289:2560.</li>&#xD;&#xA;    <li>Brook RD, Appel LJ, Rubenfire M, et al. American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity. Beyond medications and diet: alternative approaches to lowering blood pressure; a scientific statement from the American Heart Association. Hypertension 2013; 61:1360.</li>&#xD;&#xA;    <li>Pescatello LS, Franklin BA, Fagard R, et al. American College of Sports Medicine position stand: exercise and hypertension. Med Sci Sports Exerc 2004; 36:533.</li>&#xD;&#xA;    <li>Mancia G, Fagard R, Narkiewicz K, et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014; 23:3.</li>&#xD;&#xA;    <li>Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014; 30:485.</li>&#xD;&#xA;    <li>U.S. Preventive Services Task Force Procedure Manual. Available at:&nbsp;<a href=\"http://www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual\" target=\"_blank\">http://www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual</a>. Published July 2008.</li>&#xD;&#xA;    <li>American Heart Association. Methodology Manual and Policies from the ACCF/AHA Task Force on Practice Guidelines. American Heart Association website. Available at: <a href=\"http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf\" target=\"_blank\">http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf</a>. Published June 2010.</li>&#xD;&#xA;    <li>Gibbons RJ, Smith S, Antman E. American College of Cardiology/American Heart Association clinical practice guidelines, Part I: where do they come from? Circulation 2003; 107:2979.</li>&#xD;&#xA;    <li>Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults &ndash; the evidence report: National Institutes of Health [published correction appears in Obes Res 1998; 6:464]. Obes Res 1998; 6:51S.</li>&#xD;&#xA;    <li>Writing ESC guidelines. European Society of Cardiology.</li>&#xD;&#xA;    <li>McAlister FA. The Canadian Hypertension Education Program &ndash; a unique Canadian initiative. Can J Cardiol 2006; 22:559.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original table modified for this publication. From: Pescatello LS, MacDonald HV, Ash GI, et al. Assessing the Existing Professional Exercise Recommendations for Hypertension: A Review and Recommendations for Future Research Priorities. Mayo Clin Proc 2015; 90:801. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115400 Version 1.0</div></div></div>"},"115401":{"type":"graphic_algorithm","displayName":"Antithrombotic therapy in KD based on CAA size","title":"Overview of antithrombotic therapy in patients with Kawasaki disease according to the size of coronary artery abnormalities<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div style=\"width: 1332px\" class=\"figure\"><div class=\"ttl\">Overview of antithrombotic therapy in patients with Kawasaki disease according to the size of coronary artery abnormalities<SUP>[1,2]</SUP></div><div class=\"cntnt\"><img style=\"width:1312px; height:578px;\" src=\"images/PEDS/115401_AntithrmbtcthrpyKDCAAsz.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content on Kawasaki disease (KD) and CAAs. Refer to UpToDate topics on the evaluation and management of cardiovascular sequelae of KD for additional details of our approach to treatment and the overall efficacy of these treatments.</div><div class=\"graphic_footnotes\">CAA: coronary artery aneurysm; LMWH: low molecular weight heparin.<br />* CAA size is classified according to the echocardiographic luminal diameter, normalized for body surface area as Z-scores or standard deviation units. Echocardiography should be performed in all patients with KD as soon as the diagnosis is suspected in order to establish a baseline for longitudinal follow-up. Repeat echocardiograms are usually obtained at one to two weeks and again four to six weeks after discharge.<br />¶ Some children who have coronary artery dimensions within the normal range (ie, Z-score &lt;2) have substantial reduction in coronary artery dimension over time, suggesting that the coronary artery was initially dilated. Such patients are categorized as \"dilation only\" despite always having coronary artery dimensions within the normal range.<br />Δ For details regarding long-term follow-up for patients with KD and CAAs, refer to UpToDate content on management of cardiovascular sequelae of KD.<br /><FONT class=lozenge>◊</FONT> Other antiplatelet agents (eg, clopidogrel) are reasonable alternatives for patients who are intolerant to aspirin.<br />§ Some experts use dual antiplatelet therapy for patients with \"high-risk\" CAAs that do not meet criteria for systemic anticoagulation. The evidence to support this practice is limited and consensus is lacking as to the appropriate criteria for identification of high-risk patients. In our practice, we use dual antiplatelet therapy in patients with a maximum Z-score of about 7.5 to &lt;10. Other experts may consider additional high-risk features, such as long length and distal location of aneurysms, large total number of CAAs, multiple branches affected, luminal irregularities, vessel wall abnormalities (calcification, luminal myofibroblastic proliferation), functional abnormalities (impaired vasodilation, impaired flow reserve), absence or poor quality of collateral vessels, previous revascularization performed, previous coronary artery thrombosis, previous myocardial infarction, and ventricular dysfunction.<br />¥ When \"triple therapy\" is used, the second antiplatelet agent is generally discontinued after 6 months.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135:e927.</LI>&#xD;&#xA;<LI>Manlhiot C, Millar K, Golding F, McCrindle BW. Improved classification of coronary artery abnormalities based only on coronary artery z-scores after Kawasaki disease. Pediatr Cardiol 2010; 31:242.</LI></OL></div><div id=\"graphicVersion\">Graphic 115401 Version 1.0</div></div></div>"},"115408":{"type":"graphic_figure","displayName":"Caliper measurements for pectus excavatum","title":"Assessment of pectus excavatum using thoracic calipers","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Assessment of pectus excavatum using thoracic calipers</div><div class=\"cntnt\"><img style=\"width:529px; height:372px;\" src=\"images/PEDS/115408_Calipermeasurementsforpectusexcavatum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Assessment of PE using thoracic calipers. Measurements are generally performed during quiet breathing, rather than maximal inspiration or expiration.<br />(A) Measurement at maximal sternal depression <br />(B) Measurement of thoracic width <br />The ratio of B/A is analogous to the CT-based&nbsp;PSI. However, there are no standards for defining PE severity using caliper measurements, and they cannot be used as a substitute for PSI. The primary use of caliper measurements is to document the deformity and monitor changes over time. </div><div class=\"graphic_footnotes\">PE: pectus excavatum; CT: computed tomography; PSI: pectus severity index.</div><div id=\"graphicVersion\">Graphic 115408 Version 1.0</div></div></div>"},"115417":{"type":"graphic_figure","displayName":"Pacemaker/defibrillator pad placement for sternotomy","title":"Placement of transcutaneous pacemaker/defibrillator pads for sternotomy incision","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Placement of transcutaneous pacemaker/defibrillator pads for sternotomy incision</div><div class=\"cntnt\"><img style=\"width:527px; height:371px;\" src=\"images/ANEST/115417_Pacemakerdefibrillatorpadplacementforsternotomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pads are placed to ensure that the heart is between the two pads, but that neither pad will be in the sterile surgical field.</div><div id=\"graphicVersion\">Graphic 115417 Version 1.0</div></div></div>"},"115419":{"type":"graphic_algorithm","displayName":"2-stage NICU screening","title":"Two-stage newborn hearing screening for infants admitted to neonatal level 2 and 3 care unit (neonatal intensive care unit [NICU])","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Two-stage newborn hearing screening for infants admitted to neonatal level 2 and 3 care unit (neonatal intensive care unit [NICU])</div><div class=\"cntnt\"><img style=\"width:451px; height:580px;\" src=\"images/PEDS/115419_2stageNICUscreening.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 115419 Version 2.0</div></div></div>"},"115420":{"type":"graphic_algorithm","displayName":"2-stage WB screening","title":"Two-stage newborn hearing screening for infants admitted to the well-baby nursery (neonatal level 1 care)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-stage newborn hearing screening for infants admitted to the well-baby nursery (neonatal level 1 care)</div><div class=\"cntnt\"><img style=\"width:422px; height:464px;\" src=\"images/PEDS/115420_2stageWBscreening.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Screening test for stage 2 is either by OAE or automated auditory brainstem response.<br />&para; Audiologic assessment for hearing loss is based on a diagnostic auditory brainstem response and is performed by an audiologist skilled in assessing infants and young children. The preferred timing for evaluation is prior to discharge from the birth hospitalization. However if this is not possible, evaluation should be done as soon as possible and no later than 3 months of age.</div><div id=\"graphicVersion\">Graphic 115420 Version 2.0</div></div></div>"},"115421":{"type":"graphic_figure","displayName":"RI management of NB at risk for hearing loss","title":"Rhode Island system for managing infants who fail the newborn hearing screen or are at risk for hearing loss","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Rhode Island system for managing infants who fail the newborn hearing screen or are at risk for hearing loss</div><div class=\"cntnt\"><img style=\"width:567px; height:407px;\" src=\"images/PEDS/115421_RImgmtNBriskhearngloss.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Figure demonstrating the comprehensive Rhode Island management system for tracking, monitoring, and managing infants at risk for hearing loss, including those who fail the newborn hearing screen.</div><div class=\"graphic_footnotes\">RIHAP: Rhode Island Hearing Assessment Program; DOH: Department of Health; WIC: Women, Infants, and Children Food and Nutrition Program.</div><div id=\"graphicVersion\">Graphic 115421 Version 1.0</div></div></div>"},"115423":{"type":"graphic_figure","displayName":"Local anesthetics in reported cases of LAST","title":"Local anesthetics in reported cases of LAST","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Local anesthetics in reported cases of LAST</div><div class=\"cntnt\"><img style=\"width:412px; height:396px;\" src=\"images/ANEST/115423_LocalanestheticsLAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the proportion of local anesthetic drugs used in LAST cases reported between 2010 and 2014.</div><div class=\"graphic_footnotes\">LAST: local anesthetic systemic toxicity.</div><div class=\"graphic_reference\">From: Vasques F, Behr AU, Weinberg G, et al. A review of local anesthetic systemic toxicity cases since publication of the American Society of Regional Anesthesia recommendations: To whom it may concern. Reg Anesth Pain Med 2015; 40:698. DOI: <A href=\"http://journals.lww.com/rapm/Abstract/2015/11000/A_Review_of_Local_Anesthetic_Systemic_Toxicity.7.aspx\" target=_blank>10.1097/AAP.0000000000000320</A>. Copyright © 2015 American Society of Regional Anesthesia and Pain Medicine. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115423 Version 1.0</div></div></div>"},"115424":{"type":"graphic_figure","displayName":"Onset time in reported cases of LAST","title":"Onset time in reported cases of LAST","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Onset time in reported cases of LAST</div><div class=\"cntnt\"><img style=\"width:336px; height:346px;\" src=\"images/ANEST/115424_OnsettimeLAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the onset after single-shot regional anesthesia in LAST cases reported between 2010 and 2014.</div><div class=\"graphic_footnotes\">LAST: local anesthetic systemic toxicity.</div><div class=\"graphic_reference\">From: Vasques F, Behr AU, Weinberg G, et al. A review of local anesthetic systemic toxicity cases since publication of the American Society of Regional Anesthesia recommendations: To whom it may concern. Reg Anesth Pain Med 2015; 40:698. DOI: <A href=\"http://journals.lww.com/rapm/Abstract/2015/11000/A_Review_of_Local_Anesthetic_Systemic_Toxicity.7.aspx\" target=_blank>10.1097/AAP.0000000000000320</A>. Copyright © 2015 American Society of Regional Anesthesia and Pain Medicine. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115424 Version 1.0</div></div></div>"},"115425":{"type":"graphic_figure","displayName":"Distribution of central nervous system manifestations of LAST","title":"Distribution of central nervous system manifestations of LAST","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Distribution of central nervous system manifestations of LAST</div><div class=\"cntnt\"><img style=\"width:338px; height:348px;\" src=\"images/ANEST/115425_DistCNSmanifestatnsLAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the prevalence of different neurological manifestations of toxicity in the LAST cases reported between 2010 and 2014.</div><div class=\"graphic_footnotes\">LAST: local anesthetic systemic toxicity.</div><div class=\"graphic_reference\">From: Vasques F, Behr AU, Weinberg G, et al. A review of local anesthetic systemic toxicity cases since publication of the American Society of Regional Anesthesia recommendations: To whom it may concern. Reg Anesth Pain Med 2015; 40:698. DOI: <A href=\"http://journals.lww.com/rapm/Abstract/2015/11000/A_Review_of_Local_Anesthetic_Systemic_Toxicity.7.aspx\" target=_blank>10.1097/AAP.0000000000000320</A>. Copyright © 2015 American Society of Regional Anesthesia and Pain Medicine. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115425 Version 1.0</div></div></div>"},"115426":{"type":"graphic_figure","displayName":"Distribution of cardiovascular manifestations of LAST","title":"Distribution of cardiovascular manifestations of LAST","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Distribution of cardiovascular manifestations of LAST</div><div class=\"cntnt\"><img style=\"width:502px; height:361px;\" src=\"images/ANEST/115426_DistcrdvsclrmanfstnsLAST.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagram showing the prevalence of different cardiovascular manifestations of toxicity in&nbsp;LAST cases reported between 2010 and 2014.</div><div class=\"graphic_footnotes\">LAST: local anesthetic systemic toxicity; VT/VF: ventricular tachycardia/ventricular fibrillation; AV: atrioventricular; ST: ST tract.</div><div class=\"graphic_reference\">From: Vasques F, Behr AU, Weinberg G, et al. A review of local anesthetic systemic toxicity cases since publication of the American Society of Regional Anesthesia recommendations: To whom it may concern. Reg Anesth Pain Med 2015; 40:698. DOI: <A href=\"http://journals.lww.com/rapm/Abstract/2015/11000/A_Review_of_Local_Anesthetic_Systemic_Toxicity.7.aspx\" target=_blank>10.1097/AAP.0000000000000320</A>. Copyright © 2015 American Society of Regional Anesthesia and Pain Medicine. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115426 Version 1.0</div></div></div>"},"115427":{"type":"graphic_table","displayName":"Oculocutaneous albinism genetic classification","title":"Genetic classification of oculocutaneous albinism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic classification of oculocutaneous albinism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"12.5%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of albinism</td> <td class=\"subtitle1\">MIM #</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Encoding function</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>OCA1*</td> <td>606933</td> <td class=\"divider_bottom\" rowspan=\"3\"><em>TYR</em></td> <td class=\"divider_bottom\" rowspan=\"3\">11q14-11q21</td> <td class=\"divider_bottom\" rowspan=\"3\">Tyrosinase, which catalyzes several steps in melanogenesis</td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>OCA1A: No melanin </li> <li>OCA1B: Varying amounts of melanin are present </li> </ul> </td> </tr> <tr> <td>OCA1A</td> <td>203100</td> </tr> <tr class=\"divider_bottom\"> <td>OCA1B</td> <td>606952</td> </tr> <tr class=\"divider_bottom\"> <td>OCA2</td> <td>203200</td> <td><em>OCA2</em> (previously called <em>P</em> gene)</td> <td>15q11.2-15q12</td> <td>Melanosomal membrane protein</td> <td> <ul> <li>Common in sub-Saharan Africa due to 2.7 kb deletion </li> <li>Includes brown OCA </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>OCA3</td> <td>203290</td> <td><em>TYRP1</em></td> <td>9p23</td> <td>Stabilizes tyrosinase and regulates eumelanin production</td> <td> <ul> <li>Previously called red or rufous OCA </li> <li>Common in Africa </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>OCA4</td> <td>696574</td> <td><em>SLC45A2</em> (previously called <em>MATP</em> and <em>AIM1</em>)</td> <td>5p13.2</td> <td>Membrane transport protein</td> <td> <ul> <li>Minimal to near normal melanin </li> <li>Phenotype similar to OCA2 </li> <li>Common in Japan </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>OCA5</td> <td>615312</td> <td>Unknown</td> <td>4q24</td> <td>Unknown</td> <td> <ul> <li>Described in a Pakistani family </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>OCA6</td> <td>609802</td> <td><em>SLC24A5</em></td> <td>15q21.1</td> <td>Melanosome maturation</td> <td> <ul> <li>Described in a Chinese family </li> </ul> </td> </tr> <tr> <td>OCA7</td> <td>615179</td> <td><em>C10orf11</em></td> <td>10q22.2-10q22.3</td> <td>Melanocyte differentiation</td> <td> <ul> <li>Described in families on the&nbsp;Faroe Islands </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OCA: oculocutaneous albinism.<br />* OCA1 includes previously described temperature-sensitive OCA, minimal pigment OCA, and yellow OCA.</div><div class=\"graphic_reference\">Original figure modified for this publication. From: Summer CG. Albinism. In: Taylor and Hoyt's Pediatric Ophthalmology and Strabismus, 5th ed, Lambert SR, Lyons CJ (Eds), Elsevier, Atlanta 2017. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115427 Version 1.0</div></div></div>"},"115428":{"type":"graphic_table","displayName":"Classification of parenteral and oral cephalosporins","title":"Classification of parenteral and oral cephalosporins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of parenteral and oral cephalosporins</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">First generation</td> <td class=\"subtitle1\">Second generation</td> <td class=\"subtitle1\">Second generation/Cephamycins*</td> <td class=\"subtitle1\">Third generation</td> <td class=\"subtitle1\">Fourth generation</td> <td class=\"subtitle1\">Advanced generation and combination agents</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Parenteral cephalosporins</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Cefazolin (Ancef, Kefzol) </li> <li>Cephalothin (Keflin, <span style=\"white-space: nowrap;\">Seffin)<sup>&#182;</sup></span></li> <li>Cephapirin <span style=\"white-space: nowrap;\">(Cefadyl)<sup>&#182;</sup></span></li> <li>Cephradine <span style=\"white-space: nowrap;\">(Velosef)<sup>&#182;</sup></span></li> </ul> </td> <td> <ul> <li>Cefamandole <span style=\"white-space: nowrap;\">(Mandol)<sup>&#182;</sup></span></li> <li>Cefonicid <span style=\"white-space: nowrap;\">(Monocid)<sup>&#182;</sup></span> </li> <li>Cefuroxime (Kefurox, Zinacef) </li> </ul> </td> <td> <ul> <li>Cefmetazole <span style=\"white-space: nowrap;\">(Zefazone)<sup>&#182;</sup></span></li> <li>Cefotetan (Cefotan) </li> <li>Cefoxitin (Mefoxin) </li> </ul> </td> <td> <ul> <li>Cefoperazone <span style=\"white-space: nowrap;\">(Cefobid)<sup>&#182;</sup></span> </li> <li>Cefotaxime (Claforan) </li> <li>Ceftazidime (Fortaz)<sup>&#916;</sup> </li> <li>Ceftizoxime <span style=\"white-space: nowrap;\">(Cefizox)<sup>&#182;</sup></span> </li> <li>Ceftriaxone (Rocephin) </li> <li>Moxalactam<sup>&#182;</sup></li> </ul> </td> <td> <ul> <li>Cefepime (Maxipime) </li> <li>Cefpirome <span style=\"white-space: nowrap;\">(Cefrom)<sup>&#182;</sup></span></li> </ul> </td> <td> <ul> <li>Ceftaroline (Teflaro) </li> <li>Ceftobiprole <span style=\"white-space: nowrap;\">(Zeftera)<sup>&#182;</sup></span></li> <li><span style=\"white-space: nowrap;\">Ceftolozane-tazobactam <span style=\"white-space: nowrap;\">(Zerbaxa)<span class=\"_TELERIK_InsertParagraph\">&nbsp;</span></span></span></li> <li><span style=\"white-space: nowrap;\">Ceftazidime-avibactam (Avycaz, Zavicefta)</span></li> <li><span style=\"white-space: nowrap;\">Cefoperazone-sulbactam<sup>&#182;</sup></span></li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oral cephalosporins</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cefadroxil (Duricef, Ultracef) </li> <li>Cephalexin (Keflex, Biocef, Keftab) </li> <li>Cephradine <span style=\"white-space: nowrap;\">(Velosef)<sup>&#182;</sup></span></li> </ul> </td> <td> <ul> <li>Cefaclor <span style=\"white-space: nowrap;\">(Ceclor)<sup>&#182;</sup></span></li> <li>Cefprozil (Cefzil) </li> <li>Cefuroxime-axetil (Ceftin) </li> <li>Loracarbef <span style=\"white-space: nowrap;\">(Lorabid)<sup>&#182;</sup></span></li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Cefdinir (Omnicef) </li> <li>Cefditoren (Spectracef) </li> <li>Cefixime (Suprax) </li> <li>Cefpodoxime-proxetil (Vantin) </li> <li>Ceftibuten (Cedax) </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cefamycins have a chemical structure that is distinct from that of cephalosporins but functionally similar, and they are often classified as cephalosporins.<br />¶&nbsp;No longer marketed in the United States.<br />Δ Unlike most other third generation cephalosporins, ceftazidime has expected activity against <EM innerHtml>Pseudomonas </EM>species; however, it has relatively poor activity against gram-positive organisms.</div><div class=\"graphic_reference\">Original table modified for this publication. Craig WA, Andes DR. Cephalosporins. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Bennett JE, Dolin R, Blaser MJ (Eds), 8th ed, Elsevier, Philadelphia 2015. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115428 Version 1.0</div></div></div>"},"115429":{"type":"graphic_figure","displayName":"Estimation of gestational age by fundal height","title":"Estimation of gestational age by fundal height","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estimation of gestational age by fundal height</div><div class=\"cntnt\"><img style=\"width:414px; height:604px;\" src=\"images/OBGYN/115429_Estimationofgestationalagebyfundalheight.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The solid lines indicate the height of the fundus by weeks of gestation in a normally grown singleton gestation.</div><div id=\"graphicVersion\">Graphic 115429 Version 1.0</div></div></div>"},"115430":{"type":"graphic_picture","displayName":"Oculocutaneous albinism type 1A","title":"Oculocutaneous albinism type 1A","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oculocutaneous albinism type 1A</div><div class=\"cntnt\"><img style=\"width:378px; height:533px;\" src=\"images/DERM/115430_Oculocutaneousalbinism1A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White hair and eyelashes in a patient with oculocutaneous albinism type 1A (OCA1A).</div><div id=\"graphicVersion\">Graphic 115430 Version 1.0</div></div></div>"},"115431":{"type":"graphic_diagnosticimage","displayName":"Primary thrombosis of right subclavian vein","title":"Primary thrombosis of right subclavian vein","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Primary thrombosis of right subclavian vein</div><div class=\"cntnt\"><img style=\"width:764px; height:744px;\" src=\"images/SURG/115431_Rtprmrythrmbssubclavnvn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MR venography shows&nbsp;the appearance of the subclavian veins in a 14-year-old girl following resolution of primary right upper extremity deep vein thrombosis with anticoagulation&nbsp;(A). With elevation of the extremities,&nbsp;dynamic MR venography demonstrated compression of subclavian veins bilaterally (B). After anticoagulation was discontinued, she presented with recurrent symptoms. Catheter-based venography showed chronic occlusion (C),&nbsp;and she underwent right first rib resection and open subclavian venoplasty, which resolved her symptoms.</div><div class=\"graphic_footnotes\">MR: magnetic resonance.</div><div id=\"graphicVersion\">Graphic 115431 Version 1.0</div></div></div>"},"115432":{"type":"graphic_picture","displayName":"Oculocutaneous albinism type 1B","title":"Oculocutaneous albinism type 1B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oculocutaneous albinism type 1B</div><div class=\"cntnt\"><img style=\"width:375px; height:565px;\" src=\"images/DERM/115432_Oculocutaneousalbinism1B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patient with oculocutaneous albinism type 1B (OCA1B), due to two mutations in the <EM>TYR</EM> gene, was born with white hair and lashes but, later in childhood, developed some pigment.</div><div id=\"graphicVersion\">Graphic 115432 Version 1.0</div></div></div>"},"115433":{"type":"graphic_picture","displayName":"Oculocutaneous albinism type 2","title":"Oculocutaneous albinism type 2","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Oculocutaneous albinism type 2</div><div class=\"cntnt\"><img style=\"width:535px; height:706px;\" src=\"images/DERM/115433_Oculocutaneousalbinism2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An African-American girl with oculocutaneous albinism type 2.</div><div id=\"graphicVersion\">Graphic 115433 Version 1.0</div></div></div>"},"115434":{"type":"graphic_figure","displayName":"Mechanisms of increased renal plasma flow in pregnancy","title":"Mechanisms of increased renal plasma flow in pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanisms of increased renal plasma flow in pregnancy</div><div class=\"cntnt\"><img style=\"width:380px; height:359px;\" src=\"images/OBGYN/115434_Mchincrnlplsmflwprgncy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Working model of vascular and renal effects of relaxin in pregnancy.</div><div class=\"graphic_footnotes\">hCG: human chorionic gonadotropin; MMP: matrix metalloproteinase; ET: endothelin; NO: nitric oxide; GFR: glomerular filtration rate; RPF: renal plasma flow.</div><div class=\"graphic_reference\">Adapted from: Conrad KP. Maternal vasodilation in pregnancy: The emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011; 301:R267.</div><div id=\"graphicVersion\">Graphic 115434 Version 1.0</div></div></div>"},"115436":{"type":"graphic_table","displayName":"Comparison of types of diabetes insipidus in pregnancy","title":"Comparison of types of diabetes insipidus in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of types of diabetes insipidus in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Central DI in pregnancy</td> <td class=\"subtitle1\">Nephrogenic DI in pregnancy</td> <td class=\"subtitle1\">Transient DI of pregnancy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Associations</strong></td> <td>Surgical trauma, head trauma, pituitary adenoma, autoimmune or other infiltration, idiopathic, <em>AVP</em> gene mutation, Wolfram syndrome, anorexia nervosa, toxin (alcohol, snake venom)</td> <td><em>AVPR2</em> and <em>Aquaporin-2</em> gene mutations, lithium toxicity, medullary cystic kidney disease, polycystic kidney, hypokalemia, hypercalcemia, sickle cell disease or trait</td> <td>May be associated with preeclampsia and/or liver abnormalities. Can result in postpartum DI due to placental abruption resulting in release of vasopressinase.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vasopressin sensitivity: Pathophysiology</strong></td> <td>Sensitive: Decreased secretory reserve of <em>AVP</em> from pituitary; <em>AVP</em> levels may be further decreased by clearance by placental vasopressinase</td> <td>Resistant: Renal resistance to <em>AVP</em></td> <td>Sensitive: Increased placental vasopressinase mediated clearance of <em>AVP</em></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Timing of presentation</strong></td> <td>May present in any trimester, may be recurrent</td> <td>May present in any trimester, may be recurrent</td> <td>Typically presents in the third trimester, though symptoms may be as early as fourth week of gestation. Rarely occurs postpartum (placental abruption).</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Diagnosis: Response to DDAVP administration</strong></td> <td>Urine osmolality normalized</td> <td>No change to urine osmolality</td> <td>Urine osmolality normalized</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Diagnosis: Plasma <em>AVP</em> level</strong></td> <td>Low to absent</td> <td>Normal to high</td> <td>Low to absent</td> </tr> <tr> <td><strong>Management</strong></td> <td>Responds to DDAVP, may respond to <em>AVP</em> (although the latter can be destroyed by placental vasopressinase during pregnancy)</td> <td>May be resistant to both <em>AVP</em> and DDAVP; consider hydrochlorothiazide or amiloride</td> <td>Responds to DDAVP, resistant to <em>AVP</em></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DI: diabetes insipidus; <em>AVP</em>: <em>arginine vasopressin</em>; DDAVP: desmopressin.</div><div class=\"graphic_reference\">Reproduced from: Ananthakrishnan S. Diabetes insipidus during pregnancy. Best Pract Res Clin Endocrinol Metab 2016; 30:305. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115436 Version 1.0</div></div></div>"},"115437":{"type":"graphic_picture","displayName":"Fetal surface of placenta","title":"Fetal surface of placenta","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Fetal surface of placenta</div><div class=\"cntnt\"><img style=\"width:630px; height:459px;\" src=\"images/OBGYN/115437_Fetalsurfaceplacenta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arteries (arrow) cross over the veins (dashed arrow).</div><div id=\"graphicVersion\">Graphic 115437 Version 1.0</div></div></div>"},"115443":{"type":"graphic_picture","displayName":"Binding injured pelvis with sheet 2","title":"Binding injured pelvis with sheet 2","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Binding injured pelvis with sheet 2</div><div class=\"cntnt\"><img style=\"width:720px; height:514px;\" src=\"images/SURG/115443_Bindinginjpelvissheet2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sheet is positioned over the greater trochanters, and the ends of the sheet are crossed in an overlapping manner anteriorly and are pulled tight. Clamps secure the smooth and snug sheet. </div><div id=\"graphicVersion\">Graphic 115443 Version 2.0</div></div></div>"},"115444":{"type":"graphic_picture","displayName":"Control of pelvic bleeding with aortic balloon","title":"Control of pelvic bleeding with aortic balloon","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Control of pelvic bleeding with aortic balloon</div><div class=\"cntnt\"><img style=\"width:760px; height:480px;\" src=\"images/SURG/115444_PlcfctrctrlplcbdREBOA2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A sheet has been placed around the pelvis for initial fracture stabilization. For preemptive control of bleeding from a right-sided pelvic fracture, a 7-French arterial sheath has been placed into the&nbsp;right common femoral artery and the REBOA balloon inflated in zone III. The catheter is held in position using an occlusive dressing. The bedside plain abdominal film (B) shows balloon deployment in zone III, just above the aortic bifurcation. Right superior and inferior rami fractures and separation of&nbsp;the&nbsp;right sacroiliac joint can also be seen. </div><div class=\"graphic_footnotes\">REBOA: resuscitative endovascular balloon occlusion of the aorta.</div><div id=\"graphicVersion\">Graphic 115444 Version 1.0</div></div></div>"},"115445":{"type":"graphic_algorithm","displayName":"Antiplatelet therapy for diabetic muscle infarction","title":"Antiplatelet therapy for diabetic muscle infarction*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Antiplatelet therapy for diabetic muscle infarction*</div><div class=\"cntnt\"><img style=\"width:401px; height:231px;\" src=\"images/RHEUM/115445_Antptthpydbtcmsclinfctn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drug.<br />* Refer to UpToDate topic on diabetic muscle infarction.<br />&para; In patients on both aspirin and an NSAID, refer to UpToDate topic on cardiovascular adverse effects of NSAIDs for a discussion of coadministration of aspirin and NSAIDs.<br />&Delta; Contraindications to aspirin include active peptic ulcer disease, aspirin-exacerbated respiratory disease, and aspirin allergy.</div><div id=\"graphicVersion\">Graphic 115445 Version 1.0</div></div></div>"},"115446":{"type":"graphic_diagnosticimage","displayName":"Left spontaneous pneumothorax CT","title":"Left spontaneous pneumothorax on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Left spontaneous pneumothorax on computed tomography</div><div class=\"cntnt\"><img style=\"width:714px; height:754px;\" src=\"images/PULM/115446_LspntneouspneumothoraxCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic coronal multiplanar reformation image shows a spontaneous small left apical pneumothorax (arrowhead) and two apical bullae (arrow) in patient with severe paraseptal emphysema and apical bullae.</div><div id=\"graphicVersion\">Graphic 115446 Version 1.0</div></div></div>"},"115447":{"type":"graphic_diagnosticimage","displayName":"Right tension pneumothorax","title":"Radiograph of tension pneumothorax due to trauma","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Radiograph of tension pneumothorax due to trauma</div><div class=\"cntnt\"><img style=\"width:762px; height:354px;\" src=\"images/PULM/115447_Righttensionpneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph shows a large right pneumothorax with complete collapse of the right lung (arrowhead) in a patient with traumatic rupture of the right hemidiaphragm; the image also shows shift of the trachea to the left and widening of the right intercostal spaces, when compared to the left side. Multiple gas-containing bowel loops project above the level of the right hemidiaphragm (dashed arrow).<br />(B) Prior to the development of the pneumothorax, computed tomography of the chest in the same patient shows multiple intrathoracic loops of bowel at the periphery of the ruptured right hemidiaphragm (arrow).</div><div id=\"graphicVersion\">Graphic 115447 Version 1.0</div></div></div>"},"115448":{"type":"graphic_diagnosticimage","displayName":"Tension hydropneumothorax","title":"Left tension hydropneumothorax","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Left tension hydropneumothorax</div><div class=\"cntnt\"><img style=\"width:762px; height:506px;\" src=\"images/PULM/115448_Tensionhydropneumothorax.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph shows a left tension hydropneumothorax after balloon dilation of a lower esophageal stricture. The left apical pneumothorax (arrow) is seen with basal accumulation of pleural effusion and a gas-liquid level. The left hemidiaphragm is completely obscured and the cardiomediastinal structures, including the trachea are displaced to the right.<br />(B) An oral esophagram with nonionic, water-soluble contrast material in the same patient shows extravasation of contrast material into the mediastinum and left pleural space, indicating an esophageal tear.</div><div id=\"graphicVersion\">Graphic 115448 Version 1.0</div></div></div>"},"115449":{"type":"graphic_diagnosticimage","displayName":"TB empyema","title":"Tuberculous empyema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculous empyema</div><div class=\"cntnt\"><img style=\"width:401px; height:762px;\" src=\"images/PULM/115449_TBempyema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial view of computed tomography of the thorax shows a right peripheral crescentic collection of liquid surrounded by a circumferential calcific shell (arrow), with thickening of the adjacent extrapleural layer of fat, thickening of the cortex and sclerosis of the adjacent right ribs. Due to restriction of the right lung expansion, the right hemithorax is smaller than the left and the cardiomediastinal structures are shifted to the right.<br />(B) Coronal multiplanar reformation of the chest CT images demonstrates the craniocaudal extent of the pleural process.</div><div id=\"graphicVersion\">Graphic 115449 Version 1.0</div></div></div>"},"115451":{"type":"graphic_table","displayName":"Anticancer agents: Interactions with antiretroviral agents","title":"Anticancer agents: Potential for interaction with antiretroviral agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticancer agents: Potential for interaction with antiretroviral agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"25%\"></colgroup><colgroup span=\"2\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticancer drugs</td> <td class=\"subtitle1\">Route of elimination*</td> <td class=\"subtitle1\">Effect on CYP450/transporters<sup>&#182;</sup></td> <td class=\"subtitle1\">Effect of ARV on cancer drugs as a substrate</td> <td class=\"subtitle1\">Alteration to ARV due to enzyme or transporter induction or inhibition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Alkylating agents</td> </tr> <tr> <td class=\"indent1\">Bendamustine<sup>[1,2]</sup></td> <td><strong><em>CYP1A2</em></strong>, ABCB1, ABCG2</td> <td>None</td> <td>3</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Busulfan<sup>[3,4,11]</sup></td> <td>Glutathione S-transferase, CYP3A4</td> <td>None</td> <td>3</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Carmustine<sup>[5]</sup></td> <td>Not determined</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Chlorambucil<sup>[6-8,11]</sup></td> <td>ABCC1, ABCC2</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide<sup>[9-11,16,167,168]</sup></td> <td>CYP2A6, <strong><em>CYP2B6</em></strong>, CYP2C8, CYP2C9, CYP2C19, CYP3A4/5</td> <td> <p>Inducer: CYP2B6, CYP2C8, CYP2C9</p> Inhibitor: CYP3A4, UGT<sup>&#916;</sup></td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Dacarbazine<sup>[12]</sup></td> <td>CYP1A2 , CYP2E1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Estramustine<sup>[13]</sup></td> <td>Alkaline phosphatase</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Ifosfamide<sup>[9,11,14-17]</sup></td> <td>CYP2A6, <strong><em>CYP2B6</em></strong>, CYP2C8, CYP2C9, CYP2C19, <strong><em>CYP3A4/5</em></strong></td> <td> <p>Inducer: CYP2C8, CYP2C9</p> Inhibitor: CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Lomustine<sup>[18-20]</sup></td> <td>CYP2D6</td> <td>Inhibitor: CYP2D6, CYP3A4</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Mechlorethamine<sup>[21]</sup></td> <td>Not determined</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Melphalan<sup>[8,22]</sup></td> <td>Chemical hydrolysis, ABCC1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Procarbazine<sup>[23]</sup></td> <td>Auto-oxidation</td> <td>Inhibitor: <strong><em>Monoamine oxidase</em></strong></td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Streptozocin<sup>[24]</sup></td> <td>Not determined</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Temozolomide<sup>[25-27]</sup></td> <td>Hydrolysis, ABCB1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Thiotepa<sup>[28-31]</sup></td> <td>Glutathione S-transferase, CYP2B6, CYP3A4/5</td> <td>Inhibitor: CYP2B6</td> <td>2</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trabectedin<sup>[250-253]</sup></td> <td>CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, <strong><em>CYP3A4/5</em></strong>, glutathione S-transferase, UGT2B15, UGT<sup>&#916;</sup>, ABCB1</td> <td>None</td> <td>4</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Anthracyclines/anthracenedione</td> </tr> <tr> <td class=\"indent1\">Daunorubicin<sup>[8,32,33,37]</sup></td> <td><strong><em>Aldoketoreductase</em></strong>, NADPH-dependent cytochrome reductase, ABCB1, ABCC1, ABCG2</td> <td>Inducer: ABCB1</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Doxorubicin<sup>[8,11,16,18,19,32-35,37]</sup></td> <td><strong><em>Aldoketoreductase</em></strong>, NADPH-dependent cytochrome reductase, CYP2D6, CYP3A4, ABCB1, ABCC1, ABCC2, ABCG2, SLC22A16</td> <td> <p>Inducer: ABCB1</p> Inhibitor: CYP2B6, CYP2D6, CYP3A4</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Epirubicin<sup>[8,11,33,36,37]</sup></td> <td><strong><em>Aldoketoreductase</em></strong>, NADPH-dependent cytochrome reductase, ABCG2</td> <td>Inducer: ABCB1</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Idarubicin<sup>[37,38]</sup></td> <td><strong><em>Aldoketoreductase</em></strong>, NADPH-dependent cytochrome reductase, ABCB1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mitoxantrone<sup>[8,20,39,187]</sup></td> <td>ABCB1, ABCG2</td> <td> <p>Inducer: CYP2E1</p> Inhibitor: CYP3A4, SLC47A1</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Antiandrogen or androgen receptor antagonist</td> </tr> <tr> <td class=\"indent1\">Abiraterone<sup>[173]</sup></td> <td><strong><em>CYP3A4</em></strong>, SULT2A1</td> <td>Inhibitor: CYP1A2, CYP2C8, CYP2C9, CYP2C19, <strong><em>CYP2D6</em></strong>, CYP3A4/5, ABCB1</td> <td>4</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Enzalutamide<sup>[188]</sup></td> <td><strong><em>CYP2C8</em></strong>, <strong><em>CYP3A4</em></strong></td> <td> <p>Inducer: <strong><em>CYP2C9</em></strong>, <strong><em>CYP2C19</em></strong>, <strong><em>CYP3A4</em></strong></p> Inhibitor: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, ABCB1</td> <td>4</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Antitumor antibiotic</td> </tr> <tr> <td class=\"indent1\">Bleomycin<sup>[11,40]</sup></td> <td>Non-enzymatic</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Dactinomycin<sup>[41]</sup></td> <td>Not determined</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mitomycin C<sup>[11,42,43]</sup></td> <td>NADPH-dependent cytochrome reductase, xanthine oxidase, ABCB1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Antimetabolite</td> </tr> <tr> <td class=\"indent1\">Capecitabine<sup>[16,44,45,56]</sup></td> <td><strong><em>Carboxylesterase</em></strong>, cytidine deaminase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, ABCC4, ABCG2</td> <td>Inhibitor: <strong><em>CYP2C9</em></strong></td> <td>1</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Cladribine<sup>[47]</sup></td> <td><strong><em>Deoxycytidine kinase</em></strong>, 5'-nucleotidase</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Clofarabine<sup>[46,49,50]</sup></td> <td><strong><em>Deoxycytidine kinase</em></strong>, 5'-nucleotidase, ABCG2, SLC22A1, SLC22A6, SLC22A8</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Cytarabine<sup>[11,51-53,189]</sup></td> <td><strong><em>Cytidine deaminase</em></strong>, <strong><em>deoxycytidine kinase</em></strong>, 5'-nucleotidase, SLC28A1, SLC29A1</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Fludarabine<sup>[48,54]</sup></td> <td><strong><em>Deoxycytidine kinase</em></strong>, 5'-nucleotidase</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">5-Fluorouracil<sup>[11,16,45,52,55,56]</sup></td> <td><strong><em>Dihydropyrimidine dehydrogenase</em></strong>, thymidine phosphorylase, ABCC4, ABCG2, SLC22A7</td> <td>Inhibitor: <strong><em>CYP2C9</em></strong></td> <td>1</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Gemcitabine<sup>[16,57,58]</sup></td> <td><strong><em>Cytidine deaminase</em></strong>, cytidylate kinase, deoxycytidylate deaminase, <strong><em>deoxycytidine kinase</em></strong>, SLC28A1, SLC28A3, SLC29A1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Hydroxyurea<sup>[59,190,191]</sup></td> <td>SLCO1B3</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">6-Mercaptopurine<sup>[11,16,60-63]</sup></td> <td><strong><em>Thiopurine methyltransferase</em></strong>, ABCC4, SLC28A2, SLC28A3, SLC29A1, SLC29A2</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Methotrexate<sup>[8,11,16,64-69,189]</sup></td> <td>ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCG2, SLC19A1, SLC22A6, SLC22A7, SLC22A8, SLC22A9, SLC46A1, SLCO1A2, SLCO1B1, SLCO1B3, SLCO4C1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Nelarabine<sup>[70]</sup></td> <td><strong><em>Adenosine deaminase</em></strong></td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Pemetrexed<sup>[71,72,192]</sup></td> <td><strong><em>Non-enzymatic</em></strong>, SLC1A91, SLC22A8</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Pentostatin<sup>[73]</sup></td> <td>Non-enzymatic</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">6-Thioguanine<sup>[16,61,62,64]</sup></td> <td><strong><em>Thiopurine methyltransferase</em></strong>, ABCC4</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trifluridine/tipiracil<sup>[254,255]</sup></td> <td><strong><em>Thymidine phosphorylase</em></strong>, SLC22A2</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Antimicrotubular</td> </tr> <tr> <td class=\"indent1\">Cabazitaxel<sup>[74]</sup></td> <td>CYP2C8, <strong><em>CYP3A4/5</em></strong>, ABCB1</td> <td>Inhibitor: ABCB1, ABCG2, SLCO1B1, SLCO1B3</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Docetaxel<sup>[8,11,16,75-79,189,193]</sup></td> <td>CYP1B1, <strong><em>CYP3A4/5</em></strong>, ABCB1, ABCC1, ABCC2, ABCG2, SLC22A7, SLCO1B1, SLCO1B3</td> <td>Inhibitor: CYP3A4</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Eribulin<sup>[80,81]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, SLCO1B3</td> <td>Inhibitor: CYP3A4, ABCB1</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Ixabepilone<sup>[82]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1</td> <td>Inhibitor: ABCB1</td> <td>4</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Paclitaxel<sup>[8,11,16,75,77,79,83,84,189]</sup></td> <td>CYP1B1, <strong><em>CYP2C8</em></strong>, <strong><em>CYP3A4</em></strong>, ABCB1, ABCC1, ABCC2, ABCG2, SLC22A7, SLCO1B1, SLCO1B3</td> <td>Inducer: CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Apoptosis-targeting agent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Venetoclax<sup>[256-260]</sup></td> <td><strong><em>CYP3A4/5</em></strong>, ABCB1, ABCG2</td> <td> <p>Inducer: CYP2C8, CYP3A4</p> Inhibitor: <strong><em>ABCB1</em></strong>, ABCG2, CYP2C8, CYP2C9, UGT1A1</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Aromatase inhibitor</td> </tr> <tr> <td class=\"indent1\">Anastrozole<sup>[85,86]</sup></td> <td>CYP2C8, CYP2C9, CYP3A4/5, UGT1A4</td> <td>Inhibitor: CYP1A2, CYP2C8, CYP2C9, CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Exemestane<sup>[87,88,194]</sup></td> <td>CYP1A1/2, <strong><em>CYP3A4</em></strong>, CYP4A11, aldoketoreductase, UGT2B17</td> <td>None</td> <td>4</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Letrozole<sup>[89,90]</sup></td> <td>CYP2A6, CYP3A4</td> <td>Inhibitor: <strong><em>CYP2A6</em></strong>, CYP2C19</td> <td>2</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Camptothecins</td> </tr> <tr> <td class=\"indent1\">Irinotecan<sup>[16,91-94,195]</sup></td> <td><strong><em>Carboxylesterase</em></strong>, CYP2B6, <strong><em>CYP3A4/5</em></strong>, UGT1A1, UGT1A9, UGT1A10, ABCB1, ABCC1, ABCC2, ABCG2, SLCO1B1</td> <td>None</td> <td>4</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Topotecan<sup>[8,95,96]</sup></td> <td>Non-enzymatic, CYP3A4, UGT<sup>&#916;</sup>, ABCB1, ABCC4, ABCG2</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Cyclin-dependent kinase inhibitor</td> </tr> <tr> <td class=\"indent1\">Palbociclib<sup>[261-264]</sup></td> <td><strong><em>CYP3A4/5</em></strong>, SULT2A1, UGT<sup>&#916;</sup>, ABCB1, ABCG2</td> <td>Inhibitor: <strong><em>CYP3A4</em></strong></td> <td>4</td> <td>4</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ribociclib<sup>[265]</sup></td> <td><strong><em>CYP3A4</em></strong>, UGT<sup>&#916;</sup></td> <td>Inhibitor: CYP1A2, CYP2E1, <strong><em>CYP3A4/5</em></strong>, ABCB11, ABCG2, SLC22A2, SLC47A1</td> <td>3</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">DNA methylation inhibitor</td> </tr> <tr> <td class=\"indent1\">Azacitidine<sup>[174,175,196]</sup></td> <td><strong><em>Cytidine deaminase</em></strong>, hydrolysis</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Decitabine<sup>[197,198]</sup></td> <td><strong><em>Cytidine deaminase</em></strong></td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Epipodophyllotoxin</td> </tr> <tr> <td class=\"indent1\">Etoposide<sup>[8,11,16,19,97-101]</sup></td> <td>CYP1A2, CYP2E1, <strong><em>CYP3A4/5</em></strong>, UGT1A1, ABCB1, ABCC1, ABCC3</td> <td>Inhibitor: CYP2C9, CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Teniposide<sup>[8,11,19,99,102]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1</td> <td>Inhibitor: CYP2C9, CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Estrogen receptor antagonist; selective estrogen receptor modulator (SERM)</td> </tr> <tr> <td class=\"indent1\">Fulvestrant<sup>[103]</sup></td> <td><strong><em>CYP3A4</em></strong></td> <td>None</td> <td>3</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Raloxifene<sup>[199]</sup></td> <td>SULT1A1, SULT1A3, SULT1B1, SULT1C2, SULT1E1, SULT2A1, SULT2B1b, <strong><em>UGT</em></strong><sup>&#916;</sup></td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tamoxifen<sup>[16,104-112,199,200-202]</sup></td> <td>CYP1A1/2, CYP2A6, CYP2B6, <strong><em>CYP2C9</em></strong>, CYP2C19, <strong><em>CYP2D6</em></strong>, CYP2E1, <strong><em>CYP3A4/5</em></strong>, SULT1A1, SULT1E1, SULT2A1, UGT1A3, UGT1A4, UGT1A8, UGT1A10, UGT2B7, UGT2B15</td> <td> <p>Inducer: <strong><em>CYP3A4</em></strong></p> Inhibitor: CYP2B, CYP2C8, CYP2C9, CYP3A4, ABCB1</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Hedgehog inhibitor</td> </tr> <tr> <td class=\"indent1\">Sonidegib<sup>[266-268]</sup></td> <td><strong><em>CYP3A4/5</em></strong></td> <td>Inhibitor: CYP2B6, CYP2C9, ABCG2</td> <td>5</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vismodegib<sup>[178-181,203]</sup></td> <td>CYP2C9, CYP3A4/5, ABCB1</td> <td>Inhibitors: CYP2C8, CYP2C9, CYP2C19, ABCB1, ABCG2</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Histone deacetylase inhibitor</td> </tr> <tr> <td class=\"indent1\">Belinostat<sup>[269-271]</sup></td> <td>CYP2A6, CYP2C9, CYP3A4, ABCB1, <strong><em>UGT1A1</em></strong>, UGT2B7</td> <td> <p>Inducer: CYP1A2</p> Inhibitor: CYP2C8, CYP2C9</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Panobinostat<sup>[272-275]</sup></td> <td>CYP2D6, CYP2C19, <strong><em>CYP3A4</em></strong>, ABCB1, UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A9, UGT2B4</td> <td>Inhibitor: <strong><em>CYP2D6</em></strong>, CYP2C19, CYP3A4, SLC22A1, SLC22A2, SLC22A8, SLCO1B1, SLCO1B3</td> <td>3</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Romidepsin<sup>[113-115]</sup></td> <td>CYP1A1, CYP2B6, CYP2C19, <strong><em>CYP3A4/5</em></strong>, ABCB1</td> <td>Inhibitor: ABCB11, SLCO1B1</td> <td>3</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vorinostat<sup>[117,118]</sup></td> <td><strong><em>Hydrolysis</em></strong>, UGT1A8, UGT1A9, UGT1A10, <strong><em>UGT2B17</em></strong></td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Immunomodulator</td> </tr> <tr> <td class=\"indent1\">Lenalidomide<sup>[204-206]</sup></td> <td>Hydrolysis, ABCB1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pomalidomide<sup>[207]</sup></td> <td><strong><em>CYP1A2</em></strong>, CYP2C19, CYP2D6, CYP3A4, ABCB1</td> <td>None</td> <td>4</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Arsenic trioxide<sup>[116]</sup></td> <td>Methylation</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Asparaginase<sup>[120]</sup></td> <td>Not applicable</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Mitotane<sup>[176,208]</sup></td> <td>Not determined</td> <td>Inducer: <strong><em>CYP3A4</em></strong></td> <td>1</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Omacetaxine mepesuccinate<sup>[209]</sup></td> <td>Esterases, ABCB1</td> <td>None</td> <td>1</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tretinoin<sup>[119,121,122,177]</sup></td> <td>CYP1A1, <strong><em>CYP2C8</em></strong>, CYP2C9, CYP3A4/7</td> <td> <p>Inducer: CYP2E1</p> Inhibitor: CYP1A1, CYP2C9, CYP2C19</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">mTOR inhibitor</td> </tr> <tr> <td class=\"indent1\">Everolimus<sup>[123,124,210,211]</sup></td> <td>CYP2C8, <strong><em>CYP3A4/5</em></strong>, ABCB1</td> <td>Inhibitor: CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1, ABCG2</td> <td>4</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Temsirolimus<sup>[125-128,211]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1</td> <td>Inhibitor: CP2D6, CYP3A4, ABCB1, ABCG2</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Platinums</td> </tr> <tr> <td class=\"indent1\">Carboplatin<sup>[11,129,189]</sup></td> <td><strong><em>Renal</em></strong>, ATP7A, ATP7B, SLC28A1, SLC31A1, SLC31A2</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Cisplatin<sup>[11,16,129-131,189]</sup></td> <td><strong><em>Renal</em></strong>, ABCC1, ABCC2, ATP7A, ATP7B, SLC22A1, SLC22A2, SLC31A1, SLC31A2, SLC47A1</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Oxaliplatin<sup>[16,129,131,189]</sup></td> <td><strong><em>Renal</em></strong>, SLC22A1, SLC22A2, SLC22A3, SLC22A4, SLC22A5, SLC31A1, SLC47A1, SLC47A2</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">PARP inhibitor</td> </tr> <tr> <td class=\"indent1\">Niraparib<sup>[276-278]</sup></td> <td><strong><em>Carboxylesterase</em></strong>, CYP1A2, CYP2D6, CYP3A4/5, UGT<sup>&#916;</sup>, ABCB1, ABCG2</td> <td> <p>Inducer: CYP1A2</p> Inhibitor: ABCG2</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Olaparib<sup>[279-281]</sup></td> <td>CYP1A1, CYP2A6, <strong><em>CYP3A4/5</em></strong>, ABCB1</td> <td> <p>Inducer: CYP2B6, CYP2C9, CYP2C19, CYP3A4</p> Inhibitor: CYP3A4, ABCB1, ABCG2, SLC22A1, SLC22A2, SLC22A8, SLC47A1, SLC47A2, SLCO1B1</td> <td>4</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rucaparib<sup>[282,283]</sup></td> <td>CYP1A2, <strong><em>CYP2D6</em></strong>, CYP3A4, ABCB1, ABCG2</td> <td> <p>Inducer: CYP1A2</p> Inhibitor: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, UGT1A1, ABCB1, ABCC4, ABCG2, SLC22A1, SLC22A6, SLC22A8, SLC47A1, SLC47A2, SLCO1B1, SLCO1B3</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Proteasome inhibitor</td> </tr> <tr> <td class=\"indent1\">Bortezomib<sup>[132,133,212]</sup></td> <td>CYP1A2, CYP2C9, <strong><em>CYP2C19</em></strong>, CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1</td> <td>Inhibitor: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Carfilzomib<sup>[213,214]</sup></td> <td><strong><em>Epoxide hydrolysis</em></strong>, <strong><em>peptidase</em></strong>, ABCB1</td> <td>Inhibitor: CYP3A</td> <td>1</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ixazomib<sup>[284]</sup></td> <td>CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1</td> <td>None</td> <td>4</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Kinase inhibitor</td> </tr> <tr> <td class=\"indent1\">Afatinib<sup>[215,216]</sup></td> <td>FMO3, <strong><em>ABCB1</em></strong>, ABCG2</td> <td>Inhibitor: ABCB1, ABCG2</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Alectinib<sup>[285-287]</sup></td> <td>CYP2B6, CYP2C8, CYP2C9, CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1 (metabolite)</td> <td> <p>Inducer: CYP2B6, CYP3A4</p> Inhibitor: CYP2C8, CYP3A4, ABCB1, ABCB11, ABCG2</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Axitinib<sup>[182-186,217]</sup></td> <td>CYP1A2, CYP2C19, <strong><em>CYP3A4/5</em></strong>, UGT1A1, ABCB1, SLCO1B1</td> <td>Inhibitor: CYP1A2, CYP2C8, ABCB1, SLCO1B1</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Bosutinib<sup>[218-222]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1</td> <td>Inhibitor: ABCB1, ABCG2</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Cabozantinib<sup>[223]</sup></td> <td>CYP2C9, <strong><em>CYP3A4</em></strong></td> <td> <p>Inducer: CYP1A1</p> Inhibitor: CYP2C8, CYP2C9, CYP2C19, CYP3A4, ABCB1</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Ceritinib<sup>[224,225]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1</td> <td>Inhibitor: <strong><em>CYP2C9</em></strong>, <strong><em>CYP3A</em></strong></td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Cobimetinib<sup>[288,289]</sup></td> <td><strong><em>CYP3A4</em></strong>, UGT2B7, ABCB1</td> <td>Inhibitor: CYP2D6, CYP3A4</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Crizotinib<sup>[134,226]</sup></td> <td><strong><em>CYP3A4/5</em></strong>, ABCB1, SLCO1B1, SLCO1B3</td> <td>Inhibitor: CYP2B6, <strong><em>CYP3A4</em></strong>, ABCB1</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Dabrafenib<sup>[227-230]</sup></td> <td><strong><em>CYP2C8</em></strong>, <strong><em>CYP3A4</em></strong>, ABCB1, ABCG2</td> <td> <p>Inducer: <strong><em>CYP2B6</em></strong>, <strong><em>CYP2C8</em></strong>, <strong><em>CYP2C9</em></strong>, <strong><em>CYP2C19</em></strong>, <strong><em>CYP3A4</em></strong>, UGT<sup>&#916;</sup></p> Inhibitor: ABCG2, SLCO1B1, SLCO1B3, SLC22A6, SLC22A8</td> <td>4</td> <td>4</td> </tr> <tr> <td class=\"indent1\">Dasatinib<sup>[135-137,218,226,231,232]</sup></td> <td><strong><em>CYP3A4</em></strong>, FMO3, UGT<sup>&#916;</sup>, ABCB1, ABCC4, ABCG2, SLCO1B1, SLCO1B3</td> <td>Inhibitor: CYP3A4, UGT1A9, UGT2B15, ABCB1, ABCG2</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Erlotinib<sup>[16,138-142,233-238]</sup></td> <td><strong><em>CYP1A1/2</em></strong>, CYP2C8, <strong><em>CYP3A4/5</em></strong>, ABCB1, ABCG2</td> <td>Inhibitor: CYP2C8, CYP3A4, UGT1A1, ABCB1, ABCC10, ABCG2</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Gefitinib<sup>[16,139,140,143-145,226,239]</sup></td> <td>CYP1A1, <strong><em>CYP2D6</em></strong>, <strong><em>CYP3A4/5</em></strong>, ABCB1, ABCG2, SLCO1B3</td> <td>Inhibitor: CYP2C19, CYP2D6, UGT1A1, UGT1A7, UGT1A9, UGT2B7, ABCG2</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Ibrutinib<sup>[240]</sup></td> <td>CYP2D6, <strong><em>CYP3A4</em></strong></td> <td> <p>Inducer: CYP450<sup>&#916;</sup></p> Inhibitor: ABCB1</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Idelalisib<sup>[290,291]</sup></td> <td>Aldehyde oxidase, <strong><em>CYP3A</em></strong>, UGT1A4, ABCB1, ABCG2</td> <td> <p>Inducer: CYP2B6, CYP3A4</p> Inhibitor: CYP2C8, CYP2C9, CYP2C19, <strong><em>CYP3A</em></strong>, UGT1A1, SLCO1B1, SLCO1B3</td> <td>4</td> <td>5</td> </tr> <tr> <td class=\"indent1\">Imatinib<sup>[16,136,146-148,226,231,241-243]</sup></td> <td>CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, <strong><em>CYP3A4/5</em></strong>, ABCB1, ABCG2, SLCO1B3</td> <td>Inhibitor: CYP2C9, <strong><em>CYP2D6</em></strong>, <strong><em>CYP3A4</em></strong>, UGT1A9, UGT2B15, ABCB1, ABCC10, ABCG2</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Lapatinib<sup>[149,236,244,245]</sup></td> <td>CYP2C8, CYP2C19, <strong><em>CYP3A4/5</em></strong>, ABCB1, ABCG2</td> <td> <p>Inducer: ABCB1</p> Inhibitor: <strong><em>CYP2C8</em></strong>, <strong><em>CYP3A4</em></strong>, <strong><em>ABCB1</em></strong>, ABCC10, ABCG2, SLCO1B1</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Lenvatinib<sup>[292-296]</sup></td> <td>Aldehyde oxidase, <strong><em>CYP3A4</em></strong>, ABCB1, ABCG2</td> <td> <p>Inducer: CYP3A</p> Inhibitor: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1, UGT1A4, ABCB11, SLC22A1, SLC22A2, SLC22A6, SLC22A8, SLCO1B1</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Nilotinib<sup>[136,150,151,217,218,226]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCG2, SLCO1B1, SLCO1B3</td> <td> <p>Inducer: <strong><em>CYP2B6</em></strong>, <strong><em>CYP2C8</em></strong>, <strong><em>CYP2C9</em></strong></p> Inhibitor: <strong><em>CYP2C8</em></strong>, <strong><em>CYP2C9</em></strong>, <strong><em>CYP2D6</em></strong>, <strong><em>CYP3A4</em></strong>, UGT1A1, <strong><em>ABCB1</em></strong>, ABCG2, SLCO1B1</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Osimertinib<sup>[297-299]</sup></td> <td>CYP1A2, CYP2A6, CYP2C9, CYP2E1, <strong><em>CYP3A4/5</em></strong>, ABCB1, ABCG2</td> <td> <p>Inducer: CYP1A2, CYP2C, CYP3A, ABCB1</p> Inhibitor: CYP3A4, ABCG2</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Pazopanib<sup>[152,153,217,226]</sup></td> <td>CYP1A2, CYP2C8, <strong><em>CYP3A4</em></strong>, ABCB1, ABCG2, SLCO1B1, SLCO1B3</td> <td>Inhibitor: <strong><em>CYP2C8</em></strong>, <strong><em>CYP2D6</em></strong>, <strong><em>CYP3A4</em></strong>, UGT1A1, SLCO1B1</td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Regorafenib<sup>[246]</sup></td> <td><strong><em>CYP3A4</em></strong>, UGT1A9</td> <td>Inhibitor: CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4, UGT1A1, UGT1A9, ABCB1, <strong><em>ABCG2</em></strong></td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Sorafenib<sup>[154-156,217,226,231,247]</sup></td> <td><strong><em>CYP3A4</em></strong>, UGT1A9, ABCB1, ABCG2, SLCO1B1, SLCO1B3</td> <td>Inhibitor: <strong><em>CYP2B6</em></strong>, <strong><em>CYP2C8</em></strong>, CYP2C9, CYP2C19, CYP2D6, CYP3A4, <strong><em>UGT1A1</em></strong>, <strong><em>UGT1A9</em></strong>, UGT2B15, ABCB1, ABCC2, ABCC4, SLCO1B1</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Sunitinib<sup>[157-160,226,247,248]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCG2, SLCO1B1</td> <td>Inhibitor: ABCB1, ABCC2, ABCC4, ABCG2</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Trametinib<sup>[249,300]</sup></td> <td><strong><em>Hydrolytic enzymes</em></strong> (amidases or carboxylesterases), ABCB1</td> <td> <p>Inducer: CYP3A4</p> Inhibitor: CYP2C8</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Vandetanib<sup>[161-163,226]</sup></td> <td><strong><em>CYP3A4</em></strong>, FMO1, FMO3, UGT<sup>&#916;</sup>, SLCO1B3</td> <td>Inhibitor: ABCB1, ABCGG2, <strong><em>SLC22A2</em></strong></td> <td>4</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vemurafenib<sup>[164,165,226]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCG2, SLCO1B3</td> <td> <p>Inducer: CYP3A4</p> Inhibitor: <strong><em>CYP1A2</em></strong>, CYP2D6, <strong><em>ABCB1</em></strong></td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vinca alkaloids</td> </tr> <tr> <td class=\"indent1\">Vinblastine<sup>[8,11,18,19,166]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCC2</td> <td> <p>Inducer: ABCB1</p> Inhibitor: CYP2D6, CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Vincristine<sup>[8,11,16,169,170]</sup></td> <td><strong><em>CYP3A4/5</em></strong>, ABCB1, ABCC1, ABCC2, ABCC3, ABCC10</td> <td>Inhibitor: CYP3A4</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Vinorelbine<sup>[18,171,172]</sup></td> <td><strong><em>CYP3A4</em></strong></td> <td>Inhibitor: CYP2D6, CYP3A4</td> <td>3</td> <td>2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">DDI potential code and clinical relevance: &#xD;&#xA;<OL class=decimal_heading>&#xD;&#xA;<LI>Interaction unlikely or known minor interaction not requiring modification to therapy.</LI>&#xD;&#xA;<LI>Possible interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity.</LI>&#xD;&#xA;<LI>Potential for significant interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity. Consider therapy modification if unable to monitor closely.</LI>&#xD;&#xA;<LI>Potential for clinically significant interaction based on pharmacology of the drug or known interaction. Need for dose adjustment or consideration of therapy modification.</LI>&#xD;&#xA;<LI>Major clinically significant interaction or potential critical interaction. Co-administration is contraindicated.</LI></OL></div><div class=\"graphic_footnotes\">ARV: antiretroviral; CYP: cytochrome P450; ABC: ATP-binding cassette sub-family/member; UGT: uridine 5'-diphospho-glucuronosyltransferase; NADPH: nicotinamide adenine dinucleotide phosphate; SLC: sodium-coupled nucleoside transport family/member; SULT: sulfotransferase; OATP: organic anion transporter protein; SLCO: solute carrier organic anion transporter family/member; DNA: deoxyribonucleic acid; mTOR: mechanistic target of rapamycin; ATP: copper- and platinum drug-efflux transporters; PARP: poly ADP ribose polymerase; FMO: flavin-containing monooxygenase; OAT: organic anion transporter; DDI: drug-drug interaction.<br />* The major routes of elimination are in bold italic font. The minor routes of elimination are in regular font.<br />¶ The strong inhibitors or inducers of an enzyme/transporter are in bold italic font. Inhibitors or inducers of an enzyme/transporter that have caused clinically significant interactions are in bold italic font.<br />Δ Isozyme not specified.<br /><HR>&#xD;&#xA;<EM>References:</EM> &#xD;&#xA;<OL style=\"FONT-STYLE: italic\">&#xD;&#xA;<LI>Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59:759.</LI>&#xD;&#xA;<LI>Cephalon, Inc. Treanda (bendamustine HCl) for injection, package insert: prescribing information. (http://www.treandahcp.com/PDF/TREANDA_final_PI.pdf) Frazer, PA. October 2016.</LI>&#xD;&#xA;<LI>Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56:3678.</LI>&#xD;&#xA;<LI>Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36:525.</LI>&#xD;&#xA;<LI>Heritage Pharmaceuticals, Inc. BiCNU (carmustine for injection) package insert: prescribing information. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf) Eatontown, NJ. March 2017.</LI>&#xD;&#xA;<LI>Smitherman PK, Townsend AJ, Kute TE, Morrow CS. Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther 2004; 308:260.</LI>&#xD;&#xA;<LI>GlaxoSmithKline. LEUKERAN (chlorambucil) tablets, package insert. (https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf) Research Triangle Park, NC. October 2011.</LI>&#xD;&#xA;<LI>Sparreboom A, Danesi R, Ando Y, et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003; 6:71.</LI>&#xD;&#xA;<LI>Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53:5629.</LI>&#xD;&#xA;<LI>Lindley C, Hamilton G, McCune JS, et al. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos 2002; 30:814.</LI>&#xD;&#xA;<LI>Baumhakel M, Kasel D, Rao-Schymanski RA, et al. Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001; 39:517.</LI>&#xD;&#xA;<LI>Reid JM, Kuffel MJ, Miller JK, et al. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999; 5:2192.</LI>&#xD;&#xA;<LI>Tritsch GL, Shukla SK, Mittelman A, Murphy GP. Estracyt (NSC 89199) as a substrate for phosphatases in human serum. Invest Urol 1974; 12:38.</LI>&#xD;&#xA;<LI>Granvil CP, Madan A, Sharkawi M, et al. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999; 27:533.</LI>&#xD;&#xA;<LI>Walker D, Flinois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994; 47:1157.</LI>&#xD;&#xA;<LI>McDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med 2011; 5;795.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Ifosfamide Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA2037. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Le Guellec C, Lacarelle B, Catalin J, Durand A. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol 1993; 32:491.</LI>&#xD;&#xA;<LI>Zhou-Pan XR, Seree E, Zhou XJ, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53:5121.</LI>&#xD;&#xA;<LI>Zhou XJ, Zhou-Pan XR, Gauthier T, et al. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol 1993; 45:853.</LI>&#xD;&#xA;<LI>Recordati Rare Diseases, Inc. MUSTARGEN (mechlorethamine hydrochloride) powder, for solution, prescribing information. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=920e22b5-823b-0961-c776-9280ce6c62a1. Lebanon, NJ. February 2013.</LI>&#xD;&#xA;<LI>Apo-Pharma USA. Alkeran (melphalan) tablets: prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf. Rockville, MD. June 2011.</LI>&#xD;&#xA;<LI>Sigma-Tau Pharmaceuticals Inc. MATULANE brand of procarbazine hydrochloride capsules prescribing information. Available at: http://www.matulane.com/pdf/prescribe-info_matulane_20140422164502_508945.pdf. Gaithersburg, MD. March 2008.</LI>&#xD;&#xA;<LI>Teva Parenteral Medicines, Inc. Zanosar (streptozocin sterile powder) package insert. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=15d161ed-9e7b-4c92-ba45-0556d2423e67. Irvine, CA. May 2007.</LI>&#xD;&#xA;<LI>Merck &amp; Co., Inc. TEMODAR (temozolomide) prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/t/temodar_capsules/temodar_pi.pdf. Whitehouse Station, NJ. May 2014.</LI>&#xD;&#xA;<LI>Tsang LL, Quarterman, CP Gescher A, Slack JA. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991; 27:342.</LI>&#xD;&#xA;<LI>Schaich M, Kestel L, Pfirrmann M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009; 20:175.</LI>&#xD;&#xA;<LI>Jacobson PA, Green K, Birnbaum A, Remmel RP. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA. Cancer Chemother Pharmacol 2002; 49:461.</LI>&#xD;&#xA;<LI>Dirven HA, Dictus EL, Broeders, NL, et al. The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa. Cancer Res 1995; 55:1701.</LI>&#xD;&#xA;<LI>Turpeinen M, Nieminen R, Juntunen T, et al. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626.</LI>&#xD;&#xA;<LI>Ekhart C, Doodeman VD, Rodenhuis S, et al. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol 2009; 67:50.</LI>&#xD;&#xA;<LI>Loveless H, Arena E, Felsted RL, Bachur NR. Comparative mammalian metabolism of adriamycin and daunorubicin. Cancer Res 1978; 38:593.</LI>&#xD;&#xA;<LI>Le Bot MA, Glaise D, Kernaleguen D, et al. Metabolism of doxorubicin, daunorubicin and epirubicin in human and rat hepatoma cells. Pharmacol Res 1991; 24:243.</LI>&#xD;&#xA;<LI>Mercier C, Decleves X, Masseguin C, et al. P-glycoprotein (ABCB1) but not multidrug resistance-associated protein 1 (ABCC1) is induced by doxorubicin in primary cultures of rat astrocytes. J Neurochem 2003; 87:820.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Doxorubicin Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA165292177. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Pfizer injectables. Ellence (epirubicin hydrochloride injection) prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=657. New York, NY. December 2014.</LI>&#xD;&#xA;<LI>Hargrave RM, Davey MW, Davey RA, Kidman AD. Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs 1995; 6:432.</LI>&#xD;&#xA;<LI>Gillies HC, Herriott D, Liang R, et al. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23:303.</LI>&#xD;&#xA;<LI>Hospira Worldwide, Inc. MitoXANTRONE injection, USP (concentrate) prescribing information. Available at: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=accf9569-4b57-4e83-a7db-4e890a75d1ba. Lake Forest, IL. February 2013.</LI>&#xD;&#xA;<LI>Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 1992; 19:3.</LI>&#xD;&#xA;<LI>Tattersall MH, Sodergren JE, Dengupta SK, et al. Pharmacokinetics of actinoymcin D in patients with malignant melanoma. Clin Pharmacol Ther 1975; 17:701.</LI>&#xD;&#xA;<LI>Pan SS, Andrews PA, Glover CJ, Bachur NR. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 1984; 259:959.</LI>&#xD;&#xA;<LI>Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385.</LI>&#xD;&#xA;<LI>Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40:85.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Fluoropyrimidine Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA150653776. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Genzyme Corporation. Clolar (clofarabine) injection for intravenous, use prescribing information. Available at: http://products.sanofi.us/clolar/clolar.html. Cambridge, MA. October 2016.</LI>&#xD;&#xA;<LI>Kawasaki H, Carrera CJ, Piro LD, et al. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81:597.</LI>&#xD;&#xA;<LI>Sandoz. Fludara (fludarabine phosphate) injection for intravenous use: prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022137s003lbl.pdf. Princeton, NJ February 2011.</LI>&#xD;&#xA;<LI>Nagai S, Takenaka K, Nachagari D, et al. Deoxycytidine kinase modulates the impact of the ABC transporter ABCG2 on clofarabine cytotoxicity. Cancer Res 2011; 71:1781.</LI>&#xD;&#xA;<LI>Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006; 5:855.</LI>&#xD;&#xA;<LI>Hospira, Inc. CYTARABINE injection, powder, lyophilized, for solution: prescribing information. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=681b5dc4-4fcf-4fab-ad78-02cb9a4a5dd0. Lake Forest, IL. July 2016.</LI>&#xD;&#xA;<LI>Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47:131.</LI>&#xD;&#xA;<LI>Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 1989; 7:622.</LI>&#xD;&#xA;<LI>Brockman RW, Cheng YC, Schabel FM, Jr., Montgomery JA. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res 1980; 40:3610.</LI>&#xD;&#xA;<LI>Shiotani T, Weber G. Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem 1981; 256:219.</LI>&#xD;&#xA;<LI>Gunes A, Coskun U, Boruban C, et al. Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. Basic Clin Pharmacol Toxicol 2006; 98:197.</LI>&#xD;&#xA;<LI>Wong A, Soo RA, Yong WP, Innocenti F. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 2009; 41:77.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Gemcitabine Pathway, Pharmacodynamics. Available at: http://www.pharmgkb.org/pathway/PA2036. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Bristol-Myers Squibb Company. DROXIA (hydroxyurea capsules, USP) prescribing information. Available at: https://packageinserts.bms.com/pi/pi_droxia.pdf. Princeton, NJ. March 2016.</LI>&#xD;&#xA;<LI>Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651.</LI>&#xD;&#xA;<LI>Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276:33747.</LI>&#xD;&#xA;<LI>Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64:753.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics. Available at: https://www.pharmgkb.org/pathway/PA2040. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Ifergan I, Shafran A, Jansen G, et al. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 2004; 279:25527.</LI>&#xD;&#xA;<LI>Vlaming ML, van Esch A, Pala Z, et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 2009; 8:3350.</LI>&#xD;&#xA;<LI>Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120:1689.</LI>&#xD;&#xA;<LI>Mikkelsen TS, Thorn CF, Yang JJ, et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011; 21:679.</LI>&#xD;&#xA;<LI>Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A 2004; 101:3569.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Methotrexate Pathway, Pharmacokinetics. Available at: https://www.pharmgkb.org/pathway/PA165816349. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. ARRANON (nelarabine) injection: prescribing information. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/arranon.pdf. East Hanover, NJ. June 2015.</LI>&#xD;&#xA;<LI>Sorensen, JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011; 7:919.</LI>&#xD;&#xA;<LI>Lilly USA, LLC. ALIMTA (pemetrexed for injection) lyophilized powder, for solution, for intravenous use: prescribing information. Available at: https://pi.lilly.com/us/alimta-pi.pdf. Indianapolis, IN. September 2013.</LI>&#xD;&#xA;<LI>Hospira, Inc. NIPENT (pentostat) injection, powder, lyophilized, for solution: prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=4565. Lake Forest. July 2015.</LI>&#xD;&#xA;<LI>Sanofi Aventis LLC, USA. JEVTANA (cabazitaxel) injection: prescribing information. Available at: http://products.sanofi.us/jevtana/jevtana.html. Bridgewater, NJ. September 2016.</LI>&#xD;&#xA;<LI>Nallani SC, Goodwin B, Buckley AR, et al. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 2004; 54:219.</LI>&#xD;&#xA;<LI>Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56:1296.</LI>&#xD;&#xA;<LI>Smith NF, Acharya MR, Desai N, et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4:815.</LI>&#xD;&#xA;<LI>Koolen SL, Oostendorp RL, Beijnen JH, et al. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010; 69:465.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Taxane Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA154426155. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin-A review of preclinical and clinical studies. Crit Rev Oncol Hematol 2011.</LI>&#xD;&#xA;<LI>Zhang ZY, King BM, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 2008; 62:707.</LI>&#xD;&#xA;<LI>Bristol-Myers Squibb Company. IXEMPRA Kit (ixabepilone) for injection: prescribing information. Available at: http://ixempra.com/downloads/full_pi.pdf. Princeton, NJ. January 2016.</LI>&#xD;&#xA;<LI>Desai PB, Duan JZ, Zhu YW, Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998; 23:417.</LI>&#xD;&#xA;<LI>Cianfrocca M, Lee S, Von Roenn J, et al. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol 2011; 64:827.</LI>&#xD;&#xA;<LI>Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 1997; 25:598.</LI>&#xD;&#xA;<LI>Kamdem LK, Liu Y, Stearns V, et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol 2010; 70:854.</LI>&#xD;&#xA;<LI>Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011; 39:98.</LI>&#xD;&#xA;<LI>Pfizer, Inc. AROMASIN (exemestane) tablets, oral: prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=523. New York, NY. October 2016.</LI>&#xD;&#xA;<LI>Murai K, Yamazaki H, Nakagawa K, et al. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica 2009; 39:795.</LI>&#xD;&#xA;<LI>Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol 2009; 64:867.</LI>&#xD;&#xA;<LI>Fujita K, Sparreboom A. Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 2010; 5:209.</LI>&#xD;&#xA;<LI>Corona G, Vaccher E, Sandron S, et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 2008; 83:601.</LI>&#xD;&#xA;<LI>Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6:2012.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Irinotecan Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA2001. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24:7612.</LI>&#xD;&#xA;<LI>Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res 1998; 4:783.</LI>&#xD;&#xA;<LI>Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther 1998; 286:1294.</LI>&#xD;&#xA;<LI>Lagas JS, Fan L, Wagenaar E, et al. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin Cancer Res 2010; 16:130.</LI>&#xD;&#xA;<LI>Relling MV, Nemec J, Schuetz EG, et al. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 1994; 45:352.</LI>&#xD;&#xA;<LI>Yang J, Bogni A, Schuetz EG, et al. Etoposide pathway. Pharmacogenet Genomics 2009; 19:552.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Etoposide Pathway, Pharmacokinetics/Pharmacodynamics. Available at: http://www.pharmgkb.org/pathway/PA2025. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Relling MV, Aoyama T, Gonzalez FJ, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 252:442.</LI>&#xD;&#xA;<LI>Astra Zeneca. FASLODEX (fulvestrant) injection: prescribing information. Wilmington, DE. 2011.</LI>&#xD;&#xA;<LI>Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53:171.</LI>&#xD;&#xA;<LI>Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30:869.</LI>&#xD;&#xA;<LI>Coller JK, Krebsfaenger N, Klein K, et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002; 54:157.</LI>&#xD;&#xA;<LI>Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002; 30:608.</LI>&#xD;&#xA;<LI>Zhao XJ, Jones DR, Wang YH, et al. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 2002; 32:863.</LI>&#xD;&#xA;<LI>Walsky RL, Gaman EA, Obach RS. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 2005; 45:68.</LI>&#xD;&#xA;<LI>Boruban MC, Yasar U, Babaoglu MO, Sencan O, et al. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother 2006; 18:421.</LI>&#xD;&#xA;<LI>Sridar C, Kent UM, Notley LM, et al. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther 2002; 301:945.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Tamoxifen Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA145011119. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005; 28:124.</LI>&#xD;&#xA;<LI>Celgene Corporation. ISTODAX (romidepsin) for injection: prescribing information. Available at: http://www.celgene.com/content/uploads/istodax-pi.pdf. Summit, NJ. July 2016.</LI>&#xD;&#xA;<LI>Iwamoto FM, Lamborn KR, Kuhn JG, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011; 13:509.</LI>&#xD;&#xA;<LI>Cephalon, Inc. TRISENOX (arsenic trioxide) injection: prescribing information. Available at: http://www.trisenox.com/trisenox-prescribing-information.pdf. Frazer, PA. August 2016.</LI>&#xD;&#xA;<LI>Merck &amp; Co. ZOLINZA (vorinostat) capsules: prescribing information. Available at: https://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf. Whitehouse Station, NJ. May 2015.</LI>&#xD;&#xA;<LI>Balliet RM, Chen G, Gallagher CJ, et al. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69:2981.</LI>&#xD;&#xA;<LI>McSorley LC, Daly AK. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 2000; 60:517.</LI>&#xD;&#xA;<LI>Lundbeck, Inc. ELSPAR (asparaginase) injection, powder, lyophilized for solution: prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/101063s5169lbl.pdf. Deerfield, IL. July 2013.</LI></OL></div><div class=\"graphic_reference\"><OL start=121>&#xD;&#xA;<LI>Yamazaki H, Shimada T. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 1999; 29:231.</LI>&#xD;&#xA;<LI>Adedoyin A, Stiff DD, Smith DC, et al. All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 1998; 41:133.</LI>&#xD;&#xA;<LI>Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43:83.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. AFINITOR (everolimus) tablets, for oral administration: prescribing information. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/afinitor.pdf. East Hanover, NJ. June 2016.</LI>&#xD;&#xA;<LI>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. TORISEL Kit (temsirolimus) injection: prescribing information. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=490. Philadelphia, PA. July 2016.</LI>&#xD;&#xA;<LI>Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 2009; 64:263.</LI>&#xD;&#xA;<LI>Boni JP, Leister C, Burns J, Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008; 98:1797.</LI>&#xD;&#xA;<LI>Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 2012; 59:447.</LI>&#xD;&#xA;<LI>Burger H, Loos WJ, Eechoute K, et al. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 2011.</LI>&#xD;&#xA;<LI>Sprowl JA, Gregorc V, Lazzari C, et al. Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy. Clin Pharmacol Ther 2012; 91:1022.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Platinum Pathway, Pharmacokinetics/Pharmacodynamics. Available at: http://www.pharmgkb.org/pathway/PA150642262. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Venkatakrishnan K, Rader M, Ramanathan RK, et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009; 31 Pt 2:2444.</LI>&#xD;&#xA;<LI>Millennium Pharmaceuticals, Inc. VELCADE (bortezomib) for injection: prescribing information. Available at: http://www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf. Cambridge, MA. September 2015.</LI>&#xD;&#xA;<LI>Pfizer, Inc. XALKORI (crizotinib) capsules, oral: prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=676. New York, NY. July 2017.</LI>&#xD;&#xA;<LI>Bristol-Myers Squibb Company. SPRYCEL (dasatinib) tablet: prescribing information. Available at: https://packageinserts.bms.com/pi/pi_sprycel.pdf. Princeton, NJ September 2016.</LI>&#xD;&#xA;<LI>Dohse M, Scharenberg C, Shukla S, et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 2010; 38:1371.</LI>&#xD;&#xA;<LI>Wang L, Christopher LJ, Cui D, et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 2008; 36:1828.</LI>&#xD;&#xA;<LI>Marchetti S, de Vries NA, Buckle T, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 2008; 7:2280.</LI>&#xD;&#xA;<LI>Li J, Zhao M, He P, et al. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13:3731.</LI>&#xD;&#xA;<LI>Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 2007; 6:432.</LI>&#xD;&#xA;<LI>Liu Y, Ramírez J, House L, Ratain MJ. Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 2010; 38:32.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Erlotinib Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA154426903. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Astra Zeneca. Iressa (gefitinib) tablets: prescribing information. Available at: https://www.azpicentral.com/iressa/iressa.pdf#page=1. Wilmington, DE. July 2015.</LI>&#xD;&#xA;<LI>Nakamura Y, Oka M, Soda H, et al. Gefitinib (\"Iressa\", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 2005; 65:1541.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Gefitinib Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA152325160. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. GLEEVEC (imatinib mesylate) tablets, for oral use: prescribing information. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/gleevec_tabs.pdf. East Hanover, NJ. September 2016.</LI>&#xD;&#xA;<LI>van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007; 13:7394.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Imatinib Pathway, Pharmacokinetics/Pharmacodynamics. Available at: http://www.pharmgkb.org/pathway/PA164713427. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. TYKERB (lapatinib) tablets: prescribing information. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tykerb.pdf. East Hanover, NJ. June 2015.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) capsules: prescribing information. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf. East Hanover, NJ. February 2017.</LI>&#xD;&#xA;<LI>Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011; 51:75.</LI>&#xD;&#xA;<LI>Goh BC, Reddy NJ, Dandamudi UB, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 2010; 88:652.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. VOTRIENT (pazopanib) tablets: prescribing information. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/votrient.pdf. East Hanover, NJ. August 2016.</LI>&#xD;&#xA;<LI>Bayer HealthCare Pharmaceuticals, Inc. NEXAVAR (sorafenib) tablets, oral: prescribing information. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Wayne, NJ November 2013.</LI>&#xD;&#xA;<LI>Flaherty KT, Lathia C, Frye RF, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol 2011.</LI>&#xD;&#xA;<LI>Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther 2011; 336:223.</LI>&#xD;&#xA;<LI>Pfizer, Inc. SUTENT (sunitinib malate) capsules, oral: prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=607. New York, NY. April 2015.</LI>&#xD;&#xA;<LI>Tang SC, Lagas JS, Lankheet NA, Poller B, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 2012; 130:223.</LI>&#xD;&#xA;<LI>Rudek MA, Moore PC, Mitsuyasu RT, et al. A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. Cancer 2014; 120:1194.</LI>&#xD;&#xA;<LI>Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009; 37:359.</LI>&#xD;&#xA;<LI>Astra Zeneca. CAPRELSA (vandetanib) tablets: prescribing information. Available at: http://www.caprelsa.com/files/caprelsa-pi.pdf. Wilmington, DE. July 2016.</LI>&#xD;&#xA;<LI>Martin P, Oliver S, Robertson J, et al. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. Drugs R D 2011; 11:37.</LI>&#xD;&#xA;<LI>Zheng LS, Wang F, Li YH, et al. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 2009; 4:e5172.</LI>&#xD;&#xA;<LI>Genentech USA, Inc. ZELBORAF (vemurafenib) tablet, oral: prescribing information. South San Francisco, CA. 2011.</LI>&#xD;&#xA;<LI>Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032). J Pharmacol Exp Ther 2012; 342:33.</LI>&#xD;&#xA;<LI>Smith NF, Mani S, Schuetz EG, et al. Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. Ann Pharmacother 2010; 44:1709.</LI>&#xD;&#xA;<LI>Rajaonarison JF, Lacarelle B, Catalin J, et al. Effect of anticancer drugs on the glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes. Drug Metab Dispos 1993; 21:823.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Cyclophosphamide Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA2034. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Dennison JB, Kulanthaivel P, Barbuch RJ, et al. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 2006; 34:1317.</LI>&#xD;&#xA;<LI>PharmGKB. The Pharmacogenetics and Pharmacogenomics Knowledge Base - Vinka Alkaloid Pathway, Pharmacokinetics. Available at: http://www.pharmgkb.org/pathway/PA150981002. (Accessed on May 19, 2014).</LI>&#xD;&#xA;<LI>Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000; 28:1121.</LI>&#xD;&#xA;<LI>Beulz-Rich D, Grud P, Puozzo C, et al. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol 2005; 19:545.</LI>&#xD;&#xA;<LI>Janssen Biotech, Inc. ZYTIGA (abiraterone acetate) tablets, for oral administration: prescribing information. Available at: https://www.zytiga.com/shared/product/zytiga/zytiga-prescribing-information.pdf. Horsham, PA. May 2016.</LI>&#xD;&#xA;<LI>Celgene Corporation. VIDAZA (azacitidine for injection) for SC or IV use: prescribing information. Available at: http://www.celgene.com/content/uploads/vidaza-pi.pdf. Summit, NJ. August 2016.</LI>&#xD;&#xA;<LI>Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol. 2005 10; 23(17):3906-11.</LI>&#xD;&#xA;<LI>van Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effort on CYP3A4 activity. Eur J Endocrinol 2011; 164:621.</LI>&#xD;&#xA;<LI>Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450a involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58:1341.</LI>&#xD;&#xA;<LI>Genentech USA, Inc. ERIVEDGE (vismodegib) capsule, for oral use: prescribing information. South San Francisco, CA. January 2012.</LI>&#xD;&#xA;<LI>Wong H, Chen JZ, Chou B, et al. Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor. Xenobiotica. 2009 39:850.</LI>&#xD;&#xA;<LI>Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 2009; 11:96.</LI>&#xD;&#xA;<LI>Graham RA, Lum BL, Morrison G, et al. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 2011; 39:1460.</LI>&#xD;&#xA;<LI>Pfizer, Inc. INLYTA (axitinib) tablets, for oral administration: prescribing information. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=759. New York, NY. August 2014.</LI>&#xD;&#xA;<LI>Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474.</LI>&#xD;&#xA;<LI>Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010; 65:563.</LI>&#xD;&#xA;<LI>Pithavala YK, Tong W, Mount J, et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 2012; 30:273.</LI>&#xD;&#xA;<LI>Brennan M, Williams JA, Chen Y, et al. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012; 68:645.</LI>&#xD;&#xA;<LI>Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298:F997.</LI>&#xD;&#xA;<LI>Astellas Pharma US, Inc. XTANDI (enzalutamide) capsules, package insert. Available at: https://www.astellas.us/docs/us/12A005-ENZ-WPI.pdf. Northbrook, IL. October 2016.</LI>&#xD;&#xA;<LI>Sprowl JA, Sparreboom A. Uptake carriers and oncology drug safety. Drug Metab Dispos 2014; 42:611.</LI>&#xD;&#xA;<LI>Walker AL, Franke RM, Sparreboom A, Ware RE. Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol 2011; 39:446.</LI>&#xD;&#xA;<LI>Walker AL, Lancaster CS, Finkelstein D, et al. Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol 2013; 305:C1223.</LI>&#xD;&#xA;<LI>Adjei AA, Salavaggione OE, Mandrekar SJ, et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol 2010; 5:1346.</LI>&#xD;&#xA;<LI>de Graan AJ, Lancaster CS, Obaidat A, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012; 18:4433.</LI>&#xD;&#xA;<LI>Sun D, Chen G, Dellinger RW, et al. Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics. Pharmacogenet Genomics 2010; 20:575.</LI>&#xD;&#xA;<LI>Oguri T, Takahashi T, Miyazaki M, et al. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res 2004; 24:2893.</LI>&#xD;&#xA;<LI>Chabner BA, Drake JC, Johns DG. Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol 1973; 22:2763.</LI>&#xD;&#xA;<LI>Chabot GG, Bouchard J, Momparler RL. Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 1983; 32:1327.</LI>&#xD;&#xA;<LI>Otsuka America Pharmaceutical, Inc., DACOGEN (decitabine), for injection: prescribing information. Available at: https://www.otsuka-us.com/media/static/DACOGEN-PI.pdf. Rockville, MD. October 2014.</LI>&#xD;&#xA;<LI>Falany JL, Pilloff DE, Leyh TS, Falany CN. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos 2006; 34:361.</LI>&#xD;&#xA;<LI>Nishiyama T, Ogura K, Nakano H, et al. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 2002; 63:1817.</LI>&#xD;&#xA;<LI>Kaku T, Ogura K, Nishiyama T, et al. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 2004; 67:2093.</LI>&#xD;&#xA;<LI>Sun D, Sharma AK, Dellinger RW, et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007; 35:2006.</LI>&#xD;&#xA;<LI>LoRusso PM, Piha-Paul SA, Mita M, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol 2013; 71:193.</LI>&#xD;&#xA;<LI>Kumar G, Lau H, Laskin O. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 2009; 63:1171.</LI>&#xD;&#xA;<LI>Chen N, Wen L, Lau H. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 2012; 69:789.</LI>&#xD;&#xA;<LI>Tong Z, Yerramilli U, Surapaneni S, Kumar G. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug-drug interactions. Cancer Chemother Pharmacol 2014; 73:869.</LI>&#xD;&#xA;<LI>Celgene Corporation. POMALYST (pomalidomide) capsules, for oral use, package insert. Available at: http://www.celgene.com/content/uploads/pomalyst-pi.pdf. Summit, NJ. June 2016.</LI>&#xD;&#xA;<LI>D'Avolio A, De Francia S, Basile V, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics 2013; 23:293.</LI>&#xD;&#xA;<LI>Teva Pharmaceuticals USA, Inc. SYNRIBO (omacetaxine mepesuccinate) for injection, for subcutaneous use: package insert. Available at: http://www.synribo.com/pdf/synribo_pi.pdf. North Wales, PA. December 2015.</LI>&#xD;&#xA;<LI>Moes DJ, Press RR, den Hartigh J, et al. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet 2012; 51:467.</LI>&#xD;&#xA;<LI>Minocha M1, Khurana V, Qin B, et al. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Int J Pharm 2012; 434:306.</LI>&#xD;&#xA;<LI>O'Connor R, Ooi MG, Meiller J, et al. The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol 2013; 71:1357.</LI>&#xD;&#xA;<LI>Wang Z, Yang J, Kirk C, et al. Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos 2013; 41:230.</LI>&#xD;&#xA;<LI>Amgen, Inc. KYPROLIS (carfilzomib) for injection, for intravenous use, package insert. Available at: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf. Thousand Oaks, CA, May 2017.</LI>&#xD;&#xA;<LI>Wind S, Giessmann T, Jungnik A, et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014; 34:173.</LI>&#xD;&#xA;<LI>Boehringer Ingelheim Pharmaceuticals, Inc. GILOTRIF (afatinib) tablets, for oral use: package insert. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing+Information/PIs/Gilotrif/Gilotrif.pdf. Ridgefield, CT. October 2016.</LI>&#xD;&#xA;<LI>Hu S, Mathijssen RH, de Bruijn P, et al. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer 2014; 110:894.</LI>&#xD;&#xA;<LI>Hegedus C, Ozvegy-Laczka C, Apáti A, et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009; 158:1153.</LI>&#xD;&#xA;<LI>Abbas R, Leister C, El Gaaloul M, et al. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther 2012; 34:2011.</LI>&#xD;&#xA;<LI>Skoglund K, Moreno SB, Baytar M, et al. ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro. Pharmgenomics Pers Med 2013; 6:63.</LI>&#xD;&#xA;<LI>Abbas R1, Hug BA, Leister C, et al. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects. J Clin Pharmacol 2011; 51:1721.</LI>&#xD;&#xA;<LI>Pfizer Labs. BOSULIF (bosutinib) tablets, for oral use: package insert. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=884. New York, NY. November 2016.</LI>&#xD;&#xA;<LI>Exelixis, Inc. COMETRIQ (cabozantinib) capsules, for oral use, package insert. Available at: http://www.cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf. South San Francisco, CA. May 2016; or CABOMETYX (cabozantinib) tablets, for oral use, package insert. Available at: https://hcp.cabometyx.com/downloads/CABOMETYXUSPI.pdf. South San Francisco, CA. April 2016.</LI>&#xD;&#xA;<LI>Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013; 56:5675.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. ZYKADIA (ceritinib) capsules, for oral use, package insert. Available at: https://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdf. East Hanover, NJ. September 2016.</LI>&#xD;&#xA;<LI>Zimmerman EI, Hu S, Roberts JL, et al. Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 2013; 19:1458.</LI>&#xD;&#xA;<LI>Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF. Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 2013; 344:655.</LI>&#xD;&#xA;<LI>Lawrence SK, Nguyen D, Bowen C, et al. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk. Drug Metab Dispos 2014; 42:1180.</LI>&#xD;&#xA;<LI>Bershas DA, Ouellet D, Mamaril-Fishman DB, et al. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation. Drug Metab Dispos 2013; 41:2215.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. TAFINLAR (dabrafenib) capsules, for oral use, package insert. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tafinlar.pdf. East Hanover, NJ. June 2016.</LI>&#xD;&#xA;<LI>Liu Y, Ramírez J, Ratain MJ. Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 2011; 71:917.</LI>&#xD;&#xA;<LI>Furmanski BD, Hu S, Fujita K, et al. Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib. Clin Cancer Res 2013; 19:4359.</LI>&#xD;&#xA;<LI>Calvert H, Twelves C, Ranson M, et al. Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer. Anticancer Drugs 2014; 25:832.</LI>&#xD;&#xA;<LI>Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. Cancer Chemother Pharmacol 2014; 73:613.</LI>&#xD;&#xA;<LI>Fukudo M, Ikemi Y, Togashi Y, et al. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 2013; 52:593.</LI>&#xD;&#xA;<LI>Kuang YH, Shen T, Chen X, et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010; 79:154.</LI>&#xD;&#xA;<LI>Rakhit A, Pantze MP, Fettner S, et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 2008; 64:31.</LI>&#xD;&#xA;<LI>Shi Z, Peng XX, Kim IW, et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67:11012.</LI>&#xD;&#xA;<LI>Tan AR, Gibbon DG, Stein MN, et al. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 2013; 71:1635.</LI>&#xD;&#xA;<LI>Pharmacyclics, Inc. IMBRUVICA (ibrutinib) capsules, for oral use, package insert. Available at: https://www.imbruvica.com/downloads/Prescribing_Information.pdf. Sunnyvale, CA. January 2017.</LI>&#xD;&#xA;<LI>Shen T, Kuang YH, Ashby CR, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009; 4:e7520.</LI>&#xD;&#xA;<LI>Filppula AM, Tornio A, Niemi M, et al. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol Ther 2013; 94:383.</LI>&#xD;&#xA;<LI>Koon HB, Krown SE, Lee JY, et al. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. J Clin Oncol 2014; 32:402.</LI>&#xD;&#xA;<LI>Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008; 36:695.</LI>&#xD;&#xA;<LI>Dunne G, Breen L, Collins DM, et al. Modulation of P-gp expression by lapatinib. Invest New Drugs 2011; 29:1284.</LI>&#xD;&#xA;<LI>Bayer HealthCare Pharmaceuticals, Inc. STIVARGA (regorafenib) tablets, for oral use, package insert. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf. Wayne, NJ. August 2016.</LI>&#xD;&#xA;<LI>Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009; 15:6062.</LI>&#xD;&#xA;<LI>Mizuno T, Fukudo M, Fukuda T, et al. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma. Ther Drug Monit 2014; 36:310.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. MEKINIST (trametinib) tablets, for oral use, package insert. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mekinist.pdf. Hanover, NJ. February 2017.</LI>&#xD;&#xA;<LI>Janssen Products, LP. YONDELIS (trabectedin) for injection, package insert. Available at: https://www.yondelis.com/shared/product/yondelis/yondelis-prescribing-information.pdf. Horsham, PA, May 2017.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 207953Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207953Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>Brandon EF, Sparidans RW, Guijt KJ, et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 2006; 24:3.</LI>&#xD;&#xA;<LI>Vermeir M, Hemeryck A, Cuyckens F, et al. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 2009; 77:1642.</LI>&#xD;&#xA;<LI>Taiho Oncology, Inc. LONSURF (trifluridine and tipiracil) tablets, for oral use, package insert. Available at: https://www.taihooncology.com/us/prescribing-information.pdf. Princeton, NJ. September 2015.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 207981Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>AbbVie, Inc. VENCLEXTA (venetoclax) tablets, for oral use, package insert. Available at: http://www.rxabbvie.com/pdf/venclexta.pdf. North Chicago, IL. April 2016.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 208573Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208573Orig1s000ClinPharmR.pdf. 2016.</LI>&#xD;&#xA;<LI>Agarwal SK, Hu B, Chien D, et al. Evaluation of rifampin's transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a BCL-2 inhibitor: Results of a single- and multiple-dose Study. J Clin Pharmacol 2016; 56:1335.</LI>&#xD;&#xA;<LI>Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol 2017; 83:846.</LI>&#xD;&#xA;<LI>Salem AH, Hu B, Freise KJ, et al. Evaluation of the pharmacokinetic interaction between venetoclax, a selective BCL-2 inhibitor, and warfarin in healthy volunteers. Clin Drug Investig 2017; 37:303.</LI>&#xD;&#xA;<LI>Pfizer, Inc. IBRANCE (palbociclib) capsules, for oral use, package insert. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=2191) New York, NY. March 2017.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 207103Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>Yu Y, Loi CM, Hoffman J, et al. Physiologically based pharmacokinetic modeling of palbociclib. J Clin Pharmacol 2017; 57:173.</LI>&#xD;&#xA;<LI>de Gooijer MC, Zhang P, Thota N, et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib. Invest New Drugs 2015; 33:1012.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. KISQALI (ribociclib) tablets, for oral use, package insert. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kisqali.pdf. East Hanover, NJ. March 2017.</LI>&#xD;&#xA;<LI>Sun Pharmaceutical Industries, Inc. ODOMZO (sonidegib) capsules, for oral use, package insert. Available at: https://www.odomzo.com/themes/custom/odomzo/global/pdfs/pi.pdf. Cranbury, NJ. September 2017.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 205266Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>Einolf HJ, Zhou J, Won C, et al. A physiologically-based pharmacokinetic modeling approach to predict drug-drug interactions of sonidegib (LDE225) with perpetrators of CYP3A in cancer patients. Drug Metab Dispos 2017; 45:361.</LI>&#xD;&#xA;<LI>Spectrum Pharmaceuticals, Inc. BELEODAQ (belinostat) for injection, for intravenous administration, package insert. Available at: http://www.beleodaq.com/downloads/Final_Beleodaq_PI.pdf. Irvine, CA. July 2014.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 206256Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206256Orig1s000ClinPharmR.pdf. 2014.</LI>&#xD;&#xA;<LI>Dong D, Zhang T, Lu D, et al. In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes. Xenobiotica 2017; 47:277.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. FARYDAK (panobinostat) capsules, for oral use, package insert. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/farydak.pdf. East Hanover, NJ. June 2016.</LI>&#xD;&#xA;<LI>Savelieva M, Woo MM, Schran H, et al. Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. Eur J Clin Pharmacol 2015; 71:663.</LI>&#xD;&#xA;<LI>Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol 2013; 72:747.</LI>&#xD;&#xA;<LI>Hamberg P, Woo MM, Chen LC, et al. Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 2011; 68:805.</LI>&#xD;&#xA;<LI>TESARO, Inc. ZEJULA (niraparib) capsules, for oral use, package insert. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf. Waltham, MA. March 2017.</LI>&#xD;&#xA;<LI>Zhang ZY, Wang X, Lu, S, et al. Biotransformation and disposition of niraparib, an investigational, selective human PARP-1 and PARP-2 antagonist, in vitro. ISSX Online Abstracts 2015; Supplement 10:53.</LI>&#xD;&#xA;<LI>van Andel L, Zhang Z, Lu S, et al. Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Invest New Drugs 2017. DOI: 10.1007/s10637-017-0451-2.</LI>&#xD;&#xA;<LI>AstraZeneca Pharmaceuticals, LP. LYNPARZA (olaparib) capsules, for oral use, package insert. Available at: https://www.azpicentral.com/Lynparza/pi_lynparza.pdf#page=1. Wilmington, DE. January 2017.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 206162Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf. 2014.</LI>&#xD;&#xA;<LI>Dirix L, Swaisland H, Verheul HM, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: Results of two phase I open-label studies. Clin Ther 2016; 38:2286.</LI>&#xD;&#xA;<LI>Clovis Oncology, Inc. RUBRACATM (rucaparib) tablets, for oral use, package insert. Available at: http://clovisoncology.com/files/rubraca-prescribing-info.pdf. Boulder, CO. December 2016.</LI>&#xD;&#xA;<LI>Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res 2015; 32:37.</LI>&#xD;&#xA;<LI>Millennium Pharmaceuticals, Inc. NINLARO (ixazomib) capsules, for oral use, package insert. Available at: https://www.ninlarohcp.com/pdf/prescribing-information.pdf. Cambridge, MA. November 2016.</LI>&#xD;&#xA;<LI>Genentech USA, Inc. ALECENSA (alectinib) capsules, for oral use, package insert. Available at: https://www.gene.com/download/pdf/alecensa_prescribing.pdf. South San Francisco, CA. November 2016.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 208434Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>Morcos PN, Cleary Y, Guerini E, et al. Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev 2017; 6:280.</LI>&#xD;&#xA;<LI>Genentech USA, Inc. COTELLIC (cobimetinib) tablets, for oral use, package insert. Available at: https://www.gene.com/download/pdf/cotellic_prescribing.pdf. South San Francisco, CA. May 2016.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 206192Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>Gilead Sciences, Inc. ZYDELIG (idelalisib) tablets, for oral use, package insert. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/oncology/zydelig/zydelig_pi.pdf. Foster City, CA. September 2016.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 205858Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000ClinPharmR.pdf. 2013.</LI>&#xD;&#xA;<LI>Eisai, Inc. LENVIMA (lenvatinib) capsules, for oral use, package insert. Available at: http://www.lenvima.com/pdfs/prescribing-information.pdf. Woodcliff Lake, NJ. May 2016.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 206947Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206947Orig1s000ClinPharmR.pdf. 2014.</LI>&#xD;&#xA;<LI>Gupta A, Jarzab B, Capdevila J, et al. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer. Br J Clin Pharmacol 2016; 81:1124.</LI>&#xD;&#xA;<LI>Shumaker R, Aluri J, Fan J, et al. Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants. Clin Pharmacol Drug Dev 2015; 4:155.</LI>&#xD;&#xA;<LI>Shumaker RC, Aluri J, Fan J, et al. Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. Clin Drug Investig 2014; 34:651.</LI>&#xD;&#xA;<LI>AstraZeneca Pharmaceuticals, LP. TAGRISSO (osimertinib) tablets, for oral use, package insert. Available at: https://www.azpicentral.com/tagrisso/tagrisso.pdf#page=1. Wilmington, DE. March 2017.</LI>&#xD;&#xA;<LI>US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 208065Orig1s000: Clinical pharmacology and biopharmaceutics reviews. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000ClinPharmR.pdf. 2015.</LI>&#xD;&#xA;<LI>Dickinson PA, Cantarini MV, Collier J, et al. Metabolic disposition of osimertinib in rats, dogs, and humans: Insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos 2016; 44:1201.</LI>&#xD;&#xA;<LI>Novartis Pharmaceuticals Corporation. MEKINIST (trametinib) tablets, for oral use, package insert. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mekinist.pdf. East Hanover, NJ. February 2017.</LI></OL>Modified from: Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12:905.</div><div id=\"graphicVersion\">Graphic 115451 Version 1.0</div></div></div>"},"115452":{"type":"graphic_table","displayName":"Antiretroviral drugs: Interactions with anticancer agents","title":"Antiretroviral drugs: Potential for interaction with anticancer agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiretroviral drugs: Potential for interaction with anticancer agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"25%\"></colgroup><colgroup span=\"2\" width=\"12.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antiretroviral drugs</td> <td class=\"subtitle1\">Route of elimination*</td> <td class=\"subtitle1\">Effect on CYP450/transporters<sup>&#182;</sup></td> <td class=\"subtitle1\">Effect of cancer drugs on ARV as a substrate</td> <td class=\"subtitle1\">Alteration to cancer drugs due to enzyme or transporter induction or inhibition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Nucleoside reverse-transcriptase inhibitors (NRTIs)</td> </tr> <tr> <td class=\"indent1\">Abacavir<sup>[1-4,76]</sup></td> <td>Renal excretion, ADH, <strong><em>ALDH</em></strong>, UGT<sup>&#916;</sup>, ABCB1, ABCG2</td> <td>Inhibitor: ABCB1, ABCC1, ABCC2, ABCC3, ABCG2</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Didanosine<sup>[4,5]</sup></td> <td>Renal excretion, <strong><em>purine nucleoside phosphorylase</em></strong>, ABCC4</td> <td>None</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Emtricitabine<sup>[6-8]</sup></td> <td><strong><em>Renal excretion</em></strong>, UGT<sup>&#916;</sup>, ABCC1</td> <td> <p>Inducer: ABCC5</p> Inhibitor: ABCC1</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Lamivudine<sup>[4,9-11,77]</sup></td> <td><strong><em>Renal excretion</em></strong>, ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, ABCG2, SLC22A1, SLC22A2, SLC22A3, SLC47A1, SLC47A2, SULT<sup>&#916;</sup></td> <td>Inhibitor: ABCC1, ABCC2, ABCC3</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Stavudine<sup>[4,12]</sup></td> <td><strong><em>Renal excretion</em></strong>, ABCC4</td> <td>Inducer: ABCB1</td> <td>2</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zidovudine<sup>[4,10,13-15]</sup></td> <td>CYP2A6, CYP2C9, CYP2E1, CYP3A4, UGT2B7, ABCB1, ABCC4, ABCC5, ABCG2, SLC22A6, SLC22A7, SLC22A8, SLC22A11, SLC28A1, SLC28A3</td> <td> <p>Inducer: ABCC4, ABCC5</p> Inhibitor: ABCG2</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Nucleotide reverse-transcriptase inhibitors (NtRTIs)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tenofovir<sup>[4,10,16,17,78]</sup></td> <td>Renal excretion, <strong><em>ABCB1</em></strong>, ABCC2, ABCC4, ABCC10, <strong><em>ABCG2</em></strong>, SLC22A6, SLC22A8</td> <td> <p>Inducer: ABCB1</p> Inhibitor: CYP1A2</td> <td>3</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Non-nucleoside reverse-transcriptase inhibitor (NNRTIs)</td> </tr> <tr> <td class=\"indent1\">Delavirdine<sup>[4,18,19]</sup></td> <td>CYP2D6, <strong><em>CYP3A4</em></strong></td> <td> <p>Inducer: ABCB1</p> Inhibitor: <strong><em>CYP2C9</em></strong>, CYP2C19, CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1, ABCC1, ABCC2, ABCC3, ABCG2</td> <td>3</td> <td>3 (inhibitor)</td> </tr> <tr> <td class=\"indent1\">Efavirenz<sup>[4,20-26,79-81]</sup></td> <td><strong><em>CYP2B6</em></strong>, <strong><em>CYP3A</em></strong>, UGT2B7</td> <td> <p>Inducer: <strong><em>CYP2B6</em></strong>, CYP2C19, <strong><em>CYP3A4</em></strong>, UGT1A1, ABCC1, ABCC6</p> Inhibitor: CYP2C9, CYP2C19, CYP3A4, UGT1A1, UGT1A4, UGT1A9, ABCB1, ABCB11, ABCC1, ABCC2, ABCC3, ABCG2</td> <td>4</td> <td>3 (inducer)</td> </tr> <tr> <td class=\"indent1\">Etravirine<sup>[4,27,28]</sup></td> <td><strong><em>CYP2C9</em></strong>, <strong><em>CYP2C19</em></strong>, <strong><em>CYP3A4</em></strong>, UGT1A3, UGT1A8</td> <td> <p>Inducer: <strong><em>CYP3A4</em></strong></p> Inhibitor: <strong><em>CYP2C9</em></strong>, <strong><em>CYP2C19</em></strong>, <strong><em>ABCB1</em></strong></td> <td>3</td> <td>3 (inducer)</td> </tr> <tr> <td class=\"indent1\">Nevirapine<sup>[4,24,29,30,82]</sup></td> <td>CYP2B6, CYP2D6, <strong><em>CYP3A4</em></strong>, UGT<sup>&#916;</sup>, ABCC10</td> <td> <p>Inducer: <strong><em>CYP2B6</em></strong>, <strong><em>CYP3A4</em></strong>, ABCB1</p> Inhibitor: ABCB1, ABCC1, ABCC3, ABCG2</td> <td>3</td> <td>3 (inducer)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rilpivirine<sup>[31,83-85]</sup></td> <td>CYP1A2, <strong><em>CYP3A4</em></strong>, CYP3A5, UGT1A1, UGT1A4, UGT<sup>&#916;</sup></td> <td> <p>Inducer: CYP3A4, UGT1A3, ABCB1</p> Inhibitor: CYP2B6, CYP2C19, CYP3A4, ABCB1, ABCG2, SLC22A1, SLC22A2, SLCO1B1, SLCO1B3</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ritonavir or ritonavir-boosted or cobicistat-boosted HIV-1 protease inhibitors (PI)</td> </tr> <tr> <td class=\"indent1\">Amprenavir<sup>[4,32-37]</sup></td> <td>CYP2C9, CYP2D6, <strong><em>CYP3A4</em></strong>, UGT<sup>&#916;</sup>, ABCB1</td> <td> <p>Inducer: CYP3A4, ABCB1</p> Inhibitor: <strong><em>CYP3A4</em></strong><sup>&#9674;</sup>, <strong><em>ABCB1</em></strong><sup>&#9674;</sup>, ABCC1, ABCG2, SLCO1B1, SLCO1B3</td> <td>3 (inducer)</td> <td>4 (inhibitor)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Atazanavir<sup>[4,40,47,50,60-63]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCC1, ABCG2</td> <td> <p>Inducer: ABCB1, ABCC1</p> Inhibitor: CYP2C8, <strong><em>CYP3A4</em></strong>, <strong><em>UGT1A1</em></strong>, ABCB1, ABCC1, ABCC2, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1</td> <td>3 (inducer)</td> <td>3 (inhibitor)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Darunavir<sup>[4,38-40]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCC2, SLCO1A2, SLCO1B1</td> <td> <p>Inducer: ABCB1, SLCO2B1</p> Inhibitor: <strong><em>CYP2D6</em></strong>, <strong><em>CYP3A4</em></strong><sup>&#9674;</sup>, <strong><em>ABCB1</em></strong><sup>&#9674;</sup>, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1</td> <td>3 (inducer)</td> <td>4 (inhibitor)<sup>&#9674;</sup><sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Fosamprenavir (prodrug)<sup>[32,33,41]</sup></td> <td>Hydrolyzed to amprenavir</td> <td>Refer to amprenavir</td> <td>3 (inducer)</td> <td>4 (inhibitor)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Indinavir<sup>[4,32,36,40,42-47]</sup></td> <td><strong><em>CYP3A4</em></strong>, UGT<sup>&#916;</sup>, ABCB1, ABCC2</td> <td>Inhibitor: CYP2D6, <strong><em>CYP3A4</em></strong><sup>&#9674;</sup>, UGT1A1, <strong><em>ABCB1</em></strong><sup>&#9674;</sup>, SLCO1A2, SLCO1B1, SLCO1B3</td> <td>3 (inducer)</td> <td>4 (inhibitor)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Lopinavir<sup>[4,40,47-51]</sup></td> <td><strong><em>CYP3A4</em></strong>, ABCB1, ABCC1, ABCC2, SLCO1A2, SLCO1B1</td> <td> <p>Inducer: CYP1A2, CYP2C9, CYP2C19</p> Inhibitor: <strong><em>CYP3A4</em></strong><sup>&#9674;</sup>, UGT1A1, <strong><em>ABCB1</em></strong><sup>&#9674;</sup>, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1</td> <td>3 (inducer)</td> <td>4 (inhibitor)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Ritonavir<sup>[4,24,25,32,36,40,42,44,45,52-56]</sup></td> <td>CYP1A2, CYP2B6, CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1, ABCC2</td> <td> <p>Inducer: CYP1A2, CYP2B6, CYP2C9, CYP2C19, <strong><em>CYP3A4</em></strong>, UGT<sup>&#916;</sup>, ABCB1, ABCC1</p> Inhibitor: CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, <strong><em>CYP3A</em></strong>, <strong><em>ABCB1</em></strong>, ABCB11, ABCG2, SLCO1A2, SLCO1B1, SLCO1B3, SLCO2B1</td> <td>3 (inducer)</td> <td>4 (inhibitor&#62;inducer)</td> </tr> <tr> <td class=\"indent1\">Saquinavir<sup>[4,25,32,36,39,40,42,44,45,47,50]</sup></td> <td>CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1, ABCC2, SLCO1A2, SLCO1B1, SLCO1B3</td> <td> <p>Inducer: ABCB1, ABCC1, ABCC2, ABCC4, ABCC5, ABCG2</p> Inhibitor: CYP2C9, CYP2C19, CYP2D6, <strong><em>CYP3A4</em></strong><sup>&#9674;</sup>, UGT1A1, <strong><em>ABCB1</em></strong><sup>&#9674;</sup>, ABCB11, ABCC2, ABCG2, SLCO1B1, SLCO1B3, SLCO2B1</td> <td>3 (inducer)</td> <td>4 (inhibitor)<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tipranavir<sup>[4,57-59]</sup></td> <td>CYP3A4, UGT<sup>&#916;</sup>, ABCB1</td> <td> <p>Inducer: CYP3A4, ABCB1</p> Inhibitor: CYP1A2, CYP2C9, CYP2C19, <strong><em>CYP2D6</em></strong>, CYP3A4<sup>&#9674;</sup>, <strong><em>ABCB1</em></strong><sup>&#9674;</sup>, ABCG2</td> <td>3 (inducer)</td> <td>4 (inhibitor&#62;inducer)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Non-ritonavir boosted HIV-1 PI</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nelfinavir<sup>[4,32,35,42,44,64-66,86,87]</sup></td> <td>CYP2C9, <strong><em>CYP2C19</em></strong>, CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1, ABCC4</td> <td> <p>Inducer: CYP1A1, CYP2B6, CYP2C9, CYP3A4, UGT<sup>&#916;</sup>, ABCB1, ABCC2</p> Inhibitor: CYP2D6, <strong><em>CYP3A4</em></strong>, ABCB1, ABCC4, ABCG2</td> <td>4</td> <td>3 (inhibitor)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Integrase strand transfer inhibitors</td> </tr> <tr> <td class=\"indent1\">Dolutegravir<sup>[88-91]</sup></td> <td><strong><em>CYP3A4</em></strong>, <strong><em>UGT1A1</em></strong>, UGT1A3, UGT1A9, ABCB1, ABCG2</td> <td>Inhibitor: <strong><em>SLC22A2</em></strong>, SLC22A6, SLC22A7, <strong><em>SLC47A1</em></strong></td> <td>4</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Elvitegravir<sup>[92-94]</sup></td> <td><strong><em>CYP3A4</em></strong>, UGT1A1, UGT1A3</td> <td> <p>Inducer: CYP2C9, CYP3A</p> Inhibitor: CYP2D6, <strong><em>CYP3A</em></strong><sup>&#167;</sup>, ABCB1, ABCG2, SLC22A2, SLC22A4, SLC47A1, SLC47A2, SLCO1B1, SLCO1B3</td> <td>3</td> <td>4 (inhibitor)<sup>&#9674;</sup><sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Raltegravir<sup>[4,67-69,95,96]</sup></td> <td><strong><em>UGT1A1</em></strong>, UGT1A3, UGT1A9, ABCB1, SLC15A1, SLC22A6</td> <td>Inducer: ABCB1</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Fusion inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Enfuvirtide<sup>[4,70]</sup></td> <td>Catabolism</td> <td>None known</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Entry inhibitors (chemokine receptor antagonists)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maraviroc<sup>[4,68,71-75,97]</sup></td> <td><strong><em>CYP3A4/5</em></strong>, ABCB1, SLCO1B1</td> <td>Inhibitor: ABCB1, ABCC3</td> <td>4</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Pharmacokinetic enhancer</td> </tr> <tr> <td class=\"indent1\">Cobicistat<sup>[93,94,98]</sup></td> <td>CYP2D6, <strong><em>CYP3A4</em></strong></td> <td>Inhibitor: <strong><em>CYP2D6</em></strong>, <strong><em>CYP3A</em></strong>, ABCB1, ABCG2, SLC22A2, SLC22A4, SLC47A1, SLC47A2, SLCO1B1, SLCO1B3</td> <td>&nbsp;</td> <td>4 (inhibitor)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">DDI potential code and clinical relevance: &#xD;&#xA;<OL class=decimal_heading>&#xD;&#xA;<LI>Interaction unlikely or known minor interaction not requiring modification to therapy.</LI>&#xD;&#xA;<LI>Possible interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity.</LI>&#xD;&#xA;<LI>Potential for significant interaction based on pharmacology of the drug. No modification to therapy but monitor closely for signs of toxicity. Consider therapy modification if unable to monitor closely.</LI>&#xD;&#xA;<LI>Potential for clinically significant interaction based on pharmacology of the drug or known interaction. Need for dose adjustment or consideration of therapy modification.</LI>&#xD;&#xA;<LI>Major clinically significant interaction or potential critical interaction. Co-administration is contraindicated.</LI></OL></div><div class=\"graphic_footnotes\">ARV: antiretroviral; ADH: alcohol dehydrogenase; ALDH: aldehyde dehydrogenase; UGT: uridine 5'-diphospho-glucuronosyltransferase; ABC: ATP-binding cassette sub-family/member; SLC: sodium-coupled nucleoside transport family/member; SULT: sulfotransferase; CYP: cytochrome P450; SLCO: solute carrier organic anion transporter family/member; HIV: human immunodeficiency virus; DDI: drug-drug interaction.<br />* The major routes of elimination are in bold italic font. The minor routes of elimination are in regular font.<br />¶ The strong inhibitors or inducers of an enzyme/transporter are in bold italic font. Inhibitors or inducers of an enzyme/transporter that have caused clinically significant interactions are in bold italic font.<br />Δ Isozyme not specified.<br /><FONT class=lozenge>◊</FONT> When used with ritonavir.<br />§ When used with cobicistat.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Walsh JS, Reese MJ, Thurmond LM. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes. Chem Biol Interact 2002; 142:135.</li>&#xD;&#xA;    <li>Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet 2008; 47:351.</li>&#xD;&#xA;    <li>McDowell JA, Chittick GE, Ravitch JR, et al. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43:2855.</li>&#xD;&#xA;    <li>Weiss, J, Haefeli, WE. Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy. International review of cell and molecular biology 2010; 280:219.</li>&#xD;&#xA;    <li>Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother 2004; 48:1089.</li>&#xD;&#xA;    <li>Zong J, Chittick GE, Wang LH, et al. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol 2007; 47:877.</li>&#xD;&#xA;    <li>Gilead Sciences, Inc. Emtriva (emtricitabine) capsules and oral solution prescribing information (http://www.gilead.com/pdf/emtriva_pi.pdf). Foster City, CA November 2012.</li>&#xD;&#xA;    <li>Bousquet L, Pruvost A, Didier N, et al. Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences 2008; 35:247.</li>&#xD;&#xA;    <li>Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999; 36:41.</li>&#xD;&#xA;    <li>McDonagh EM, Whirl-Carrillo M, Garten Y, et al. From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomarkers in medicine 2011; 5:795.</li>&#xD;&#xA;    <li>Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics. Available at: http://curation.pharmgkb.org/pathway/PA165860384. Accessed 04/23/14.</li>&#xD;&#xA;    <li>Grasela DM, Stoltz RR, Barry M, et al. Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis. Antimicrob Agents Chemother 2000; 44:2149.</li>&#xD;&#xA;    <li>Court MH, Krishnaswamy S, Hao Q, et al. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 2003; 31:1125.</li>&#xD;&#xA;    <li>Blum MR, Liao SH, Good SS, de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85:189.</li>&#xD;&#xA;    <li>Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics . Available at: http://curation.pharmgkb.org/pathway/PA165859361. Accessed 04/23/14.</li>&#xD;&#xA;    <li>Gilead Sciences, Inc. VIREAD (tenofovir disoproxil fumarate) tablets prescribing information (http://www.gilead.com/pdf/viread_pi.pdf). Foster City, CA February 2016.</li>&#xD;&#xA;    <li>Pharm GKB The Pharmacogenetics and Pharmacogenomics Knowledge Base - Tenofovir/Adefovir Pathway, Pharmacodynamics. Available at: http://curation.pharmgkb.org/pathway/PA155028030. Accessed 04/23/14.</li>&#xD;&#xA;    <li>Voorman RL, Payne NA, Wienkers LC, et al. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos 2001; 29:41.</li>&#xD;&#xA;    <li>Voorman RL, Maio SM, Hauer MJ, et al. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998; 26:631.</li>&#xD;&#xA;    <li>Hariparsad N, Nallani SC, Sane RS, et al. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44:1273.</li>&#xD;&#xA;    <li>Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49:513.</li>&#xD;&#xA;    <li>Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287.</li>&#xD;&#xA;    <li>Belanger AS, Caron P, Harvey M, et al. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 2009; 37:1793.</li>&#xD;&#xA;    <li>Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320:72.</li>&#xD;&#xA;    <li>McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. The Journal of pharmacology and experimental therapeutics 2006; 318:1068.</li>&#xD;&#xA;    <li>Ji HY, Lee H, Lim SR, et al. Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. Molecules 2012; 17:851.</li>&#xD;&#xA;    <li>Scholler-Gyure M, Kakuda TN, Raoof, A, et al. Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 2009; 48:561.</li>&#xD;&#xA;    <li>Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug metabolism and disposition: the biological fate of chemicals 2012; 40:803.</li>&#xD;&#xA;    <li>Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488.</li>&#xD;&#xA;    <li>Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27:895.</li>&#xD;&#xA;    <li>Janssen Therapeutics, Division of Janssen Products, LP. EDURANT (rilpivirine) tablets prescribing information (http://www.edurant.com/shared/prescribing-information-edurant.pdf). Titusville, NJ August 2015.</li>&#xD;&#xA;    <li>Granfors MT, Wang JS, Kajosaari LI, et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98:79.</li>&#xD;&#xA;    <li>Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical pharmacokinetics 2006; 45:137.</li>&#xD;&#xA;    <li>Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87:803.</li>&#xD;&#xA;    <li>Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29:754.</li>&#xD;&#xA;    <li>Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999; 16:1206.</li>&#xD;&#xA;    <li>Singh R, Chang SY, Taylor LC. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. Rapid Commun Mass Spectrom 1996; 10:1019.</li>&#xD;&#xA;    <li>Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007; 46:739.</li>&#xD;&#xA;    <li>Konig SK, Herzog M, Theile D, et al. Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother 2010; 65:2319.</li>&#xD;&#xA;    <li>Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica; the fate of foreign compounds in biological systems 2010; 40:163.</li>&#xD;&#xA;    <li>Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 2004; 48:791.</li>&#xD;&#xA;    <li>von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38:106.</li>&#xD;&#xA;    <li>Zucker SD, Qin X, Rouster SD, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98:12671.</li>&#xD;&#xA;    <li>von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998; 87:1184.</li>&#xD;&#xA;    <li>Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190.</li>&#xD;&#xA;    <li>Balani SK, Woolf EJ, Hoagland VL, et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab Dispos 1996; 24:1389.</li>&#xD;&#xA;    <li>Ye ZW, Camus S, Augustijns P, Annaert P. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 2010; 31:178.</li>&#xD;&#xA;    <li>Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999; 27:902.</li>&#xD;&#xA;    <li>Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm Res 2004; 21:1622.</li>&#xD;&#xA;    <li>Zhang D, Chando TJ, Everett DW, et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33:1729.</li>&#xD;&#xA;    <li>Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. Journal of acquired immune deficiency syndromes 2006; 42:52.</li>&#xD;&#xA;    <li>Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277:423.</li>&#xD;&#xA;    <li>Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004; 36:1034.</li>&#xD;&#xA;    <li>Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52:1663.</li>&#xD;&#xA;    <li>Greenblatt DJ, von Moltke LL, Daily JP, et al. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999; 19:293.</li>&#xD;&#xA;    <li>Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46:111.</li>&#xD;&#xA;    <li>Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007; 27:888.</li>&#xD;&#xA;    <li>King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45:665.</li>&#xD;&#xA;    <li>Mukwaya G, MacGregor T, Hoelscher D, et al. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother 2005; 49:4903.</li>&#xD;&#xA;    <li>Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44:1324.</li>&#xD;&#xA;    <li>Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther 2006; 11:53.</li>&#xD;&#xA;    <li>Bristol-Myers Squibb Company. REYATAZ (atazanavir sulfate) Capsules Package Insert (http://packageinserts.bms.com/pi/pi_reyataz.pdf). Princeton, NJ September 2015.</li>&#xD;&#xA;    <li>Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19:1635.</li>&#xD;&#xA;    <li>Wu E, Sandoval T, Zhang K, et al. Cytochrome P450 isoforms involved in the metabolism of nelfinavir mesylate, an HIV-1 protease inhibitor. ISSX Proc. 1998; 13:110.</li>&#xD;&#xA;    <li>Lillibridge JH, Liang BH, Kerr BM, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998; 26:609.</li>&#xD;&#xA;    <li>Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007; 35:1853.</li>&#xD;&#xA;    <li>Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657.</li>&#xD;&#xA;    <li>Zembruski NC, Buchel G, Jodicke L, et al. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. The Journal of antimicrobial chemotherapy 2011; 66:802.</li>&#xD;&#xA;    <li>Moss DM, Kwan WS, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrobial agents and chemotherapy 2011; 55:879.</li>&#xD;&#xA;    <li>Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004; 44:793.</li>&#xD;&#xA;    <li>Hyland R, Dickins M, Collins C, et al. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 2008; 66:498.</li>&#xD;&#xA;    <li>Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005; 33:587.</li>&#xD;&#xA;    <li>Boffito M, Abel S. A review of the clinical pharmacology of maraviroc. Introduction. Br J Clin Pharmacol 2008; 65 Suppl 1:1.</li>&#xD;&#xA;    <li>Abel S, van der Ryst E, Rosario MC, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008; 65 Suppl 1:5.</li>&#xD;&#xA;    <li>Siccardi M, D'Avolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T&gt;C polymorphism. Pharmacogenetics and genomics 2010; 20:759.</li>&#xD;&#xA;    <li>Grilo NM, Charneira C, Pereira SA, et al. Bioactivation to an aldehyde metabolite--possible role in the onset of toxicity induced by the anti-HIV drug abacavir. Toxicol Lett 2014; 224:416.</li>&#xD;&#xA;    <li>M&uuml;ller F, K&ouml;nig J, Hoier E, et al. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol 2013; 86:808.</li>&#xD;&#xA;    <li>Mallants R, Van Oosterwyck K, Van Vaeck L, et al. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 2005; 35:1055.</li>&#xD;&#xA;    <li>Michaud V, Ogburn E, Thong N, et al. Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. Clin Pharmacol Ther 2012; 91:475.</li>&#xD;&#xA;    <li>Oswald S, Meyer zu Schwabedissen HE, Nassif A, et al. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther 2012; 91:506.</li>&#xD;&#xA;    <li>Lee LS, Pham P, Flexner C. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz. Ann Acad Med Singapore 2012; 41:559.</li>&#xD;&#xA;    <li>Liptrott NJ, Pushpakom S, Wyen C, et al; German Competence Network for HIV/AIDS. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics 2012; 22:10.</li>&#xD;&#xA;    <li>Weiss J, Haefeli WE. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents 2013; 41:484.</li>&#xD;&#xA;    <li>Lade JM, Avery LB, Bumpus NN. Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother 2013; 57:5067.</li>&#xD;&#xA;    <li>Moss DM, Liptrott NJ, Curley P, et al. Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. Antimicrob Agents Chemother 2013; 57:5612.</li>&#xD;&#xA;    <li>Fukuda Y, Takenaka K, Sparreboom A, et al. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol 2013; 84:361.</li>&#xD;&#xA;    <li>Kirby BJ, Collier AC, Kharasch ED, et al. Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011; 39:2329.</li>&#xD;&#xA;    <li>Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 2013; 52:981.</li>&#xD;&#xA;    <li>Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos 2013; 41:353.</li>&#xD;&#xA;    <li>Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol 2013; 75:990.</li>&#xD;&#xA;    <li>ViiV Healthcare. TIVICAY (dolutegravir) tablets prescribing information (https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF). Research Triangle Park, NC June 2016.</li>&#xD;&#xA;    <li>Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 2011; 50:229.</li>&#xD;&#xA;    <li>Lepist EI, Murray BP, Tong L, et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters [poster A1-1724]. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2011; Chicago, IL.</li>&#xD;&#xA;    <li>Gilead Sciences, Inc. STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets prescribing information (http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/stribild/stribild_pi.pdf). Foster City, CA January 2017.</li>&#xD;&#xA;    <li>Gr&eacute;co JM, Simons G, Darsonval V, et al. [External fasciocutaneous flap of the leg with a distal pedicle]. Ann Chir Plast Esthet 1986; 31:109.</li>&#xD;&#xA;    <li>Wechsler B, Piette JC, Du LT. Treatment of lupus erythematosus disseminatus. Rev Prat 1990; 40:1952.</li>&#xD;&#xA;    <li>Lu Y, Hendrix CW, Bumpus NN. Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc. Drug Metab Dispos 2012; 40:2221.</li>&#xD;&#xA;    <li>Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012; 56:5409.</li>&#xD;&#xA;</ol>&#xD;&#xA;Original table modified for this publication. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12:905. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115452 Version 1.0</div></div></div>"},"115462":{"type":"graphic_picture","displayName":"Chediak-Higashi syndrome","title":"Chediak-Higashi syndrome","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Chediak-Higashi syndrome</div><div class=\"cntnt\"><img style=\"width:464px; height:302px;\" src=\"images/DERM/115462_ChediakHigashisyndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Silvery-blond hair color in a patient with Chediak-Higashi syndrome.</div><div id=\"graphicVersion\">Graphic 115462 Version 1.0</div></div></div>"},"115469":{"type":"graphic_table","displayName":"Cervical prep protocol abortion","title":"Cervical preparation protocols for aspiration abortion","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cervical preparation protocols for aspiration abortion</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weeks</td> <td class=\"subtitle1\">Hospital-based academic practice A</td> <td class=\"subtitle1\">Hospital-based academic practice B</td> <td class=\"subtitle1\">Freestanding nonprofit clinic</td> <td class=\"subtitle1\">Freestanding private clinic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">&#60;12</td> <td>Mechanical dilation alone</td> <td>Mechanical dilation alone</td> <td>Mechanical dilation alone</td> <td>Mechanical dilation alone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">12</td> <td>Nulliparous: Misoprostol 400 mcg buccal two to three hours</td> <td> <p>Misoprostol 400 mcg three to four hours</p> <p><strong>OR</strong></p> 1 Dilapan overnight </td> <td>Nulliparous: Misoprostol 400 mcg buccal two to three hours</td> <td> <p>Nulliparous: Misoprostol 400 mcg vaginal two to three hours</p> Multiparous: Misoprostol 400 mcg vaginal one to three hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">13</td> <td>Misoprostol 400 mcg buccal two to three hours</td> <td> <p>Misoprostol 400 mcg three to four hours</p> <p><strong>OR</strong></p> 1 Dilapan overnight</td> <td>Nulliparous: Misoprostol 400 mcg buccal two to three hours</td> <td>Misoprostol 400 mcg vaginal two to three hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">14</td> <td>Misoprostol 400 mcg buccal two to three hours</td> <td> <p>Misoprostol 400 mcg three to four hours</p> <p><strong>OR</strong></p> 2 Dilapan overnight</td> <td>Misoprostol 400 mcg buccal two to three hours</td> <td>Misoprostol 400 mcg vaginal two to three hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">15</td> <td>Misoprostol 400 mcg buccal two to three hours</td> <td> <p>Misoprostol 400 mcg three to four hours</p> <p><strong>OR</strong></p> 2 Dilapan overnight</td> <td>Misoprostol 400 mcg buccal two to three hours</td> <td>Misoprostol 400 mcg vaginal two to four hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">16</td> <td> <p>Same-day: 2 to 4 Dilapan, 1 laminaria*</p> <p>Day one: Minimum 2 Dilapan, 1 laminaria</p> Day two: D&#38;E </td> <td> <p>Misoprostol 400 mcg three to four hours</p> <p><strong>OR</strong></p> 3 Dilapan overnight<sup>&#916;</sup></td> <td>1 to 2 Dilapan and misoprostol 400 mcg buccal two to three hours</td> <td>Misoprostol 400 mcg vaginal two to four hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">17</td> <td> <p>Same-day: 3 to 5 Dilapan, 1 laminaria*</p> <p>Day one: Minimum 2 Dilapan, 1 laminaria</p> Day two: D&#38;E </td> <td> <p>Misoprostol 400 mcg three to four hours</p> <p><strong>OR</strong></p> 3 Dilapan overnight<sup>&#916;</sup></td> <td>1 to 2 Dilapan and misoprostol 400 mcg buccal three to four</td> <td>4 Dilapan<sup>&#9674;</sup> with misoprostol 400 mcg vaginal four to five hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">18</td> <td> <p>Day one: Minimum 3 Dilapan, 1 laminaria</p> Day two: D&#38;E</td> <td> <p>Day one: 4 Dilapan<sup>&#916;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 1 to 2 Dilapan and mifepristone</p> Day two: Misoprostol 800 mcg rectally prior to dilator removal; D&#38;E</td> <td>4 Dilapan<sup>&#9674;</sup> with misoprostol 400 mcg vaginal four to five hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">19</td> <td> <p>Day one: Minimum 4 Dilapan, 1 laminaria<sup>&#182;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 4 Dilapan<sup>&#916;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 1 to 2 Dilapan and mifepristone</p> Day two: Misoprostol 800 mcg rectally prior to dilator removal; D&#38;E</td> <td>4 Dilapan<sup>&#9674;</sup> with misoprostol 400 mcg vaginal four to five hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">20</td> <td> <p>Day one: Minimum 5 Dilapan, 1 laminaria<sup>&#182;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 5 Dilapan<sup>&#916;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 3 to 4 Dilapan and mifepristone</p> Day two: Misoprostol 800 mcg rectally prior to dilator removal; D&#38;E</td> <td>4 Dilapan<sup>&#9674;</sup> with misoprostol 400 mcg vaginal four to five hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">21</td> <td> <p>Day one: Minimum 6 Dilapan, 1 laminaria<sup>&#182;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 6 Dilapan<sup>&#916;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 4 to 5 Dilapan and mifepristone</p> Day two: Misoprostol 800 mcg rectally prior to dilator removal; D&#38;E</td> <td> <p>Day one: Mifepristone</p> Day two: Misoprostol 400 mcg vaginal two to four hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">22</td> <td> <p>Day one: Minimum 7 Dilapan, 1 laminaria<sup>&#182;</sup></p> Day two: D&#38;E</td> <td> <p>Day one: 7 Dilapan and mifepristone</p> Day two: D&#38;E</td> <td> <p>Day one: 5 to 6 Dilapan and mifepristone</p> Day two: Misoprostol 800 mcg rectally prior to dilator removal; D&#38;E</td> <td> <p>Day one: Mifepristone</p> Day two: Misoprostol 400 mcg vaginal two to four hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">23</td> <td> <p>Day one: Minimum 8 Dilapan, 1 laminaria, mifepristone</p> Day two: D&#38;E</td> <td> <p>Day one: 8 Dilapan and mifepristone</p> Day two: D&#38;E</td> <td> <p>Day one: 6 to 8 Dilapan and mifepristone</p> Day two: Misoprostol 800 mcg rectally prior to dilator removal; D&#38;E</td> <td> <p>Day one: 6 to 8 Dilapan<sup>&#9674;</sup>, intracardiac lidocaine, mifepristone</p> Day two: Misoprostol 400 mcg vaginal one to three hours; D&#38;E</td> </tr> <tr> <td class=\"centered\">24</td> <td> <p>Day one: Minimum 9 Dilapan, 1 laminaria, mifepristone</p> Day two: D&#38;E</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Day one: 8 to 10 Dilapan<sup>&#9674;</sup>, intracardiac lidocaine, mifepristone</p> Day two: Misoprostol 400 mcg vaginal one to three hours; D&#38;E</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">D&amp;E: dilation and evacuation.<br />* Same-day procedures require dilators for at least&nbsp;four hours. 400 mcg buccal misoprostol is also given if insufficient dilators are placed.<br />&para; Mifepristone added for young teens, if the cervix is noncompliant, or if the minimum number of dilators is not placed.<br />&Delta; Mifepristone added if insufficient dilators placed.<br /><span class=\"lozenge\">&loz;</span> Gabapentin 300 mg administered 30 minutes prior to dilator insertion.</div><div id=\"graphicVersion\">Graphic 115469 Version 2.0</div></div></div>"},"115473":{"type":"graphic_algorithm","displayName":"Symptomatic management of diabetic muscle infarction","title":"Symptomatic management of diabetic muscle infarction*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Symptomatic management of diabetic muscle infarction*</div><div class=\"cntnt\"><img style=\"width:434px; height:481px;\" src=\"images/RHEUM/115473_Symptcmgmtdbtcmsclinftn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">NSAID: nonsteroidal antiinflammatory drug; COX-2: cyclooxygenase-2.<br />* Refer to UpToDate topic on diabetic muscle infarction.<br />¶ Refer to UpToDate topics on management of adults with diabetes mellitus.<br />Δ Contraindications to NSAIDs may include renal disease, hypertension, heart failure, ischemic heart disease, anticoagulation therapy, and risk of peptic ulcer disease and gastrointestinal hemorrhage. Refer to UpToDate content on adverse effects of nonselective and COX-2 selective NSAIDs for further discussion of contraindications to the use of NSAIDs and of their adverse effects.<br /><FONT class=lozenge>◊ </FONT>In patients on both aspirin and an NSAID, refer to UpToDate topic on cardiovascular adverse effects of NSAIDs for a discussion of coadministration of aspirin and NSAIDs.<br />§ Refer to UpToDate topic on the treatment of chronic non-cancer pain for a discussion of management of nociceptive pain.</div><div id=\"graphicVersion\">Graphic 115473 Version 1.0</div></div></div>"},"115474":{"type":"graphic_algorithm","displayName":"Approach to medication-assisted treatment for OUD","title":"Approach to medication-assisted treatment for opioid use disorder*","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to medication-assisted treatment for opioid use disorder*</div><div class=\"cntnt\"><img style=\"width:289px; height:508px;\" src=\"images/PSYCH/115474_ApprmedicatnasstdrxOUD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OUD: Opioid use disorder.<br />* Medication-assisted treatment typically includes integrated, adjunctive psychosocial treatment. We suggest beginning with addiction counseling and participation in a mutual help group. Inadequate response to medication may result in increases to the number and/or types of interventions.<br />¶ Opioid withdrawal and treatment with an opioid antagonist should be avoided in pregnant women with OUD. The selection of medication to treat opioid use disorder during pregnancy is discussed in the topic on methadone substitution therapy for OUD during pregnancy.<br />Δ Completed withdrawal is needed prior to naltrexone, but not prior to buprenorphine or methadone. For some patients, however, the choice of medications is not made until after withdrawal. Initial agonist dosing after withdrawal should be adjusted accordingly, given the lower level of physical dependence in such cases.<br /><FONT class=lozenge>◊</FONT> Naltrexone is generally suggested for highly motivated patients with mild OUD; however, for some patients with more severe OUD, naltrexone may be preferred by the patient or buprenorphine and methadone may be unavailable.<br />§ Supervised daily oral naltrexone is a reasonable alternative to long-acting injectable naltrexone in highly motivated patients who refuse injections or have good external support.<br />¥ Treatment failure as indicated by poor attendance and/or continual, ongoing illicit opioid use.</div><div id=\"graphicVersion\">Graphic 115474 Version 1.0</div></div></div>"},"115475":{"type":"graphic_table","displayName":"Primary care PTSD screen for DSM-5 (PC-PSTD-5)","title":"Primary care PTSD screen for DSM-5 (PC-PSTD-5)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary care PTSD screen for DSM-5 (PC-PSTD-5)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"95%\"></colgroup><colgroup width=\"5%\"></colgroup> <tbody> <tr> <td><strong>Sometimes things happen to people that are unusually or especially frightening, horrible, or traumatic.</strong> For example: <ul class=\"decimal_heading\"> <li>A serious accident or fire </li> <li>A physical or sexual assault or abuse </li> <li>An earthquake or flood </li> <li>A war </li> <li>Seeing someone be killed or seriously injured </li> <li>Having a loved one die through homicide or suicide </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Have you ever experienced this kind of event?</strong> If 'No,' screen total = 0; if 'Yes,' continue with screening.</td> <td>YES/NO</td> </tr> <tr> <td colspan=\"2\"><strong>In the past month, have you...</strong></td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\"> <li>Had nightmares about the event(s) or thought about the event(s) when you did not want to? </li> </ol> </td> <td>YES/NO</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Tried hard not to think about the event(s) or went out of your way to avoid situations that reminded you of the event(s)? </li> </ol> </td> <td>YES/NO</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Been constantly on guard, watchful, or easily startled? </li> </ol> </td> <td>YES/NO</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Felt numb or detached from people, activities, or your surroundings? </li> </ol> </td> <td>YES/NO</td> </tr> <tr> <td class=\"indent1\"> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Felt guilty or unable to stop blaming yourself or others for the events(s) or any problems the event(s) may have caused? </li> </ol> </td> <td>YES/NO</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Respondents were asked to answer \"yes\" or \"no\" to all items.</div><div class=\"graphic_footnotes\">PTSD: Posttraumatic stress disorder.</div><div class=\"graphic_reference\">From: Journal of General Internal Medicine, The Primary Care PTSD Screen for DSM-5 (PC-PTSD-5): Development and Evaluation Within a Veteran Primary Care Sample, Vol. 31, 2016, p. 1206, Prins A, Bovin MJ, Smolenski DJ, et al, © Society of General Internal Medicine 2016. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 115475 Version 1.0</div></div></div>"},"115478":{"type":"graphic_diagnosticimage","displayName":"US calcific tendinopathy resorptive phase long axis","title":"Ultrasound of calcific tendinopathy of the shoulder: Resorptive phase seen in long axis","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Ultrasound of calcific tendinopathy of the shoulder: Resorptive phase seen in long axis</div><div class=\"cntnt\"><img style=\"width:547px; height:292px;\" src=\"images/SM/115478_USclfctdptyrpvphslgxs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a calcific deposit (dashed arrow)&nbsp;in the supraspinatus tendon in a long axis view. Below the deposit lies the surface of humeral head (arrow). </div><div id=\"graphicVersion\">Graphic 115478 Version 2.0</div></div></div>"},"115485":{"type":"graphic_table","displayName":"Sirolimus starting dose in neonates and infants","title":"Starting dosing regimens for sirolimus in neonates and infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Starting dosing regimens for sirolimus in neonates and infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age group (months)</td> <td class=\"subtitle1\" colspan=\"2\">Dose (mg/m<sup>2</sup>/dose every 12 hours)</td> </tr> <tr> <td class=\"subtitle2\">Target range: 6 to 10 ng/mL<br /> (predose concentration or \"trough\")</td> <td class=\"subtitle2\">Target range: 10 to 15 ng/mL<br /> (predose concentration or \"trough\")</td> </tr> <tr> <td class=\"centered\">0 to 1</td> <td class=\"centered\">0.28</td> <td class=\"centered\">0.4</td> </tr> <tr> <td class=\"centered\">1 to 2</td> <td class=\"centered\">0.34</td> <td class=\"centered\">0.5</td> </tr> <tr> <td class=\"centered\">2 to 3</td> <td class=\"centered\">0.4</td> <td class=\"centered\">0.6</td> </tr> <tr> <td class=\"centered\">3 to 4</td> <td class=\"centered\">0.46</td> <td class=\"centered\">0.7</td> </tr> <tr> <td class=\"centered\">4 to 6</td> <td class=\"centered\">0.58</td> <td class=\"centered\">0.9</td> </tr> <tr> <td class=\"centered\">6 to 9</td> <td class=\"centered\">0.7</td> <td class=\"centered\">1.1</td> </tr> <tr> <td class=\"centered\">9 to 12</td> <td class=\"centered\">0.82</td> <td class=\"centered\">1.3</td> </tr> <tr> <td class=\"centered\">12 to 24</td> <td class=\"centered\">1</td> <td class=\"centered\">1.4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Starting dosing regimens for sirolimus in neonates and infants. Simulations based on pharmacokinetic data in patient with vascular anomalies.</div><div class=\"graphic_reference\">Data from: Mizuno T, Fukuda T, Emoto C, et al. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer 2017.</div><div id=\"graphicVersion\">Graphic 115485 Version 1.0</div></div></div>"},"115486":{"type":"graphic_figure","displayName":"TPO levels versus platelet counts in various disorders","title":"The relation of TPO levels to platelet counts in various disorders of platelet production","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">The relation of TPO levels to platelet counts in various disorders of platelet production</div><div class=\"cntnt\"><img style=\"width:636px; height:575px;\" src=\"images/HEME/115486_TPOlevelsplateletcounts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum TPO levels&nbsp;were measured using a quantitative ELISA assay in 118 healthy volunteers, 39 patients with consumptive thrombocytopenia (eg, ITP, DIC), 49 patients with hypoproliferative thrombocytopenia (eg, acute leukemia, stem cell transplantation), and 34 patients with thrombocytosis due to myeloproliferative disorders. The mean TPO level in healthy volunteers was 39 pg/mL&nbsp;(interquartile range, 7 to 99 pg/mL). In consumptive thrombocytopenias (gray squares), TPO levels were increased (median,&nbsp;63 pg/mL; range, 48 to 98), with a median platelet count of 73,000/microL (range, 28,000 to 146,000/microL). By contrast, in hypoproliferative thrombocytopenias (white diamonds), serum TPO levels were significantly higher (median 706 pg/mL; range, 358 to 1546 pg/mL), with similar platelet counts (median, 59,000/microL; range,&nbsp;30,000 to 117,000/microL).&nbsp;In myeloproliferative disorders with thrombocytosis (black triangles), TPO levels were similar to consumptive thrombocytopenia (median, 87 pg/mL; range, 38 to 126pg/mL), despite the high platelet counts (median, 550,000/microL; range, 413,000 to 693,000/microL). All patients in these studies had normal liver function.</div><div class=\"graphic_footnotes\">TPO: thrombopoietin; ELISA: enzyme-linked immunosorbent assay;&nbsp;ITP: immune thrombocytopenia; DIC: disseminated intravascular coagulation.</div><div class=\"graphic_reference\">Courtesy of Robert Makar, MD and David Kuter, MD, D.Phil. Data from: Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol 2013; 88:1041.</div><div id=\"graphicVersion\">Graphic 115486 Version 1.0</div></div></div>"},"115504":{"type":"graphic_algorithm","displayName":"Initial management of psoriasis in children","title":"Initial management of psoriasis in children","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Initial management of psoriasis in children</div><div class=\"cntnt\"><img style=\"width:721px; height:427px;\" src=\"images/DERM/115504_Intlmgmtpsoriasischldrn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to UpToDate topics on the management of psoriatic juvenile idiopathic arthritis.<br />¶ Topical therapy is often inadequate for children with moderate to severe disease; however, we typically attempt topical therapy prior to initiating phototherapy or systemic therapy to identify those children who can be sufficiently managed with topical therapy.<br />Δ All listed treatments are reasonable first-line choices. Selection among these agents is dependent upon factors such as patient age, disease severity, comorbidities, tolerance of risks and side effects, and prior treatment history. Refer to UpToDate topics on the management of plaque psoriasis in children for additional information on treatment selection. Alternative systemic therapies include acitretin, cyclosporine, and fumaric acid esters.<br /><FONT class=lozenge>◊</FONT> Phototherapy and systemic therapy are generally avoided in children under the age of four due to safety concerns. However, use of these interventions may be necessary in rare, refractory cases.<br />§ Refer to UpToDate table on topical corticosteroids.<br />¥ Topical calcineurin inhibitors are preferred over topical corticosteroids for long-term therapy.<br />‡ Often, patients find medications in shampoos, foams, solutions, gels, sprays, or oils preferable for application to the scalp. The vehicle options should be discussed with the child or caregiver to identify the most acceptable regimen.</div><div id=\"graphicVersion\">Graphic 115504 Version 1.0</div></div></div>"},"115506":{"type":"graphic_table","displayName":"Anticoagulant selection HIT","title":"Selection of a non-heparin anticoagulant in a patient with suspected or confirmed HIT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of a non-heparin anticoagulant in a patient with suspected or confirmed HIT</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Features affecting selection</td> <td class=\"subtitle1\">Mechanism, administration, and monitoring</td> </tr> <tr> <td class=\"indent1\">Argatroban</td> <td> <ul> <li>Short-acting&nbsp; </li> <li>Can be used in renal impairment; no dose adjustment needed&nbsp; </li> <li>Hepatically eliminated; dose adjustment needed in hepatic impairment&nbsp; </li> <li>Can be used in pregnancy </li> <li>Use in breastfeeding unknown </li> </ul> </td> <td> <ul> <li>Parenteral direct thrombin inhibitor </li> <li>Administered by continuous intravenous infusion </li> <li>Monitored and adjusted by aPTT; obtain aPTT prior to initiation, two hours after starting infusion, and after dose changes </li> <li>Half-life approximately 40 to 50 minutes (prolonged to approximately 180 minutes in hepatic impairment) </li> <li>Prolongs the PT/INR </li> <li>No reversal agent (but effect is rapidly reversed upon discontinuation) </li> <li>Expensive </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bivalirudin</td> <td> <ul> <li>Short-acting </li> <li>Renally eliminated; dose adjustment needed in renal impairment </li> <li>Can be used in hepatic impairment; no dose adjustment is needed </li> <li>Multi-organ failure in critical illness: Dose adjustment is needed </li> <li>Can be used in pregnancy </li> <li>Use in breastfeeding unknown </li> </ul> </td> <td> <ul> <li>Parenteral direct thrombin inhibitor </li> <li>Administered by continuous intravenous infusion </li> <li>Monitored and adjusted by aPTT; obtain aPTT prior to infusion, two hours after starting infusion, and after dose changes </li> <li>Half-life approximately 25 minutes (prolonged to approximately 3.5 hours in ESRD) </li> <li>Prolongs the PT/INR, less so than argatroban </li> <li>No reversal agent (but effect is rapidly reversed upon discontinuation) </li> <li>Expensive </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Danaparoid (not available in United States)</td> <td> <ul> <li>Parenteral agent; may be given subcutaneously following initial intravenous bolus </li> <li>Renally eliminated; dose adjustment needed in renal impairment </li> <li>Can be used in hepatic impairment; no dose adjustment is needed </li> <li>Can be used in pregnancy </li> <li>Can be used in breastfeeding </li> </ul> </td> <td> <ul> <li>Parenteral inhibitor of thrombin and factor Xa (indirect, heparinoid, derived from porcine intestine) </li> <li>Administered intravenously or subcutaneously (intravenous dosing preferred if an invasive procedure is likely to be needed) </li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed* </li> <li>Half-life (anti-factor Xa activity) is approximately 25 hours; prolonged to 29 to 35 hours in renal impairment </li> <li>No reversal agent </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fondaparinux</td> <td> <ul> <li>Subcutaneous agent </li> <li>Renally eliminated; dose adjustment is needed for CrCl 30 to 50 mL/minute and should not be used if CrCl is &#60;30 mL/minute </li> <li>Can be used in hepatic impairment; no dose adjustment is needed </li> <li>Not suitable if likely to undergo urgent invasive procedure due to long half-life </li> <li>Can be used in pregnancy </li> </ul> </td> <td> <ul> <li>Parenteral inhibitor of factor Xa (indirect) </li> <li>Administered subcutaneously, once per day </li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed* </li> <li>Half-life 17 to 21 hours; prolonged in renal impairment, older adults, and low body weight </li> <li>No reversal agent </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Apixaban</td> <td> <ul> <li>Oral agent </li> <li>Renally and hepatically eliminated (less dependent on renal function than other direct oral anticoagulants); no close adjustment is needed for CrCl &#8805;25 mL/minute or mild to moderate hepatic impairment </li> <li>Do not use if CrCl &#60;25 mL/minute, serum creatinine &#62;2.5 mg/dL, dialysis-dependent, or severe hepatic impairment </li> <li>Subject to CYP3A4 and P-gp drug interactions </li> <li>Use in pregnancy and breastfeeding unknown </li> </ul> </td> <td> <ul> <li>Oral direct factor Xa inhibitor </li> <li>Administered orally, twice-daily dosing </li> <li>Half-life approximately 12 hours </li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed* </li> <li>No reversal agent </li> <li>Not dialyzable </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dabigatran</td> <td> <ul> <li>Oral agent </li> <li>Mostly renally eliminated; no dose adjustment needed for CrCl &#62;30 mL/minute or hepatic impairment<sup>&#182;</sup> </li> <li>Do not use if CrCl &#8804;30 mL/minute or dialysis-dependent </li> <li>Subject to P-gp drug interactions </li> <li>Use in pregnancy and breastfeeding unknown </li> </ul> </td> <td> <ul> <li>Oral direct thrombin inhibitor </li> <li>Administered orally, twice-daily dosing </li> <li>For patients with a thromboembolism, therapy should be preceded by five days of parenteral anticoagulation </li> <li>Half-life 12 to 17 hours; prolonged up to 28 hours in severe renal impairment </li> <li>No routine coagulation test monitoring; refer to UpToDate for monitoring options in selected cases </li> <li>Reversal agent available (idarucizumab) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Edoxaban</td> <td> <ul> <li>Oral agent </li> <li>Renally and hepatically eliminated; no dose adjustment required for CrCl &#62;50 ml/minute or mild hepatic impairment </li> <li>Dose adjustment is needed for CrCl 15 to 50 mL/minute </li> <li>Do not use if CrCl &#8804;15 mL/minute or &#62;95 mL/minute, dialysis-dependent, or moderate to severe hepatic impairment </li> <li>Dose adjustment needed for body weight &#8804;60 kg </li> <li>Subject to CYP3A4 and P-gp drug interactions </li> <li>Use in pregnancy and breastfeeding unknown </li> </ul> </td> <td> <ul> <li>Oral direct factor Xa inhibitor </li> <li>Administered orally, once-daily dosing </li> <li>For patients with a&nbsp; thromboembolism, therapy should be preceded by five days of parenteral anticoagulation </li> <li>Half-life 10 to 14 hours; prolonged in renal impairment </li> <li>No routine coagulation test monitoring; anti-factor Xa activity can be monitored if needed* </li> <li>No reversal agent </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Rivaroxaban</td> <td> <ul> <li>Renally and hepatically eliminated; no dose adjustment is needed for CrCl &#62;30 mL/minute or mild hepatic impairment </li> <li>Do not use if CrCl &#8804;30 mL/minute, dialysis-dependent, or moderate to severe hepatic impairment </li> <li>Subject to CYP3A4 and P-gp drug interactions </li> <li>Use in pregnancy and breastfeeding unknown </li> </ul> </td> <td> <ul> <li>Oral direct factor Xa inhibitor </li> <li>Administered orally, twice-daily dosing for first 21 days of VTE treatment, followed by once-daily dosing </li> <li>Half-life five to nine hours </li> <li>No routine monitoring; anti-factor Xa activity can be monitored if needed* </li> <li>No reversal agent </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Warfarin</td> <td> <ul> <li><strong>Cannot</strong> be used until stable anticoagulation with another non-heparin anticoagulant has been established and the platelet count has normalized </li> <li>Can be used in severe renal or hepatic impairment; monitor INR closely </li> <li>Subject to many drug and dietary interactions </li> <li>Can be used in patients with a mechanical heart valve </li> <li>Teratogen: Avoid in first trimester of pregnancy unless benefits outweigh risks (eg, mechanical heart valve) </li> </ul> </td> <td> <ul> <li>Oral vitamin K antagonist, interferes with synthesis of thrombin and factors VII, IX, and X </li> <li>Administered orally, once-daily dosing with regular monitoring and dose adjustments based on the PT/INR </li> <li>Requires at least five consecutive days of overlapping non-heparin anticoagulant that is continued until the INR is therapeutic </li> <li>If transitioning from argatroban to warfarin, refer to institutional guidelines for INR target as both agents elevate the INR </li> <li>Reversal agent available (vitamin K, PCC) </li> <li>Inexpensive </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for details of the clinical evaluation for HIT, HIT antibody testing, duration of non-heparin anticoagulant therapy, and other considerations. For patients with a thromboembolic event who are treated with dabigatran or edoxaban, the oral anticoagulant must be preceded by&nbsp;five days of a parenteral anticoagulant. For agents that inhibit factor Xa, anti-factor Xa testing may be useful in selected patients (eg, prior to urgent neurosurgery, extremes of body weight, renal impairment). If anti-factor Xa testing is used, it must be calibrated for the specific anticoagulant. Anti-factor-Xa activity testing calibrated for fondaparinux or danaparoid is not available in many clinical settings.</div><div class=\"graphic_footnotes\">HIT: heparin-induced thrombocytopenia; aPTT: activated partial thromboplastin time; PT: prothrombin&nbsp;time; INR: international normalized ratio; ESRD: end-stage renal disease; factor&nbsp;Xa: activated factor X;&nbsp;CrCl: creatinine clearance; PCC: prothrombin complex concentrate.<br />* If anti-factor Xa monitoring is used, it must be done using an assay calibrated for the specific drug the patient is taking.<br />¶ In some countries other than the United States, the approved product information recommends a dose reduction in patients with moderate renal impairment and elevated risk of bleeding.</div><div id=\"graphicVersion\">Graphic 115506 Version 3.0</div></div></div>"},"115507":{"type":"graphic_table","displayName":"Sensitivity and specificity of parathyroid hormone","title":"Sensitivity and specificity of parathyroid hormone using cutoffs of published clinical practice guidelines to predict bone turnover as assessed by bone formation rate/bone surface","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivity and specificity of parathyroid hormone using cutoffs of published clinical practice guidelines to predict bone turnover as assessed by bone formation rate/bone surface</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Sensitivity</td> <td class=\"subtitle1\">Specificity</td> </tr> <tr> <td colspan=\"3\"><strong>NKF-KDOQI guideline cutoffs</strong></td> </tr> <tr> <td class=\"indent1\">iPTH &#60;150 pg/mL for low turnover</td> <td class=\"centered\">68.6%</td> <td class=\"centered\">61.2%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">iPTH &#62;300 pg/mL for high turnover</td> <td class=\"centered\">58.0%</td> <td class=\"centered\">77.7%</td> </tr> <tr> <td colspan=\"3\"><strong>KDIGO guideline cutoffs</strong></td> </tr> <tr> <td class=\"indent1\">iPTH &#60;2 &times; ULN for low turnover</td> <td class=\"centered\">65.0%</td> <td class=\"centered\">67.3%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">iPTH &#62;9 &times; ULN for high turnover</td> <td class=\"centered\">37.0%</td> <td class=\"centered\">85.8%</td> </tr> <tr> <td colspan=\"3\"><strong>KDIGO guideline cutoffs</strong></td> </tr> <tr> <td class=\"indent1\">wPTH &#60;2 &times; ULN for low turnover</td> <td class=\"centered\">73.5%</td> <td class=\"centered\">56.7%</td> </tr> <tr> <td class=\"indent1\">wPTH &#62;9 &times; ULN for high turnover</td> <td class=\"centered\">30.7%</td> <td class=\"centered\">87.9%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NKF-KDOQI: National Kidney Foundation-Kidney Disease Outcomes Quality Initiative; iPTH: intact parathyroid hormone; KDIGO: Kidney Disease: Improving Global Outcomes; ULN: upper limit of normal; wPTH: whole parathyroid hormone.</div><div class=\"graphic_reference\">Reproduced from: Sprague SM, Bellorin-Font E, Jorgetti V. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 2016; 67:563. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115507 Version 1.0</div></div></div>"},"115509":{"type":"graphic_picture","displayName":"Amelanotic mucosal melanoma clinical","title":"Amelanotic mucosal melanoma","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Amelanotic mucosal melanoma</div><div class=\"cntnt\"><img style=\"width:459px; height:612px;\" src=\"images/DERM/115509_Amelanoticmucosalmelanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical appearance of a nonpigmented lesion of the right labia.</div><div class=\"graphic_reference\">Reproduced with permission from: Blum A, Beck-Zoul U, Held L, Haase S. Dermoscopic appearance of an amelanotic mucosal melanoma. Dermatol Pract Concept 2016; 6(4): 23-25. Copyright © 2016 Blum et al.</div><div id=\"graphicVersion\">Graphic 115509 Version 1.0</div></div></div>"},"115510":{"type":"graphic_picture","displayName":"Amelanotic mucosal melanoma dermoscopy","title":"Dermoscopic image of amelanotic mucosal melanoma","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of amelanotic mucosal melanoma</div><div class=\"cntnt\"><img style=\"width:459px; height:612px;\" src=\"images/DERM/115510_Amelntcmcslmelanmdrmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polarized dermoscopy showing a distinct asymmetric, sharply demarcated, homogenous, white papule (4 × 5 mm) with polymorphous vessels (eg, linear, curved, hairpin-like with different diameter).</div><div class=\"graphic_reference\">Reproduced with permission from: Blum A, Beck-Zoul U, Held L, Haase S. Dermoscopic appearance of an amelanotic mucosal melanoma. Dermatol Pract Concept 2016; 6(4): 23-25. Copyright © 2016 Blum et al.</div><div id=\"graphicVersion\">Graphic 115510 Version 1.0</div></div></div>"},"115513":{"type":"graphic_table","displayName":"Symptoms of ND-PAE in children 0 through 11 months","title":"ND-PAE symptom diagnosis guidelines for children 0 through 11 months of age: Neurocognitive, self-regulation, and adaptive domains","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ND-PAE symptom diagnosis guidelines for children 0 through 11 months of age: Neurocognitive, self-regulation, and adaptive domains</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neurocognitive domains</td> <td class=\"subtitle1\">Self-regulation domains</td> <td class=\"subtitle1\">Adaptive domains</td> </tr> <tr> <td><strong>General cognitive impairment:</strong> <ul class=\"decimal_heading\"> <li>Mild or global developmental delays </li> </ul> </td> <td><strong>Mood or behavioral regulation:</strong> <ul class=\"decimal_heading\"> <li>Difficulties going to sleep </li> <li>Difficulties staying asleep throughout the night </li> <li>Is a light sleeper </li> <li>Frequent meltdowns </li> <li>Moody </li> <li>Irritable </li> <li>Difficulty with adapting to changes </li> <li>Fussy </li> <li>Gets frustrated easily </li> <li>Has difficulty handling exciting events (parties, holidays, cannot be taken to a store or restaurant) </li> <li>Difficulty calming down or being soothed </li> <li>Overreaction to environmental events and stressors </li> <li>Easily overwhelmed in stimulating environments </li> </ul> <strong>Attention:</strong> <ul class=\"decimal_heading\"> <li>Difficulty shifting attention </li> <li>Difficulty maintaining focused play or exploration of toys </li> </ul> <strong>Impulse control:</strong> <ul class=\"decimal_heading\"> <li>Difficulty waiting </li> <li>Chaotic disorganized play </li> </ul> </td> <td><strong>Communication:</strong> <ul class=\"decimal_heading\"> <li>Delayed acquisition of language </li> <li>Poor exploration of toys </li> </ul> <strong>Social:</strong> <ul class=\"decimal_heading\"> <li>Overly friendly with strangers </li> </ul> <strong>Daily living:</strong> <ul class=\"decimal_heading\"> <li>Delays in early feeding skills </li> <li>Difficulties with adapting to environmental events </li> </ul> <strong>Motor:</strong> <ul class=\"decimal_heading\"> <li>Delayed attainment of fine and gross motor skills </li> <li>Frequent falls or loss of balance </li> <li>Poor coordination </li> <li>Poor motor skills </li> <li>Struggles with using hands to complete tasks </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ND-PAE: neurobehavioral disorder associated with prenatal alcohol exposure.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 138, Page e20151553, Copyright &copy; 2016 by the AAP.</div><div id=\"graphicVersion\">Graphic 115513 Version 1.0</div></div></div>"},"115514":{"type":"graphic_table","displayName":"Symptoms of ND-PAE in children 1 through 4 years","title":"ND-PAE symptom diagnosis guidelines for children 1 through 4 years of age: Neurocognitive, self-regulation, and adaptive domains","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ND-PAE symptom diagnosis guidelines for children 1 through 4 years of age: Neurocognitive, self-regulation, and adaptive domains</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neurocognitive domains</td> <td class=\"subtitle1\">Self-regulation domains</td> <td class=\"subtitle1\">Adaptive domains</td> </tr> <tr> <td><strong>General cognitive impairment:</strong> <ul class=\"decimal_heading\"> <li>Mild or global developmental delays </li> <li>Problems applying knowledge to new situations </li> <li>Lack of elaborate imaginative play </li> </ul> <strong>Executive functioning:</strong> <ul class=\"decimal_heading\"> <li>Difficulty transitioning from one activity to another </li> <li>Problems learning sequential information &ndash; first to last, days of the week, least to most </li> <li>Repeatedly making the same mistakes </li> <li>Has trouble organizing himself/herself </li> <li>Cannot describe events orderly or in a logical sequence </li> <li>Is disorganized </li> <li>Is inflexible </li> <li>Acts without thinking </li> <li>Gets stuck on things </li> <li>Poor understanding of consequences </li> <li>Poor linking of acts to consequences </li> <li>Difficulty thinking about things differently </li> <li>Does not plan to complete complex tasks </li> <li>Lies about things that don't make sense </li> </ul> <strong>Learning:</strong> <ul class=\"decimal_heading\"> <li>Requires repeated exposures to things to learn properly </li> <li>Struggles with learning early academic concepts </li> <li>Struggles with early math concepts (one to one correspondence in counting objects, object constancy) </li> </ul> <strong>Memory:</strong> <ul class=\"decimal_heading\"> <li>Problems remembering something learned recently </li> <li>Cannot hold information in their memory </li> <li>Cannot carryout multiple step plans </li> <li>Has poor recall of information or events </li> <li>Frequently forgets things </li> </ul> <strong>Visual-spatial reasoning:</strong> <ul class=\"decimal_heading\"> <li>Difficulty constructing three-dimensional figures out of blocks </li> <li>Has poor understanding of his/her body in space </li> <li>Difficult copying simple visual patterns </li> <li>Difficulty with learning spatial words (left, right, up, down) </li> </ul> </td> <td><strong>Mood or behavioral regulation:</strong> <ul class=\"decimal_heading\"> <li>Difficulties going to sleep </li> <li>Difficulties staying asleep throughout the night </li> <li>Is a light sleeper </li> <li>Frequent meltdowns </li> <li>Moody </li> <li>Irritable </li> <li>Difficulty with adapting to changes </li> <li>Gets frustrated easily </li> <li>Has difficulty handling exciting events (parties, holidays, cannot be taken to a store or restaurant) </li> <li>Difficulty calming down </li> <li>Becomes too upset </li> <li>Is easily overwhelmed </li> <li>Is easily overstimulated </li> <li>Problems calming self </li> <li>Cannot play independently </li> <li>Cannot entertain himself/herself </li> <li>Frequent behavioral outbursts </li> <li>Mood lability </li> <li>Is too intense at times </li> <li>Is hyperresponsive to things </li> <li>Gives up easily </li> <li>Negative affect or irritability </li> </ul> <strong>Attention:</strong> <ul class=\"decimal_heading\"> <li>Difficulty shifting attention </li> <li>Trouble staying focused </li> <li>Difficulty maintaining focus on task at hand </li> <li>Difficulty encoding new information </li> <li>Difficulty focusing on new information </li> <li>Difficulty sustaining mental effort </li> </ul> <strong>Impulse control:</strong> <ul class=\"decimal_heading\"> <li>Difficulty waiting </li> <li>Does not think before responding </li> <li>Difficulty complying with rules </li> <li>Engages in risky behavior </li> <li>Has poor impulse controls </li> <li>Difficulty delaying gratification </li> <li>Confabulating </li> <li>Taking possessions of others </li> <li>Frequently interrupting others </li> <li>Needs constant supervision </li> <li>Difficulty waiting turn </li> </ul> </td> <td><strong>Communication:</strong> <ul class=\"decimal_heading\"> <li>Delayed acquisition of language </li> <li>Difficulty using language to express self so that the listener understands </li> <li>Talking too much </li> <li>Problems linking words with feelings </li> <li>Making comments that seem out of context </li> <li>Reduced verbal fluency </li> <li>Difficulty following along in a conversation </li> </ul> <strong>Social:</strong> <ul class=\"decimal_heading\"> <li>Overly friendly with strangers </li> <li>Gullible or na&#239;ve </li> <li>Is unaware of personal space </li> <li>Difficulty reading social cues </li> <li>Difficulty understanding social consequences </li> <li>Socially immature/acts too young </li> <li>Difficulty attending to facial or social cues </li> <li>Difficulty interacting with friends/peers </li> <li>Is not aware of his/her actions on others </li> </ul> <strong>Daily living:</strong> <ul class=\"decimal_heading\"> <li>Struggles understanding time </li> <li>Delayed toileting, feeding, or bathing </li> <li>Persistent problems in carrying out common daily routines, such as getting dressed </li> </ul> <strong>Motor:</strong> <ul class=\"decimal_heading\"> <li>Problems in coordination and balance </li> <li>Problems in integration of left and right motor activities </li> <li>Delayed attainment of gross motor skills </li> <li>Is accident prone </li> <li>Poor fine motor skills (poor drawing and handwriting, difficulty manipulating buttons or zippers, difficulty using eating utensils) </li> <li>Difficulty learning coordinated motor skills </li> <li>Bumps into things frequently </li> <li>Falls frequently </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ND-PAE: neurobehavioral disorder associated with prenatal alcohol exposure.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 138, Page e20151553, Copyright &copy; 2016 by the AAP.</div><div id=\"graphicVersion\">Graphic 115514 Version 1.0</div></div></div>"},"115515":{"type":"graphic_table","displayName":"Symptoms of ND-PAE in children 5 through 21 years","title":"Title: ND-PAE symptom diagnosis guidelines for children 5 through 21 years of age: Neurocognitive, self-regulation, and adaptive domains","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Title: ND-PAE symptom diagnosis guidelines for children 5 through 21 years of age: Neurocognitive, self-regulation, and adaptive domains</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neurocognitive domains</td> <td class=\"subtitle1\">Self-regulation domains</td> <td class=\"subtitle1\">Adaptive domains</td> </tr> <tr> <td><strong>General cognitive impairment:</strong> <ul class=\"decimal_heading\"> <li>Intellectual impairment </li> <li>Problems applying knowledge to new situations </li> <li>Difficulty with abstract reasoning </li> </ul> <strong>Executive functioning:</strong> <ul class=\"decimal_heading\"> <li>Difficulty transitioning from one activity to another </li> <li>Problems learning sequential information &ndash; first to last, days of the week, least to most </li> <li>Repeatedly making the same mistakes </li> <li>Poor planning and organization </li> <li>Difficulty changing strategies or thinking about things in more than one way </li> </ul> <strong>Learning:</strong> <ul class=\"decimal_heading\"> <li>Lower academic achievement than expected for intellectual level </li> <li>Math learning disability </li> </ul> <strong>Memory:</strong> <ul class=\"decimal_heading\"> <li>Problems remembering something learned recently </li> <li>Difficulty with multi-step verbal instructions </li> <li>Frequently losing or misplacing possessions </li> <li>Problems remembering personal information such as one's telephone number or other developmentally appropriate information that should be well-known* </li> </ul> <strong>Visual-spatial reasoning:</strong> <ul class=\"decimal_heading\"> <li>Deficits in the perception and analysis of visual or spatial information </li> <li>Problems understanding directionality like north or south </li> <li>Problems aligning numbers in columns </li> <li>Disorganized or poorly planned drawings or constructions </li> <li>Difficulty reading and following a map </li> <li>Difficulty solving puzzles </li> </ul> </td> <td><strong>Mood or behavioral regulation:</strong> <ul class=\"decimal_heading\"> <li>Difficulties going to sleep </li> <li>Difficulties staying asleep throughout the night </li> <li>Is a light sleeper </li> <li>Frequent meltdowns </li> <li>Moody </li> <li>Irritable </li> <li>Difficulty with adapting to changes </li> <li>Gets frustrated easily </li> <li>Has difficulty handling exciting events (parties, holidays, cannot be taken to a store or restaurant) </li> <li>Difficulty calming down </li> <li>Becomes too upset </li> <li>Is easily overwhelmed </li> <li>Is easily overstimulated </li> <li>Problems calming self </li> <li>Cannot play independently </li> <li>Cannot entertain himself/herself </li> <li>Frequent behavioral outbursts </li> <li>Frequently upset </li> <li>Is too intense at times </li> <li>Is hyperresponsive to things </li> <li>Gives up easily </li> <li>Has problems fitting in with others </li> <li>Frequently loses things </li> <li>Gets angry easily </li> <li>Has a short fuse </li> <li>Grabs at things </li> <li>Often tests or pushes limits </li> </ul> <strong>Attention:</strong> <ul class=\"decimal_heading\"> <li>Difficulty shifting attention </li> <li>Trouble staying focused </li> <li>Difficulty maintaining focus on task at hand </li> <li>Difficulty encoding new information </li> <li>Difficulty focusing on new information </li> <li>Difficulty sustaining mental effort </li> </ul> <strong>Impulse control:</strong> <ul class=\"decimal_heading\"> <li>Difficulty waiting </li> <li>Does not think before responding </li> <li>Difficulty complying with rules </li> <li>Engages in risky behavior </li> <li>Has poor impulse controls </li> <li>Difficulty delaying gratification </li> <li>Confabulating </li> <li>Takes possessions of others </li> <li>Frequently interrupting others </li> <li>Needs constant supervision* </li> <li>Difficulty waiting turn* </li> </ul> </td> <td><strong>Communication:</strong> <ul class=\"decimal_heading\"> <li>Difficulty understanding jokes, idioms, or metaphors </li> <li>Difficulty using language to express self so that the listener understands </li> <li>Talking too much </li> <li>Problems linking words with feelings </li> <li>Making comments that seem out of context </li> <li>Reduced verbal fluency* </li> <li>Difficulty understanding spoken language* </li> </ul> <strong>Social:</strong> <ul class=\"decimal_heading\"> <li>Overly friendly with strangers </li> <li>Gullible or na&#239;ve </li> <li>Is unaware of personal space </li> <li>Difficulty reading social cues </li> <li>Difficulty understanding social consequences </li> <li>Socially immature/acts too young </li> <li>Difficulty making and keeping friends </li> <li>Superficial friendships but no close friends </li> <li>Poor judgment in choice of friends </li> <li>Has friends who are much younger or much older </li> <li>Makes inappropriate social overtures (may be sexual or intruding on boundaries of others) </li> <li>Easily led by others </li> <li>Demands a lot of social attention* </li> <li>Demands a lot of attention<sup>&#182;</sup> </li> <li>Difficulty attending to facial or social cues<sup>&#182;</sup> </li> <li>Is not aware of his/her actions on others<sup>&#182;</sup> </li> </ul> <strong>Daily living:</strong> <ul class=\"decimal_heading\"> <li>Problems following rules of personal safety </li> <li>Difficulty managing daily schedule </li> <li>Slow to understand the function of money or to tell time* </li> <li>Poor understanding of money values and time management<sup>&#182;</sup> </li> <li>Difficulty keeping appointments<sup>&#182;</sup> </li> <li>Problems managing finances<sup>&#182;</sup> </li> <li>Difficulty securing or maintaining employment<sup>&#182;</sup> </li> <li>Difficulties with taking care of himself/herself<sup>&#182;</sup> </li> </ul> <strong>Motor:</strong> <ul class=\"decimal_heading\"> <li>Problems in coordination and balance </li> <li>Problems in integration of left and right motor activities </li> <li>Problems in visual motor integration </li> <li>Poor handwriting* </li> <li>Difficulty learning coordinated motor skills<sup>&#182;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ND-PAE: neurobehavioral disorder associated with prenatal alcohol exposure.<br />* Applies to children age 5 through 10 but not children age 11 through 21.<br />&para; Applies to children age 11 through 21 but not children age 5 through 10.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 138, Page e20151553, Copyright &copy; 2016 by the AAP.</div><div id=\"graphicVersion\">Graphic 115515 Version 1.0</div></div></div>"},"115518":{"type":"graphic_picture","displayName":"Iris transillumination","title":"Iris transillumination","html":"<div class=\"graphic\"><div style=\"width: 753px\" class=\"figure\"><div class=\"ttl\">Iris transillumination</div><div class=\"cntnt\"><img style=\"width:733px; height:638px;\" src=\"images/DERM/115518_Iristransillumination.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit lamp photomicrograph showing full iris transillumination in a patient with OCA1A. The light is reflected from the retina and choroid back through the iris. The circular outline is the image of the lens that is posterior to the iris. Radial iris vessels are easily seen.</div><div class=\"graphic_footnotes\">OCA1A: oculocutaneous albinism type 1A.</div><div class=\"graphic_reference\">Reproduced from: Summers CG, Knobloch WH, Witkop CJ Jr, King RA. Hermansky-Pudlak syndrome: Ophthalmic findings. Ophthalmology 1988; 95:545. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115518 Version 1.0</div></div></div>"},"115519":{"type":"graphic_picture","displayName":"Iris transillumination 2","title":"Iris transillumination","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Iris transillumination</div><div class=\"cntnt\"><img style=\"width:720px; height:598px;\" src=\"images/DERM/115519_Iristransillumination2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit lamp photomicrograph showing punctate iris transillumination in a patient with OCA1B. The light is reflected from the retina and choroid back through punctate defects in pigment in the posterior iris epithelium.</div><div class=\"graphic_footnotes\">OCA1B: oculocutaneous albinism type 1B.</div><div class=\"graphic_reference\">Reproduced from: Summers CG, Knobloch WH, Witkop CJ Jr, King RA. Hermansky-Pudlak syndrome: Ophthalmic findings. Ophthalmology 1988; 95:545. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115519 Version 1.0</div></div></div>"},"115520":{"type":"graphic_picture","displayName":"Foveal hypoplasia albinism","title":"Foveal hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Foveal hypoplasia</div><div class=\"cntnt\"><img style=\"width:713px; height:754px;\" src=\"images/DERM/115520_Fovealhypoplasiaalbinism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of the right eye in a patient with OCA1A with two mutations in the <em>TYR</em> gene, showing foveal hypoplasia, failure of vessels to wreathe the intended fovea, and a mildly small optic nerve with peripapillary halo. The defocused choroidal vessels can be seen beneath the retinal vessels throughout the fundus.</div><div class=\"graphic_footnotes\">OCA1A: oculocutaneous albinism type 1A.</div><div id=\"graphicVersion\">Graphic 115520 Version 1.0</div></div></div>"},"115521":{"type":"graphic_picture","displayName":"Foveal hypoplasia 2","title":"Foveal hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Foveal hypoplasia</div><div class=\"cntnt\"><img style=\"width:754px; height:677px;\" src=\"images/DERM/115521_Fovealhypoplasia2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of the left eye in a patient with OCA2 with two mutations in the <EM>OCA2</EM> gene, showing foveal hypoplasia, failure of vessels to wreathe the intended fovea, and a mildly small optic nerve with peripapillary halo. The defocused choroidal vessels can be seen beneath the retinal vessels beyond the macula.</div><div class=\"graphic_footnotes\">OCA2: oculocutaneous albinism type 2.</div><div id=\"graphicVersion\">Graphic 115521 Version 1.0</div></div></div>"},"115522":{"type":"graphic_picture","displayName":"Normal fovea","title":"Normal fovea","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Normal fovea</div><div class=\"cntnt\"><img style=\"width:768px; height:622px;\" src=\"images/DERM/115522_Normalfovea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fundus photograph of the right eye in a Caucasian patient without albinism, showing a normal fovea with annular reflex (camera light artifact centrally), normal wreathing of retinal vessels around the fovea, and a normal optic nerve. The choroidal vessels cannot be visualized.</div><div id=\"graphicVersion\">Graphic 115522 Version 1.0</div></div></div>"},"115523":{"type":"graphic_picture","displayName":"Granular macular melanin","title":"Granular macular melanin","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Granular macular melanin</div><div class=\"cntnt\"><img style=\"width:720px; height:542px;\" src=\"images/DERM/115523_Granularmacularmelanin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Composite fundus photograph of right eye of a patient with OCA1B (two mutations in <em>TYR</em>) with granular melanin in the macula and foveal hypoplasia, but with better vision than often seen in albinism (best-corrected binocular visual acuity of 20/25).</div><div class=\"graphic_footnotes\">OCA1B: oculocutaneous albinism type 1B.</div><div id=\"graphicVersion\">Graphic 115523 Version 1.0</div></div></div>"},"115525":{"type":"graphic_picture","displayName":"Ocular albinism","title":"Ocular albinism","html":"<div class=\"graphic\"><div style=\"width: 761px\" class=\"figure\"><div class=\"ttl\">Ocular albinism</div><div class=\"cntnt\"><img style=\"width:741px; height:753px;\" src=\"images/DERM/115525_Ocularalbinism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Composite fundus photograph of the right eye of a woman who is an obligate carrier for ocular albinism, which is an X-linked disorder. The fundus has areas of normal melanin expression in the retinal pigment epithelium adjacent to areas with absent melanin production (X-inactivation). Vision is normal unless overexpression of the mutant X chromosome occurs.</div><div id=\"graphicVersion\">Graphic 115525 Version 1.0</div></div></div>"},"115528":{"type":"graphic_table","displayName":"The HD care team","title":"The Huntington disease care team","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Huntington disease care team</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Health professional</td> <td class=\"subtitle1\">Role in HD Care</td> </tr> <tr> <td>Neurologist</td> <td>Overall care coordination (\"team leader\"); neurological management</td> </tr> <tr> <td>Psychiatrist</td> <td>Overall care coordination (\"team leader\"); psychiatric management</td> </tr> <tr> <td>Psychologist</td> <td>Counseling about relationships, grief, chronic disease, symptom management, etc; family support</td> </tr> <tr> <td>Neuropsychologist</td> <td>Neuropsychological assessment and counseling about cognitive changes</td> </tr> <tr> <td>Geneticist or genetic counselor</td> <td>Genetic counseling, predictive testing, prenatal or preimplantation genetic testing</td> </tr> <tr> <td>Social worker</td> <td>Disability, financial planning, management of social crises, accessing community services, placement outside the home; advance directives; counseling (if licensed)</td> </tr> <tr> <td>Physical therapy</td> <td>Gait assessment and assistive devices; exercise program</td> </tr> <tr> <td>Occupational therapy</td> <td>Assessment of driving, home safety, and activities of daily living; equipment for seating, feeding, hygiene, etc</td> </tr> <tr> <td>Speech therapy</td> <td>Speech assessment, alternative communication devices; dysphagia assessment and counseling</td> </tr> <tr> <td>Dietician</td> <td>Nutritional assessment and counseling</td> </tr> <tr> <td>Nursing</td> <td>Case management, telephone counseling, support</td> </tr> <tr> <td>Research team</td> <td>Counseling about research opportunities; enrollment in research</td> </tr> <tr> <td>Chaplain</td> <td>Family support, spiritual advice</td> </tr> <tr> <td>Lay organization volunteer</td> <td>Liaison with HD support groups, advocacy, other organization activities</td> </tr> <tr> <td>Primary care physician</td> <td>Primary care, preventive health, management of medical complications in late stages</td> </tr> <tr> <td>Dentist</td> <td>Aggressive, proactive dental care</td> </tr> <tr> <td>Hospice care team</td> <td>Comfort- and dignity-directed care in terminal stages</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HD: Huntington disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Nance M. Team care for Huntington's disease. In: A Physician's Guide to the Management of Huntington's Disease, 3rd edition, Nance M, Paulsen JS, Rosenblatt A, Wheelock V (Eds), Huntington's Disease Society of America 2011. Copyright © 2011 Huntington's Disease Society of America.</div><div id=\"graphicVersion\">Graphic 115528 Version 1.0</div></div></div>"},"115533":{"type":"graphic_figure","displayName":"Reported HCV prevalence and infections among adults","title":"Reported HCV prevalence and infections among adults","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Reported HCV prevalence and infections among adults</div><div class=\"cntnt\"><img style=\"width:702px; height:675px;\" src=\"images/ID/115533_RptHCVprvlncinfctnadlts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61:S52. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115533 Version 1.0</div></div></div>"},"115537":{"type":"graphic_figure","displayName":"Statin-associated muscle symptoms clinical index (SAMS)","title":"Statin-associated muscle symptoms clinical index (SAMS-CI)","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Statin-associated muscle symptoms clinical index (SAMS-CI)</div><div class=\"cntnt\"><img style=\"width:596px; height:825px;\" src=\"images/PC/115537_SAMSclinicalindex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This index evaluates muscle symptoms using several domains that encompass the statin regimen (location and pattern of muscle symptoms, timing of muscle symptom onset in relation to starting statin regimen, timing of muscle symptom improvement after withdrawal of statin); timing of recurrence after rechallenge with the statin regimen; and previous symptoms on statin regimen prior to the current exposure. A score is selected on the basis of the patterns in the different domains. A total score is used to assess the likelihood of the patient's muscle symptoms from statin use. A score of ≤4 is \"unlikely\", 5 to 8 is \"possible\", and 9 to 11 is \"probable\".</div><div class=\"graphic_reference\">From: Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther 2017; 31:179. Available at: <A href=\"https://link.springer.com/article/10.1007%2Fs10557-017-6723-4\" target=_blank>https://link.springer.com/article/10.1007%2Fs10557-017-6723-4</A> (Accessed November 9, 2017). Reproduced under the terms of the <A href=\"https://creativecommons.org/licenses/by/4.0/\" target=_blank>Creative Commons Attribution License</A>.</div><div id=\"graphicVersion\">Graphic 115537 Version 1.0</div></div></div>"},"115538":{"type":"graphic_figure","displayName":"Skeletal muscle gene expression in statin myalgia","title":"Skeletal muscle gene expression in statin myalgia","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Skeletal muscle gene expression in statin myalgia</div><div class=\"cntnt\"><img style=\"width:776px; height:571px;\" src=\"images/PC/115538_Sktlmsclgnexpsnstnmylg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hypothetical scheme of statin-induced blockade of mevalonate biosynthesis and its consequences for skeletal muscle gene expression and myopathy. Potential differences in inter-organ uptake, metabolism and flux of statins in genetically susceptible patients lead to greater skeletal muscle toxicity. Inhibition of mevalonate and its downstream reaction products result in reduced availability of geranylpyrophosphate and farnesyl-pyrophosphate, needed for prenylation/lipidation of signaling proteins. Altered signal transduction pathways reprogram skeletal muscle gene expression. Genetic polymorphisms and significantly altered genes that putatively underpin skeletal muscle pathology are indicated.</div><div class=\"graphic_reference\">Reproduced from: Elam MB, Majumdar G, Mozhui K, et al. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One 2017; 12:e0181308. Available at: <a href=\"http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181308\"  target=\"_blank\">http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181308</a> (Accessed on November 9, 2017). Copyright &copy; 2017 Elam MB, Majumdar G, Mozhui K, et al. Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\"  target=\"_blank\">Creative Commons Attribution License</a>. Original figure published in: Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: From clinical trials to everyday practice. Pharmacol Res 2014; 88:107. Illustration modified with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115538 Version 1.0</div></div></div>"},"115539":{"type":"graphic_table","displayName":"Spectrum of statin-associated muscle adverse events","title":"Spectrum of statin-associated muscle adverse events","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of statin-associated muscle adverse events</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li><strong>Myalgia</strong> - Unexplained muscle discomfort often described as \"flu-like\" symptoms with normal CK level. The spectrum of myalgia complaints includes: </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Muscle aches; </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Muscle soreness; </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Muscle stiffness; </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Muscle tenderness; and </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Muscle cramps with or shortly after exercise (not nocturnal cramping) </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li><strong>Myopathy</strong> - Muscle weakness (not attributed to pain and not necessarily associated with elevated CK) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li><strong>Myositis</strong> - Muscle inflammation </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Myonecrosis</strong> - Muscle enzyme elevations or hyperCKemia </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Mild: &#62;3-fold greater than baseline untreated CK levels or normative upper limit that are adjusted for age, race, and sex </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Moderate: &#8805;10-fold greater than untreated baseline CK levels or normative upper limit that are adjusted for age, race, and sex </li> </ul> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <ul> <li>Severe: &#8805;50-fold above baseline CK levels or normative upper limit that are adjusted for age, race, and sex </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Myonecrosis with myoglobinuria or acute renal failure</strong> (increase in serum creatinine &#8805;0.5 mg/dL (clinical rhabdomyolysis)) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CK: creatine kinase.</div><div class=\"graphic_reference\">Reproduced from: Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8:S58. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115539 Version 1.0</div></div></div>"},"115540":{"type":"graphic_figure","displayName":"Combat and operational stress continuum model","title":"Combat and operational stress continuum model","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Combat and operational stress continuum model</div><div class=\"cntnt\"><img style=\"width:609px; height:436px;\" src=\"images/PSYCH/115540_Cmbtoprtnlstrsscntnmmdl.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: US Marine Corps. Combat and Operational Stress Control. In: Marine Corps Reference Publication 6-11C (MCRP 6-11C). Washington, DC, 2010. Available at: <a href=\"http://www.marines.mil/Portals/59/Publications/MCRP%206-11C%20%20Combat%20and%20Operational%20Stress%20Control.pdf\" target=\"_blank\">http://www.marines.mil/Portals/59/Publications/MCRP%206-11C%20%20Combat%20and%20Operational%20Stress%20Control.pdf</a> (Accessed on November 13, 2017).</div><div id=\"graphicVersion\">Graphic 115540 Version 1.0</div></div></div>"},"115549":{"type":"graphic_algorithm","displayName":"Management of atopic dermatitis","title":"Management of atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">Management of atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:659px; height:1309px;\" src=\"images/DERM/115549_Mgmtatopicdermatitis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For examples of low-, medium-, and high-potency topical corticosteroids, please refer to the&nbsp;UpToDate table on topical corticosteroids.</div><div class=\"graphic_footnotes\">TCS: topical corticosteroid; TCI: topical calcineurin inhibitor.<br />* Trigger/exacerbating factors: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Irritants (soaps, detergents)</LI>&#xD;&#xA;<LI>Skin infections (<EM>Staphylococcus aureus</EM>, herpes simplex)</LI>&#xD;&#xA;<LI>Contact, inhalant, or food allergens</LI></UL>¶ Mild atopic dermatitis – Areas of dry skin, infrequent itching (with or without small areas of redness); little impact on everyday activities, sleep, and psychosocial wellbeing.<br />Δ Moderate atopic dermatitis – Areas of dry skin, frequent itching, redness (with or without excoriation and localized skin thickening); moderate impact on everyday activities and psychosocial wellbeing, frequently disturbed sleep.<br /><FONT class=lozenge>◊</FONT> Severe atopic dermatitis – Widespread areas of dry skin, incessant itching, redness (with or without excoriation, extensive skin thickening, bleeding, oozing, cracking, and alteration of pigmentation); severe limitation of everyday activities and psychosocial functioning, nightly loss of sleep.<br />§ Crisaborole is approved for mild to moderate atopic dermatitis in adults and children &gt;2 years.<br />¥ TCIs are approved for mild to moderate atopic dermatitis in adults and children &gt;2 years. TCIs include tacrolimus and pimecrolimus.<br />‡ Dupilumab is approved for moderate to severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies.</div><div id=\"graphicVersion\">Graphic 115549 Version 1.0</div></div></div>"},"115550":{"type":"graphic_picture","displayName":"Cicatricial skin lesions","title":"Newborn infant with cicatricial (scarring) skin lesions due to congenital varicella infection","html":"<div class=\"graphic\"><div style=\"width: 710px\" class=\"figure\"><div class=\"ttl\">Newborn infant with cicatricial (scarring) skin lesions&nbsp;due to&nbsp;congenital varicella infection</div><div class=\"cntnt\"><img style=\"width:690px; height:517px;\" src=\"images/PEDS/115550_cicatricialskinlesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cicatricial (scarring) skin lesions associated with congenital varicella infection&nbsp;are typically depressed and pigmented in a dermatomal distribution. Other features of congenital varicella&nbsp;syndrome include intrauterine growth restriction, ocular defects, limb abnormalities, and central nervous system abnormalities.</div><div class=\"graphic_reference\">From: Ramachandra S, Metta AK, Haneef NS, Kodali S. Fetal varicella syndrome. Indian J Dermatol Venereol Leprol 2010; 76:724. DOI: <a href=\"http://www.ijdvl.com/article.asp?issn=0378-6323;year=2010;volume=76;issue=6;spage=724;epage=724;aulast=Ramachandra\" target=\"_blank\">10.4103/0378-6323.72475</a>. Copyright &copy; 2010 Indian Association of Dermatologists, Venereologists &amp; Leprologists. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115550 Version 1.0</div></div></div>"},"115551":{"type":"graphic_table","displayName":"Causes of halitosis","title":"Causes of halitosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of halitosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Types of halitosis</td> <td class=\"subtitle1\">Comments/associated clinical features</td> </tr> <tr> <td class=\"subtitle2_left\">Physiologic</td> <td class=\"divider_bottom\">Common, worse in morning (\"morning breath\")</td> </tr> <tr> <td class=\"subtitle2_left\">Pathologic</td> <td class=\"divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent1\"><strong>Oral origin</strong></td> <td>Most common; odor largely confined to the mouth or stronger from the mouth than the nose with organoleptic testing*</td> </tr> <tr> <td class=\"indent2\">Gingivitis/periodontitis</td> <td>Gingival erythema, swelling, bleeding, tooth mobility</td> </tr> <tr> <td class=\"indent2\">Excessive tongue coating</td> <td>Positive tongue organoleptic testing</td> </tr> <tr> <td class=\"indent2\">Dry mouth</td> <td>May be associated with drugs,<sup>&#182;</sup> some medical conditions (eg, Sj&#246;gren's)</td> </tr> <tr> <td class=\"indent2\">Tonsillar pathology</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Tonsillitis </li> </ul> </td> <td>Enlarged, erythematous tonsils; associated fever and enlarged anterior cervical lymph nodes</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Peritonsillar abscess </li> </ul> </td> <td>Swollen, fluctuant tonsil, with deviation of the uvula; drooling; trismus</td> </tr> <tr> <td class=\"indent3\"> <ul> <li>Chronic caseous tonsillitis with or without tonsilloliths </li> </ul> </td> <td>Tonsillar crypts containing caseous material, tonsilloliths</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Dental prosthesis</td> <td>Strong odor from dental prosthesis with organoleptic testing*</td> </tr> <tr> <td class=\"indent1\"><strong>Nasal origin</strong></td> <td>Relatively uncommon; odor stronger from the nose than the mouth with organoleptic testing*</td> </tr> <tr> <td class=\"indent2\">Rhinosinusitis</td> <td>May be associated with fever, sinus tenderness, purulent nasal discharge</td> </tr> <tr> <td class=\"indent2\">Postnasal drip</td> <td>Drip need not be infected &ndash; odor results from action of the bacteria present on the tongue on the material in the drip</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Foreign body</td> <td>More common in children</td> </tr> <tr> <td class=\"indent1\"><strong>Respiratory tract origin</strong></td> <td>Uncommon</td> </tr> <tr> <td class=\"indent2\">Bronchiectasis</td> <td>May be associated with a chronic cough and/or purulent sputum</td> </tr> <tr> <td class=\"indent2\">Bronchitis</td> <td>Generally an acute or subacute process</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Lung abscess</td> <td>Often associated with fever, weight loss</td> </tr> <tr> <td class=\"indent1\"><strong>Gastrointestinal tract origin</strong></td> <td>Uncommon</td> </tr> <tr> <td class=\"indent2\">Zenker diverticulum</td> <td>Most patients present over age 60; male predominance; may be associated dysphagia</td> </tr> <tr> <td class=\"indent2\">Gastrocolic fistula</td> <td>Usually associated with colon cancer; abdominal pain and weight loss often present</td> </tr> <tr> <td class=\"indent2\"><em>Helicobacter pylori</em> (not well established as causative)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">GERD (not well established as causative)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"><strong>Upper aerodigestive tract origin</strong></td> <td>Uncommon</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Malignancy</td> <td>A malignancy can arise anywhere along the upper aerodigestive tract, including the oral cavity, nasal cavity, oropharynx, nasopharynx, hypopharynx, larynx, trachea, and esophagus</td> </tr> <tr> <td class=\"indent1\"><strong>Systemic origin</strong></td> <td>Uncommon; odor with similar quality emanates from both the mouth and the nose with organoleptic testing*</td> </tr> <tr> <td class=\"indent2\">Trimethylaminuria</td> <td>Genetic disorder causing a characteristic fishy odor</td> </tr> <tr> <td class=\"indent2\">Advanced renal disease</td> <td>Elevated levels of urea can produce odor</td> </tr> <tr> <td class=\"indent2\">Diabetic ketoacidosis</td> <td>Ketoacidosis can produce a characteristic fruity odor</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Advanced liver disease</td> <td>Jaundice, ascites, edema</td> </tr> <tr> <td class=\"subtitle2_left\">Subjective</td> <td class=\"divider_bottom\">Relatively common</td> </tr> <tr> <td class=\"indent2\">Psychologic</td> <td>The persistent belief that halitosis is present despite a negative evaluation is halitophobia</td> </tr> <tr> <td class=\"indent2\">Neurologic</td> <td>Disorders of taste and smell can result in the belief that bad breath is present when, objectively, it is not</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease.<br />* Organoleptic testing is a subjective process in which the clinician scores the strength of the odor from the mouth (possibly including samples from the tongue, teeth, or dentures) and nose.<br />¶ The list of drugs that can cause&nbsp;dry mouth&nbsp;is extensive. Included are diuretics, antihistamines and decongestants, tricyclic antidepressants, and amphetamines.</div><div id=\"graphicVersion\">Graphic 115551 Version 3.0</div></div></div>"},"115552":{"type":"graphic_algorithm","displayName":"Dx evaluation: Hematuria due to COL4 mutation ","title":"Diagnostic evaluation to detect COL4 gene mutation for patients with persistent hematuria","html":"<div class=\"graphic\"><div style=\"width: 755px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation to detect COL4 gene mutation for patients with persistent hematuria</div><div class=\"cntnt\"><img style=\"width:735px; height:599px;\" src=\"images/PEDS/115552_DxAlportsyndrome.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgA: immunoglobulin A; C3: complement component 3; DNA: deoxyribonucleic acid.<br />* Thin basement membrane disease and Alport syndrome (hereditary nephritis) present with persistent glomerular hematuria and are caused by mutations of the <em>COL4</em> gene, which encodes the collagen IV protein. This algorithm reflects the diagnostic evaluation based on the author's approach for the UpToDate topic on clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis).<br />&para; Ocular findings characteristic of Alport syndrome include anterior lenticonus, dot and fleck retinopathy, and corneal changes (posterior polymorphous dystrophy and recurrent corneal erosion). Refer to the UpToDate topic clinical manifestations, diagnosis, and treatment of Alport syndrome (hereditary nephritis) for more details.<br />&Delta; Renal biopsy is the best diagnostic test in this clinical setting to determine the underlying glomerular disorder, as there is a similar likelihood of renal disease due to <em>COL4</em> mutation or IgA nephropathy.<br /><span class=\"lozenge\">&loz;</span> Next generation DNA sequencing is the preferred diagnostic test for patients with a likely or high probability of having a <em>COL4</em> mutation. However, this may not be available for some patients and families, and renal or skin biopsy is an alternate diagnostic procedure. A skin biopsy is a less invasive diagnostic tool. It uses a monoclonal antibody against the alpha-5(IV) chain. If there is absent protein in a male patient or a mosaic pattern in a female patient, the diagnosis of X-linked Alport syndrome is confirmed.<br />&sect; The diagnostic findings for Alport syndrome on renal biopsy are longitudinal splitting of the lamina densa of the glomerular basement membrane (GBM), detected by electron microscopy, and immunostaining pattern for type IV collagen demonstrating absence or an abnormal distribution of the alpha-3(IV), alpha-4(IV), and/or alpha-5(IV) chains of the GBM.<br />&yen; Renal biopsy to determine the underlying glomerular disorder as no <em>COL4</em> mutation was detected by molecular testing.</div><div id=\"graphicVersion\">Graphic 115552 Version 1.0</div></div></div>"},"115554":{"type":"graphic_algorithm","displayName":"Evaluation of intraoperative hypotension by TEE","title":"Evaluation of intraoperative hypotension by transesophageal echocardiography (TEE)","html":"<div class=\"graphic\"><div style=\"width: 838px\" class=\"figure\"><div class=\"ttl\">Evaluation of intraoperative hypotension by transesophageal echocardiography (TEE)</div><div class=\"cntnt\"><img style=\"width:818px; height:466px;\" src=\"images/ANEST/115554_EvlintraopertvhyptesnTEE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is often more than one cause of intraoperative hypotension as well as pre-existing cardiac conditions (eg, dilated cardiomyopathy), so findings on transesophageal echocardiogram may not entirely fit the schema shown here. Also, a single pathophysiologic process may cause hypotension via multiple mechanisms. For an example, refer to footnote ¶¶.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiogram; LV: left ventricle; RV: right ventricle; SVR: systemic vascular resistance; LVOT: left ventricular outflow tract; RA: right atrium; MR: mitral regurgitation; AR: aortic regurgitation.<br />* Patients with hyperdynamic, normal, or only mildy impaired LV systolic function are unlikely to have shock due to LV systolic dysfunction so other causes of hypotension should be considered.<br />¶ Hypovolemia typically manifests as small LV size at end-diastole. Associated with normal (or hyperdynamic) LV systolic function.<br />Δ Low SVR typically manifests as hyperdynamic LV systolic function, with a normal (or small) LV cavity size at end-diastole and small LV size at end-systole.<br /><FONT class=lozenge>◊</FONT> Dynamic LVOT obstruction may occur with or without left ventricular hypertrophy. Acute mitral regurgitation may be induced by dynamic LVOT.<br />§ Multiple views may be required to identify a loculated effusion or hematoma that may cause cardiac tamponade.<br />¥ In the setting of pulmonary embolus, thrombus may be visualized in the right heart and/or in the pulmonary arteries.<br />‡ Acute inferior myocardial infarction may be complicated by RV infarction; hemodynamic compromise is generally greater than expected with inferior myocardial infarction alone.<br />† Causes of acute MR include ruptured chordae tendinae (due to degenerative disease, infective endocarditis, trauma, rheumatic heart disease, or spontaneous rupture), papillary muscle rupture (due to acute myocardial infarction or ischemia, or trauma), papillary muscle displacement due to myocardial infarction or ischemia, or induction of MR in the setting of dynamic LVOT obstruction (refer to footnote ◊).<br />** Causes of acute AR include endocarditis, aortic dissection, spontaneous or traumatic rupture of an aortic cusp, and as a complication of a procedure (such as aortic balloon valvotomy or transcatheter aortic valve implantation).<br />¶¶ Ascending aortic dissection may cause hypotension due to hypovolemia (aortic rupture), cardiac tamponade, acute aortic valve regurgitation, and/or acute myocardial ischemia/infarction.<br />ΔΔ Aortic stenosis is a chronic condition that may cause acute hypotension in response to hemodynamic alterations such as vasodilation.<br /><FONT class=double_lozenge>◊◊</FONT> With tension pneumothorax/hemothorax, TEE may detect cardiac displacement and/or compression.<br />§§ With air embolism, intracardiac or intravascular bubbles may be identified (particularly in the RA and RV).<br />¥¥ Causes of cardiogenic shock include acute myocardial infarction (with or without mechanical complications such as free wall rupture or interventricular septal rupture), myocarditis, and various types of cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 115554 Version 1.0</div></div></div>"},"115559":{"type":"graphic_picture","displayName":"Copper IUD with standard and postpartum inserters","title":"Copper IUD with standard and postpartum inserters","html":"<div class=\"graphic\"><div style=\"width: 713px\" class=\"figure\"><div class=\"ttl\">Copper IUD with standard and postpartum inserters</div><div class=\"cntnt\"><img style=\"width:693px; height:323px;\" src=\"images/OBGYN/115559_CopperIUDstandardpstprtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IUD: intrauterine device; PPIUD: postpartum intrauterine device.</div><div class=\"graphic_reference\">From: Singh S, Das V, Agarwal A, et al. A dedicated postpartum intrauterine device inserter: Pilot experience and proof of concept. Glob Health Sci Pract 2016; 4:132. Copyright &copy; 2016 Singh et al. Reproduced under the <a href=\"https://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">Creative Commons License</a>. Available at: <a href=\"http://dx.doi.org/10.9745/GHSP-D-15-00355\" target=\"_blank\">http://dx.doi.org/10.9745/GHSP-D-15-00355</a>.</div><div id=\"graphicVersion\">Graphic 115559 Version 1.0</div></div></div>"},"115563":{"type":"graphic_figure","displayName":"US HHS and NIH testing schedules for perinatal HIV","title":"Virologic testing schedules for infants exposed to HIV according to perinatal HIV transmission risk","html":"<div class=\"graphic\"><div style=\"width: 757px\" class=\"figure\"><div class=\"ttl\">Virologic testing schedules for infants exposed to HIV according to perinatal HIV transmission risk</div><div class=\"cntnt\"><img style=\"width:737px; height:280px;\" src=\"images/PEDS/115563_USHHSNIHttshdlprtlHIV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; NAT: nucleic acid test; ART: antiretroviral therapy; RNA: ribonucleic acid. <br />* For higher-risk infants, additional virologic diagnostic testing should be considered at birth and 2 to 4 weeks after cessation of ART prophylaxis (ie, at 8 to 10 weeks of life).</div><div class=\"graphic_reference\">Reproduced from: Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf</a>. Accessed (Nov 15, 2017).</div><div id=\"graphicVersion\">Graphic 115563 Version 1.0</div></div></div>"},"115571":{"type":"graphic_table","displayName":"Differences CKD-MBD and postmenopausal osteoporosis","title":"Differences between CKD-MBD and postmenopausal osteoporosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differences between CKD-MBD and postmenopausal osteoporosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical factor</td> <td class=\"subtitle1\">CKD-MBD</td> <td class=\"subtitle1\">Postmenopausal osteoporosis</td> </tr> <tr> <td>PTH levels</td> <td>Increased</td> <td>Usually normal*</td> </tr> <tr> <td>Alkaline phosphatase</td> <td>Increased</td> <td>Usually normal*</td> </tr> <tr> <td>Bone mineral density</td> <td>Weakly related to fracture risk</td> <td>Predicts risk of fracture</td> </tr> <tr> <td>Bone loss</td> <td>Mostly in cortical bone</td> <td>Trabecular and cortical bone</td> </tr> <tr> <td>Bone formation rate</td> <td>Either very low (in adynamic bone disease) or very high</td> <td>Generally normal or slightly increased</td> </tr> <tr> <td>Vascular calcification</td> <td>Strongly associated</td> <td>Weakly associated</td> </tr> <tr> <td>Laboratory findings<sup>&#182;</sup></td> <td>Abnormal</td> <td>Normal or mildly abnormal</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CKD-MBD: chronic kidney disease-mineral and bone disorder; PTH: parathyroid hormone; FGF-23: fibroblast growth factor 23; BMP-7: bone morphogenetic protein 7.<br />* May be increased if secondary or primary hyperparathyroidism exists<br />¶ Including levels of calcium ions, phosphate, FGF-23, BMP-7, Klotho, 1,25-hydroxyvitamin D3, iron, bicarbonate, sclerostin, and cytokines.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Nephrology. Ott SM. Therapy for patients with CKD and low bone mineral density. Nat Rev Nephrol 2013; 9:681. Copyright © 2013. <A href=\"http://www.nature.com/nrneph/\" target=_blank>www.nature.com/nrneph/</A>.</div><div id=\"graphicVersion\">Graphic 115571 Version 2.0</div></div></div>"},"115573":{"type":"graphic_table","displayName":"iRECIST for immunotherapy of cancer: Comparison with RECIST 1.1","title":"Consensus-based guideline for assessing response to immunotherapy in cancer (iRECIST): Comparison with standard RECIST 1.1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consensus-based guideline for assessing response to immunotherapy in cancer (iRECIST): Comparison with standard RECIST 1.1</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">RECIST 1.1</td> <td class=\"subtitle1\">iRECIST</td> </tr> <tr> <td>Definitions of measurable and non-measurable disease; numbers and site of target disease</td> <td>Measurable lesions are &#8805;10 mm in diameter (&#8805;15 mm for nodal lesions); maximum of five lesions (two per organ); all other disease is considered non-target (must be &#8805;10 mm in short axis for nodal disease)</td> <td>No change from RECIST 1.1; however, new lesions are assessed as per RECIST 1.1 but are recorded separately on the case report form (but not included in the sum of lesions for target lesions identified at baseline)</td> </tr> <tr> <td>Complete response, partial response, or stable disease</td> <td>Cannot have met criteria for progression before complete response, partial response, or stable disease</td> <td>Can have had iUPD (one or more instances), but not iCPD, before iCR, iPR, or iSD</td> </tr> <tr> <td>Confirmation of complete response or partial response</td> <td>Only required for non-randomised trials</td> <td>As per RECIST 1.1</td> </tr> <tr> <td>Confirmation of stable disease</td> <td>Not required</td> <td>As per RECIST 1.1</td> </tr> <tr> <td>New lesions</td> <td>Result in progression; recorded but not measured</td> <td>Results in iUPD but iCPD is only assigned on the basis of this category if at next assessment additional new lesions appear or an increase in size of new lesions is seen (&#8805;5 mm for sum of new lesion target or any increase in new lesion non-target); the appearance of new lesions when none have previously been recorded, can also confirm iCPD</td> </tr> <tr> <td>Independent blinded review and central collection of scans</td> <td>Recommended in some circumstances (eg, in some trials with progression-based endpoints planned for marketing approval)</td> <td>Collection of scans (but not independent review) recommended for all trials</td> </tr> <tr> <td>Confirmation of progression</td> <td>Not required (unless equivocal)</td> <td>Required</td> </tr> <tr> <td>Consideration of clinical status</td> <td>Not included in assessment</td> <td>Clinical stability is considered when deciding whether treatment is continued after iUPD</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">\"i\" indicates immune responses assigned using iRECIST.</div><div class=\"graphic_footnotes\">RECIST: Response Evaluation Criteria in Solid Tumours; iUPD: unconfirmed progression; iCPD: confirmed progression; iCR: complete response; iPR: partial response; iSD: stable disease.</div><div class=\"graphic_reference\">Reproduced from: Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18:e143. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115573 Version 1.0</div></div></div>"},"115574":{"type":"graphic_table","displayName":"Assignment of timepoint responses using iRECIST","title":"Immune response criteria for immunotherapy (iRECIST): Assignment of timepoint response","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immune response criteria for immunotherapy (iRECIST): Assignment of timepoint response</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Timepoint response with no previous iUPD in any category</td> <td class=\"subtitle1\">Timepoint response with previous iUPD in any category*</td> </tr> <tr> <td>Target lesions: iCR; non-target lesions: iCR; new lesions: no</td> <td>iCR</td> <td>iCR</td> </tr> <tr> <td>Target lesions: iCR; non-target lesions: non-iCR/non-iUPD; new lesions: no</td> <td>iPR</td> <td>iPR</td> </tr> <tr> <td>Target lesions: iPR; non-target lesions: non-iCR/non-iUPD; new lesions: no</td> <td>iPR</td> <td>iPR</td> </tr> <tr> <td>Target lesions: iSD; non-target lesions: non-iCR/non-iUPD; new lesions: no</td> <td>iSD</td> <td>iSD</td> </tr> <tr> <td>Target lesions: iUPD with no change, or with a decrease from last timepoint; non-target lesions: iUPD with no change, or decrease from last timepoint; new lesions: yes</td> <td>Not applicable</td> <td>New lesions confirm iCPD if new lesions were previously identified and they have increased in size (&#8805;5 mm in sum of measures for new lesion target or any increase for new lesion non-target) or number; if no change is seen in new lesions (size or number) from last timepoint, assignment remains iUPD</td> </tr> <tr> <td>Target lesions: iSD, iPR, iCR; non-target lesions: iUPD; new lesions: no</td> <td>iUPD</td> <td>Remains iUPD unless iCPD is confirmed on the basis of a further increase in the size of non-target disease (does not need to meet RECIST 1.1 criteria for unequivocal progression)</td> </tr> <tr> <td>Target lesions: iUPD; non-target lesions: non-iCR/non-iUPD, or iCR; new lesions: no</td> <td>iUPD</td> <td>Remains iUPD unless iCPD is confirmed on the basis of a further increase in sum of measures &#8805;5 mm; otherwise, assignment remains iUPD</td> </tr> <tr> <td>Target lesions: iUPD; non-target lesions: iUPD; new lesions: no</td> <td>iUPD</td> <td>Remains iUPD unless iCPD is confirmed based on a further increase in previously identified target lesion iUPD in sum of measures &#8805;5 mm or non-target lesion iUPD (previous assessment need not have shown unequivocal progression)</td> </tr> <tr> <td>Target lesions: iUPD; non-target lesions: iUPD; new lesions: yes</td> <td>iUPD</td> <td>Remains iUPD unless iCPD is confirmed on the basis of a further increase in previously identified target lesion iUPD sum of measures &#8805;5 mm, previously identified non-target lesion iUPD (does not need to be unequivocal), or an increase in the size or number of new lesions previously identified</td> </tr> <tr> <td>Target lesions: non-iUPD or progression; non-target lesions: non-iUPD or progression; new lesions: yes</td> <td>iUPD</td> <td>Remains iUPD unless iCPD is confirmed on the basis of an increase in the size or number of new lesions previously identified</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Target lesions, non-target lesions, and new lesions defined according to RECIST 1.1 principles; if no pseudoprogression occurs, RECIST 1.1 and iRECIST categories for complete response, partial response, and stable disease would be the same.</div><div class=\"graphic_footnotes\">iUPD: unconfirmed progression; iCR: complete response; non-iCR/non-iUPD: criteria for neither CR nor PD have been met; iPR: partial response; iSD: stable disease; iCPD: confirmed progression; RECIST: Response Evaluation Criteria in Solid Tumours.<br />&#x9;* Previously identified in assessment immediately before this timepoint. \"i\" indicates immune responses assigned using iRECIST.</div><div class=\"graphic_reference\">Reproduced from: Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18:e143. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115574 Version 1.0</div></div></div>"},"115578":{"type":"graphic_picture","displayName":"Traumatic asphyxia in a child","title":"Traumatic asphyxia in a child","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Traumatic asphyxia in a child</div><div class=\"cntnt\"><img style=\"width:564px; height:754px;\" src=\"images/EM/115578_Traumaticasphyxiachild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 20-month-old child suffered traumatic asphyxia as part of a motor vehicle collision. This picture taken during recovery shows persistent and multiple petechiae of the face and a subconjunctival hemorrhage (thick arrow).</div><div class=\"graphic_reference\">From: Montes-Tapia F, Barreto-Arroyo I, Cura-Esquivel I, et al. Traumatic asphyxia. Pediatr Emerg Care 2014; 30:114. DOI: <a href=\"http://journals.lww.com/pec-online/Abstract/2014/02000/Traumatic_Asphyxia.10.aspx\" target=\"_blank\">10.1097/PEC.0000000000000067</a>. Copyright &copy; 2014. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115578 Version 2.0</div></div></div>"},"115581":{"type":"graphic_figure","displayName":"Ileal ureter interposition ","title":"Ileal ureter interposition ","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Ileal ureter interposition </div><div class=\"cntnt\"><img style=\"width:487px; height:692px;\" src=\"images/SURG/115581_Ilealureterinterposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ileal ureter reconstruction is used for a long-segment ureteral injury/stricture&nbsp;for which other reconstructions&nbsp;(eg,&nbsp;Boari flap, psoas hitch) are not options.&nbsp;For the ileal ureter,&nbsp;a segment of ileum has been isolated from the intestinal tract and is sutured&nbsp;to the&nbsp;ureter proximally&nbsp;and to the bladder distally. </div><div id=\"graphicVersion\">Graphic 115581 Version 1.0</div></div></div>"},"115582":{"type":"graphic_waveform","displayName":"ECG in ARVC patient with diffuse T wave changes","title":"ECG in ARVC patient with diffuse T wave changes","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">ECG in ARVC patient with diffuse T wave changes</div><div class=\"cntnt\"><img style=\"width:658px; height:352px;\" src=\"images/CARD/115582_ECGARVCdiffusTwavchngs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ECG in a patient with ARVC showing inversion of T waves and prolonged S wave upstroke&nbsp;in the right precordial leads (V1, V2, and V3).</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ARVC: arrhythmogenic right ventricular cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 115582 Version 1.0</div></div></div>"},"115589":{"type":"graphic_figure","displayName":"Comparison of angles of male and female faces","title":"Comparison of angles of male and female faces","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Comparison of angles of male and female faces</div><div class=\"cntnt\"><img style=\"width:764px; height:468px;\" src=\"images/OBGYN/115589_Companglsmalefemaleface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Line illustrations demonstrating the differences between male (A) and female (B) faces. The male face is square and angulated with sharp lines and a strong jaw, while the female face is curved, round, oval, and heart-shaped with smooth lines and smaller overall.</div><div class=\"graphic_reference\">Reproduced from: Altman K. Facial feminization surgery: Current state of the art. Int J Oral Maxillofac Surg 2012; 41:885. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115589 Version 1.0</div></div></div>"},"115591":{"type":"graphic_figure","displayName":"Mandibular angle reduction for MtF transgender surgery","title":"Mandibular angle reduction for male-to-female transgender surgery","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Mandibular angle reduction for male-to-female transgender surgery</div><div class=\"cntnt\"><img style=\"width:764px; height:744px;\" src=\"images/OBGYN/115591_MdraglrdnMtFtnsgdrsgry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mandibular angle shave by reducing the lipping at the mandibular angle (A) and subsequent result (B). Shading indicates area to be contoured.</div><div class=\"graphic_reference\">Reproduced from: Altman K. Facial feminization surgery: Current state of the art. Int J Oral Maxillofac Surg 2012; 41:885. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115591 Version 1.0</div></div></div>"},"115592":{"type":"graphic_figure","displayName":"Chin width reduction in male-to-female transgender surgery","title":"Chin width reduction in male-to-female transgender surgery","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Chin width reduction in male-to-female transgender surgery</div><div class=\"cntnt\"><img style=\"width:765px; height:285px;\" src=\"images/OBGYN/115592_ChnwrdtnmTftrsgdrsrgry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chin width reduction (A) and fixation (B).</div><div class=\"graphic_reference\">Reproduced from: Altman K. Facial feminization surgery: Current state of the art. Int J Oral Maxillofac Surg 2012; 41:885. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115592 Version 1.0</div></div></div>"},"115593":{"type":"graphic_figure","displayName":"Thyroid cartilage reduction (chondrolaryngoplasty)","title":"Thyroid cartilage reduction (chondrolaryngoplasty) for male-to-female transgender surgery","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Thyroid cartilage reduction (chondrolaryngoplasty) for male-to-female transgender surgery</div><div class=\"cntnt\"><img style=\"width:762px; height:368px;\" src=\"images/OBGYN/115593_Thydcrtgrdtnchdrlyngpsty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thyroid cartilage, demonstrating the areas of resection in thyroid shave (shading).</div><div class=\"graphic_reference\">Reproduced from: Altman K. Facial feminization surgery: Current state of the art. Int J Oral Maxillofac Surg 2012; 41:885. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115593 Version 1.0</div></div></div>"},"115597":{"type":"graphic_picture","displayName":"Streptococcal pharyngitis","title":"Streptococcal pharyngitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Streptococcal pharyngitis</div><div class=\"cntnt\"><img style=\"width:401px; height:600px;\" src=\"images/EM/115597_Streptococcalpharyngitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with streptococcal pharyngitis has prominent bilateral tonsillar exudate without peritonsillar swelling, and scattered tonsillar petechiae.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2018 Scott Camazine, MD, PhD. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115597 Version 1.0</div></div></div>"},"115599":{"type":"graphic_table","displayName":"Hermansky-Pudlak syndrome genetic classification","title":"Genetic classification of Hermansky-Pudlak syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic classification of Hermansky-Pudlak syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"12.5%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of HPS</td> <td class=\"subtitle1\">MIM #</td> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Locus</td> <td class=\"subtitle1\">Encoding function</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>HPS-1</td> <td>203300</td> <td><em>HPS1</em></td> <td>10q23.1-10q23.3</td> <td>Transmembrane protein in BLOC-3 within BLOC-4 and BLOC-5</td> <td> <ul> <li>Common in northwestern Puerto Rico due to founder effect </li> <li>Progressive pulmonary fibrosis and colitis </li> </ul> </td> </tr> <tr> <td>HPS-2</td> <td>608233</td> <td><em>ADTB3A</em>, <em>AP3B1</em>, <em>HPS2</em></td> <td>5q14.1</td> <td>Lysosomal trafficking</td> <td> <ul> <li>Neutropenia and/or immune defects </li> <li>Pulmonary fibrosis, conductive hearing loss, dysplastic hip </li> </ul> </td> </tr> <tr> <td>HPS-3</td> <td>614072</td> <td><em>HPS3</em></td> <td>3q24</td> <td>Vesicle-related protein</td> <td> <ul> <li>Found in central Puerto Rico </li> <li>Mild systemic findings </li> <li>Colitis </li> </ul> </td> </tr> <tr> <td>HPS-4</td> <td>614073</td> <td><em>HPS4</em></td> <td>22q11.2-22q12.2</td> <td>Involved in BLOC-3 and BLOC-4</td> <td> <ul> <li>Pulmonary fibrosis, colitis </li> </ul> </td> </tr> <tr> <td>HPS-5</td> <td>614074</td> <td><em>HPS5</em>, <em>RU2,</em> <em>KIAA1017</em></td> <td>11p13-11p15</td> <td>Organelle biogenesis</td> <td> <ul> <li>Hyperlipidemia, elevated creatinine clearance </li> </ul> </td> </tr> <tr> <td>HPS-6</td> <td>614075</td> <td><em>HPS6</em>, <em>RU</em></td> <td>10q24.32</td> <td>Organelle biogenesis</td> <td> <ul> <li>Mild systemic findings </li> </ul> </td> </tr> <tr> <td>HPS-7</td> <td>614076</td> <td><em>DTNBP1</em>, <em>HPS7</em></td> <td>6p22.3</td> <td>Component of BLOC-1</td> <td> <ul> <li>Mild lung disease </li> </ul> </td> </tr> <tr> <td>HPS-8</td> <td>614077</td> <td><em>BLOC1S3</em>, <em>HPS8</em></td> <td>19q13.32</td> <td>Vesicular transport protein</td> <td> <ul> <li>Mild systemic findings </li> </ul> </td> </tr> <tr> <td>HPS-9</td> <td>614171</td> <td><em>BLOC1S6</em>, <em>PLDN</em>, <em>PA</em>, <em>HPS9</em></td> <td>15q21.1</td> <td>Intracellular vesicle trafficking</td> <td> <ul> <li>Few cases described </li> </ul> </td> </tr> <tr> <td>HPS-10</td> <td>617050</td> <td><em>AP3D1</em></td> <td>19p13.3</td> <td>Lysosomal biogenesis</td> <td> <ul> <li>Microcephaly, seizures, global delay </li> <li>Immunodeficiency </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HPS: Hermansky-Pudlak syndrome; BLOC: biogenesis of lysosome-related organelles complex.</div><div class=\"graphic_reference\">Original figure modified for this publication. From: Summer CG. Albinism. In: Taylor and Hoyt's Pediatric Ophthalmology and Strabismus, 5th ed, Lambert SR, Lyons CJ (Eds), Elsevier, Atlanta 2017. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115599 Version 1.0</div></div></div>"},"115602":{"type":"graphic_table","displayName":"Gradual dose escalation protocol for progestin","title":"Gradual dose escalation protocol for progestin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gradual dose escalation protocol for progestin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Day</td> <td class=\"subtitle1\">Dose (based on progestin component)</td> <td class=\"subtitle1\">Number of capsules &times; capsule dose per day</td> <td class=\"subtitle1\">Total daily dose</td> </tr> <tr> <td>Day 1</td> <td>1.25 mcg in AM; 2.5 mcg in PM</td> <td>1 &times; 1.25 mcg; 2 &times; 1.25 mcg</td> <td>3.75 mcg</td> </tr> <tr> <td>Day 2</td> <td>2.5 mcg in AM, 12.5 mcg in PM</td> <td>2 &times; 1.25 mcg; 1 &times; 12.5 mcg</td> <td>15 mcg</td> </tr> <tr> <td>Day 3</td> <td>12.5 mcg in AM, 25 mcg in PM</td> <td>1 &times; 12.5 mcg; 2 &times; 12.5 mcg</td> <td>37.5 mcg</td> </tr> <tr> <td>Day 4</td> <td>37.5 mcg in AM, 37.5 mcg in PM</td> <td>3 &times; 12.5 mcg; 3 &times; 12.5 mcg</td> <td>75 mcg</td> </tr> <tr> <td>Day 5</td> <td>50 mcg in AM, 75 mcg in PM</td> <td>1 &times; 50 mcg; 1 &times; 50 mcg + 2 &times; 12.5 mcg</td> <td>125 mcg</td> </tr> <tr> <td>Day 6</td> <td>250 mcg</td> <td>2 &times; 125 mcg</td> <td>250 mcg</td> </tr> <tr> <td>Day 7</td> <td>500 mcg</td> <td>4 &times; 125 mcg</td> <td>500 mcg</td> </tr> <tr> <td>Day 8</td> <td>500 mcg</td> <td>4 &times; 125 mcg</td> <td>500 mcg</td> </tr> <tr> <td>Day 9</td> <td>1 mg</td> <td>1 &times; 1 mg</td> <td>1 mg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Target dose for this protocol: Norethindrone 1 mg/ethinyl estradiol 0.02 mg.<br />​Note that this protocol has been performed in a very small number of patients by experienced allergy specialists. The efficacy in larger numbers of patients awaits further study. UpToDate suggests that allergy specialists supervise such protocols whenever possible.</div><div class=\"graphic_reference\">Reproduced from: Foer D, Buchheit JM, Gargiulo AR, et al. Progesterone hypersensitivity in 24 cases: Diagnosis, management, and proposed renaming and classification. J Allergy Clin Immunol Pract 2016; 4:723. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115602 Version 2.0</div></div></div>"},"115603":{"type":"graphic_table","displayName":"IM progesterone desensitization protocol for IVF","title":"IM progesterone desensitization protocol for IVF","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">IM progesterone desensitization protocol for IVF</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Dose (IM progesterone 50 mg/mL)</td> </tr> <tr> <td>0 minutes</td> <td>1 mg</td> </tr> <tr> <td>30 minutes</td> <td>2 mg</td> </tr> <tr> <td>60 minutes</td> <td>4 mg</td> </tr> <tr> <td>90 minutes</td> <td>8 mg</td> </tr> <tr> <td>120 minutes</td> <td>16 mg</td> </tr> <tr> <td>150 minutes</td> <td>18.5 mg</td> </tr> <tr> <td>Total dose</td> <td>50 mg</td> </tr> <tr> <td>Target daily dose</td> <td>Intravaginal progesterone 90 to 180 mg (ie, 8% gel once or twice daily) or IM progesterone 50 to 75 mg daily, depending on IVF protocol</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Patients were premedicated with H1 and H2 blockers completed in an outpatient infusion center with a registered nurse trained in desensitization.<br />​Note that this protocol has been performed in a very small number of patients by experienced allergy specialists. The efficacy in larger numbers of patients awaits further study. UpToDate suggests that allergy specialists supervise such protocols whenever possible.</div><div class=\"graphic_footnotes\">IM: intramuscular; IVF: in vitro fertilization.</div><div class=\"graphic_reference\">Reproduced from: Foer D, Buchheit JM, Gargiulo AR, et al. Progesterone hypersensitivity in 24 cases: Diagnosis, management, and proposed renaming and classification. J Allergy Clin Immunol Pract 2016; 4:723. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115603 Version 2.0</div></div></div>"},"115606":{"type":"graphic_picture","displayName":"Pierre Robin sequence with nasal trumpet","title":"Neonate with Pierre Robin sequence with a nasopharyngeal airway (nasal trumpet) in place","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Neonate with Pierre Robin sequence with a nasopharyngeal airway (nasal trumpet) in place</div><div class=\"cntnt\"><img style=\"width:761px; height:571px;\" src=\"images/PEDS/115606_Nasalairwaymicrognathia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Neonate with upper airway obstruction due to Pierre Robin sequence (micrognathia, glossoptosis, and a U-shaped palatal cleft). The infant's upper airway obstruction was effectively managed with a nasopharyngeal airway (nasal trumpet,&nbsp;seen in the right nare). A feeding tube is present in the left nare.</div><div class=\"graphic_reference\">Reproduced with permission from: Abel F, Bajaj Y, Wyatt M, Wallis C. The successful use of the nasopharyngeal airway in Pierre Robin sequence: an 11-year experience. Arch Dis Child 2012; 97(4):331-4. Copyright &copy; 2012 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 115606 Version 1.0</div></div></div>"},"115607":{"type":"graphic_picture","displayName":"Mandibular distraction osteogenesis","title":"Mandibular distraction osteogenesis in Pierre Robin sequence","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Mandibular distraction osteogenesis in Pierre Robin sequence</div><div class=\"cntnt\"><img style=\"width:608px; height:775px;\" src=\"images/PEDS/115607_Extdstnmndblrdstnostgss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph (panel A) and panorex radiograph (panel B) of a child with Pierre Robin sequence undergoing mandibular distraction osteogenesis. The procedure typically is&nbsp;performed in&nbsp;early infancy&nbsp;in an effort to avoid a tracheotomy. Mandibular distraction osteogenesis involves bilateral division of the mandibular body and gradual advancement with an adjustable fixation device (panel A). New bone is gradually laid down in the tissue defect. The tongue&nbsp;moves progressively forward with the mandible, improving airway obstruction.</div><div class=\"graphic_reference\">(A) From: Sesenna E, Magri AS, Magnani C, et al. Mandibular distraction in neonates: indications, techniques, results. Ital J Pediatr 2012; 38. Available at: <a href=\"https://ijponline.biomedcentral.com/articles/10.1186/1824-7288-38-7\"  target=\"_blank\">https://ijponline.biomedcentral.com/articles/10.1186/1824-7288-38-7</a> (Accessed November 15, 2017). Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/2.0/\" target=\"_blank\">Creative Commons Attribution License</a>.<br />(B) Reproduced with permission from: Newbury PA, Adams NS, Girotto JA. Mandibular Distraction Osteogenesis: Upper Airway Management in Pierre Robin Sequence. Eplasty 2015; 15.</div><div id=\"graphicVersion\">Graphic 115607 Version 1.0</div></div></div>"},"115611":{"type":"graphic_picture","displayName":"Gingival inclusion cyst","title":"Gingival inclusion cysts (Bohn nodules) in a newborn infant","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Gingival inclusion cysts (Bohn nodules) in a&nbsp;newborn infant</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/PEDS/115611_Palatalgingivalcystnwbrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Epithelial inclusion cysts (also called Bohn nodules) appear as white or translucent round papules along the gingival ridges. They are thought to arise from fusion abnormalities or remnants of minor mucous salivary glands.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115611 Version 1.0</div></div></div>"},"115612":{"type":"graphic_table","displayName":"Causes of pulsus paradoxus","title":"Causes of pulsus paradoxus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pulsus paradoxus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td class=\"subtitle2_single\">Pericardial</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Cardiac tamponade </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Constrictive pericarditis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Nonpericardial</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Right ventricular myocardial infarction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Restrictive cardiomyopathy </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Noncardiac</td> </tr> <tr> <td class=\"subtitle2_single\">Pulmonary</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Asthma and COPD </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Obstructive sleep apnea </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pulmonary embolism </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Tension pneumothorax </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Bilateral pleural effusions </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Marked obesity </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hypovolemic shock </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pectus excavatum </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Extrinsic cardiac compression </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 115612 Version 1.0</div></div></div>"},"115615":{"type":"graphic_waveform","displayName":"ECG ARVC anterior T wave changes","title":"ECG in ARVC patient with anterior T wave changes","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">ECG in ARVC patient with anterior T wave changes</div><div class=\"cntnt\"><img style=\"width:658px; height:355px;\" src=\"images/CARD/115615_ECGARVCantTwvepslnwv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ECG in a patient with ARVC showing inversion of T waves&nbsp;in the right precordial leads (V1, V2, and V3).</div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ARVC: arrhythmogenic right ventricular cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 115615 Version 1.0</div></div></div>"},"115616":{"type":"graphic_diagnosticimage","displayName":"CMR in patient with ARVC","title":"CMR in patient with ARVC","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">CMR in patient with ARVC</div><div class=\"cntnt\"><img style=\"width:762px; height:213px;\" src=\"images/CARD/115616_CMRpatientARVC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) End diastole, short-axis cine bright blood image.<br />(B) End systole, short-axis image from same level as (A). Arrows – dyskinetic regions in the lateral and inferior walls.<br />(C) End diastole, axial cine image showing dilated RV.</div><div class=\"graphic_footnotes\">CMR: cardiac magnetic resonance; ARVC: arrhythmogenic right ventricular cardiomyopathy; RV: right ventricle.</div><div id=\"graphicVersion\">Graphic 115616 Version 1.0</div></div></div>"},"115617":{"type":"graphic_algorithm","displayName":"Evaluation of suspected Kawasaki disease","title":"Evaluation of suspected Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:589px; height:523px;\" src=\"images/ALLRG/115617_EvaltnsespectdKawasakidx.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">KD: Kawasaki disease; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ALT: alanine aminotransferase; WBC: white blood cell; hpf: high-power field.<br />* KD most commonly occurs in children over six months up to five years of age, although it can occur in young infants, older children, and adults.<br />&para; The diagnosis of KD can be made with four days of fever if &ge;4 clinical criteria are present, particularly the peripheral extremity changes. Rarely, an experienced clinician can make the diagnosis with only three days of fever. However, patients who receive early treatment before five days of illness are more likely to fail initial IVIG therapy.<br />&Delta; Clinical diagnostic criteria for KD:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Bilateral bulbar conjunctival injection without exudate</li>&#xD;&#xA;    <li>Oral mucous membrane changes, including erythema and/or fissuring of lips, strawberry tongue, and/or erythema of oropharyngeal mucosa</li>&#xD;&#xA;    <li>Peripheral extremity changes, including erythema of palms and/or soles and/or edema of hands and/or feet (acute phase) and/or periungual desquamation (subacute phase)</li>&#xD;&#xA;    <li>Polymorphous rash (maculopapular, diffuse erythroderma, or erythema multiforme-like)</li>&#xD;&#xA;    <li>Cervical lymphadenopathy (at least one lymph node &ge;1.5 cm in diameter, usually unilateral)</li>&#xD;&#xA;</ul>&#xD;&#xA;<span class=\"lozenge\">&loz;</span> Infants &le;6 months of age with KD are more likely to lack clinical features of KD other than fever and are at increased risk for coronary artery aneurysms. Thus, there is a lower threshold for treatment in this population.<br />&sect; Supplemental laboratory criteria:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Anemia for age</li>&#xD;&#xA;    <li>Platelet count &ge;450,000 after the seventh day of fever</li>&#xD;&#xA;    <li>Albumin &le;3.0 g/dL</li>&#xD;&#xA;    <li>Elevated ALT level</li>&#xD;&#xA;    <li>WBC count &ge;15,000/mm<sup>3</sup></li>&#xD;&#xA;    <li>&ge;10 WBC/hpf on urinalysis</li>&#xD;&#xA;</ul>&#xD;&#xA;&yen; Echocardiogram is considered positive if the Z-score of the left anterior descending coronary artery or right coronary artery is &ge;2.5, a coronary artery aneurysm is observed, or &ge;3 other suggestive features exist including decreased left ventricular function, mitral regurgitation, pericardial effusion, or Z-scores in the left anterior descending coronary artery or right coronary artery of 2 to 2.5.<br />&Dagger; For patients with incomplete KD and a positive echocardiogram, treatment should be given if the patient is still within 10 days of fever onset, the fever is still present after 10 days, the patient has clinical or laboratory signs of ongoing inflammation, or the coronary arteries are continuing to dilate despite a lack of fever, inflammation, or clinical signs of KD.</div><div class=\"graphic_reference\">Adapted from: McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Circulation 2017; 135:e927.</div><div id=\"graphicVersion\">Graphic 115617 Version 1.0</div></div></div>"},"115618":{"type":"graphic_picture","displayName":"Herpes simplex vesicles","title":"Herpes simplex infection","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Herpes simplex infection</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115618_Herpessimplexvesicles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grouped vesicles on erythematous background are characteristic of recurrent&nbsp;herpes simplex infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115618 Version 1.0</div></div></div>"},"115620":{"type":"graphic_table","displayName":"Abuse deterrent opioids","title":"Available abuse deterrent opioids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Available abuse deterrent opioids</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic compound</td> <td class=\"subtitle1\">Year of approval</td> <td class=\"subtitle1\">ADF mechanism</td> <td class=\"subtitle1\">Dosages available</td> <td class=\"subtitle1\">Deterrence label</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Oxycodone</td> </tr> <tr> <td class=\"indent1\">OxyContin (oxycodone extended-release)</td> <td>2010</td> <td>Difficult to crush and&nbsp;if dissolved, the tablet forms a viscous gel that&nbsp;is difficult to inject&nbsp;IV.</td> <td>10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</td> <td>IV, nasal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Xtampza ER (oxycodone extended-release)</td> <td>2016</td> <td> <p>Capsules contain microspheres of oxycodone and inactive ingredients that hinder dosage dumping via intranasal and oral abuse.</p> Microspheres cannot be readily dissolved and will solidify within a needle to&nbsp;prevent injection. </td> <td>9 mg, 13.5 mg, 18 mg, 27 mg, 36 mg</td> <td>IV, nasal, oral</td> <td>A good option for patients unable to swallow tablets. The capsules can be opened so that the microspheres may be safely poured into a feeding tube, sprinkled onto food, or placed directly into the mouth.<sup>[1]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Hydrocodone</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hysingla&#174; ER (hydrocodone extended-release)</td> <td>2014</td> <td>Difficult to crush and if&nbsp;dissolved, the tablet forms a viscous gel that&nbsp;is difficult to inject&nbsp;IV.</td> <td>20 mg, 30 mg, 40 mg, 60 mg, 80 mg, 100 mg, 120 mg</td> <td>IV, nasal, oral</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Morphine</td> </tr> <tr> <td class=\"indent1\">Embeda&#174; (morphine&nbsp;and naltrexone extended-release)</td> <td>2014</td> <td>Sequestered naltrexone (opioid antagonist):<br /> Pellets in capsules consist of morphine around a core of sequestered naltrexone. When taken as directed, morphine is released and absorbed while the naltrexone core passes through the gastrointestinal tract. If the pellets undergo physical manipulation, naltrexone is released from the core to block euphoria caused by rapid morphine release. </td> <td>20 mg/0.8 mg, 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, 100 mg/4 mg</td> <td>Nasal, oral</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">MorphaBond&#174; (morphine extended release)&nbsp;</td> <td>2015</td> <td>Contains inactive ingredients that make tablet resistant to physical and chemical manipulation while maintaining ER properties when snorted or injected IV.</td> <td>15 mg, 30 mg, 60 mg, 100 mg</td> <td>Nasal, IV&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Arymo&#174; ER (morphine extended-release)</td> <td>2017</td> <td>Contains proprietary polymer matrix technology which makes the tablet resistant to physical and chemical manipulation.&nbsp;When&nbsp;dissolved, inner active drug forms a viscous hydrogel that is difficult to snort or inject IV.</td> <td>15 mg, 30 mg, 60 mg</td> <td>IV</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADF: abuse deterrent formulation; IV: intravenous; ER: extended release.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Collegium Pharmaceutical Inc. Xtampza ER Full Prescribing Information, 2016. <a href=\"http://www.xtampzaer.com/hcp/assets/pdf/xtampza-pi.pdf\" target=\"_blank\">http://www.xtampzaer.com/hcp/assets/pdf/xtampza-pi.pdf</a> (Accessed on July 11, 2017).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115620 Version 1.0</div></div></div>"},"115621":{"type":"graphic_algorithm","displayName":"Rx thrush infants 1 through 11 months","title":"Our approach to the management of oropharyngeal candidiasis (thrush) in infants 1 through 11 months of age","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Our approach to the management of oropharyngeal candidiasis (thrush) in infants 1 through 11 months of age</div><div class=\"cntnt\"><img style=\"width:611px; height:654px;\" src=\"images/PEDS/115621_Rxthrushinfants111mnth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with the UpToDate topic on <EM>Candida</EM> infection in children.</div><div class=\"graphic_footnotes\">* Decolonize/sterilize pacifiers and reusable bottle nipples by boiling after each use. Refer to UpToDate content on problems of breastfeeding for information on candidal decolonization of the nipples of breastfeeding women.<br />¶ Nystatin suspension may be squirted into the mouth or applied with gauze or a cotton swab.<br />Δ Refer to UpToDate content on <EM>Candida</EM> infections in children for details.</div><div id=\"graphicVersion\">Graphic 115621 Version 2.0</div></div></div>"},"115622":{"type":"graphic_algorithm","displayName":"Rx thrush children 12 months and older","title":"Our approach to the management of oral thrush in children ≥12 months","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Our approach to the management of oral thrush in children &ge;12 months</div><div class=\"cntnt\"><img style=\"width:582px; height:1044px;\" src=\"images/PEDS/115622_Rxthrshchldn12mntholdr.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Predisposing factors for oral thrush in children &ge;12 months include cellular immune deficiency and treatment with antibiotics, inhaled glucocorticoids, chemotherapy, or radiation therapy. Evaluation for cellular immune deficiency may be warranted for children &ge;12 months who develop thrush in the absence of a predisposing factor.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; IV: intravenous.<br />* Nystatin solution should be swished and held in the mouth as long as possible before being swallowed.<br />¶ Lozenges should not be used in children younger than four years.<br />Δ IV fluconazole may be warranted for immunocompromised children with thrush and oropharyngeal pain that interferes with eating.<br /><FONT class=lozenge>◊</FONT> Fluconazole-resistant <EM>Candida</EM> may be suspected in children who are known to be colonized with a resistant species (eg, <EM>Candida glabrata</EM>, <EM>Candida krusei</EM>), children who have been receiving azole antifungal prophylaxis, and children cared for in medical centers with a high proportion of resistant species.<br />§ Refer to Lexicomp monograph for dosing.</div><div id=\"graphicVersion\">Graphic 115622 Version 2.0</div></div></div>"},"115623":{"type":"graphic_figure","displayName":"Patterns of referred pain due to an abdominal cause in a child","title":"Patterns of referred pain due to an abdominal cause in a child","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Patterns of referred pain due to an abdominal cause in a child</div><div class=\"cntnt\"><img style=\"width:543px; height:426px;\" src=\"images/EM/115623_Patternsofreferredpainc.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 115623 Version 1.0</div></div></div>"},"115635":{"type":"graphic_figure","displayName":"Dispensed prescriptions for ADF opioids","title":"Dispensed prescriptions for available ADF opioids","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Dispensed prescriptions for available ADF opioids</div><div class=\"cntnt\"><img style=\"width:626px; height:522px;\" src=\"images/ANEST/115635_DspnsdprscrptnsADFopioid.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nationally estimated number of prescriptions dispensed for available ADF opioids from US outpatient retail pharmacies, 2012 to 2016.</div><div class=\"graphic_footnotes\">ADF: abuse deterrent formulation.</div><div class=\"graphic_reference\">Reproduced from: FDA Briefing Document: Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, July 26, 2017. Food and Drug Administration Center for Drug Evaluation and Research, 2017. Available at: <A href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568075.pdf\" target=_blank>https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568075.pdf</A> (Accessed on November 22, 2017).</div><div id=\"graphicVersion\">Graphic 115635 Version 1.0</div></div></div>"},"115636":{"type":"graphic_figure","displayName":"Abuse deterrent legislation by state","title":"Abuse-deterrent legislation by state as of April, 2017","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Abuse-deterrent legislation by state as of April, 2017</div><div class=\"cntnt\"><img style=\"width:766px; height:432px;\" src=\"images/ANEST/115636_Abusedetrrntlegsltnstate.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Wagner A. States have stalled on potential opioid abuse solution: Deterrent formulation drugs. Multistate Insider, April 24, 2017. Available at <A href=\"https://www.multistate.us/blog/state-efforts-have-stalled-on-potential-opioid-abuse-solution-deterrent-formulation-drugs\" target=_blank>https://www.multistate.us/blog/state-efforts-have-stalled-on-potential-opioid-abuse-solution-deterrent-formulation-drugs</A> (accessed on November 16, 2017).</div><div id=\"graphicVersion\">Graphic 115636 Version 1.0</div></div></div>"},"115650":{"type":"graphic_figure","displayName":"P. knowlesi life cycle","title":"<EM>Plasmodium knowlesi</EM> life cycle","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\"><EM>Plasmodium knowlesi</EM> life cycle</div><div class=\"cntnt\"><img style=\"width:600px; height:768px;\" src=\"images/ID/115650_Pknowlesilifecycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>(1)</STRONG> <EM>Plasmodium</EM>-infected <EM>Anopheles </EM>mosquito bites a human and transmits sporozoites into the bloodstream. <STRONG>(2)</STRONG> Sporozoites migrate through the blood to the liver where they invade hepatocytes and divide to form multinucleated schizonts (pre-erythrocytic stage). <STRONG>(3) </STRONG>The schizonts rupture and release merozoites into the circulation where they invade red blood cells. Within red cells, merozoites mature from ring forms to trophozoites to multinucleated schizonts (erythrocytic stage). <STRONG>(4) </STRONG>Some merozoites differentiate into male or female gametocytes. These cells are ingested by the <EM>Anopheles </EM>mosquito and mature in the midgut, where sporozoites develop and migrate to the salivary glands of the mosquito. The mosquito completes the cycle of transmission by biting another host. Transmission is predominantly zoonotic. Human-mosquito-human transmission has been demonstrated in a laboratory setting but has not yet been proven to occur in the natural environment.</div><div id=\"graphicVersion\">Graphic 115650 Version 1.0</div></div></div>"},"115651":{"type":"graphic_figure","displayName":"Classification of pediatric fracture at base of thumb metacarpal","title":"Classification of pediatric fracture patterns seen at the base of the thumb metacarpal","html":"<div class=\"graphic\"><div style=\"width: 795px\" class=\"figure\"><div class=\"ttl\">Classification of pediatric fracture patterns seen at the base of the thumb metacarpal</div><div class=\"cntnt\"><img style=\"width:775px; height:473px;\" src=\"images/SM/115651_Clsspdfrctrbsthbmtcrpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classification of pediatric fracture patterns seen at the base of the thumb metacarpal.<br />(A) Shaft fracture.<br />(B) Salter-Harris type II fracture with a medial \"metaphyseal flag\".<br />(C) Salter-Harris type II fracture with a lateral \"metaphyseal flag\".<br />(D) Salter-Harris type III fracture (pediatric Bennett's fracture).</div><div class=\"graphic_reference\">Reproduced from: Eiff P, Hatch R. Fracture Management for Primary Care, 3rd ed, Elsevier Saunders, Philadelphia 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115651 Version 1.0</div></div></div>"},"115652":{"type":"graphic_figure","displayName":"P. knowlesi map","title":"Predicted risk of <em>Plasmodium knowlesi</em> infection in humans","html":"<div class=\"graphic\"><div style=\"width: 775px\" class=\"figure\"><div class=\"ttl\">Predicted risk of <em>Plasmodium knowlesi</em> infection in humans</div><div class=\"cntnt\"><img style=\"width:755px; height:529px;\" src=\"images/ID/115652_Pknowlesimap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This risk prediction map is based on modeling using records from countries where infection data coverage is high and is applied to regions where infection data are sparse. The model incorporated environmental and socioeconomic predictors as well as the distribution of the reservoir and vector species.</div><div class=\"graphic_footnotes\"><strong><span style=\"color: #ff0000;\"></span></strong></div><div class=\"graphic_reference\">From: Shearer FM, Huang Z, Weiss DJ, et al. Estimating geographical variation in the risk of zoonotic Plasmodium knowlesi infection in countries eliminating malaria. PLoS Negl Trop Dis 2016; 10:e0004915. Available at: <a href=\"http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004915\"  target=\"_blank\">http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0004915</a> (Accessed on Nov 16, 2017). Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 115652 Version 1.0</div></div></div>"},"115654":{"type":"graphic_table","displayName":"Severe P. knowlesi malaria","title":"Definition of severe <EM>Plasmodium knowlesi</EM> malaria<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definition of severe <EM>Plasmodium knowlesi</EM> malaria<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Manifestations</td> <td class=\"subtitle1\">Definitions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Either of the following:</td> </tr> <tr> <td class=\"indent1\"><em>P. knowlesi</em> hyperparasitemia</td> <td>&#62;100,000/microL or &#62;2% of infected red blood cells</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Jaundice and <em>P. knowlesi</em> parasitemia &#62;20,000/microL</td> <td>Plasma or serum bilirubin &#62;3 mg/dL (&#62;50 micromol/L)</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">OR</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">One or more of the criteria below occurring in the presence of <em>P. knowlesi</em> parasitemia and in the absence of an alternative cause:</td> </tr> <tr> <td class=\"indent1\">Acute kidney injury</td> <td>Plasma or serum creatinine &#62;3 mg/dL (&#62;265 micromol/L)</td> </tr> <tr> <td class=\"indent1\">Respiratory distress</td> <td>Oxygen saturation &#60;92% with respiratory rate &#62;30 breaths/minute</td> </tr> <tr> <td class=\"indent1\">Shock</td> <td>Systolic blood pressure &#60;80 mmHg with cool peripheries or impaired capillary refill</td> </tr> <tr> <td class=\"indent1\">Severe anemia</td> <td>Hemoglobin &#60;7 g/dL or hematocrit &#60;20%</td> </tr> <tr> <td class=\"indent1\">Significant bleeding</td> <td>Including recurrent or prolonged bleeding (from the nose, gums, or venipuncture sites), hematemesis, or melena</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> <td>Blood glucose &#60;40 mg/dL (&#60;2.2 mmol/L)</td> </tr> <tr> <td class=\"indent1\">Metabolic acidosis</td> <td>Bicarbonate &#60;15 mmol/L or lactate &#62;5 mmol/L</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>World Health Organization. Severe malaria. Trop Med Int Health 2014; 19 Suppl 1:7.</LI></OL></div><div id=\"graphicVersion\">Graphic 115654 Version 1.0</div></div></div>"},"115657":{"type":"graphic_diagnosticimage","displayName":"Grade III renal laceration","title":"Grade III renal laceration","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Grade III renal laceration</div><div class=\"cntnt\"><img style=\"width:509px; height:765px;\" src=\"images/SURG/115657_GradeIIIrenallaceration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial parenchymal phase CT image demonstrates a laceration more than 1 cm deep (arrow) with adjacent fluid collection (arrowhead). At this time, urinary extravasation cannot be excluded, and the injury cannot be graded appropriately.<br />(B) Axial delayed phase CT image demonstrates the laceration (arrow) and adjacent fluid collection (arrowhead). Contrast is present in the collecting systems bilaterally, without evidence of contrast-enhanced urinary extravasation into the laceration or adjacent fluid collection, confirming that the fluid represents a hematoma. With this additional knowledge, the injury can now be designated a grade III laceration.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced from: Gross JA, Lehnert BE, Linnau KF, et al. Imaging of urinary system trauma. Radiol Clin North Am 2015; 53:773. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115657 Version 1.0</div></div></div>"},"115660":{"type":"graphic_algorithm","displayName":"Hypernatremia: General approach to the management in adults","title":"Hypernatremia: General approach to the management in adults","html":"<div class=\"graphic\"><div style=\"width: 739px\" class=\"figure\"><div class=\"ttl\">Hypernatremia: General approach to the management in adults</div><div class=\"cntnt\"><img style=\"width:719px; height:1087px;\" src=\"images/NEPH/115660_Hypernatremiamgmtadults.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ADH: antidiuretic hormone; UV: urine volume; UNa: urine sodium concentration; UK: urine potassium concentration; SNa: serum sodium concentration; IV: intravenous; D5W: 5% dextrose in water.</div><div id=\"graphicVersion\">Graphic 115660 Version 1.0</div></div></div>"},"115662":{"type":"graphic_table","displayName":"Congenital Zika lab test interpretation","title":"Interpretation of results of laboratory testing in infants with suspected congenital Zika virus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of results of laboratory testing in infants with suspected congenital Zika virus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Infant test result*</td> <td class=\"subtitle1\" rowspan=\"2\">Interpretation<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2\">rRT-PCR</td> <td class=\"subtitle2\">IgM</td> </tr> <tr> <td>Positive</td> <td>Any result</td> <td>Confirmed congenital Zika virus infection<sup>&#916;</sup></td> </tr> <tr> <td>Negative</td> <td>Nonnegative (including \"positive,\" \"presumptive positive,\" \"possible positive,\" or \"equivocal\")<sup>&#9674;</sup></td> <td>Probable congenital Zika virus infection<sup>&#167;</sup></td> </tr> <tr> <td>Negative</td> <td>Negative</td> <td>Congenital Zika virus infection unlikely<sup>&#165;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">rRT-PCR: real-time reverse transcription-polymerase chain reaction; IgM: immunoglobulin M; PRNT: plaque reduction neutralization test; CSF: cerebrospinal fluid.<br />* Laboratory testing for Zika virus infection in the infant includes serum and urine Zika virus rRT-PCR and serum Zika virus IgM. If IgM is positive, PRNT is used to exclude a false-positive result. In addition, if CSF is available, it should be tested for Zika virus with rRT-PCR and IgM. The initial samples should be collected from the infant within the first few days after birth if possible to distinguish between congenital, perinatal, and postnatal infection.<br />¶ Laboratory results should be interpreted in the context of timing of infection during pregnancy, maternal serology results, clinical findings consistent with congenital Zika syndrome, and any confirmatory testing with PRNT.<br />Δ Congenital Zika virus infection is confirmed if testing was performed within the first few days after birth. If testing was delayed and the infant lives in an area where there is ongoing transmission of Zika virus, a positive rRT-PCR does not distinguish between congenital and postnatal infection. However, if there was&nbsp;confirmed maternal Zika virus infection during pregnancy, a positive&nbsp;rRT-PCR in the infant&nbsp;is highly suggestive of congenital Zika virus infection even&nbsp;if&nbsp;testing was delayed.<br /><FONT class=lozenge>◊</FONT> The PRNT is used to confirm the specificity of IgM antibodies detected against Zika virus and to rule out a false-positive IgM result. A positive (or \"presumptive positive\" or \"possible positive\" or \"equivocal\") Zika virus IgM with negative PRNT suggests a false-positive result.<br />§ Interpretation of the infant's results within the context of maternal testing is particularly important in this setting. In the context of confirmed maternal Zika virus infection during pregnancy, a positive IgM in the infant is highly suggestive of congenital Zika virus infection. A positive IgM in the CSF is also highly suggestive of congenital Zika virus infection.<br />¥ Congenital Zika virus infection is unlikely if specimens are collected within the first few days after birth and the clinical evaluation is normal; however, health care providers should remain alert for any new findings of congenital Zika virus infection.</div><div class=\"graphic_reference\">Adapted from: Adebanjo T, Godfred-Cato S, Viens L, et al. Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection - United States, October 2017. MMWR Morb Mortal Wkly Rep 2017; 66:1089.</div><div id=\"graphicVersion\">Graphic 115662 Version 1.0</div></div></div>"},"115665":{"type":"graphic_table","displayName":"EULAR-ACR classification for adult and juvenile IIMs","title":"EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>When no better explanation for the symptoms and signs exists, these classification criteria can be used.</strong></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\" rowspan=\"2\">Variable</td> <td class=\"subtitle1\" colspan=\"2\">Score points</td> <td class=\"subtitle1\" rowspan=\"2\">Definition</td> </tr> <tr> <td class=\"subtitle2\">Without muscle biopsy</td> <td class=\"subtitle2\">With muscle biopsy</td> </tr> <tr> <td colspan=\"4\"><strong>Age of onset</strong></td> </tr> <tr> <td class=\"indent1\">Age of onset of first symptom assumed to be related to the disease &#8805;18 years and &#60;40 years</td> <td class=\"centered\">1.3</td> <td class=\"centered\">1.5</td> <td>Age &#8804;18 years at onset for first symptom assumed to be related to the disease &#60;40.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Age of onset of first symptom assumed to be related to the disease &#8805;40 years</td> <td class=\"centered\">2.1</td> <td class=\"centered\">2.2</td> <td>Age (years) at onset of first symptom assumed to be related to the disease &#8805;40.</td> </tr> <tr> <td colspan=\"4\"><strong>Muscle weakness</strong></td> </tr> <tr> <td class=\"indent1\">Objective symmetric weakness, usually progressive, of the proximal upper extremities</td> <td class=\"centered\">0.7</td> <td class=\"centered\">0.7</td> <td>Weakness of proximal upper extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time.</td> </tr> <tr> <td class=\"indent1\">Objective symmetric weakness, usually progressive, of the proximal lower extremities</td> <td class=\"centered\">0.8</td> <td class=\"centered\">0.5</td> <td>Weakness of proximal lower extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time.</td> </tr> <tr> <td class=\"indent1\">Neck flexors are relatively weaker than neck extensors</td> <td class=\"centered\">1.9</td> <td class=\"centered\">1.6</td> <td>Muscle grades for neck flexors are relatively lower than neck extensors as defined by manual muscle testing or other objective strength testing.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">In the legs, proximal muscles are relatively weaker than distal muscles</td> <td class=\"centered\">0.9</td> <td class=\"centered\">1.2</td> <td>Muscle grades for proximal muscles in the legs are relatively lower than distal muscles in the legs as defined by manual muscle testing or other objective strength testing.</td> </tr> <tr> <td colspan=\"4\"><strong>Skin manifestations</strong></td> </tr> <tr> <td class=\"indent1\">Heliotrope rash</td> <td class=\"centered\">3.1</td> <td class=\"centered\">3.2</td> <td>Purple, lilac-colored or erythematous patches over the eyelids or in a periorbital distribution, often associated with periorbital edema.</td> </tr> <tr> <td class=\"indent1\">Gottron papules</td> <td class=\"centered\">2.1</td> <td class=\"centered\">2.7</td> <td>Erythematous to violaceous papules over the extensor surfaces of joints, which are sometimes scaly. May occur over the finger joints, elbows, knees, malleoli, and toes.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gottron sign</td> <td class=\"centered\">3.3</td> <td class=\"centered\">3.7</td> <td>Erythematous to violaceous macules over the extensor surfaces of joints, which are not palpable.</td> </tr> <tr> <td colspan=\"4\"><strong>Other clinical manifestations</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dysphagia or esophageal dysmotility</td> <td class=\"centered\">0.7</td> <td class=\"centered\">0.6</td> <td>Difficulty in swallowing or objective evidence of abnormal motility of the esophagus.</td> </tr> <tr> <td colspan=\"4\"><strong>Laboratory measurements</strong></td> </tr> <tr> <td class=\"indent1\">Anti-Jo-1 (anti-histidyl-tRNA synthetase) autoantibody present</td> <td class=\"centered\">3.9</td> <td class=\"centered\">3.8</td> <td>Autoantibody testing in serum performed with standardized and validated test, showing positive result.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Elevated serum levels of creatine kinase (CK)* <strong>or</strong><br /> lactate dehydrogenase (LD)* <strong>or</strong><br /> aspartate aminotransferase (ASAT/AST/SGOT)* <strong>or</strong><br /> alanine aminotransferase (ALAT/ALT/SGPT)*</td> <td class=\"centered\">1.3</td> <td class=\"centered\">1.4</td> <td>The most abnormal test values during the disease course (highest absolute level of enzyme) above the relevant upper limit of normal.</td> </tr> <tr> <td colspan=\"4\"><strong>Muscle biopsy features&#8212;presence of:</strong></td> </tr> <tr> <td class=\"indent1\">Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibers</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.7</td> <td>Muscle biopsy reveals endomysial mononuclear cells abutting the sarcolemma of otherwise healthy, non-necrotic muscle fibers, but there is no clear invasion of the muscle fibers.</td> </tr> <tr> <td class=\"indent1\">Perimysial and/or perivascular infiltration of mononuclear cells</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.2</td> <td>Mononuclear cells are located in the perimysium and/or located around blood vessels (in either perimysial or endomysial vessels).</td> </tr> <tr> <td class=\"indent1\">Perifascicular atrophy</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">1.9</td> <td>Muscle biopsy reveals several rows of muscle fibers, which are smaller in the perifascicular region than fibers more centrally located.</td> </tr> <tr> <td class=\"indent1\">Rimmed vacuoles</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">3.1</td> <td>Rimmed vacuoles are bluish by H&#38;E staining and reddish by modified Gomori trichrome stains.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EULAR: European League Against Rheumatism; ACR: American College of Rheumatology; H&amp;E: hematoxylin and eosin.<br />* Serum levels above the upper limit of normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Lundberg IE, Tj&auml;rnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76(12):1955-64. Copyright &copy; 2017 BMJ Publishing Group Ltd.</div><div id=\"graphicVersion\">Graphic 115665 Version 1.0</div></div></div>"},"115675":{"type":"graphic_picture","displayName":"MtF gender confirmation surgery: Completed vaginoplasty","title":"MtF gender confirmation surgery: Photo of completed vaginoplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Photo of completed vaginoplasty</div><div class=\"cntnt\"><img style=\"width:240px; height:320px;\" src=\"images/OBGYN/115675_Completedvaginoplasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cecile Unger, MD, MPH.</div><div id=\"graphicVersion\">Graphic 115675 Version 4.0</div></div></div>"},"115676":{"type":"graphic_movie","displayName":"MtF gender confirmation surgery: Video presentation","title":"MtF gender confirmation surgery: Video presentation","html":"<div class=\"graphic normal\"><div style=\"width: 836px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Video presentation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/115676_MtFgenderconfirmsurgvid.mp4\" style=\"width:816px;height:480px\"></div><img style=\"width:648px; height:359px;\" src=\"images/OBGYN/115676_MtFgenderconfirmsurgimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115676 Version 1.0</div></div></div>"},"115677":{"type":"graphic_table","displayName":"Etiologies difficult-to-wean patient","title":"Etiologies of the difficult-to-wean patient","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of the difficult-to-wean patient</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"45%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Etiologies</td> <td class=\"subtitle1\">Investigations</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Respiratory/ventilatory</td> </tr> <tr> <td class=\"indent1\">Increased ventilator demand</td> <td>Hypoxemia (eg, atelectasis, morbid obesity, abdominal distension, lung disease, sepsis), elevated dead space (eg, hyperinflation, pulmonary embolism, dehydration), excess carbon dioxide production (eg, fever, infection, overfeeding [refer to nutritional, below], metabolic acidosis, or neuropsychiatric factors [eg, delirium, anxiety, pain]).</td> <td class=\"divider_bottom\" rowspan=\"5\">Clinical examination including neurological examination, chest radiograph, arterial blood gases, routine chemistries, thyroid function tests, nutrition assessment, and occasionally CT chest and/or abdomen or CT angiography. Rarely, nerve conduction studies or bronchoscopy.</td> <td class=\"divider_bottom\" rowspan=\"5\"> <ul> <li>Treat underlying etiology (eg, bronchodilation, antibiotics, pulmonary toilet, fluids, diuresis). Administer oxygen. </li> <li>Adjust mechanical ventilator settings, when indicated (eg, for auto-PEEP). </li> <li>Correct feeding or metabolic disturbances. </li> <li>Optimize sedative analgesics. </li> <li>Rarely, ETT change, physical therapy, thoracocentesis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Increased resistive load</td> <td>Bronchoconstriction (eg, COPD, asthma), airway edema (eg, lower respiratory infection), secretions (eg, tracheobronchitis, pneumonia), equipment issues (refer to ventilator circuit below).</td> </tr> <tr> <td class=\"indent1\">Increased elastic load</td> <td>Dynamic hyperinflation (eg, COPD, asthma, increased minute ventilation), alveolar filling (eg, pulmonary edema), atelectasis, pleural disease (eg, pleural effusion, pneumothorax), chest wall disease, or abdominal distension (eg, morbid obesity, ileus, ascites).</td> </tr> <tr> <td class=\"indent1\">Reduced neuromuscular capacity</td> <td>Electrolyte abnormalities (eg, hypophosphatemia, hypomagnesemia, hypocalcemia, hypokalemia), medications (eg, steroids, neuromuscular blocking agents), malnutrition (refer to nutritional below), hypothyroidism, systemic inflammation (eg, sepsis), neuropathy (eg, Guillain-Barr&#233; syndrome, critical illness polyneuropathy), and myopathy (eg, critical illness myopathy).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Decreased ventilatory drive</td> <td>Excess sedation, metabolic alkalosis (eg, nasogastric suctioning, volume depletion, diuretics and other causes of chloride depletion), central nervous system disease (eg, stroke, encephalopathy), central sleep apnea, or obesity hypoventilation syndrome.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cardiac</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Weaning may induce myocardial ischemia in susceptible patients.</td> <td class=\"divider_bottom\" rowspan=\"3\">A continuous multi-lead EKG during spontaneous breathing trials or EKG pre-and post-weaning trial. BNP or N-terminal pro-BNP pre-and post-weaning trial. Transthoracic echocardiography. Rarely, cardiac catheterization.</td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>Maximize cardiac medications (eg, beta blockade, diuresis, ACE inhibition, or vasodilators before or during SBT). </li> <li>Rarely, coronary re-perfusion interventions or inotropic agents. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Pulmonary edema may develop in patients with cardiac dysfunction or ischemia.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Fluid overload may present similarly in patients with normal cardiac function.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Psychological</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Psychologic issues (eg, depression, anxiety, delirium, pain) and oversedation may limit ventilation and impede cooperation with a SBT.</td> <td>Clinical history and examination including pain assessment.</td> <td> <ul> <li>Patients education, optimize sedative analgesia medications, which may involve increasing, adjusting, or weaning psychoactive medications. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Ventilator circuit</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td>Equipment dead space, circuit compliance, gas compression volume, exhalation valve dysfunction, and increased resistance (eg, endotracheal tube luminal narrowing due to inspissated secretions and debris or small-sized ETT).</td> <td>Examine waveforms (eg, ventilator asynchrony), ventilator pressures (eg, peak inspiratory pressure, plateau pressure), and equipment (eg, blocked exhalation valve, excess condensation).</td> <td> <ul> <li>Equipment modifications (eg, change tubing, ventilator, endotracheal tube, etc), pulmonary toilet. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Nutritional</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Protein catabolism and underfeeding leading to respiratory muscle weakness. Overfeeding leading to increased carbon dioxide production and increased ventilatory load.</td> <td>Calculate nutrition needs.</td> <td> <ul> <li>Administer adequate nutrition. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">COPD: chronic obstructive pulmonary disease; CT: computed tomography; PEEP: positive end-expiratory pressure; ETT: endotracheal tube; EKG: electrocardiogram; BNP: brain natriuretic peptide; ACE: angiotensin converting enzyme; SBT: spontaneous breathing trial.</div><div id=\"graphicVersion\">Graphic 115677 Version 1.0</div></div></div>"},"115678":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Scrotal flap markings","title":"MtF gender confirmation surgery: Scrotal flap markings","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Scrotal flap markings</div><div class=\"cntnt\"><img style=\"width:557px; height:724px;\" src=\"images/OBGYN/115678_Scrotalflapmarkings.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115678 Version 2.0</div></div></div>"},"115679":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Orchiectomy","title":"MtF gender confirmation surgery: Orchiectomy","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Orchiectomy</div><div class=\"cntnt\"><img style=\"width:535px; height:724px;\" src=\"images/OBGYN/115679_Orchiectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115679 Version 2.0</div></div></div>"},"115680":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Removal of penile epithelium","title":"MtF gender confirmation surgery: Removal of penile epithelium to tunica albuginea​","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Removal of penile epithelium to tunica albuginea​</div><div class=\"cntnt\"><img style=\"width:591px; height:724px;\" src=\"images/OBGYN/115680_Removalpenileepithelium.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115680 Version 2.0</div></div></div>"},"115681":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Ligation of deep penile artery","title":"MtF gender confirmation surgery: Ligation of deep penile arteries","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Ligation of deep penile arteries</div><div class=\"cntnt\"><img style=\"width:515px; height:724px;\" src=\"images/OBGYN/115681_Ligationdeeppenileartery.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115681 Version 2.0</div></div></div>"},"115682":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Creation of neoclitoris","title":"MtF gender confirmation surgery: Creation of neoclitoris","html":"<div class=\"graphic\"><div style=\"width: 688px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Creation of neoclitoris</div><div class=\"cntnt\"><img style=\"width:668px; height:603px;\" src=\"images/OBGYN/115682_Creationneoclitoris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The excess glans is excised, and the clitoral flap is folded on itself to position the neoclitoris approximately 5 cm above the intended location of the neourethral meatus.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115682 Version 2.0</div></div></div>"},"115683":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Creation of urethral meatus","title":"MtF gender confirmation surgery: Creation of urethral meatus","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Creation of urethral meatus</div><div class=\"cntnt\"><img style=\"width:704px; height:536px;\" src=\"images/OBGYN/115683_Creationurethralmeatus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The urethra is transected in the midline on the ventral side over the catheter until the level of the pubic bone. The urethral flap is trimmed and secured to the underlying fascia, leaving a mucosal bridge lining the area between the neourethral meatus and the neoclitoris.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115683 Version 2.0</div></div></div>"},"115684":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Transection of perineal tendon","title":"MtF gender confirmation surgery: Transection of perineal tendon for creation of neovagina","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Transection of perineal tendon for creation of neovagina</div><div class=\"cntnt\"><img style=\"width:704px; height:686px;\" src=\"images/OBGYN/115684_Transectionperinealtendon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse incision is made in the perineum below the bulbous urethra, transecting the perineal tendon and creating a cavity by separating the levator ani muscles laterally.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115684 Version 2.0</div></div></div>"},"115685":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Dissection of neovagina cavity","title":"MtF gender confirmation surgery: Dissection of neovagina cavity","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Dissection of neovagina cavity</div><div class=\"cntnt\"><img style=\"width:704px; height:589px;\" src=\"images/OBGYN/115685_Dissectionneovaginacavity.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Creation of neovagina cavity.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115685 Version 2.0</div></div></div>"},"115686":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Full-length neovagina cavity","title":"MtF gender confirmation surgery: Full-length neovagina cavity","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Full-length neovagina cavity</div><div class=\"cntnt\"><img style=\"width:518px; height:724px;\" src=\"images/OBGYN/115686_Fulllengthneovaginacavty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection of the neovagina cavity is carried past the level of the prostatic urethra anterior to the rectoprostatic fascia for a total length of approximately 15 cm.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115686 Version 2.0</div></div></div>"},"115687":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Graft formed over stent","title":"MtF gender confirmation surgery: Vaginal graft sewn over vaginal stent","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Vaginal graft sewn over vaginal stent</div><div class=\"cntnt\"><img style=\"width:646px; height:724px;\" src=\"images/OBGYN/115687_Graftformedoverstent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The prepared graft is sewn onto a large vaginal stent.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115687 Version 2.0</div></div></div>"},"115688":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Completion of neovagina graft","title":"MtF gender confirmation surgery: Completion of neovagina graft","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Completion of neovagina graft</div><div class=\"cntnt\"><img style=\"width:704px; height:605px;\" src=\"images/OBGYN/115688_Completionneovaginagraft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The stent is passed through the penile tube, and the flaps are sutured together to create the full neovagina graft.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115688 Version 2.0</div></div></div>"},"115689":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Labia minora and clitoral hood","title":"MtF gender confirmation surgery: Creation of labia minora and clitoral hood","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Creation of labia minora and clitoral hood</div><div class=\"cntnt\"><img style=\"width:704px; height:487px;\" src=\"images/OBGYN/115689_Labiaminoraclitoralhood.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Labia minora and a clitoral hood are created using the maintained distal penile skin.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115689 Version 2.0</div></div></div>"},"115690":{"type":"graphic_figure","displayName":"MtF gender confirmation surgery: Creation of labia majora","title":"MtF gender confirmation surgery: Creation of labia majora","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">MtF gender confirmation surgery: Creation of labia majora</div><div class=\"cntnt\"><img style=\"width:617px; height:704px;\" src=\"images/OBGYN/115690_Creationlabiamajora.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Drains are placed to drain the labia majora, and the labia majora incision lines are closed in an aesthetically appealing way.</div><div class=\"graphic_reference\">Reprinted with permission, Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2017. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 115690 Version 2.0</div></div></div>"},"115692":{"type":"graphic_algorithm","displayName":"Indications CRT in sinus rhythm LVEF between 35 and 50 percent","title":"Indications for CRT in patients in sinus rhythm with LVEF between 35 and 50%","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Indications for CRT in patients in sinus rhythm with LVEF between 35 and 50%</div><div class=\"cntnt\"><img style=\"width:570px; height:679px;\" src=\"images/CARD/115692_CRTsnsrhyLVEF3550prcnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction; LBBB: left bundle branch block QRS pattern on ECG; NYHA: New York Heart Association.</div><div id=\"graphicVersion\">Graphic 115692 Version 1.0</div></div></div>"},"115693":{"type":"graphic_algorithm","displayName":"Indications CRT in sinus rhythm LVEF ≤35 percent","title":"Indications for referral for CRT for patients in sinus rhythm with LVEF ≤35%","html":"<div class=\"graphic\"><div style=\"width: 1124px\" class=\"figure\"><div class=\"ttl\">Indications for referral for CRT for patients in sinus rhythm with LVEF &le;35%</div><div class=\"cntnt\"><img style=\"width:1104px; height:709px;\" src=\"images/CARD/115693_CRTsnsrhyLVEFLT35prcnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRT: cardiac resynchronization therapy; LVEF: left ventricular ejection fraction; LBBB: left bundle branch block QRS pattern on ECG; non-LBBB: any QRS pattern other than LBBB; NYHA: New York Heart Association.<br />* Most patients with an LVEF ≤35% with an indication for CRT also have an indication for an implantable cardioverter-defibrillator (ICD). Evaluation for CRT includes choosing between a pacemaker (CRT-P) and a combined CRT-ICD (CRT-D).</div><div id=\"graphicVersion\">Graphic 115693 Version 2.0</div></div></div>"},"115694":{"type":"graphic_picture","displayName":"Varied manifestations of progestogen hypersensitivity","title":"Varied manifestations of progestogen hypersensitivity","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Varied manifestations of progestogen hypersensitivity</div><div class=\"cntnt\"><img style=\"width:764px; height:704px;\" src=\"images/ALLRG/115694_Vrmnfsttnprgstnhyprstvty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The polymorphic cutaneous manifestations of progestogen hypersensitivity.<br />(A) Nummular eczematous dermatitis.<br />(B) Maculopapular rash.<br />(C) Pustules and plaques.<br />(D) Annular targetoid plaques.<br />(E) Eczematous dermatitis.<br />(F) Angioedema/urticarial.</div><div class=\"graphic_reference\">Reproduced from: Buchheit KM, Bernstein JA. Progestogen hypersensitivity: Heterogeneous manifestations with a common trigger. J Allergy Clin Immunol Pract 2017; 5:566. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115694 Version 1.0</div></div></div>"},"115696":{"type":"graphic_table","displayName":"Risk factors for iron deficiency in adolescents","title":"Risk factors for iron deficiency in adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for iron deficiency in adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major risk factors</td> </tr> <tr> <td class=\"indent1\">Heavy menstrual blood loss (&#62;80 mL/month)</td> </tr> <tr> <td class=\"indent1\">Underweight or malnourished</td> </tr> <tr> <td class=\"indent1\">Alternative diets with low iron intake (eg, vegetarian or vegan)*</td> </tr> <tr> <td class=\"indent1\">History of iron deficiency anemia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Blood donation</td> </tr> <tr> <td class=\"subtitle1_single\">Minor or conditional risk factors</td> </tr> <tr> <td class=\"indent1\">Female sex</td> </tr> <tr> <td class=\"indent1\">Chronic inflammatory conditions<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Athletes participating in endurance training</td> </tr> <tr> <td class=\"indent1\">Obesity<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Periods of rapid growth</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Iron-rich foods include meats, eggs, iron-fortified cereals, and some legumes.<br />¶ eg, inflammatory bowel disease or rheumatologic conditions.<br />Δ In the United States, obesity is a risk factor for iron deficiency in adolescents in both sexes, but especially in girls.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Nead KG, Halterman JS, Kaczorowski JM, et al. Overweight children and adolescents: a risk group for iron deficiency. Pediatrics 2004; 114:104.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 115696 Version 2.0</div></div></div>"},"115699":{"type":"graphic_diagnosticimage","displayName":"Intercostal nerve neurofibroma","title":"Computed tomography of intercostal nerve neurofibroma","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Computed tomography of intercostal nerve neurofibroma</div><div class=\"cntnt\"><img style=\"width:762px; height:279px;\" src=\"images/PULM/115699_Intercostalnrvneurofbroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomography (CT) thorax in transverse plane shows a right lower thoracic mass widening the intercostal space between the ninth and tenth right ribs. The mass impinges on the right hemidiaphragm and on the liver (dashed arrows).<br />(B) Intercostal nerve neurofibroma. CT thorax with coronal plane rendering in the same patient shows the mass splaying the intercostal space between the ninth and tenth right ribs, obliterating the right lateral costophrenic sulcus (arrows). Incidental note is made of left lower lobe pneumonia.</div><div id=\"graphicVersion\">Graphic 115699 Version 1.0</div></div></div>"},"115700":{"type":"graphic_diagnosticimage","displayName":"Tuberculous empyema","title":"Computed tomography of tuberculous empyema","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Computed tomography of tuberculous empyema</div><div class=\"cntnt\"><img style=\"width:763px; height:308px;\" src=\"images/PULM/115700_Tuberculousempyema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomography (CT) of the thorax in the transverse plane shows a right pleural mass with shell-like calcification. The right lung is smaller than the left lung due to restriction by the pleural mass. The right extrapleural fat is thickened as well due to inward pull by the restricted right lung. Note the right lateral ribs are remodeled, thicker and more sclerotic, compared with the normal left-sided ribs. This finding is characteristic of a chronic empyema.<br />(B) CT thorax with coronal plane rendering in the same patient shows the right pleural mass with shell-like calcification, thick extrapleural fat, small right lung and blunted right lateral costophrenic sulcus. The right lateral ribs are thicker and more sclerotic than the contralateral left normal ribs.</div><div id=\"graphicVersion\">Graphic 115700 Version 1.0</div></div></div>"},"115701":{"type":"graphic_diagnosticimage","displayName":"Sarcomatoid malignant mesothelioma","title":"Computed tomography of sarcomatoid malignant mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Computed tomography of sarcomatoid malignant mesothelioma</div><div class=\"cntnt\"><img style=\"width:494px; height:761px;\" src=\"images/PULM/115701_Sarcomatoidmlgntmsthlioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Computed tomography (CT) thorax in transverse plane shows circumferential right nodular pleural thickening with accompanying small right pleural effusion. The right lung is encased and smaller than the contralateral left lung.<br />(B) CT thorax with coronal plane rendering in the same patient shows right lateral nodular pleural masses (arrows) and right basal masses (arrowhead) with pleural effusion. The cardiomediastinal structures are deviated to the right due to encasement of the right lung and loss of volume.</div><div id=\"graphicVersion\">Graphic 115701 Version 1.0</div></div></div>"},"115702":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor","title":"Computed tomography of fibrous pleural tumor","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Computed tomography of fibrous pleural tumor</div><div class=\"cntnt\"><img style=\"width:754px; height:629px;\" src=\"images/PULM/115702_Fibrouspleuraltumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) of the thorax in transverse plane shows a pleural mass entering the left major interlobar fissure (arrow).</div><div id=\"graphicVersion\">Graphic 115702 Version 1.0</div></div></div>"},"115703":{"type":"graphic_diagnosticimage","displayName":"Asbestos plaques","title":"Asbestos plaques","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Asbestos plaques</div><div class=\"cntnt\"><img style=\"width:466px; height:761px;\" src=\"images/PULM/115703_Asbestosplaques.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Frontal chest radiograph shows multiple mass-like unusually large calcified asbestos-related pleural plaques.<br />(B) Computed tomography (CT) of the thorax in the transverse plane shows parietal and left mediastinal calcified and non-calcified mass-like plaques.</div><div id=\"graphicVersion\">Graphic 115703 Version 1.0</div></div></div>"},"115704":{"type":"graphic_diagnosticimage","displayName":"Pleural lipoma","title":"Pleural lipoma","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Pleural lipoma</div><div class=\"cntnt\"><img style=\"width:762px; height:563px;\" src=\"images/PULM/115704_Pleurallipoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Frontal chest radiograph shows a left upper pleural mass (arrow)&nbsp;with incomplete border sign laterally and obtuse angles of interface with the chest wall.<br />(B) CT thorax with coronal plane rendering in the same patients shows the left upper lateral fatty mass protruding into the left pleural space (arrowhead).<br />(C) Computed tomography (CT) thorax in transverse plane shows a left upper lateral fatty mass protruding into the pleural space (dashed arrow).</div><div id=\"graphicVersion\">Graphic 115704 Version 1.0</div></div></div>"},"115729":{"type":"graphic_table","displayName":"AAST grading criteria for small bowel obstruction","title":"AAST grading criteria for small bowel obstruction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">AAST grading criteria for small bowel obstruction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Radiographic criteria</td> <td class=\"subtitle1\">Operative criteria</td> </tr> <tr> <td class=\"centered\">I</td> <td>Partial SBO</td> <td>Minimal intestinal distension</td> <td>Minimal intestinal distension with no evidence of obstruction</td> </tr> <tr> <td class=\"centered\">II</td> <td>Complete SBO; bowel viable and not compromised</td> <td>Intestinal distension with transition point without bowel compromise</td> <td>Intestinal distension with transition point; no evidence of bowel compromise</td> </tr> <tr> <td class=\"centered\">III</td> <td>Complete SBO with compromised but viable bowel</td> <td>Intestinal distension with transition point, no distal contrast flow, evidence of complete obstruction or impending bowel compromise</td> <td>Intestinal distention with impending bowel compromise</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Complete SBO with nonviable bowel or perforation with localized spillage</td> <td>Evidence of localized perforation or free air; bowel distension with free air or free fluid</td> <td>Intestinal distension with localized perforation or free fluid</td> </tr> <tr> <td class=\"centered\">V</td> <td>SB perforation with diffuse peritoneal contamination</td> <td>Bowel perforation with free air and free fluid</td> <td>Intestinal distension with perforation, free fluid and evidence of diffuse peritonitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AAST: American Association for the Surgery of Trauma; SBO: small bowel obstruction; SB: small bowel.</div><div class=\"graphic_reference\">From: Hernandez MC, Haddad NN, Cullinane DC, et al. The American Association for the Surgery of Trauma Severity Grade is valid and generalizable in adhesive small bowel obstruction. J Trauma Acute Care Surg 2018; 84:372. DOI: <a href=\"https://journals.lww.com/jtrauma/Abstract/2018/02000/The_American_Association_for_the_Surgery_of_Trauma.21.aspx\" target=\"_blank\">10.1097/TA.0000000000001736</a>. Copyright &copy; 2018 American Association for the Surgery of Trauma. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115729 Version 2.0</div></div></div>"},"115747":{"type":"graphic_algorithm","displayName":"F/U of placenta previa low-lying placenta on 18- to 22-week U/S","title":"Follow-up of placenta previa or low-lying placenta on routine 18- to 22-week ultrasound examination","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Follow-up of placenta previa or low-lying placenta on routine 18- to 22-week ultrasound examination</div><div class=\"cntnt\"><img style=\"width:602px; height:419px;\" src=\"images/OBGYN/115747_FUplprvllyplt1822US.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The above algorithm applies to asymptomatic women. Emergency cesarean delivery is indicated for women with placenta previa and&nbsp;active labor, severe and persistent vaginal bleeding such that the maternal hemodynamic stability cannot be achieved or maintained, or vaginal bleeding after 34 weeks of gestation.</div><div class=\"graphic_footnotes\">* The diagnosis of placenta previa is based on identification of placental tissue extending over the internal cervical os. When the placental edge is &lt;20 mm from, but not over, the internal os, the placenta is labeled \"low lying.\"</div><div id=\"graphicVersion\">Graphic 115747 Version 1.0</div></div></div>"},"115750":{"type":"graphic_picture","displayName":"Plaque type psoriasis","title":"Plaque type psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plaque type psoriasis</div><div class=\"cntnt\"><img style=\"width:262px; height:246px;\" src=\"images/DERM/115750_Plaquetypepsoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaque type psoriasis causes the skin to form red, scaly patches. These patches are usually raised up over the normal skin around them.</div><div class=\"graphic_reference\">Courtesy of James C Shaw, MD.</div><div id=\"graphicVersion\">Graphic 115750 Version 1.0</div></div></div>"},"115758":{"type":"graphic_table","displayName":"Point prevalence rates of personality disorders","title":"Point prevalence rates of personality disorders in international samples from community and clinical populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Point prevalence rates of personality disorders in international samples from community and clinical populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Personality disorder</td> <td class=\"subtitle1\">Community samples<br /> (mean, percent)</td> <td class=\"subtitle1\">Clinical samples<br /> (mean, percent)</td> </tr> <tr> <td>Antisocial</td> <td class=\"centered\">1.8</td> <td class=\"centered\">5.9</td> </tr> <tr> <td>Avoidant</td> <td class=\"centered\">2.7</td> <td class=\"centered\">24.6</td> </tr> <tr> <td>Borderline</td> <td class=\"centered\">1.6</td> <td class=\"centered\">28.5</td> </tr> <tr> <td>Dependent</td> <td class=\"centered\">1.0</td> <td class=\"centered\">15.0</td> </tr> <tr> <td>Histrionic</td> <td class=\"centered\">1.2</td> <td class=\"centered\">9.7</td> </tr> <tr> <td>Narcissistic</td> <td class=\"centered\">0.8</td> <td class=\"centered\">10.1</td> </tr> <tr> <td>Obsessive-compulsive</td> <td class=\"centered\">2.5</td> <td class=\"centered\">10.5</td> </tr> <tr> <td>Paranoid</td> <td class=\"centered\">1.7</td> <td class=\"centered\">9.6</td> </tr> <tr> <td>Schizoid</td> <td class=\"centered\">1.3</td> <td class=\"centered\">1.9</td> </tr> <tr> <td>Schizotypal</td> <td class=\"centered\">1.3</td> <td class=\"centered\">5.7</td> </tr> <tr> <td>Any personality disorder</td> <td class=\"centered\">11.0</td> <td class=\"centered\">64.4</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: Results are mean point prevalence rates for personality disorders in community samples from 13 studies conducted in the United States (7 studies), Germany (3), Norway, Iceland, and the United Kingdom (1 each) between 1989 and 2011 and clinical samples from 9 studies conducted in the United States (4 studies), Italy (2), Norway (2), and Sweden (1) between 1985 and 2005.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Torgersen, S. Prevalence, sociodemographics, and functional impairment. In: American Psychiatric Publishing Textbook of Personality Disorders, 2nd ed, Oldham JM, Skodol AE, Bender DS (Eds), American Psychiatric Publishing, Arlington 2014.</LI>&#xD;&#xA;<LI>Torgersen, S. Epidemiology. In: The Oxford Handbook of Personality Disorders, Widiger TA (Ed), Oxford University Press, New York 2012.</LI></OL></div><div id=\"graphicVersion\">Graphic 115758 Version 1.0</div></div></div>"},"115760":{"type":"graphic_picture","displayName":"Eosinophilic pustular folliculitis infancy scalp","title":"Eosinophilic pustular folliculitis of infancy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Eosinophilic pustular folliculitis of infancy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115760_Esnphcpstlflcltsinfcysp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crops of pustules and crusted lesions on the scalp of an infant with eosinophilic pustular folliculitis of infancy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115760 Version 1.0</div></div></div>"},"115761":{"type":"graphic_picture","displayName":"Eosinophilic pustular folliculitis infancy hand","title":"Eosinophilic pustular folliculitis of infancy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Eosinophilic pustular folliculitis of infancy</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/115761_Esphlcpstlrflcltsinfyhd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crops of pustules on the dorsum of the hand of an infant with eosinophilic pustular folliculitis of infancy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115761 Version 1.0</div></div></div>"},"115776":{"type":"graphic_picture","displayName":"Neonatal herpes simplex scalp","title":"Neonatal herpes simplex skin infection","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neonatal herpes simplex skin infection</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115776_Neonatalherpessimplxsclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous vesicles are present on the scalp of this newborn with herpes simplex infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115776 Version 1.0</div></div></div>"},"115777":{"type":"graphic_picture","displayName":"Neonatal herpes simplex face","title":"Neonatal herpes simplex infection","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neonatal herpes simplex infection</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/115777_Neonatalherpessimplexfac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Grouped vesicles on an erythematous base on the face of this newborn with herpes simplex infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115777 Version 1.0</div></div></div>"},"115778":{"type":"graphic_picture","displayName":"Neonatal herpes simplex trunk","title":"Neonatal herpes simplex infection","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neonatal herpes simplex infection</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/115778_Neonatalhrpssimplextrunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vesicles and erosions on the trunk of this newborn with herpes simplex infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115778 Version 1.0</div></div></div>"},"115779":{"type":"graphic_picture","displayName":"Neonatal varicella","title":"Neonatal varicella","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neonatal varicella</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115779_Neonatalvaricella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized, pustular eruption in a newborn with varicella.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115779 Version 1.0</div></div></div>"},"115781":{"type":"graphic_table","displayName":"Diagnostic criteria - Kahn 1994","title":"Diagnostic criteria proposed by Kahn for SAPHO syndrome diagnosis, 1994<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria proposed by Kahn for SAPHO syndrome diagnosis, 1994<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol class=\"numbers_to_nine\"> <li>Chronic recurrent multifocal sterile and axial osteomyelitis, with or without dermatosis </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Acute, subacute, or chronic arthritis associated with palmoplantar pustulosis, pustular psoriasis, or severe acne </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Any sterile osteitis associated with palmoplantar pustulosis, pustular psoriasis, or severe acne </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAPHO: synovitis, acne, pustulosis, hyperostosis, osteitis.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kahn MF, Khan MA. The SAPHO syndrome. Baillieres Clin Rheumatol 1994; 8:333.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Rukavina I. SAPHO syndrome: A review. J Child Orthop 2015; 9:19. Copyright &copy; Rukavina I. Available at: <a href=\"https://link.springer.com/article/10.1007/s11832-014-0627-7\" target=\"_blank\">https://link.springer.com/article/10.1007/s11832-014-0627-7</a> (Accessed on November 27, 2017). Reproduced under the terms of the Creative Commons Attribution License.</div><div id=\"graphicVersion\">Graphic 115781 Version 1.0</div></div></div>"},"115782":{"type":"graphic_table","displayName":"Diagnostic criteria - Kahn 2003","title":"Diagnostic criteria proposed by Kahn for SAPHO syndrome diagnosis, modified in 2003<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria proposed by Kahn for SAPHO syndrome diagnosis, modified in 2003<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inclusion</td> </tr> <tr> <td class=\"indent1\">Bone-joint involvement associated with PPP and psoriasis vulgaris</td> </tr> <tr> <td class=\"indent1\">Bone-joint involvement associated with severe acne</td> </tr> <tr> <td class=\"indent1\">Isolated sterile* hyperostosis/osteitis (adults)</td> </tr> <tr> <td class=\"indent1\">Chronic recurrent multifocal osteomyelitis (children)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bone-joint involvement associated with chronic bowel diseases</td> </tr> <tr> <td class=\"subtitle1_single\">Exclusion</td> </tr> <tr> <td class=\"indent1\">Infectious osteitis</td> </tr> <tr> <td class=\"indent1\">Tumoral conditions of the bone</td> </tr> <tr> <td class=\"indent1\">Noninflammatory condensing lesions of the bone</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAPHO: synovitis, acne, pustulosis, hyperostosis, osteitis; PPP: palmoplantar pustulosis.<br />* Exception: Growth of <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kahn. American College of Rheumatology 67th Annual Scientific Meeting, Orlando, FL, October 2003.</li>&#xD;&#xA;    <li>Hayem G. SAPHO Syndrome. Rev Prat 2004; 54:1635.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Rukavina I. SAPHO syndrome: A review. J Child Orthop 2015; 9:19. Copyright &copy; Rukavina I. Available at: <a href=\"https://link.springer.com/article/10.1007/s11832-014-0627-7\" target=\"_blank\">https://link.springer.com/article/10.1007/s11832-014-0627-7</a> (Accessed on November 27, 2017). Reproduced under the terms of the Creative Commons Attribution License.</div><div id=\"graphicVersion\">Graphic 115782 Version 1.0</div></div></div>"},"115783":{"type":"graphic_table","displayName":"Diagnostic criteria - Benhamou","title":"Diagnostic criteria proposed by Benhamou for SAPHO syndrome diagnosis<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria proposed by Benhamou for SAPHO syndrome diagnosis<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol class=\"numbers_to_nine\"> <li>Osteoarticular manifestations in severe acne </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"2\"> <li>Osteoarticular manifestations in palmoplantar pustulosis </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"3\"> <li>Hyperostosis with or without dermatosis and </li> </ol> </td> </tr> <tr> <td> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Recurrent multifocal chronic osteomyelitis involving the axial or peripheral skeleton, with or without dermatosis </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SAPHO: synovitis, acne, pustulosis, hyperostosis, osteitis.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Montonen M, Lindqvist C. Diagnosis and treatment of diffuse sclerosing osteomyelitis of the jaws. Oral Maxillofac Surg Clin North Am 2003; 15:69.</LI>&#xD;&#xA;<LI>Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988; 6:109.</LI></OL>From: Rukavina I. SAPHO syndrome: A review. J Child Orthop 2015; 9:19. Copyright © Rukavina I. Available at: <A href=\"https://link.springer.com/article/10.1007/s11832-014-0627-7\" target=_blank>https://link.springer.com/article/10.1007/s11832-014-0627-7</A> (Accessed on November 27, 2017). Reproduced under the terms of the Creative Commons Attribution License.</div><div id=\"graphicVersion\">Graphic 115783 Version 1.0</div></div></div>"},"115785":{"type":"graphic_picture","displayName":"Neonatal acne 1","title":"Neonatal cephalic pustulosis (neonatal acne)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neonatal cephalic pustulosis (neonatal acne)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115785_Neonatalacne1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Profuse eruption of tiny pustules, some of which are confluent, on the face of this infant with neonatal cephalic pustulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115785 Version 1.0</div></div></div>"},"115786":{"type":"graphic_picture","displayName":"Neonatal acne 2","title":"Neonatal cephalic pustulosis (neonatal acne)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Neonatal cephalic pustulosis (neonatal acne)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115786_Neonatalacne2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse eruption of tiny, erythematous papules and pustule on the face of this infant with neonatal cephalic pustulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115786 Version 1.0</div></div></div>"},"115787":{"type":"graphic_picture","displayName":"Miliaria rubra infant face","title":"Miliaria rubra","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Miliaria rubra</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115787_Miliariarubrainfantface.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse eruption of tiny, erythematous papulovesicles on the face and upper trunk of this infant with miliaria rubra.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115787 Version 1.0</div></div></div>"},"115788":{"type":"graphic_picture","displayName":"Infantile acne 1","title":"Infantile acne","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile acne</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115788_Infantileacne1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open and closed comedones, inflammatory papules, and pustules are visible on the cheek of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115788 Version 1.0</div></div></div>"},"115789":{"type":"graphic_picture","displayName":"Infantile acne 2","title":"Infantile acne","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile acne</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/115789_Infantileacne2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Open comedones, pustules, and postinflammatory hyperpigmented macules on the cheeks of this infant with infantile acne.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115789 Version 1.0</div></div></div>"},"115791":{"type":"graphic_picture","displayName":"Acropustulosis of infancy 3","title":"Acropustulosis of infancy","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acropustulosis of infancy</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115791_Acropustulosisinfancy3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous pustules, some of which are ruptured, are present on the palms of this infant with acropustulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115791 Version 1.0</div></div></div>"},"115792":{"type":"graphic_picture","displayName":"Infantile acropustulosis 4","title":"Infantile acropustulosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile acropustulosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115792_Infantileacropustulosis4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous pustules on an erythematous base are present on the hands and forearm of this infant with acropustulosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115792 Version 1.0</div></div></div>"},"115793":{"type":"graphic_picture","displayName":"Congenital syphilis bullae","title":"Congenital syphilis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115793_Congenitalsyphilisbullae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large bullae on the soles of this newborn with congenital syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115793 Version 1.0</div></div></div>"},"115794":{"type":"graphic_picture","displayName":"Congenital syphilis papulosquamous","title":"Congenital syphilis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/115794_Congenitalsyphlspplsqmous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse, papulosquamous eruption in an infant with congenital syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115794 Version 1.0</div></div></div>"},"115796":{"type":"graphic_picture","displayName":"Diaper dermatitis","title":"Diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115796_Diaperdermatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, confluent plaques with superficial scale are present in the diaper area.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115796 Version 1.0</div></div></div>"},"115797":{"type":"graphic_picture","displayName":"Candidal diaper dermatitis 2","title":"Candidal diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Candidal diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115797_Candidaldiaperdrmatitis2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Areas of confluent erythema and desquamation in an infant with candidal diaper dermatitis. The satellite pustules are characteristic.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115797 Version 1.0</div></div></div>"},"115799":{"type":"graphic_picture","displayName":"Transient bullous dermolysis","title":"Transient bullous dermolysis of the newborn","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Transient bullous dermolysis of the newborn</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115799_Transientbullousdermolyss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large bullae and erosions on the leg of this infant with transient bullous dermolysis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115799 Version 1.0</div></div></div>"},"115803":{"type":"graphic_picture","displayName":"Diffuse cutaneous mastocytosis infant","title":"Diffuse cutaneous mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Diffuse cutaneous mastocytosis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/115803_Diffusectnsmstcytssinfnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullae and \"peau d'orange\" skin in an infant with diffuse cutaneous mastocytosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115803 Version 1.0</div></div></div>"},"115804":{"type":"graphic_picture","displayName":"Scabies infant","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/115804_Scabiesinfant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scabies in a newborn manifesting with a diffuse, erythematous, vesicular, and pustular eruption involving the palms.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115804 Version 1.0</div></div></div>"},"115806":{"type":"graphic_picture","displayName":"Atypical lymphocytes pertussis","title":"Atypical lymphocytes in a patient with pertussis","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Atypical lymphocytes in a patient with pertussis</div><div class=\"cntnt\"><img style=\"width:756px; height:509px;\" src=\"images/HEME/115806_Atyplymphocytespertussis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical lymphocytes in peripheral blood smear of child with pertussis.</div><div class=\"graphic_reference\">Republished with permission of the American Society of Hematology, from: Kadin M. Atypical lymphocytes in peripheral blood smear of child with pertussis. ASH Image Bank, permission conveyed through Copyright Clearance Center, Inc. Copyright © 2003.</div><div id=\"graphicVersion\">Graphic 115806 Version 1.0</div></div></div>"},"115807":{"type":"graphic_picture","displayName":"Linear morphea child","title":"Linear morphea","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Linear morphea</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115807_Linearmorpheachild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear morphea in a child presenting as a midline band of skin atrophy and hyperpigmentation on the forehead and scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115807 Version 1.0</div></div></div>"},"115811":{"type":"graphic_picture","displayName":"Noble false widow spider (Steatoda nobilis)","title":"Noble false widow spider (Steatoda nobilis)","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Noble false widow spider (Steatoda nobilis)</div><div class=\"cntnt\"><img style=\"width:750px; height:456px;\" src=\"images/EM/115811_NblflswdwspdSttdnbls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Steatoda nobilis</em> has a very ornate pattern on its back which looks like a house with two windows and a rounded cupola for a roof. It is found in continental Europe, Great Britain, California, and Chile.</div><div class=\"graphic_reference\">Courtesy of Richard Vetter, MS.</div><div id=\"graphicVersion\">Graphic 115811 Version 1.0</div></div></div>"},"115812":{"type":"graphic_picture","displayName":"Immature black widow spider","title":"Immature black widow spider","html":"<div class=\"graphic\"><div style=\"width: 767px\" class=\"figure\"><div class=\"ttl\">Immature black widow spider</div><div class=\"cntnt\"><img style=\"width:747px; height:515px;\" src=\"images/EM/115812_Immatureblackwidowspider.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immature black widow spiders may have a white abdomen which complicates identification.</div><div class=\"graphic_reference\">Courtesy of Richard Vetter, MS.</div><div id=\"graphicVersion\">Graphic 115812 Version 1.0</div></div></div>"},"115813":{"type":"graphic_picture","displayName":"Noble false widow spider (Steatoda nobilis) variant","title":"Noble false widow spider (Steatoda nobilis) variant","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Noble false widow spider (Steatoda nobilis) variant</div><div class=\"cntnt\"><img style=\"width:600px; height:517px;\" src=\"images/EM/115813_NblflwdwspdStdnblvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This spider displays a partial ventral pattern (swirl like a cupola).</div><div class=\"graphic_reference\">Courtesy of Richard Vetter, MS.</div><div id=\"graphicVersion\">Graphic 115813 Version 1.0</div></div></div>"},"115817":{"type":"graphic_algorithm","displayName":"Management of lower genitourinary tract injury","title":"Management of lower genitourinary tract injury","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Management of lower genitourinary tract injury</div><div class=\"cntnt\"><img style=\"width:872px; height:546px;\" src=\"images/SURG/115817_Mgmtlwrgntrnrytrctinjry.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended for use in conjunction with additional UpToDate content on trauma. Refer to UpToDate topics on the management of lower GU tract trauma for additional details of our approach to treatment and the overall efficacy of these treatments.</div><div class=\"graphic_footnotes\">GU: genitourinary; HD: hemodynamically; CT: computed tomography.<br />* The lower GU tract includes the bladder, urethra, and external genitalia. <br />¶ A suspicion for lower GU tract injury is increased with suprapubic ecchymosis, lower abdominal tenderness, pelvic fracture, penetrating injury crossing the pelvis, hematuria, difficulty voiding, scrotal/perineal ecchymosis, high-riding prostate, and penile trauma.<br />Δ Retrograde cystogram is obtained for suspected bladder injury using fluoroscopy or CT. Retrograde urethrogram is obtained for suspected urethral injury. When cystogram is needed in the setting of suspected urethral trauma, retrograde urethrogram should be performed prior to cystogram and is NOT a substitute for cystogram. Antegrade filling of the bladder as seen following intravenous contrast administration is not an acceptable method to diagnose bladder injuries and will lead to missed injuries. Negative retrograde cystogram or urethrogram effectively rules out bladder or urethral injury, respectively.<br /><FONT class=lozenge>◊</FONT> Avoid exploration of pelvic fracture-associated hematoma, which can result in uncontrolled venous bleeding.<br />§ May require intra-abdominal pelvic packing or angioembolization of bleeding from pelvic fracture. <br />¥ Complex injuries include: bladder neck injury; extraperitoneal bladder or posterior urethral injury associated with open pelvic fracture (or other pelvic fracture requiring operative repair) or with concurrent rectal/vaginal injury; or persistent hematuria with clots interfering with urinary drainage.<br />‡ Urethral drainage alone is often all that is necessary for extraperitoneal bladder injury. A&nbsp;suprapubic catheter can be considered for complex injuries. For posterior urethral injury, the choice of catheter drainage while awaiting definitive repair is debated; either suprapubic drainage or urethral catheter placement (urethral realignment) is used.<br />† Intraperitoneal bladder injury is repaired in two layers of absorbable suture. For extraperitoneal injury that requires repair, entering the bladder at the dome is suggested if there is an associated pelvic hematoma, avoiding pelvic dissection. Urgent repair/exploration of urethral injuries is not recommended unless it occurs in the setting of penetrating injury or persistent bleeding. Immediate direct repair of posterior urethral injury is associated with a high rate of complications (eg, stricture, impotence, incontinence).<br />** For anterior urethral injury that cannot be repaired immediately, urethral drainage is provided whenever possible; otherwise, a suprapubic catheter is placed.<br />¶¶ Urethral drainage is generally all that is necessary following surgical repair of intraperitoneal bladder injury. A suprapubic catheter can be considered for severe associated injuries.</div><div id=\"graphicVersion\">Graphic 115817 Version 1.0</div></div></div>"},"115818":{"type":"graphic_table","displayName":"Clinical factors that may impact choice of therapy for RLS","title":"Clinical factors that may impact choice of therapy for restless legs syndrome (RLS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical factors that may impact choice of therapy for restless legs syndrome (RLS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor that impacts the choice of agent</td> <td class=\"subtitle1\">Treatment choice</td> </tr> <tr class=\"divider_bottom\"> <td>Time of day (daytime disturbance)</td> <td>Long-acting agent (preferred)<br /> Twice a day dosing of a short-acting agent</td> </tr> <tr class=\"divider_bottom\"> <td>Sleep disturbance disproportionate to other symptoms of RLS</td> <td>Alpha-2-delta ligand</td> </tr> <tr class=\"divider_bottom\"> <td>Comorbid insomnia</td> <td>Alpha-2-delta ligand</td> </tr> <tr class=\"divider_bottom\"> <td>Pregnancy risk</td> <td>Avoid both dopaminergic agents and alpha-2-delta ligands<br /> Consider the use of iron</td> </tr> <tr class=\"divider_bottom\"> <td>Impaired renal function</td> <td>Avoid pramipexole<br /> Avoid or dose-adjust alpha-2-delta ligands</td> </tr> <tr class=\"divider_bottom\"> <td>Increased risk for falls</td> <td>Dopamine agonist</td> </tr> <tr class=\"divider_bottom\"> <td>Painful restless legs</td> <td>Alpha-2-delta ligand</td> </tr> <tr class=\"divider_bottom\"> <td>Comorbid pain syndrome</td> <td>Alpha-2-delta ligand</td> </tr> <tr class=\"divider_bottom\"> <td>History of or current impulse control disorder</td> <td>Alpha-2-delta ligand</td> </tr> <tr class=\"divider_bottom\"> <td>History of or current alcohol or substance abuse</td> <td>Avoid drugs that are hepatically metabolized (eg, ropinirole, rotigotine patch)</td> </tr> <tr class=\"divider_bottom\"> <td>Severe symptoms of RLS</td> <td>Dopamine agonist</td> </tr> <tr class=\"divider_bottom\"> <td>Excess weight, metabolic syndrome, or obstructive sleep apnea</td> <td>Dopamine agonist</td> </tr> <tr class=\"divider_bottom\"> <td>Comorbid depression</td> <td>Dopamine agonist</td> </tr> <tr class=\"divider_bottom\"> <td>Comorbid generalized anxiety disorder</td> <td>Alpha-2-delta ligand</td> </tr> <tr> <td>Hepatic impairment</td> <td> <p>Avoid ropinirole</p> <p>Use caution with rotigotine patch</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Reproduced from: Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013; 14:675. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115818 Version 2.0</div></div></div>"},"115832":{"type":"graphic_table","displayName":"Causes of salivary gland swelling","title":"Causes of salivary gland swelling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of salivary gland swelling</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acute unilateral salivary gland swelling</td> </tr> <tr> <td class=\"indent1\">Salivary gland stone</td> <td> <ul> <li>Sudden onset of pain and swelling associated with eating </li> <li>Submandibular gland most common </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Acute bacterial sialadenitis</td> <td> <ul> <li>Acute onset of pain and swelling </li> <li>Usually parotid gland </li> <li>Often with purulent discharge at duct orifice </li> <li>Typically affects older, medically debilitated patients </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">External beam radiation sialadenitis</td> <td> <ul> <li>Acute, painful swelling of salivary glands in the treatment field </li> <li>May be associated with decreased saliva production and diminished sense of taste </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acute bilateral salivary gland swelling</td> </tr> <tr> <td class=\"indent1\">Viral sialadenitis</td> <td> <ul> <li>Usually affects parotid glands </li> <li>May be unilateral initially </li> <li>Usually tender </li> <li>Viral etiologies: mumps (most common), coxsackievirus A and B, echovirus, parainfluenza virus, influenza A, Epstein-Barr virus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus</td> <td> <ul> <li>Diffuse, symmetric, cystic enlargement </li> <li>Affects the major salivary glands, most commonly the parotids </li> <li>Usually non-tender </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Radioactive iodine radiation sialadenitis</td> <td> <ul> <li>Acute painful swelling </li> <li>May be associated with decreased saliva production and diminished sense of taste </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Reaction to intravenous contrast</td> <td> <ul> <li>Most commonly involves the submandibular glands </li> <li>Rare </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chronic unilateral salivary gland swelling</td> </tr> <tr> <td class=\"indent1\">Salivary gland tumors</td> <td> <ul> <li>Subacute, painless enlargement of a single salivary gland </li> <li>Parotid gland more commonly affected than submandibular gland </li> <li>May be accompanied by facial nerve dysfunction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic bacterial sialadenitis</td> <td> <ul> <li>Recurrent episodes of pain and swelling </li> <li>Parotid gland most commonly affected </li> <li>Occasionally bilateral </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chronic bilateral salivary gland swelling</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren's syndrome</td> <td> <ul> <li>Gradual onset </li> <li>Affects parotid or submandibular glands </li> <li>Often associated with dry eyes and dry mouth </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td> <ul> <li>Gradual onset of painless swelling </li> <li>Usually affects the parotid glands </li> <li>May be accompanied by uveitis or facial nerve paralysis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malnutrition</td> <td> <ul> <li>Usually affects the parotid gland </li> <li>May be unilateral </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 115832 Version 1.0</div></div></div>"},"115834":{"type":"graphic_picture","displayName":"Biodegradable stent","title":"Biodegradable stent in left main stem bronchus","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Biodegradable stent in left main stem bronchus</div><div class=\"cntnt\"><img style=\"width:760px; height:331px;\" src=\"images/PULM/115834_Biodegradablestent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biodegradable polydioxonone stent placed via rigid bronchoscopy in left main bronchial stenosis following lung transplantation; bronchoscopic images before (A) and after (B) stent insertion.</div><div class=\"graphic_reference\">Courtesy of Hugo Oliveira, MD.</div><div id=\"graphicVersion\">Graphic 115834 Version 1.0</div></div></div>"},"115835":{"type":"graphic_algorithm","displayName":"Initial management hypocalcemia adults without CKD-MBD","title":"Initial management of hypocalcemia in adults without chronic kidney disease-mineral and bone disorder","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">Initial management of hypocalcemia in adults without chronic kidney disease-mineral and bone disorder</div><div class=\"cntnt\"><img style=\"width:709px; height:778px;\" src=\"images/ENDO/115835_InmgthypclmptwoCKDMBD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Corrected calcium [Ca] = Measured total [Ca] + (0.8 &times; (4.0 &ndash; [albumin]))<br />&para; In patients with milder degrees of hypocalcemia or chronic hypocalcemia (due to hypoparathyroidism) who become unable to take or absorb oral supplements, as may occur after complex surgical procedures requiring prolonged recuperation, IV calcium may be needed to prevent acute hypocalcemia.<br />&Delta; Initially, IV calcium (1 or 2 g of calcium gluconate, equivalent to 90 or 180 mg elemental calcium, in 50 mL of 5% dextrose [D5W] or normal saline [NS]) can be infused over 10 to 20 minutes. May repeat after 10 to 60 minutes if needed to resolve symptoms. Equivalent dose, SI units: 2.25 to 4.5 mmol calcium in 50 mL D5W or NS infused over 10 to 20 minutes.&#xD;&#xA;<ul>&#xD;&#xA;    <li>This should be followed by a slow infusion of calcium in patients with persistent hypocalcemia (eg, hypoparathyroidism, pancreatitis): An IV solution containing 1 mg/mL of elemental calcium is prepared by adding 11 g of calcium gluconate (equivalent to 1000 mg elemental calcium) to normal saline or 5% dextrose water to provide a final volume of 1000 mL.</li>&#xD;&#xA;    <li>This solution is administered at an initial infusion rate of 50 mL/hour (equivalent to 50 mg elemental/hour).</li>&#xD;&#xA;    <li>Equivalent dose, SI units: Add 24.75 mmol calcium to NS or D5W to provide a final volume of 1000 mL (final concentration of 0.025 mmol/mL) initiated at 50 mL per hour.</li>&#xD;&#xA;</ul>&#xD;&#xA;Refer to UpToDate content on treatment of hypocalcemia.<br /><span class=\"lozenge\">&loz;</span> Patients receiving digoxin should be monitored closely for acute digitalis toxicity, which can develop with calcium infusion.<br />&sect; Initially, 1.5 to 2 g of elemental calcium given as calcium carbonate or calcium citrate daily, in divided doses. Refer to UpToDate content on treatment of hypocalcemia.<br />&yen; In addition to calcium, patients with vitamin D deficiency or hypoparathyroidism require vitamin D supplementation, which often permits a lower dose of calcium supplementation. Refer to UpToDate content on hypoparathyroidism and vitamin D deficiency.<br />&Dagger; In patients with hypoparathyroidism, monitoring of urinary and serum calcium and serum phosphate is required weekly initially, until a stable serum calcium concentration (at the low end of the normal range) is reached. Thereafter, monitoring at three- to six-month intervals is sufficient. Refer to UpToDate content on hypoparathyroidism.</div><div id=\"graphicVersion\">Graphic 115835 Version 2.0</div></div></div>"},"115839":{"type":"graphic_figure","displayName":"Dispensed prescriptions for oral single-ingredient oxycodone","title":"Dispensed prescriptions for oral single-ingredient oxycodone","html":"<div class=\"graphic\"><div style=\"width: 770px\" class=\"figure\"><div class=\"ttl\">Dispensed prescriptions for oral single-ingredient oxycodone</div><div class=\"cntnt\"><img style=\"width:750px; height:438px;\" src=\"images/ANEST/115839_Dspdrxorlsglingdtoxydn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nationally estimated number of dispensed prescriptions for oral single-ingredient oxycodone from US outpatient retail pharmacies.</div><div class=\"graphic_footnotes\">M: million.</div><div class=\"graphic_reference\">Modified from: FDA Briefing Document: Joint Meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, July 26, 2017. Food and Drug Administration Center for Drug Evaluation and Research, 2017. Available at: <A href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568075.pdf\" target=_blank>https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM568075.pdf</A> (Accessed on November 22, 2017).</div><div id=\"graphicVersion\">Graphic 115839 Version 1.0</div></div></div>"},"115844":{"type":"graphic_table","displayName":"Anticancer drugs associated with SJS/TEN","title":"Anticancer drugs associated with Stevens-Johnson syndrome/toxic epidermal necrolysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anticancer drugs associated with Stevens-Johnson syndrome/toxic epidermal necrolysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">SJS</td> <td class=\"subtitle1\" colspan=\"2\">TEN</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\"><strong>Number of reported cases</strong></td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\"><strong>Number of reported cases</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Conventional chemotherapy agents</td> </tr> <tr> <td class=\"indent1\">Lenalidomide</td> <td class=\"centered\">13</td> <td>Thalidomide</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Docetaxel</td> <td class=\"centered\">4</td> <td>Procarbazine</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Thalidomide</td> <td class=\"centered\">3</td> <td>Methotrexate</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> <td class=\"centered\">3</td> <td>Gemcitabine</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> <td class=\"centered\">2</td> <td>Cytarabine</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Mechlorethamine</td> <td class=\"centered\">1</td> <td>Pemetrexed</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Paclitaxel</td> <td class=\"centered\">1</td> <td>Chlorambucil</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Fludarabine</td> <td class=\"centered\">1</td> <td>Docetaxel</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Temozolomide</td> <td class=\"centered\">1</td> <td>Doxorubicin</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> <td class=\"centered\">1</td> <td>Asparaginase</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Capecitabine</td> <td class=\"centered\">1</td> <td>6-mercaptopurine</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Cladribine</td> <td class=\"centered\">1</td> <td>Cladribine</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Etoposide</td> <td class=\"centered\">1</td> <td>S-1 (tegafur-gimeracil-oteracil potassium)</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">S-1 (tegafur-gimeracil-oteracil potassium)</td> <td class=\"centered\">1</td> <td>Lenalidomide</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Peplomycin</td> <td class=\"centered\">1</td> <td>Treosulfan</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Total</strong></td> <td class=\"centered\"><strong>35</strong></td> <td><strong>Total</strong></td> <td class=\"centered\"><strong>26</strong></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Targeted chemotherapy agents and biologics used for cancer therapy</td> </tr> <tr> <td class=\"indent1\">Imatinib</td> <td class=\"centered\">8</td> <td>Aldesleukin (IL-2)</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Rituximab</td> <td class=\"centered\">1</td> <td>Cetuximab</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">Vemurafenib</td> <td class=\"centered\">1</td> <td>Imatinib</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Cetuximab</td> <td class=\"centered\">1</td> <td>Denileukin</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Bivatuzumab mertansine</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Bortezomib</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\"><strong>Total</strong></td> <td class=\"centered\"><strong>11</strong></td> <td><strong>Total</strong></td> <td class=\"centered\"><strong>8</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis; IL-2: interleukin-2.</div><div class=\"graphic_reference\">Adapted from: Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs 2014; 25:225. DOI: <a href=\"https://journals.lww.com/anti-cancerdrugs/Abstract/2014/02000/Life_threatening_dermatologic_adverse_events_in.12.aspx\" target=\"_blank\">10.1097/CAD.0000000000000032</a>. Copyright &copy; 2014. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 115844 Version 1.0</div></div></div>"},"115855":{"type":"graphic_algorithm","displayName":"Treatment of PA","title":"Treatment of primary aldosteronism","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Treatment of primary aldosteronism</div><div class=\"cntnt\"><img style=\"width:666px; height:648px;\" src=\"images/ENDO/115855_TreatmentPA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PA: primary aldosteronism; AVS: adrenal vein sampling; ARR: aldosterone-renin ratio; MRA: mineralocorticoid-receptor antagonist; HTN: hypertension; ACE: angiotensin-converting enzyme; ARBs: angiotensin II receptor blockers; NSAIDs: nonsteroidal anti-inflammatory drugs; HCTZ: hydrochlorthiazide.<br />* Subtype is usually determined with AVS. Unilateral disease can be caused by an aldosterone-producing adenoma (APA) or primary adrenal hyperplasia (PAH). Bilateral disease is due to idiopathic adrenal hyperplasia (IHA).<br />¶ Preoperative management: Control HTN, and&nbsp;correct hypokalemia with potassium supplements or MRA.<br />Postoperative management: Stop potassium supplements and MRAs and, if possible, decrease antihypertensive therapy (starting with medications that can contribute to hyperkalemia, eg, ACE inhibitors, ARBs).<br />Monitor for hyperkalemia: Measure serum potassium during hospitalization and once weekly for four weeks after discharge. Follow serial serum creatinine in patients with renal insufficiency preoperatively.<br />Δ Refer to UpToDate content on diagnosis of primary aldosteronism for discussion of ARR and aldosterone suppression testing.<br /><FONT class=lozenge>◊</FONT> When starting MRAs, monitor potassium and creatinine first 4 to 6 weeks and after dose increases. Avoid NSAIDs and salicylates, and monitor for side effects (gynecomastia with spironolactone). If blood pressure is not well controlled with monotherapy, add antihypertensive drug: HCTZ or chlorthalidone, or ACE inhibitor.</div><div id=\"graphicVersion\">Graphic 115855 Version 1.0</div></div></div>"},"115856":{"type":"graphic_figure","displayName":"Causes of pulmonary alveolar proteinosis by age group","title":"Causes of pulmonary alveolar proteinosis in different age groups","html":"<div class=\"graphic\"><div style=\"width: 706px\" class=\"figure\"><div class=\"ttl\">Causes of pulmonary alveolar proteinosis in different age groups</div><div class=\"cntnt\"><img style=\"width:686px; height:491px;\" src=\"images/PEDS/115856_Cplmnryalvlrprtnsagegp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram showing the main causes of pulmonary alveolar proteinosis (PAP) in different age groups. Note that the size of each row is not proportionate to the relative frequency. Autoimmune PAP represents about 90% of cases overall, but is less common in children.</div><div class=\"graphic_reference\">​Reproduced with permission from Pediatrics, Vol. 140, Page e20170610. Copyright &copy; 2017 by the AAP.</div><div id=\"graphicVersion\">Graphic 115856 Version 1.0</div></div></div>"},"115857":{"type":"graphic_waveform","displayName":"ECG macroscopic T wave alternans","title":"ECG macroscopic T wave alternans","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">ECG macroscopic T wave alternans</div><div class=\"cntnt\"><img style=\"width:554px; height:466px;\" src=\"images/CARD/115857_ECGmacroscTwvealternans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of T wave alternans from a 3-year-old patient with long QT syndrome with multiple episodes of cardiac arrest. Tracings are from a 24-hour Holter recording.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div class=\"graphic_reference\">Reproduced from: Schwartz PJ, Crotti L. Long QT and short QT syndromes. In: Cardiac Electrophysiology: From Cell to Bedside, 6th ed, Zipes DP, Jalife J (Eds), Saunders, Philadelphia 2014. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115857 Version 1.0</div></div></div>"},"115858":{"type":"graphic_figure","displayName":"Time to pregnancy after discontinuing contraception","title":"Time to pregnancy after discontinuing contraception","html":"<div class=\"graphic\"><div style=\"width: 647px\" class=\"figure\"><div class=\"ttl\">Time to pregnancy after discontinuing contraception</div><div class=\"cntnt\"><img style=\"width:627px; height:408px;\" src=\"images/OBGYN/115858_Tmprgncyaftdscntctrcptn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IUC: intrauterine contraceptive; OC: oral contraceptive.</div><div class=\"graphic_reference\">Data from: Vessey MP, Lawless M, McPherson K, Yeates D. Fertility after stopping use of intrauterine contraceptive device. Br Med J 1983; 286:106.</div><div id=\"graphicVersion\">Graphic 115858 Version 1.0</div></div></div>"},"115863":{"type":"graphic_table","displayName":"Selection criteria for BP cuff size for measurement of adult BP","title":"Selection criteria for blood pressure cuff size for measurement of blood pressure in adults<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection criteria for blood pressure cuff size for measurement of blood pressure in adults<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Arm circumference</td> <td class=\"subtitle1\">Usual cuff size</td> </tr> <tr> <td>22 to 26 cm</td> <td>Small adult</td> </tr> <tr> <td>27 to 34 cm</td> <td>Adult</td> </tr> <tr> <td>35 to 44 cm</td> <td>Large adult</td> </tr> <tr> <td>45 to 52 cm</td> <td>Adult thigh</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697.</LI>&#xD;&#xA;<LI>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 2017. DOI: 10.1161/HYP.0000000000000065.</LI></OL></div><div id=\"graphicVersion\">Graphic 115863 Version 1.0</div></div></div>"},"115868":{"type":"graphic_table","displayName":"Sample child abuse documentation form","title":"Sample child abuse documentation form","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sample child abuse documentation form</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Protective services team consult</td> </tr> <tr> <td class=\"subtitle2_left\">Patient name:</td> </tr> <tr> <td class=\"subtitle2_left\">Date of birth:</td> </tr> <tr> <td class=\"subtitle2_left\">Medical record number:</td> </tr> <tr> <td class=\"subtitle2_left\">Date of consult:</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Reason for consult:</strong> Concern for child physical abuse (specifics)/child sexual abuse (specifics)</td> </tr> <tr> <td><strong>History of present injury:</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Specifics regarding injury mechanism: <ol style=\"list-style-type: lower-alpha;\"> <li>When a particular fall or other injurious event occurred; </li> <li>Where the incident occurred; </li> <li>Whether it was witnessed or not; </li> <li>Positioning of the child when found by caregiver; </li> <li>Fall surface and estimated height; </li> <li>Medical symptoms of the child preceding and immediately after an event (ie, presence or absence of apnea, seizures, respiratory change, altered mental status, swelling, bruising, skin denudation, etc); </li> <li>Any history of prior trauma (in the prior weeks to months, as applicable); </li> <li>Any discrepancies between histories provided to different health-care professionals. If differing histories have been provided, the different versions should be documented, including information regarding who provided which version, and to whom.<br /> <br /> <br /> &nbsp; </li> </ol> </li> <li>Father's interview: </li> </ol> <p class=\"indent3\">Father was interviewed independently and privately in __________ ...<br /> (within reason, a caregiver's words, in quotes, should be used as much as possible, with appropriate attribution)<br /> <br /> <br /> &nbsp;</p> <ol start=\"3\"> <li>Mother's interview: </li> </ol> <p class=\"indent3\">Mother was interviewed independently and privately in __________ ...<br /> (within reason, a caregiver's words, in quotes, should be used as much as possible, with appropriate attribution)<br /> <br /> <br /> &nbsp;</p> </td> </tr> <tr> <td class=\"subtitle2_left\">Primary pediatrician:</td> </tr> <tr> <td class=\"subtitle2_left\">Past medical history:<br /> <br /> <br /> <br /> &nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Allergies:<br /> &nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">Immunizations:<br /> &nbsp;</td> </tr> <tr> <td><strong>Family medical history:</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Maternal:<br /> <br /> <br /> &nbsp; </li> <li>Paternal:<br /> <br /> <br /> &nbsp; </li> </ol> </td> </tr> <tr> <td><strong>Social history:</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Describe your child's family and living environment. Who lives in the home with your child and what are their relationships to your child?<br /> <br /> <br /> &nbsp; </li> <li>Are you and your partner the biological parents of your child? How long have you been a couple? Do you or your partner have any other children outside of your relationship?<br /> <br /> <br /> &nbsp; </li> <li>Who is the primary caregiver for your child? What are the care giving hours? Does your child receive child care outside of your home?<br /> Risk factors: <ol style=\"list-style-type: lower-alpha;\"> <li>Does anyone who provides care for your child use substances and/or abuse alcohol? </li> <li>Does anyone who provides care for your child have any mental health issues such as depression, bipolar and/or anger management issues? Has anyone ever been on medications or hospitalized? </li> <li>Has anyone who provides care for your child been involved with law enforcement? Has anyone ever belonged to a gang or engaged in criminal activity? </li> <li>How do the people providing care for your child resolve disagreements or arguments as an adult? Have you ever been hit, pushed, slapped, choked, or verbally threatening by a partner? </li> <li>Has any caregiver for the child been the subject of a prior child protective services investigation? If so, can you tell me a little about that?<br /> <br /> <br /> &nbsp; </li> </ol> </li> <li>Attachment observations:<br /> <br /> <br /> &nbsp; </li> <li>Attributions: (describe, in three one-word adjectives [ie, \"happy\", \"fussy\", \"inconsolable\", etc], your baby/child)<br /> <br /> <br /> &nbsp; </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_left\">Developmental history:<br /> <br /> <br /> <br /> &nbsp;</td> </tr> <tr> <td><strong>Review of systems:</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Constitutional:<br /> &nbsp; </li> <li>HEENT:<br /> &nbsp; </li> <li>CV:<br /> &nbsp; </li> <li>Respiratory:<br /> &nbsp; </li> <li>GI:<br /> &nbsp; </li> <li>GU:<br /> &nbsp; </li> <li>Musculoskeletal:<br /> &nbsp; </li> <li>Dermatologic:<br /> &nbsp; </li> <li>Neurological:<br /> &nbsp; </li> <li>Allergic/Immunologic:<br /> &nbsp; </li> </ol> </td> </tr> <tr> <td><strong>Physical exam:</strong> (with emphasis on detailed trauma/skin exam)</td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Vitals:<br /> &nbsp; </li> <li>General:<br /> &nbsp; </li> <li>HEENT: (including ophthalmology examination, when appropriate)<br /> &nbsp; </li> <li>Neck:<br /> &nbsp; </li> <li>Heart/CV:<br /> &nbsp; </li> <li>Lungs/chest:<br /> &nbsp; </li> <li>Abdomen:<br /> &nbsp; </li> <li>Extremities/muscle:<br /> &nbsp; </li> <li>Skin: (refer to photodocumentation also)<br /> &nbsp; </li> <li>GU:<br /> &nbsp; </li> <li>Neurological:<br /> &nbsp; </li> </ol> </td> </tr> <tr> <td><strong>Labs/imaging:</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>PT/PTT/INR:<br /> &nbsp; </li> <li>CBC:<br /> &nbsp; </li> <li>CMP:<br /> &nbsp; </li> <li>Head CT: (when appropriate - personally reviewed with pediatric neuroradiology)<br /> &nbsp; </li> <li>MR brain: (when appropriate - personally reviewed with pediatric neuroradiology)<br /> &nbsp; </li> <li>MR spine: (when appropriate - personally reviewed with pediatric neuroradiology)<br /> &nbsp; </li> <li>MRA/V head and neck: (when appropriate - personally reviewed with pediatric neuroradiology)<br /> &nbsp; </li> <li>Skeletal survey: (personally reviewed with pediatric radiology)<br /> &nbsp; </li> </ol> </td> </tr> <tr> <td><strong>Impression:</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <ol> <li>Level of concern for abuse: (state basis) <ol style=\"list-style-type: lower-alpha;\"> <li>High concern; </li> <li>Low concern; </li> <li>Indeterminate, but with significant psychosocial or other historical factors warranting report/further investigation; or </li> <li>Indeterminate with no other significant concerns.<br /> <br /> <br /> &nbsp; </li> </ol> </li> <li>Level of diagnostic confidence for abuse: (state basis) <ol style=\"list-style-type: lower-alpha;\"> <li>High probability of abuse; </li> <li>Probable abuse; </li> <li>Indeterminate; </li> <li>Probable accident or other medical etiology; or </li> <li>High probability of accident or other medical etiology.<br /> <br /> <br /> &nbsp; </li> </ol> </li> </ol> </td> </tr> <tr> <td><strong>Recommendations:</strong></td> </tr> <tr> <td> <ol> <li>Discharge planning:<br /> <br /> <br /> &nbsp; </li> <li>Follow-up child abuse evaluation:<br /> <br /> <br /> &nbsp; </li> <li>Follow-up skeletal survey in two weeks:<br /> <br /> <br /> &nbsp; </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HEENT: head, ears, eyes, nose, and throat; CV: cardiovascular; GI: gastrointestinal; GU: genitourinary; PT: prothrombin time; PTT: partial thromboplastin time; INR: international normalized ratio; CBC: complete blood count; CMP: comprehensive metabolic panel; CT: computed tomography; MR: magnetic resonance; MRA/V: magnetic resonance angiogram/venography.</div><div class=\"graphic_reference\">Courtesy of Sandeep K Narang, MD, JD. Reproduced with permission from Ann &amp; Robert H. Lurie Children's Hospital of Chicago.</div><div id=\"graphicVersion\">Graphic 115868 Version 1.0</div></div></div>"},"115875":{"type":"graphic_table","displayName":"Cancer risk in autoimmune rheumatic diseases","title":"Cancer risk in the autoimmune rheumatic diseases reported in recent meta-analyses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cancer risk in the autoimmune rheumatic diseases reported in recent meta-analyses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Author (year)</td> <td class=\"subtitle1\">Pooled SIR or RR for all cancers</td> <td class=\"subtitle1\">Tumor types with increased risk</td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>Simon (2015)<sup>[1]</sup></td> <td>1.09 (1.06, 1.13)</td> <td>Lymphoma (Hodgkin, non-Hodgkin), lung, melanoma</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>Bernatsky (2013)<sup>[2]</sup></td> <td>1.14 (1.05, 1.23)</td> <td>Lymphoma (non-Hodgkin), lung, leukemia, thyroid</td> </tr> <tr> <td>Systemic sclerosis (scleroderma)</td> <td>Onishi (2013)<sup>[3]</sup></td> <td>1.41 (1.18, 1.68)</td> <td>Lung, liver, hematologic, bladder</td> </tr> <tr> <td> <p>Myositis</p> <p><span class=\"indent1\"><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; line-height: 107%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> Polymyositis</span> </p> <p><span class=\"indent1\"></span>&nbsp;</p> <p><span class=\"indent1\"><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; line-height: 107%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> Dermatomyositis</span> </p> </td> <td>Yang (2015)<sup>[4]</sup></td> <td> <p>&nbsp;</p> <p><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; line-height: 107%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> 1.62 (1.19, 2.04) </p> <p>&nbsp;</p> <p><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; line-height: 107%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash; </span>5 .50 (4.31, 6.70) </p> </td> <td> <p>&nbsp;</p> <p><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; line-height: 107%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> Lung, kidney, breast, lymphoma, bladder, endometrial, cervical, thyroid, brain </p> <p>&nbsp;</p> <p><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif; line-height: 107%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">&ndash;</span> Ovary, breast, lung, colorectal, cervical, bladder, nasopharyngeal, esophagus, pancreas, kidney </p> </td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> <td>Liang (2014)<sup>[5]</sup></td> <td>1.53 (1.17, 1.88)</td> <td>Non-Hodgkin lymphoma, thyroid</td> </tr> <tr> <td>ANCA-associated vasculitis</td> <td>Shang (2015)<sup>[6]</sup></td> <td>1.74 (1.37, 2.21)</td> <td>Non-melanoma skin, leukemia, bladder, lymphoma, liver, lung</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SIR: standardized incidence ratio; RR: risk ratio; ANCA: antineutrophil cytoplasmic antibody.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis. Arthritis Res Ther 2015; 17:212.</LI>&#xD;&#xA;<LI>Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: An updated international multi-centre cohort study. J Autoimmun 2013; 42:130.</LI>&#xD;&#xA;<LI>Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: Meta-analysis of population-based cohort studies. Arthritis Rheum 2013; 65:1913.</LI>&#xD;&#xA;<LI>Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: A metaanalysis study. J Rheumatol 2015; 42:282.</LI>&#xD;&#xA;<LI>Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: A systematic review and meta-analysis. Ann Rheum Dis 2014; 73:1151.</LI>&#xD;&#xA;<LI>Shang W, Ning Y, Xu X, et al. Incidence of cancer in ANCA-associated vasculitis: A meta-analysis of observational studies. PLoS One 2015; 10:e0126016.</LI></OL>Reproduced from: Egiziano G, Bernatsky S, Shah AA. Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link. Best Pract Res Clin Rheumatol 2016; 30:53. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115875 Version 1.0</div></div></div>"},"115883":{"type":"graphic_algorithm","displayName":"Management of sclerosing mesenteritis","title":"Approach to the management of sclerosing mesenteritis in adults","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Approach to the management of sclerosing mesenteritis in adults</div><div class=\"cntnt\"><img style=\"width:590px; height:960px;\" src=\"images/GAST/115883_Apprmngsclrmsntrtsadlts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Non-obstructive symptoms include abdominal pain, systemic symptoms including fever, weight loss, and altered bowel habits.<br />&para; Patients with bowel obstruction are managed conservatively when feasible. Surgical bypass is indicated to alleviate symptoms in those whose symptoms are dominated by focal intestinal obstruction. Refer to UpToDate topic reviews.<br />&Delta; Treatment with azathioprine is an alternative approach.<br /><span class=\"lozenge\">&loz;</span> Treatment with pentoxyfylline is an alternative approach.<br />&sect; Treatment with colchicine is controversial. Refer to UpToDate topic review on sclerosing mesenteritis.</div><div id=\"graphicVersion\">Graphic 115883 Version 1.0</div></div></div>"},"115886":{"type":"graphic_algorithm","displayName":"Overview of treatment of adults with hyponatremia","title":"Overview of the initial treatment of adults with moderate to severe hyponatremia (serum sodium <130 mEq/L)","html":"<div class=\"graphic\"><div style=\"width: 1096px\" class=\"figure\"><div class=\"ttl\">Overview of the initial treatment of adults with moderate to severe hyponatremia (serum sodium &lt;130 mEq/L)</div><div class=\"cntnt\"><img style=\"width:1076px; height:1550px;\" src=\"images/NEPH/115886_Ovwtrmtadltshyponatremia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; SIADH: syndrome of inappropriate antidiuretic hormone secretion.<br />* Severe symptoms of hyponatremia include seizures, obtundation, coma, and respiratory arrest.<br />¶ General measures include the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Identify and treat the underlying cause of hyponatremia.</LI>&#xD;&#xA;<LI>Identify drugs taken by the patient that could contribute to hyponatremia. Discontinue those drugs unless there is no reasonable substitute and stopping the medication would cause serious harm.</LI>&#xD;&#xA;<LI>Reduce intake of electrolyte-free water (impose fluid restriction, eliminate&nbsp;IV hypotonic fluids, increase dietary salt).</LI>&#xD;&#xA;<LI>Other therapies in patients with SIADH and chronic hyponatremia include loop diuretics, oral salt tablets, and urea. (Refer to UpToDate topics on treatment of hyponatremia and treatment of SIADH.)</LI></UL>Δ Autocorrection of hyponatremia is present if the serum sodium is rising spontaneously without intervention or treatment. Autocorrection should be suspected, even before a spontaneous rise in serum sodium is noted, in the following hyponatremic patients: those with a rapidly reversible cause of hyponatremia who have a brisk urine output and those with a urine output that is increasing over time and a urine cation concentration (ie, the sum of the urine sodium and potassium concentration) that is lower than the serum sodium.</div><div id=\"graphicVersion\">Graphic 115886 Version 1.0</div></div></div>"},"115887":{"type":"graphic_figure","displayName":"Scoop stretcher patient transfer","title":"Scoop stretcher patient transfer","html":"<div class=\"graphic\"><div style=\"width: 648px\" class=\"figure\"><div class=\"ttl\">Scoop stretcher patient transfer</div><div class=\"cntnt\"><img style=\"width:628px; height:794px;\" src=\"images/EM/115887_Scoopstretcherpatienttransfer.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 115887 Version 1.0</div></div></div>"},"115888":{"type":"graphic_figure","displayName":"Slide board patient transfer","title":"Slide board patient transfer","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Slide board patient transfer</div><div class=\"cntnt\"><img style=\"width:547px; height:650px;\" src=\"images/EM/115888_Slideboardpatienttransfer.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 115888 Version 1.0</div></div></div>"},"115892":{"type":"graphic_table","displayName":"ASCO 2017 platelet transfusion","title":"Information from the ASCO 2017 platelet transfusion guidelines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Information from the ASCO 2017 platelet transfusion guidelines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Platelet products</td> </tr> <tr> <td class=\"indent1\"><strong>Source of platelets</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Platelets can be prepared from units of whole blood and pooled (\"pooled platelets\") or obtained by apheresis (\"single-donor platelets\"). The efficacy and risks of these products are similar, and they can be used interchangeably in most circumstances. In most centers, pooled platelets are less expensive. Single-donor platelets are necessary when histocompatible platelet transfusions (eg, HLA-A- and HLA-B-antigen-matched)&nbsp;are needed.</td> </tr> <tr> <td class=\"indent1\"><strong>Rh(D) alloimmunization</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Rh(D) alloimmunization in Rh(D)-negative recipients can be prevented/reduced by using products from Rh(D)-negative donors or by using anti-D immunoprophylaxis. The major risks of Rh(D) alloimmunization are related to hemolytic disease of the fetus and newborn (HDFN). Thus, these approaches may be used for females with the potential for future childbearing. However, rates of Rh(D) alloimmunization are low in patients with cancer, and these approaches need not be applied universally.</td> </tr> <tr> <td class=\"indent1\"><strong>Leukoreduction</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">White blood cells (WBCs) present in the platelet product may cause alloantibody-mediated refractoriness to platelet transfusion in some individuals; leukoreduction can reduce this risk. It is appropriate to provide leukoreduced blood products (including platelets) to individuals with AML from the time of diagnosis. Leukoreduced products may also be useful for individuals with other types of leukemia, those with other types of cancer who are receiving chemotherapy, or those with other bone marrow disorders who require frequent transfusions. Other advantages of prestorage leukoreduction include reduction in the rates of transfusion reactions and CMV transmission. The majority of blood products are prestorage leukoreduced in many countries.</td> </tr> <tr> <td class=\"subtitle1_single\">Prophylactic platelet transfusion thresholds*</td> </tr> <tr> <td class=\"indent1\"><strong>Hematologic malignancies and allogeneic HCT</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Transfuse for a platelet count &#60;10,000/microL. Higher thresholds may apply in certain circumstances (eg, active bleeding, need for invasive procedure, fever, hyperleukocytosis, rapidly declining platelet count, anticipated delay in seeking care for bleeding [eg, outpatient who lives far from the treatment center], coagulation abnormalities such as in acute promyelocytic leukemia, or other indications based on the judgment of the treating clinician).</td> </tr> <tr> <td class=\"indent1\"><strong>Autologous hematopoietic stem cell transplantation</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Children:</strong> Same as described above for hematologic malignancies and allogeneic HCT.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Adults:</strong> For the majority of patients, same as described above for hematologic malignancies and allogeneic HCT. In some experienced centers, it may be appropriate to transfuse at the first sign of bleeding rather than prophylactically<sup>&#182;</sup>, based on evidence that the risk of severe bleeding is similar with this approach and platelet usage may be decreased. This approach requires ability to monitor the patient closely and to intervene rapidly at the first sign of bleeding. Clinical judgment applies.</td> </tr> <tr> <td class=\"indent1\"><strong>Chronic stable severe thrombocytopenia in the absence of active treatment (eg, MDS, AA)</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">It may be appropriate to transfuse for bleeding or an invasive procedure or during active treatment. Clinical judgment applies.</td> </tr> <tr> <td class=\"indent1\"><strong>Solid tumors</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">The risk of bleeding is related to the depth and duration of thrombocytopenia. Transfusion for a platelet count &#60;10,000/microL is appropriate for most patients. Higher thresholds may apply in certain circumstances (eg, active bleeding, need for invasive procedure, fever, necrotic tumor).</td> </tr> <tr> <td class=\"indent1\"><strong>Surgical or invasive procedures</strong></td> </tr> <tr> <td class=\"indent2\"><strong>Major procedures:</strong> Transfusion for a platelet count &#60;40,000 to 50,000/microL is appropriate for most procedures in most patients.</td> </tr> <tr> <td class=\"indent2\"><strong>Minor procedures:</strong> Transfusion for a platelet count &#60;20,000/microL is appropriate for selected procedures such as bone marrow aspirate/biopsy or insertion/removal of a central venous catheter.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Lumbar puncture:</strong> High-quality data are lacking. Other guidelines have suggested transfusion for a platelet count &#60;50,000/microL.</td> </tr> <tr> <td class=\"subtitle1_single\">Refractoriness to platelet transfusion</td> </tr> <tr> <td class=\"indent1\"><strong>Diagnosis</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Refractoriness to platelet transfusion may be suspected when the platelet count does not increase as expected following transfusion. In such cases, a post-transfusion platelet count should be obtained 10 to 60 minutes after all platelet transfusions if possible. Refractoriness to platelet transfusion may be diagnosed when transfusion of ABO-compatible platelets stored for &#60;72 hours fails to result in a reasonable increase in platelet count 10 to 60 minutes after transfusion on at least two occasions. The expected increase may be determined by calculating the CCI; a CCI of &#8805;5000/microL is reasonable. Alternatively, an increment of &#8805;2000/microL for each unit in a pooled concentrate or &#8805;10,000/microL for each unit of single donor (apheresis) platelets is reasonable. For children, an increment of &#8805;3500/square meter for each apheresis unit is reasonable.</td> </tr> <tr> <td class=\"indent1\"><strong>Management</strong></td> </tr> <tr> <td class=\"indent2\">Refractoriness may be due to immune or non-immune causes. Non-immune causes include fever, sepsis splenomegaly, and medications. Individuals with alloimmune refractoriness to platelet transfusions are best managed with transfusions from histocompatible donors matched for HLA-A and HLA-B antigens. Refer to the UpToDate topic on platelet refractoriness for further details.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table refers to children and adults unless otherwise specified. Platelet transfusions in newborns are discussed separately in UpToDate. Refer to UpToDate and the ASCO guideline for additional details and supporting evidence.</div><div class=\"graphic_footnotes\">ASCO: American Society of Clinical Oncology; HLA: human leukocyte antigen; AML: acute myeloid leukemia; CMV: cytomegalovirus; HCT: hematopoietic cell transplantation; MDS: myelodysplastic syndrome; AA: aplastic anemia; CCI: corrected count increment.<br />* Prophylactic platelet transfusions are administered to prevent bleeding in patients with thrombocytopenia when the platelet count drops below a certain threshold. The threshold depends on the patient's diagnosis, clinical status, and other treatments being administered.<br />¶ Refer to UpToDate for a discussion of UpToDate authors' approaches.</div><div class=\"graphic_reference\">Modified from: Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2017; 35.</div><div id=\"graphicVersion\">Graphic 115892 Version 1.0</div></div></div>"},"115894":{"type":"graphic_diagnosticimage","displayName":"Hemo- and pneumothorax in an adolescent","title":"Hemo- and pneumothorax in an adolescent","html":"<div class=\"graphic\"><div style=\"width: 713px\" class=\"figure\"><div class=\"ttl\">Hemo- and pneumothorax in an adolescent</div><div class=\"cntnt\"><img style=\"width:693px; height:765px;\" src=\"images/EM/115894_Hemopneumothoraxadlscnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Upright chest radiograph shows a combined hemo- and pneumo-thoraxi (thick and thin arrows, respectively).<br />(B) Supine radiograph shortly after chest tube placement.<br />(C) Resolution of pneumothorax with a residual hemothorax (arrows).</div><div class=\"graphic_reference\">Courtesy of Matthew Eisenberg, MD.</div><div id=\"graphicVersion\">Graphic 115894 Version 1.0</div></div></div>"},"115900":{"type":"graphic_figure","displayName":"Mechanism of action for ICI","title":"Mechanism of action for immune checkpoint inhibition targeting CTLA-4 and PD-1","html":"<div class=\"graphic\"><div style=\"width: 706px\" class=\"figure\"><div class=\"ttl\">Mechanism of action for immune checkpoint inhibition targeting CTLA-4 and PD-1</div><div class=\"cntnt\"><img style=\"width:686px; height:570px;\" src=\"images/RHEUM/115900_MechanismactionICI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Inhibition of T-cell activation by interactions with tumor cells and APCs. PD-L1 and PD-L2 on tumor cells and APCs bind to PD-1 on the T cell, and B7 on APCs binds to CTLA-4 on the T cell.<br />(B) Antibodies to PD-1 or CTLA-4 block inhibitory interactions, allowing for positive costimulation (B7 binds CD28).</div><div class=\"graphic_footnotes\">CTLA-4: cytotoxic lymphocyte antigen protein 4; PD-1: programmed cell death receptor 1; MHC: major histocompatibility complex; CD28: cluster of differentiation 28; PD-L1: programmed cell death ligand 1; PD-L2: programmed cell death ligand 2; APCs: antigen-presenting cells.</div><div class=\"graphic_reference\">Reproduced from: Cappelli LC, Shah AA, Bingham CO III. Immune-related adverse effects of cancer immunotherapy&mdash;Implications for rheumatology. Rheum Dis Clin N Am 2017; 43:65. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115900 Version 1.0</div></div></div>"},"115901":{"type":"graphic_table","displayName":"Signs and symptoms of chronic graft-versus-host disease","title":"Signs and symptoms of chronic graft-versus-host disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of chronic graft-versus-host disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"4\" width=\"21%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ or site</td> <td class=\"subtitle1\">Diagnostic (sufficient to establish the diagnosis of chronic GVHD)</td> <td class=\"subtitle1\">Distinctive* (seen in chronic GVHD but insufficient alone to establish a diagnosis)</td> <td class=\"subtitle1\">Other features or unclassified entities<sup>&#182;</sup></td> <td class=\"subtitle1\">Common<sup>&#916;</sup> (seen with both acute and chronic GVHD)</td> </tr> <tr class=\"divider_bottom\"> <td>Skin</td> <td> <ul> <li>Poikiloderma </li> <li>Lichen planus-like features </li> <li>Sclerotic features </li> <li>Morphea-like features </li> <li>Lichen sclerosus-like features </li> </ul> </td> <td> <ul> <li>Depigmentation </li> <li>Papulosquamous lesions </li> </ul> </td> <td> <ul> <li>Sweat impairment </li> <li>Ichthyosis </li> <li>Keratosis pilaris </li> <li>Hypopigmentation </li> <li>Hyperpigmentation </li> </ul> </td> <td> <ul> <li>Erythema </li> <li>Maculopapular rash </li> <li>Pruritus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Nails</td> <td>&nbsp;</td> <td> <ul> <li>Dystrophy </li> <li>Longitudinal ridging, splitting or brittle features </li> <li>Onycholysis </li> <li>Pterygium unguis </li> <li>Nail loss (usually symmetric, affects most nails) </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Scalp and body hair</td> <td>&nbsp;</td> <td> <ul> <li>New onset of scarring or nonscarring scalp alopecia (after recovery from chemoradiotherapy) </li> <li>Loss of body hair </li> <li>Scaling </li> </ul> </td> <td> <ul> <li>Thinning scalp hair, typically patchy, coarse or dull (not explained by endocrine or other causes) </li> <li>Premature gray hair </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Mouth</td> <td> <ul> <li>Lichen planus-like changes </li> </ul> </td> <td> <ul> <li>Xerostomia </li> <li>Mucoceles </li> <li>Mucosal atrophy </li> <li>Ulcers </li> <li>Pseudomembranes </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Gingivitis </li> <li>Mucositis </li> <li>Erythema </li> <li>Pain </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Eyes</td> <td>&nbsp;</td> <td> <ul> <li>New-onset dry, gritty, or painful eyes </li> <li>Cicatricial conjunctivitis </li> <li>KCS </li> <li>Confluent areas of punctate keratopathy </li> </ul> </td> <td> <ul> <li>Photophobia </li> <li>Periorbital hyperpigmentation </li> <li>Blepharitis (erythema of the eyelids with edema) </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>Genitalia</td> <td> <ul> <li>Lichen planus-like features </li> <li>Lichen sclerosus-like features </li> </ul> </td> <td> <ul> <li>Erosions </li> <li>Fissures </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Females</td> <td> <ul> <li>Vaginal scarring or clitoral/labial agglutination </li> </ul> </td> <td> <ul> <li>Ulcers </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Males</td> <td> <ul> <li>Phimosis or urethral/meatus scarring or stenosis </li> </ul> </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>GI tract</td> <td> <ul> <li>Esophageal web </li> <li>Strictures or stenosis in the upper to mid third of the esophagus </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Exocrine pancreatic insufficiency </li> </ul> </td> <td> <ul> <li>Anorexia </li> <li>Nausea </li> <li>Vomiting </li> <li>Diarrhea </li> <li>Weight loss </li> <li>Failure to thrive (infants and children) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Liver</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <ul> <li>Total bilirubin, alkaline phosphatase &#62;2 &times; upper limit of normal </li> <li>ALT &#62;2 &times; upper limit of normal </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lung</td> <td> <ul> <li>Bronchiolitis obliterans diagnosed with lung biopsy </li> <li>BOS<sup>&#9674;</sup> </li> </ul> </td> <td> <ul> <li>Air trapping and bronchiectasis on chest CT </li> </ul> </td> <td> <ul> <li>Cryptogenic organizing pneumonia </li> <li>Restrictive lung disease<sup>&#167;</sup> </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Muscles, fascia, joints</td> <td> <ul> <li>Fasciitis </li> <li>Joint stiffness or contractures secondary to fasciitis or sclerosis </li> </ul> </td> <td> <ul> <li>Myositis or polymyositis<sup>&#165;</sup> </li> </ul> </td> <td> <ul> <li>Edema </li> <li>Muscle cramps </li> <li>Arthralgia or arthritis </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hematopoietic and immune</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <ul> <li>Thrombocytopenia </li> <li>Eosinophilia </li> <li>Lymphopenia </li> <li>Hypo- or hypergammaglobulinemia </li> <li>Autoantibodies (AIHA, ITP) </li> <li>Raynaud's phenomenon </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td>Other</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <ul> <li>Pericardial or pleural effusions </li> <li>Ascites </li> <li>Peripheral neuropathy </li> <li>Nephrotic syndrome </li> <li>Myasthenia gravis </li> <li>Cardiac conduction abnormality or cardiomyopathy </li> </ul> </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GVHD: graft-versus-host disease; KCS: keratoconjunctivitis sicca; GI: gastrointestinal; ALT: alanine aminotransferase;&nbsp;BOS: bronchiolitis obliterans syndrome; CT: computed tomography; AIHA: autoimmune hemolytic anemia; ITP: idiopathic thrombocytopenic purpura.<br />* In all cases, infection, drug effect, malignancy, or other causes must be excluded.<br />¶ Can be acknowledged as part of the chronic GVHD manifestations if diagnosis is confirmed.<br />Δ Common refers to shared features by both acute and chronic GVHD.<br /><FONT class=lozenge>◊</FONT> BOS can be diagnostic for lung chronic GVHD only if distinctive sign or symptom present in another organ.<br />§ Pulmonary entities under investigation or unclassified.<br />¥ Diagnosis of chronic GVHD requires biopsy.</div><div class=\"graphic_reference\">Reproduced from: Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21:389. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115901 Version 1.0</div></div></div>"},"115902":{"type":"graphic_picture","displayName":"Hermansky-Pudlak hair","title":"Hermansky-Pudlak syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hermansky-Pudlak syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115902_HermanskyPudlakhair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A child with Hermansky-Pudlak syndrome presenting with light brown hair and blue eyes.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115902 Version 1.0</div></div></div>"},"115903":{"type":"graphic_picture","displayName":"Hermansky-Pudlak skin","title":"Hermansky-Pudlak syndrome","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hermansky-Pudlak syndrome</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/115903_HermanskyPudlakskin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple solar lentigines and actinic keratoses in a patient with Hermansky-Pudlak syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 115903 Version 1.0</div></div></div>"},"115904":{"type":"graphic_algorithm","displayName":"Continence surgery in women undergoing prolapse repair","title":"Decision to perform a continence procedure in women undergoing surgical repair of pelvic organ prolapse (POP)","html":"<div class=\"graphic\"><div style=\"width: 585px\" class=\"figure\"><div class=\"ttl\">Decision to perform a continence procedure in women undergoing surgical repair of pelvic organ prolapse (POP)</div><div class=\"cntnt\"><img style=\"width:565px; height:471px;\" src=\"images/OBGYN/115904_Contncsrgrywmnprolpsrpr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">POP: pelvic organ prolapse; SUI: stress urinary incontinence.<br />* For discussion of prolapse grading, refer to UpToDate content on the diagnostic evaluation of&nbsp;POP in women.<br />¶ For information on urinary stress testing, refer to UpToDate content on the preoperative evaluation of women undergoing surgical treatment of SUI.<br />Δ For information on the routes of&nbsp;POP repair, refer to UpToDate content on the surgical repair of apical prolapse in women.<br /><FONT class=lozenge>◊</FONT> Examples of vaginal prolapse repair include sacrospinous ligament suspension and uterosacral ligament suspension.<br />§ Examples of abdominal prolapse repair include sacrocolpopexy and sacrocervicopexy.<br />¥ Elevation of prolapsed structures to approximate normal pelvic support during clinical or urodynamic urinary function testing.<br />‡ While performing a Burch urethropexy utilizing the same abdominal surgical route as the prolapse repair, surgeons may also reasonably perform a transvaginal midurethral sling procedure.<br />† For further discussion on the risks and benefits of incontinence surgery in women without SUI, refer to UpToDate content on the combined surgical treatment of POP and SUI.</div><div class=\"graphic_reference\">Courtesy of Charles W Nager, MD, and Jasmine Tan-Kim, MD</div><div id=\"graphicVersion\">Graphic 115904 Version 1.0</div></div></div>"},"115909":{"type":"graphic_algorithm","displayName":"Management of idiopathic retroperitoneal fibrosis","title":"Management of primary or drug-related secondary retroperitoneal fibrosis*","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Management of primary or drug-related secondary retroperitoneal fibrosis*</div><div class=\"cntnt\"><img style=\"width:759px; height:1219px;\" src=\"images/NEPH/115909_Mgmtidpthcrtrprtnlfbrss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; PCP: <EM innerHtml>Pneumocystis </EM>pneumonia.<br />* This algorithm does not include specific management of nondrug-related secondary retroperitoneal fibrosis (ie, due to malignancy or infection). Refer to UpToDate topics on treatment of retroperitoneal fibrosis.<br />¶ Significant ureteral obstruction is defined as unilateral or bilateral hydronephrosis in setting of reduced renal function due to obstruction.<br />Δ Refer to UpToDate content on treatment of retroperitoneal fibrosis for discussion of selected interventional procedures.<br /><FONT class=lozenge>◊</FONT> If patient cannot tolerate high-dose glucocorticoids, he or she may benefit from addition of other agents, such as tamoxifen. Refer to UpToDate content on treatment of retroperitoneal fibrosis. Patients receiving ≥20 mg daily prednisone for one month or more who have another cause of immunocompromise (eg, second immunosuppressive agent such as mycophenolate mofetil&nbsp;or methotrexate or certain hematologic malignancies) may require PCP prophylaxis. Refer to related UpToDate content on glucocorticoid effects on the immune&nbsp;system&nbsp;for details.<br />§ Remission is defined as significant reduction of mass size and resolution of symptoms.<br />¥ All patients receiving methotrexate should be treated with folic acid or leucovorin to prevent hematologic and other side effects. Refer to related UpToDate content on use of methotrexate in the treatment of rheumatoid arthritis.<br />‡ Both rituximab and tocilizumab are considered investigational therapies.<br />† Former ingredient in some analgesic combinations; withdrawn in most countries due to toxicities.</div><div class=\"graphic_reference\">Adapted from: Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016; 27:1880.</div><div id=\"graphicVersion\">Graphic 115909 Version 1.0</div></div></div>"},"115917":{"type":"graphic_table","displayName":"Comparison cervical spine injury versus cervical burner","title":"Comparison of physical features of cervical spinal cord injury and brachial plexus injury (burner or stinger)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of physical features of cervical spinal cord injury and brachial plexus injury (burner or stinger)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cervical spinal cord injury</td> <td class=\"subtitle1\">Brachial plexus injury (\"Burner\" or \"Stinger\")</td> </tr> <tr class=\"divider_bottom\"> <td>Mechanism</td> <td> <ul> <li>Axial spine compression (eg, diving, gymnastics, wrestling, or hockey) </li> <li>Motor vehicle collision </li> <li>Falls with excessive neck flexion or extension </li> </ul> </td> <td> <ul> <li>Stretch injury to the neck typically during tackling in American football or rugby </li> <li>Direct blow to the supraclavicular fossa (rugby) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Symptoms</td> <td> <ul> <li>Neck pain or stiffness </li> <li>Unilateral or bilateral paresthesias, weakness, or paralysis </li> <li>Lower extremity symptoms </li> <li>May be transient or persistent </li> </ul> </td> <td> <ul> <li>Only unilateral symptoms involving the upper extremity </li> <li>Transient supraclavicular pain, paresthesias, or weakness (usually resolves after a few minutes) </li> </ul> </td> </tr> <tr> <td>Physical examination</td> <td> <ul> <li>Posterior midline neck tenderness </li> <li>Decreased active neck range of motion </li> <li>Abnormal neurologic examination often consisting of spinal&nbsp;sensory level above the nipple,&nbsp;flaccid paralysis with absent reflexes in the acute phase subsequently followed by quadriparesis, </li> <li>Often associated with head injury </li> </ul> </td> <td> <ul> <li>No posterior midline neck tenderness </li> <li>Pain localized to the neck musculature that may limit neck motion </li> <li>Compression or percussion of the top of the head may reproduce symptoms (Spurling test) </li> <li>Upper extremity weakness typically fully resolves but may persist </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 115917 Version 1.0</div></div></div>"},"115919":{"type":"graphic_table","displayName":"Molecular tests in diffuse gliomas in adults","title":"Molecular tests in diffuse gliomas in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular tests in diffuse gliomas in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Method(s) of testing</td> <td class=\"subtitle1\">Clinical implications and notes</td> </tr> <tr> <td><em>IDH1/2</em> mutation</td> <td>IHC for R132H-mutant IDH1*, sequencing of <em>IDH1/2</em></td> <td>IDH1 IHC is required for all grade II and III diffuse gliomas; when negative, sequencing of <em>IDH1/2</em> should be prioritized for grade II and III gliomas and for glioblastoma in patients &#60;55 years old; IDH mutations confer improved prognosis across all tumor grades.</td> </tr> <tr> <td><em>MGMT</em> promotor methylation</td> <td>Methylation-specific PCR, array-based methylation assay</td> <td>Methylation confers improved prognosis in high-grade gliomas and is predictive of improved responsiveness to alkylating-agent chemotherapy; no diagnostic value.</td> </tr> <tr> <td>1p/19q-codeletion</td> <td>FISH, LOH assay, aCGH, MLPA, PCR-based</td> <td>Required for diffuse gliomas with oligodendroglial component; not routinely performed on glioblastoma specimens; indicated when oligodendroglial pattern predominates to help distinguish between glioblastoma and anaplastic oligodendroglioma; in the absence of an IDH mutation, codeletion by FISH should raise suspicion for partial or incomplete deletions, which are associated with some subsets of IDH-wildtype astrocytomas and a worse prognosis.</td> </tr> <tr> <td><em>ATRX</em> mutations</td> <td>IHC for nuclear ATRX expression or sequencing</td> <td>Loss of nuclear staining indicates the presence of an <em>ATRX</em> mutation, strongly associated with astrocytic lineage; <em>ATRX</em> mutations are mutually exclusive with 1p/19q-codeletion but should not be used as a substitute for 1p/19q testing.</td> </tr> <tr> <td><em>TERT</em> promotor mutations</td> <td>Sequencing</td> <td><em>TERT</em> mutations occur in IDH-wildtype glioblastomas and in IDH-mutant 1p/19q-codeleted oligodendrogliomas; in glioblastoma and lower-grade IDH-wildtype astrocytomas, <em>TERT</em> mutations are associated with poor prognosis.</td> </tr> <tr> <td><em>TP53</em></td> <td>IHC for mutant p53</td> <td>Mutant p53 staining is present in vast majority of astrocytic tumors but is not entirely sensitive or specific for astrocytic differentiation; no independent clinical or prognostic implications beyond assisting in pathologic diagnosis.</td> </tr> <tr> <td><em>EGFR</em> amplification and mutations</td> <td>FISH, aCGH, sequencing</td> <td><em>EGFR</em> amplification is specific but not sensitive for glioblastoma; results may be relevant for clinical trials but no current therapeutic or prognostic implications.</td> </tr> <tr> <td>Gain of chromosome 7/loss of 10q</td> <td>FISH, aCGH</td> <td>Combination of tri/polysomy 7 and LOH 10q in an IDH-wildtype grade II or III astrocytoma is associated with aggressive clinical course similar to glioblastoma; often seen along with <em>TERT</em> mutations and <em>EGFR</em> amplification.</td> </tr> <tr> <td><em>PTEN</em> mutations</td> <td>Sequencing</td> <td>Occurs in 20 to 30% of glioblastomas, as a rule accompanied by LOH 10q; may be relevant for clinical trials but has low diagnostic value and no current therapeutic implications.</td> </tr> <tr> <td><em>BRAF</em> V600E mutations</td> <td>IHC for V600E-mutant BRAF&nbsp;or <em>BRAF</em>&nbsp;sequencing</td> <td>Rare in glioblastoma and adult low-grade glioma (&#60;5%) but has clinical trial and potential therapeutic implications.</td> </tr> <tr> <td>Histone <em>H3F3A</em> and <em>HIST1H3B</em> mutations</td> <td>IHC for K27M mutations, sequencing</td> <td>Mostly found in pediatric and young adult midline gliomas; young adult high-grade gliomas of the cortex may have <em>H3F3A</em> G34R/V mutations, usually combined with <em>ATRX</em> and <em>TP53</em> mutations; usually associated with poor prognosis.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><EM>IDH1/2</EM>: isocitrate dehydrogenase type 1 or type 2; IHC: immunohistochemistry; <EM>MGMT</EM>: O6-methylguanine-DNA methyltransferase; PCR: polymerase chain reaction; FISH: fluorescence in situ hybridization; LOH: loss of heterozygosity; aCGH: array comparative genomic hybridization; MLPA: multiplex ligation-dependent probe amplification; <EM>ATRX</EM>: alpha-thalassemia/mental retardation syndrome X-linked; <EM>TERT</EM>: telomerase reverse transcriptase; <EM>EGFR</EM>: epidermal growth factor receptor; <EM>PTEN</EM>: phosphatase and tensin homolog.<br />* Most common IDH mutation in diffuse gliomas (approximately 90%).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.</LI>&#xD;&#xA;<LI>van den Bent MJ, Weller M, Wen PY, et al. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol 2017; 19:614.</LI></OL></div><div id=\"graphicVersion\">Graphic 115919 Version 1.0</div></div></div>"},"115922":{"type":"graphic_table","displayName":"Example of anesthetic considerations for ERAS protocols","title":"Example of anesthetic considerations in protocols for enhanced recovery after surgery (ERAS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of anesthetic considerations in protocols for enhanced recovery after surgery (ERAS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial preoperative visit (weeks prior to surgery)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Optimize medical conditions. </li> <li>Patient education and counseling: <ul> <li>Counseling regarding surgical, anesthetic, analgesic plans. </li> <li>Establish expectations. </li> <li>Smoking cessation: Two to four weeks before surgery. </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Day before surgery</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Patient to shower at home with Hibiclens wipes, no shaving and no lotion/perfume. </li> <li>Minimize fasting period: No solid food after midnight (or six hours preoperatively). </li> <li>Hydrate well during the fasting period (drink two glasses of water prior to going to bed and two glasses of water prior to traveling to the hospital). </li> <li>Carbohydrate loading (optional): Gatorade at home just prior to traveling to the hospital. </li> <li>For major abdominal procedures: Mechanical bowel preparation and oral antibiotics. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Day of surgery: Preoperative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Pain prophylaxis: <ul> <li>Acetaminophen 1.5 g orally two hours before surgery. </li> <li>Gabapentin 600 mg orally two hours before surgery (avoid in patients &#62;65 years age, chronic renal insufficiency). </li> </ul> </li> <li>Thromboprophylaxis: Subcutaneous LMWH 5000 units 30 to 60 minutes before surgery plus bilateral sequential compression devices prior to induction of anesthesia. </li> <li>Avoid midazolam. </li> <li>Scopolamine patch in patients at high PONV risk. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Induction of anesthesia: Fentanyl (approximately 1 to 1.5 mcg/kg IBW) three to five minutes prior to propofol induction dose (approximately 1 to 1.5 mg/kg IBW), plus rocuronium 0.6 to 1 mg/kg. </li> <li>Ventilation: Lung protective ventilation &ndash; tidal volume 6 to 8 mL/kg IBW, PEEP 5 cm H<sub>2</sub>O, start with a respiratory rate 8 breaths/minute, maintain ETCO<sub>2</sub> approximately 40 mmHg. </li> <li>Maintenance with 50% oxygen plus 50% nitrous oxide (if no contraindications) plus desflurane or sevoflurane to achieve approximately 1 MAC. </li> <li>Minimize intraoperative opioid dose: <ul> <li>Fentanyl intraoperative dosing: 25 to 50 mcg boluses as necessary to a total of &#8804;1 mcg/kg IBW per hour (in opioid-na&#239;ve patients). Of note, during a laparoscopic approach, patients can have hypertension and/or tachycardia due to increased intraabdominal pressure (and other reasons) that is not necessarily due to pain. Thus, treating this hemodynamic response with opioids is inappropriate. If necessary to control hypertension and/or tachycardia, use vasoactive drugs such as labetalol, metoprolol, or esmolol. </li> </ul> </li> <li>Morphine (0.05 to 0.1 mg/kg IBW) or hydromorphone (5 to 10 mcg/kg IBW) administered approximately 20 minutes prior to expected time of extubation (typically when the surgeon starts closing the abdomen). </li> <li>Antibiotic prophylaxis. </li> <li>Pain prophylaxis: <ul> <li>Acetaminophen 1 g IV (if not given orally preoperatively). </li> <li>Ketorolac 15 to 30 mg IV (if no contraindications and if a COX-2 specific inhibitor was not given preoperatively). </li> <li>Local/regional analgesia technique: <ul> <li>Open procedures: TAP blocks or surgical site infiltration (of the peritoneum, fascia, and subdermal layers) performed at the end of surgery, but before wound closure. </li> <li>Laparoscopic procedures: Port site local anesthetic infiltration. </li> </ul> </li> </ul> </li> <li>PONV prophylaxis: Dexamethasone 8 mg after induction of anesthesia and ondansetron 4 mg (if no contraindications). </li> <li>Fluid therapy: Avoid fluid overload. Use baseline balanced electrolyte solution (approximately 2 to 3 mL/kg per hour). <ul> <li>Open procedures: Goal-directed fluid therapy using systolic pressure variation (SPV) from arterial line, if placed. <ul> <li>Algorithm: If baseline SPV or PPV is &#60;15%, administer 200 mL of balanced electrolyte solution; repeat until SPV or PPV &#60;15%. </li> </ul> </li> </ul> </li> <li>Maintain normothermia (core body temperature of 36 to 38&#176;C [96.8 to 100.4&#176;F]). </li> <li>Glycemic control: Maintain blood glucose values &#60;200 mg/dL using subcutaneous insulin protocol. </li> <li>Neostigmine or sugammadex dose based on peripheral nerve stimulator assessment at the ulnar nerve. </li> <li>Discontinue nasogastric tube at the end of surgery, if appropriate. </li> <li>Avoid intra-abdominal or perineal drains, if possible. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Postoperative</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Control comorbid conditions: Manage hypertension; control blood glucose values &#60;200 mg/dL. </li> <li>Pain management: <ul> <li>Acetaminophen 1000 mg orally every eight hours as scheduled dosing. If oral liquids are not tolerated, administer acetaminophen intravenously. </li> <li>NSAID (eg, meloxicam 15 mg, orally once a day) or COX-2 specific inhibitor, if no contraindication. If oral liquids are not tolerated, administer IV NSAID. </li> <li>Gabapentin until discharge: 300 mg orally three times daily if CrCl &#62;60 mL/minute, 300 mg&nbsp;orally twice daily if CrCl is 30 to 60 mL/minute, or 300 mg&nbsp;orally daily if CrCl is &#60;30 mL/minute. </li> <li>For breakthrough pain: Oxycodone IR 10 mg orally three times daily as needed. If unable to take oxycodone, then use tramadol 50 mg four times daily as needed. If oral liquids are not tolerated, administer morphine (2 mg, IV boluses, up to 10 mg) or hydromorphone (0.2 mg, IV bolus, up to 1 mg). </li> </ul> </li> <li>PONV: Ondansetron 4 mg IV and/or promethazine 0.625 mg IV. </li> <li>Early removal of urinary catheter, typically on the evening of the surgical procedure. </li> <li>Fluid management: <ul> <li>Laparoscopic procedures: Heplock on day of surgery. </li> <li>Open procedures: Balanced electrolyte solution 50 mL/hour on day of surgery or until tolerating oral diet. </li> <li>Bolus 500 mL balanced electrolyte solution if urine output &#60;0.5 mL/kg per hour. </li> </ul> </li> <li>Thromboprophylaxis: <ul> <li>On day of surgery: Subcutaneous LMWH 5000 units&nbsp;six to eight hours after surgery. </li> <li>On POD 1: Enoxaparin 40 mg subcutaneous administration plus bilateral SCDs. </li> </ul> </li> <li>Bowel regimen: Docusate 100 mg orally twice daily or Senna 1 tab orally twice daily. </li> <li>Nutrition: Early consumption of oral fluids (approximately 800 mL), typically the evening of surgery plus high calorie supplements twice daily. </li> <li>Gum chewing encouraged. </li> <li>Activities: <ul> <li>Physical therapy consult, if necessary. </li> <li>Early mobilization using structured program, typically on the evening of the surgical procedure. </li> <li>Up in chair for all meals. </li> <li>Out of bed (chair and ambulation in hallway) for at least six hours per day. </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These recommendations are not intended to supersede clinical judgment or individual patient choices or values. Ultimately, clinical decision-making must always be customized to the individual situation.</div><div class=\"graphic_footnotes\">LMWH: low molecular weight heparin; PONV: postoperative nausea and vomiting; IBW: ideal body weight; PEEP: positive end-expiratory pressure; ETCO<SUB>2</SUB>: end-tidal carbon dioxide; MAC: minimum alveolar concentration of inhalation agent; IV: intravenously; TAP: transversus abdominis plane; SPV: systolic pressure variation; PPV: pulse pressure variation; NSAID: nonsteroidal antiinflammatory drug; CrCL: creatinine clearance;&nbsp;IR: intermediate-release; POD: postoperative day; SCDs: sequential compression devices.</div><div class=\"graphic_reference\">Reproduced with permission from Girish P Joshi, MB, BS, MD, FFARCSI.</div><div id=\"graphicVersion\">Graphic 115922 Version 1.0</div></div></div>"},"115929":{"type":"graphic_algorithm","displayName":"Management of acalculous cholecystitis ","title":"Approach to the management of acalculous cholecystitis in adults","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Approach to the management of acalculous cholecystitis in adults</div><div class=\"cntnt\"><img style=\"width:476px; height:576px;\" src=\"images/GAST/115929_Mgmtacalculouscholecystts.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The choice of antibiotic depends on whether the infection is community-acquired or healthcare-associated, individual risk factors for infection with resistant bacteria, and risk for adverse outcomes. Refer to UpToDate content on acalculous cholecystitis and antimicrobial approach to intra-abdominal infections.<br />¶ Evaluate for comorbidities. Cholecystectomy is an alternative approach in patients at low surgical and anesthetic risk (eg, ASA class I or II).<br />Δ Failure to improve is defined as persistent fever, signs of sepsis, or evidence of new multiorgan dysfunction.<br /><FONT class=lozenge>◊</FONT> The duration of antibiotic therapy&nbsp;depends on the adequacy of control of infection and the clinical stability of the patient. Refer to UpToDate content on acalculous cholecystitis and antimicrobial approach to intra-abdominal infections.<br />§ In patients with gallstones or sludge who are not surgical candidates, the cholecystostomy tube is removed when drainage is minimal.</div><div id=\"graphicVersion\">Graphic 115929 Version 1.0</div></div></div>"},"115930":{"type":"graphic_algorithm","displayName":"Treatment of Richter's transformation","title":"Treatment of Richter's transformation","html":"<div class=\"graphic\"><div style=\"width: 651px\" class=\"figure\"><div class=\"ttl\">Treatment of Richter's transformation</div><div class=\"cntnt\"><img style=\"width:631px; height:511px;\" src=\"images/HEME/115930_TrtmntRichterstrnsfrmtn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CLL: chronic lymphocytic leukemia; SLL: small lymphocytic leukemia; DLBCL: diffuse large B cell lymphoma; HL: Hodgkin lymphoma; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; da-EPOCH-R: dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine;&nbsp;CR: complete remission; HCT: hematopoietic cell transplantation; FDG-PET/CT: fluorodeoxyglucose positron emission tomography with computed tomography.<br />* Richter's transformation should be suspected in patients with a sudden clinical deterioration, characterized by a marked increase in lymphadenopathy at one or more sites, splenomegaly, and/or worsening \"B\" symptoms (ie, fever, night sweats, weight loss). Laboratory studies may demonstrate an elevated serum level of lactate dehydrogenase (LDH), anemia, and thrombocytopenia.<br />¶ We suggest using whole body FDG-PET/CT to determine the preferred biopsy site. If possible, the site of greatest FDG avidity should be biopsied.<br />Δ Observation until progression is an acceptable alternative to consolidation with transplant for those who achieve a CR after initial anthracycline-based combination chemotherapy if the DLBCL variant Richter's is clonally unrelated to the prior CLL, or if they are diagnosed simultaneously. If clonal relationship cannot be determined (as is common in clinical practice), patients with DLBCL variant who have not received therapy for CLL prior to Richter's transformation and achieve CR after initial anthracycline-based combination chemotherapy can do well without transplant consolidation.</div><div id=\"graphicVersion\">Graphic 115930 Version 1.0</div></div></div>"},"115933":{"type":"graphic_algorithm","displayName":"Kawasaki disease treatment algorithm","title":"Algorithm for the treatment of Kawasaki disease","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Algorithm for the treatment of Kawasaki disease</div><div class=\"cntnt\"><img style=\"width:527px; height:923px;\" src=\"images/ALLRG/115933_Kawasakidiseastrtmntalgo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">IVIG should be administered in a health care setting with equipment, medications (IM epinephrine), and staff who are trained to respond in event of a rare serious reaction (eg, anaphylaxis). Patients should be well hydrated prior to IVIG administration. Infusion rate is adjusted based on tolerability. Some patients may receive acetaminophen and/or H1 antihistamine prior to or during the infusion to prevent or blunt an infusion reaction. For specific recommendations, refer to UpToDate topics on overview of IVIG therapy and IVIG adverse effects.</div><div class=\"graphic_footnotes\">KD: Kawasaki disease; IVIG: intravenous immune globulin; ESR: erythrocyte sedimentation rate; CA: coronary artery; IV: intravenous; IM: intramuscular.<br />* For Japanese patients, use the Kobayashi criteria or similar validated criteria to determine if at high risk of IVIG resistance. Kobayashi criteria (score ≥5 is positive): &#xD;&#xA;<UL>&#xD;&#xA;<LI>Sodium ≤133 mmol/L (2 points).</LI>&#xD;&#xA;<LI>Aspartate aminotransferase (AST) ≥100 international units/L (2 points).</LI>&#xD;&#xA;<LI>C-reactive protein (CRP) ≥10 mg/dL (1 point).</LI>&#xD;&#xA;<LI>Neutrophils ≥80% of the white blood cell count differential (2 points).</LI>&#xD;&#xA;<LI>Platelet count ≤300,000/mm<SUP>3</SUP> (1 point).</LI>&#xD;&#xA;<LI>Days of illness at initial treatment ≤4 (2 points).</LI>&#xD;&#xA;<LI>Age ≤12 months (1 point).</LI></UL>¶ Non-Japanese patients are considered at high risk of IVIG resistance if they have one or more of the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Enlarged coronary arteries at presentation (prior to IVIG treatment).</LI>&#xD;&#xA;<LI>Age ≤12 months (and particularly age &lt;6 months).</LI>&#xD;&#xA;<LI>KD associated with shock.</LI>&#xD;&#xA;<LI>KD presenting with macrophage activation syndrome.</LI></UL>Δ Normalization of ESR typically takes one to two months. Thus, aspirin therapy is generally complete within two months of disease onset in children with no CA abnormalities.<br /><FONT class=lozenge>◊</FONT> IV prednisolone may be unavailable in some settings (eg, United States). The equivalent dose of methylprednisolone is 1.6 mg/kg/daily for 10 days then 0.8 mg/kg/day for&nbsp;5 days. For review of considerations in timing of switch from IV to oral glucocorticoid, refer to UptoDate topic on treatment of KD.</div><div id=\"graphicVersion\">Graphic 115933 Version 1.0</div></div></div>"},"115935":{"type":"graphic_table","displayName":"Diagnostic categories of CS based on clinical/imaging findings","title":"Diagnostic categories of cardiac sarcoidosis based on clinical and imaging findings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic categories of cardiac sarcoidosis based on clinical and imaging findings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Findings suggesting cardiac sarcoidosis</td> </tr> <tr> <td>Clinical findings</td> <td> <ul> <li>LVEF &#60;40% </li> <li>Sustained ventricular tachycardia (spontaneous or induced) </li> <li>Mobitz type II second degree or third degree atrioventricular block (whether or not shown to be immunosuppressant responsive) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Imaging findings</td> <td> <ul> <li>Cardiac FDG-PET with patchy focal uptake in a pattern consistent with CS </li> <li>CMR imaging with LGE in a pattern consistent with CS </li> </ul> </td> </tr> <tr> <td class=\"subtitle1\">Diagnostic category of cardiac sarcoidosis</td> <td class=\"subtitle1\">Criteria</td> </tr> <tr> <td>Definite (100% probability of CS)</td> <td> <ul> <li>Detection of noncaseating granuloma on histologic examination of myocardial tissue (endomyocardial biopsy or other myocardial specimen) with no alternative cause identified </li> </ul> </td> </tr> <tr> <td>Probable (&#8805;50% probability of CS)</td> <td> <ul> <li>With histologic diagnosis of extracardiac sarcoidosis; requires both of the following criteria: <ul> <li>One or more of the following types of cardiac findings: <ul> <li>Clinical finding suggesting CS (refer to above) </li> <li>Imaging finding by CMR or FDG-PET typical for CS (refer to above) </li> </ul> </li> <li>Other potential causes for the clinical and imaging findings have been excluded </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVEF: left ventricular ejection fraction; FDG-PET: <sup>18</sup>F-fluorodeoxyglucose-positron emission tomography; CMR: cardiac magnetic resonance; LGE: late gadolinium enhancement; CS: cardiac sarcoidosis.</div><div class=\"graphic_reference\">Original table modified for this publication. From: Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115935 Version 1.0</div></div></div>"},"115936":{"type":"graphic_algorithm","displayName":"Algorithm for medically stable adults with suicidal ideation","title":"Algorithm for level of care for medically stable adults who initially present to their outpatient clinician with suicidal ideation (thoughts)*<sup>¶</sup>","html":"<div class=\"graphic\"><div style=\"width: 771px\" class=\"figure\"><div class=\"ttl\">Algorithm for level of care for medically stable adults who initially present to their outpatient clinician with suicidal ideation (thoughts)*<sup>&para;</sup></div><div class=\"cntnt\"><img style=\"width:751px; height:533px;\" src=\"images/PSYCH/115936_Algmdystbladltscdlidtn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* This algorithm provides an overview to help determine the level of care for adults who initially present to their outpatient clinician with suicidal ideation. However, there are no evidence-based criteria for determining level of care. Medically stable patients who present with suicidal behavior should receive an immediate psychiatric assessment in an emergency department or crisis clinic.<br />Determining the level care requires a thorough psychiatric evaluation that serves to individualize the disposition, and includes the factors addressed in this algorithm, as well as other factors, such as past history of suicidal ideation and behavior, adverse childhood experiences, current and past psychopathology and general medical illnesses and response to treatment, psychosocial stressors, impulsivity, hopelessness, helplessness, worthlessness, and the availability of resources such as treatment facilities and support from others. These factors are used to judge the acuity of the suicidal ideation, the patient's readiness to act on a suicide plan, and the patient's capacity for maintaining safety. In many cases, the disposition (and treatment) will rest upon the outcome of a psychiatric evaluation in the emergency department.<br />&para; Refer to UpToDate topic on suicidal ideation and behavior in adults.<br />&Delta; Partial hospital (day program) typically provides care Monday through Friday for six to eight hours per day. Intensive outpatient programs provide less intensive care (eg, three days per week, for three hours per day).</div><div id=\"graphicVersion\">Graphic 115936 Version 1.0</div></div></div>"},"115938":{"type":"graphic_figure","displayName":"Extent of gastric lymphadenectomy","title":"Extent of gastric lymphadenectomy","html":"<div class=\"graphic\"><div style=\"width: 713px\" class=\"figure\"><div class=\"ttl\">Extent of gastric lymphadenectomy</div><div class=\"cntnt\"><img style=\"width:693px; height:732px;\" src=\"images/ONC/115938_Extentgastriclymphadnctmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numbers correspond to the lymph node station as defined in the Japanese Classification of Gastric Carcinoma.<sup>[1]</sup><br />(A) The extent of lymphadenectomy after total gastrectomy.<br />(B) The extent of lymphadenectomy after distal gastrectomy.<br />(C) The extent of lymphadenectomy after pylorus-preserving gastrectomy.<br />(D) The extent of lymphadenectomy after proximal gastrectomy.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14:101. Available at: <a href=\"https://link.springer.com/content/pdf/10.1007%2Fs10120-011-0041-5.pdf\"  target=\"_blank\">https://link.springer.com/content/pdf/10.1007%2Fs10120-011-0041-5.pdf</a> (Accessed on December 5, 2017).</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017; 20:1. Copyright &copy; 2017 Japanese Gastric Cancer Association. Available at: <a href=\"https://link.springer.com/article/10.1007%2Fs10120-016-0622-4\" target=\"_blank\">https://link.springer.com/article/10.1007%2Fs10120-016-0622-4</a> (Accessed on December 5, 2017). Reproduced under the terms of the <a href=\"https://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License</a>.</div><div id=\"graphicVersion\">Graphic 115938 Version 1.0</div></div></div>"},"115945":{"type":"graphic_table","displayName":"2017 WHO classific grading panc neuroendo neoplasms","title":"2017 World Health Organization (WHO) classification and grading of pancreatic neuroendocrine neoplasms (PanNENs)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2017 World Health Organization (WHO) classification and grading of pancreatic neuroendocrine neoplasms (PanNENs)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Classification/grade</td> <td class=\"subtitle1\">Ki-67 proliferation index* (percent)</td> <td class=\"subtitle1\">Mitotic index*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Well-differentiated PanNENs: Pancreatic neuroendocrine tumours (PanNETs)</td> </tr> <tr> <td class=\"indent1\">PanNET G1</td> <td class=\"centered\">&#60;3</td> <td class=\"centered\">&#60;2</td> </tr> <tr> <td class=\"indent1\">PanNET G2</td> <td class=\"centered\">3 to 20</td> <td class=\"centered\">2 to 20</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">PanNET G3</td> <td class=\"centered\">&#62;20</td> <td class=\"centered\">&#62;20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Poorly differentiated PanNENs: Pancreatic neuroendocrine carcinomas (PanNECs)</td> </tr> <tr> <td class=\"indent1\">PanNEC (G3)</td> <td class=\"centered\">&#62;20</td> <td class=\"centered\">&#62;20</td> </tr> <tr> <td class=\"indent2\">Small cell type</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Large cell type</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td colspan=\"3\"><strong>Mixed neuroendocrine-non-neuroendocrine neoplasm</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* The Ki-67 proliferation index is based on the evaluation of ≥500 cells in areas of higher nuclear labelling (so-called hotspots). The mitotic index is based on the evaluation of mitoses in 50 high-power fields (0.2 mm<SUP>2</SUP> each) in areas of higher density, and is expressed as mitoses per 10 high-power fields (2.0 mm<SUP>2</SUP>). The final grade is determined based on whichever index (Ki-67 or mitotic) places the tumour in the highest grade category. For assessing Ki-67, casual visual estimation (eyeballing) is not recommended; manual counting using printed images is advocated.</div><div class=\"graphic_reference\">Reproduced with permission from: WHO Classification of Tumours of Endocrine Organs, 4th ed, Lloyd RV, Osamura RY, Kl&ouml;ppel G, Rosai J (Eds), IARC Press, Lyon 2017. p.211. Copyright &copy; 2017 International Agency for Research on Cancer.</div><div id=\"graphicVersion\">Graphic 115945 Version 1.0</div></div></div>"},"115947":{"type":"graphic_table","displayName":"Complementary and alternative therapies","title":"Complementary and alternative therapies for rheumatic diseases*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complementary and alternative therapies for rheumatic diseases*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Therapies known not to be of clinical benefit (and therefore not recommended)</td> </tr> <tr> <td class=\"indent1\">Antibiotics (except minocycline for rheumatoid arthritis)</td> </tr> <tr> <td class=\"indent1\">Apheresis (for uncomplicated rheumatic diseases)</td> </tr> <tr> <td class=\"indent1\">Copper bracelets</td> </tr> <tr> <td class=\"indent1\">Dimethyl sulfoxide (DMSO)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hyperbaric oxygen</td> </tr> <tr> <td class=\"subtitle1_single\">Therapies not studied (and therefore not recommended)</td> </tr> <tr> <td class=\"indent1\">Cetyl myristoleate (CMO)</td> </tr> <tr> <td class=\"indent1\">Methylsulfonylmethane (MSM)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Shark cartilage</td> </tr> <tr> <td class=\"subtitle1_single\">Therapies with preliminary, incomplete, or inconsistent evidence of benefit but not adequately studied (and therefore not recommended)</td> </tr> <tr> <td class=\"indent1\">Acupuncture</td> </tr> <tr> <td class=\"indent1\">Ayurveda</td> </tr> <tr> <td class=\"indent1\">Diacerein</td> </tr> <tr> <td class=\"indent1\">Diet and nutritional regimens</td> </tr> <tr> <td class=\"indent1\">Glucosamine and chondroitin sulfate</td> </tr> <tr> <td class=\"indent1\">Herbal therapies</td> </tr> <tr> <td class=\"indent1\">Homeopathy</td> </tr> <tr> <td class=\"indent1\">Laser therapy</td> </tr> <tr> <td class=\"indent1\">Leeches</td> </tr> <tr> <td class=\"indent1\">Magnets</td> </tr> <tr> <td class=\"indent1\">Massage</td> </tr> <tr> <td class=\"indent1\">Manipulation</td> </tr> <tr> <td class=\"indent1\">Oral collagen</td> </tr> <tr> <td class=\"indent1\">Photopheresis</td> </tr> <tr> <td class=\"indent1\">Prayer/distant healing</td> </tr> <tr> <td class=\"indent1\">S-Adenosyl methionine (SAMe)</td> </tr> <tr> <td class=\"indent1\">Tai chi</td> </tr> <tr> <td class=\"indent1\">Venoms</td> </tr> <tr> <td class=\"indent1\">Yoga</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zinc</td> </tr> <tr> <td class=\"subtitle1_single\">Therapies generally accepted as acceptably safe and of proven value (and therefore not really complementary and alternative medicines but recommended with varying degrees of enthusiasm for reasons of culture and/or clinical efficacy)</td> </tr> <tr> <td class=\"indent1\">Exercise</td> </tr> <tr> <td class=\"indent1\">Fish/botanical oils</td> </tr> <tr> <td class=\"indent1\">Mind-body therapies</td> </tr> <tr> <td class=\"indent1\">Spa/balneotherapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><SPAN style='FONT-SIZE: 11pt; FONT-FAMILY: \"Calibri\",sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: \"Times New Roman\"; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA'>* Representative and common examples of the complementary and alternative therapies sometimes used for patients with rheumatic diseases.</SPAN></div><div id=\"graphicVersion\">Graphic 115947 Version 1.0</div></div></div>"},"115948":{"type":"graphic_picture","displayName":"Exanthematous (morbilliform) drug eruption PI","title":"Rash from drug allergy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash from drug allergy</div><div class=\"cntnt\"><img style=\"width:222px; height:277px;\" src=\"images/PI/115948_ExanthematmorbilliformPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This type of rash typically starts after taking a drug for several days. It often begins in one area and then spreads.</div><div id=\"graphicVersion\">Graphic 115948 Version 1.0</div></div></div>"},"115961":{"type":"graphic_figure","displayName":"Single anastomosis duodeno-ileal bypass (SADI)","title":"Single anastomosis duodeno-ileal bypass (SADI)","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Single anastomosis duodeno-ileal bypass (SADI)</div><div class=\"cntnt\"><img style=\"width:520px; height:667px;\" src=\"images/SURG/115961_SingleanastomosisduodenoilealbypassSADI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The single anastomosis duodeno-ileal bypass (SADI) creates a sleeve-like gastric pouch, preserves the pylorus, and divides the duodenum after the pylorus.&nbsp;The gastric pouch is then anastomosed to the distal ileum as a single end-to-side anastomosis. </div><div id=\"graphicVersion\">Graphic 115961 Version 1.0</div></div></div>"},"115963":{"type":"graphic_figure","displayName":"Ascent profile graph","title":"Ascent profile graph to identify and mitigate risk of high altitude illness","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Ascent profile graph to identify and mitigate risk of high altitude illness</div><div class=\"cntnt\"><img style=\"width:760px; height:306px;\" src=\"images/EM/115963_Ascentprofilegraph.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of different ascent profiles on a Kilimanjaro, Tanzania, showing a high-risk 5-day ascent versus moderate-risk 8-day ascent versus a low-risk schedule that follows the WMS Altitude Guidelines.</div><div class=\"graphic_reference\">Reproduced from: Campbell AD, McIntosh SE, Nyberg A, et al. Risk stratification for athletes and adventurers in high-altitude environments: Recommendations for preparticipation evaluation wilderness. Wilderness &amp; Environ Med 2015; 26:S30. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 115963 Version 1.0</div></div></div>"},"115972":{"type":"graphic_waveform","displayName":"ECG left anterior fascicular block","title":"ECG left anterior fascicular block","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">ECG left anterior fascicular block</div><div class=\"cntnt\"><img style=\"width:766px; height:449px;\" src=\"images/CARD/115972_ECGleftantfasciclrblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus rhythm at 75 beats per minute. QRS duration is normal. Note the marked left axis deviation at about -60° consistent with left anterior fascicular block. As part of this pattern, qR is present in lead aVL along with terminal S waves in the lateral precordial leads.&nbsp;Slow R wave progression V1 through V3 is nondiagnostic.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram</div><div id=\"graphicVersion\">Graphic 115972 Version 2.0</div></div></div>"},"115983":{"type":"graphic_table","displayName":"Treatment streptococcal pharyngitis in children and adolescents","title":"Treatment of pharyngitis due to group A <em>Streptococcus</em> in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of pharyngitis due to group A <em>Streptococcus</em> in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"12%\"></colgroup><colgroup span=\"3\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic class</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dosing in children and adolescents</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Penicillins</strong><br /> (preferred)</td> <td>Penicillin V</td> <td> <ul> <li>If &#8804;27 kg: 250 mg two to three times daily for 10 days </li> <li>If &#62;27 kg: 500 mg two to three times daily for 10 days </li> </ul> </td> <td> <ul> <li>Narrow spectrum </li> <li>No documented resistance </li> <li>Low cost </li> </ul> </td> <td> <ul> <li>Three-times-daily dosing; however, twice-daily regimen appears to be as effective as thrice daily<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td>Amoxicillin*</td> <td> <ul> <li>50 mg/kg per day orally (maximum 1000 mg per day) for 10 days </li> <li>May be administered once daily or in two or three equally divided doses </li> </ul> </td> <td> <ul> <li>Taste of suspension more palatable than penicillin, often preferred for children </li> <li>Available as once-daily extended-release tablet<sup>&#182;</sup> </li> </ul> </td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Penicillin G benzathine<br /> (Bicillin L-A)</td> <td> <ul> <li>If &#8804;27 kg: Penicillin G benzathine (Bicillin L-A)&nbsp;600,000 units IM as a single dose<sup>&#916;</sup> </li> <li>If &#62;27 kg: Penicillin G benzathine (Bicillin L-A) 1.2 million units IM as a single dose </li> </ul> </td> <td> <ul> <li>Can be given as a single dose </li> <li>Ensured adherence </li> <li>Only drug studied for prevention of acute rheumatic fever </li> </ul> </td> <td> <ul> <li>Variable availability </li> <li>High cost </li> <li>Injection site pain </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Cephalosporins</strong><br /> (potential alternatives for mild reactions to <span style=\"white-space: nowrap;\">penicillin<sup>&#9674;</sup>)</span></td> <td>Cephalexin*<br /> (first generation)</td> <td> <ul> <li>40 mg/kg/day divided twice daily for 10 days (maximum 500 mg/dose) </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>Narrower spectrum than later-generation cephalosporins </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr> <td>Cefuroxime*<br /> (second generation)</td> <td> <ul> <li>10 mg/kg/dose orally twice daily for 10 days (maximum 250 mg/dose) </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>Narrower spectrum than later-generation cephalosporins </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and first-generation cephalosporins </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr> <td>Cefpodoxime*<br /> (third generation)</td> <td> <ul> <li>5 mg/kg/dose orally every 12 hours (maximum 100 mg/dose) for 5 to 10 days </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>FDA approved for 5-day course </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and earlier-generation cephalosporins </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cefdinir*<br /> (third generation)</td> <td> <ul> <li>7 mg/kg/dose orally every 12 hours for 5 to 10 days or 14 mg/kg/dose every 24 hours for 10 days (maximum 600 mg/day) </li> </ul> </td> <td> <ul> <li>High efficacy rate </li> <li>FDA approved for 5-day course when dosed twice daily&nbsp; </li> </ul> </td> <td> <ul> <li>Broader spectrum than penicillin and earlier-generation cephalosporins </li> <li>Greater potential to induce antibiotic resistance </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Macrolides</strong><br /> (alternatives for patients with anaphylaxis or other IgE-mediated reactions or severe delayed reactions to <span style=\"white-space: nowrap;\">penicillin<sup>&#9674;</sup>)</span></td> <td>Azithromycin</td> <td> <ul> <li>12 mg/kg (maximum 500 mg/dose) on day 1 followed by 6 mg/kg/dose (maximum 250 mg/dose) once daily on days 2 through 5 </li> </ul> </td> <td> <ul> <li>Can be given as a 5-day course due to extended half-life </li> </ul> </td> <td> <ul> <li>Growing rates of resistance </li> <li>Rarely associated with prolonged QT interval and Tdp </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Clarithromycin*</td> <td> <ul> <li>7.5 mg/kg/dose (maximum 250 mg per dose) orally twice daily for 10 days </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Growing rates of resistance </li> <li>Greater gastrointestinal side effects than azithromycin </li> <li>Causes CYP3A4 drug interactions </li> <li>Rarely associated with prolonged QT interval and TdP </li> </ul> </td> </tr> <tr> <td><strong>Lincosamides</strong><br /> (alternative when macrolide resistance is a concern and penicillins and cephalosporins cannot be used)</td> <td>Clindamycin</td> <td> <ul> <li>7 mg/kg/dose (maximum 300 mg per dose) orally three times daily for 10 days </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Growing rates of resistance </li> <li>High side-effect profile (ie, gastrointestinal) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IM: intramuscularly; FDA: US Food and Drug Administration; TdP: torsades de pointes.<br />* Dose alteration needed for renal insufficiency.<br />¶ Once-daily extended-release amoxicillin is recommended by the 2009 American Heart Association (AHA) guidelines. It is noninferior to amoxicillin administered in multiple daily doses.&nbsp;The dose in adolescents 12 years and older is 775 mg orally once daily for 10 days.<br />Δ In children weighing ≤27 kg, the combination IM formulation of 900,000 units benzathine penicillin G with 300,000 units procaine penicillin G (Bicillin C-R 900/300) is a less painful alternative. Efficacy in larger children and adults has not been established.<br />◊ Approach to patients with penicillin allergy varies among experts and allergy severity; refer to text for additional details.</div><div class=\"graphic_reference\">Reference: ​<br /><br /><OL>&#xD;&#xA;<LI>Lan AJ, Colford JM, Colford JM Jr; The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A meta-analysis. Pediatrics; 2000 Feb; 105:E19.</LI></OL>&#xD;&#xA;<P>Data from: </P>&#xD;&#xA;<OL>&#xD;&#xA;<LI>Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of Group A Streptococcal pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:e86.</LI>&#xD;&#xA;<LI>Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation 2009; 119:1541.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Group A Streptococcal Infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.732.</LI></OL></div><div id=\"graphicVersion\">Graphic 115983 Version 2.0</div></div></div>"},"115985":{"type":"graphic_algorithm","displayName":"Treatment and prevention of streptococcal pharyngitis","title":"Treatment and prevention of streptococcal pharyngitis","html":"<div class=\"graphic\"><div style=\"width: 883px\" class=\"figure\"><div class=\"ttl\">Treatment and prevention of streptococcal pharyngitis</div><div class=\"cntnt\"><img style=\"width:863px; height:409px;\" src=\"images/ID/115985_Txprevstreptpharyngitis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; IM: intramuscular.<br />* Examples of mild, non-IgE-mediated reactions include maculopapular rashes. Examples of IgE-mediated reactions include hives, wheezing, angioedema, and anaphylaxis. Examples of severe, delayed reactions include Steven-Johnson syndrome, toxic epidermal necrolysis, acute interstitial nephritis, drug-induced hepatitis, and serum sickness.<br />&para; Approach to selecting among cephalosporins varies among experts. Some prefer to use a first-generation cephalosporin such as cephalexin, while others favor a more conservative approach and select a third-generation cephalosporin such as cefpodoxime or cefdinir.<br />&Delta; Macrolide resistance varies considerably by region, with higher rates observed in Asia and Europe when compared with the United States. Knowledge of local resistance patterns should guide antibiotic selection.<br /><span class=\"lozenge\">&loz;</span> Selection among these agents should be based on drug availability and patient preference. For patients with a history of acute rheumatic fever and penicillin allergy, antibiotic selection should be individualized.<br />&sect; Many patients with IgE-mediated reactions can tolerate cephalosporins. These patients should be referred for allergy consultation following treatment for streptococcal pharyngitis.<br />&yen; Approach to selecting among these agents varies among experts. Some prefer cephalopsorins due their high efficacy and low risk of cross-reactivity, while others favor selecting a non-cephalosporin alternative to avoid any possibility of cross-reactivity.</div><div id=\"graphicVersion\">Graphic 115985 Version 4.0</div></div></div>"},"115993":{"type":"graphic_algorithm","displayName":"Antimicrobial selection for women with uncomplicated cystitis","title":"Empiric antimicrobial selection for women with acute uncomplicated cystitis","html":"<div class=\"graphic\"><div style=\"width: 865px\" class=\"figure\"><div class=\"ttl\">Empiric antimicrobial selection for&nbsp;women with acute uncomplicated cystitis</div><div class=\"cntnt\"><img style=\"width:845px; height:1354px;\" src=\"images/ID/115993_Inmgtwnctuncmplctcysts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm outlines the approach to empiric therapy for acute uncomplicated cysitits in women when there is no concern for extension of infection beyond the bladder (eg, no suspicion for pyelonephritis and not a febrile urinary tract infection).<br /><br />For each group of antibiotic options presented, the choice among them depends on patient circumstances (allergy, tolerability, and adherence), susceptibility of prior urinary isolates, local community resistance prevalence, availability, and cost. The durations presented have not been well studied in patients with urologic dysfunction (including neurogenic bladder), and in such patients, a longer duration of therapy is reasonable.<br /><br />Doses listed are for patients with normal renal function and may require adjustment in the setting of renal impairment.<br />​</div><div class=\"graphic_footnotes\">DS: double-strength; ESBL: extended-spectrum beta-lactamase; MDR: multidrug-resistant; TMP-SMX: trimethoprim-sulfamethoxazole; UTI: urinary tract infection.<br />* Among debilitated patients, many generalized signs or symptoms, such as falls, changes in functional status, and changes in mental status, are frequently attributed to UTI, although growing evidence indicates that these are not reliable predictors of bacteriuria or cystitis. We do not routinely test urine in elderly or debilitated patients with nonspecific changes in mental or functional status in the absence of focal urinary tract symptoms and fever, and instead hydrate, carefully observe, and assess other potential contributing factors.<br />¶ The temperature threshold used to determine whether to treat a patient as uncomplicated cystitis versus complicated UTI is not well defined and should take into account baseline temperature, other potential contributors to an elevated temperature, and the risk of poor outcomes should empiric antibiotic therapy be inappropriate.<br />Δ Reasons to avoid these options include an allergy or intolerance to the agent, an unmodifiable drug interaction, or history of a resistant urinary isolate within the past three months.<br /><FONT class=lozenge>◊</FONT> Nitrofurantoin should be avoided if the creatinine clearance is &lt;30 mL/minute.<br />§ TMP-SMX and trimethoprim should be avoided if the known community prevalence among Enterobacteriaceae is &gt;20 percent, but efficacy is high for susceptible organisms.<br />¥ Studies have suggested that deferring antibiotic therapy until culture and susceptibility tests are available is a safe strategy for patients who have mild uncomplicated cystitis without evidence of infection extending beyond the bladder. Analgesics can be used for symptomatic therapy. If there are concerns about deferring antibiotics (eg, potentially because of an immunocompromising condition or because of significant bladder symptoms), it is reasonable to empirically treat with an agent (eg, first-line option, beta-lactam, or fluoroquinolone) that was initially avoided because of concerns for possible resistance.<br />‡ If all of these are appropriate options based on patient circumstances and prior urinary isolates, we favor nitrofurantoin over fosfomycin. Although they appear to have generally comparable efficacy, overuse of fosfomycin may result in increasing resistance. Thus, we favor preserving use of fosfomycin for documented MDR infections when there are no other oral options. Pivmecillinam is not as effective but is commonly used in Europe because of a low risk of selecting for resistance.<br />† If all of these are appropriate options based on patient circumstances and prior urinary isolates, we favor nitrofurantoin&nbsp;or TMP-SMX over fosfomycin. Although they appear to have generally comparable efficacy, fosfomycin retains activity against many MDR isolates, and overuse of it may result in increasing resistance. Thus, we favor preserving use of fosfomycin for documented MDR infections when there are no other oral options. Pivmecillinam is not as effective but is commonly used in Europe because of a low risk of selecting for resistance.<br />** Trimethoprim is an option for individuals who have a sulfonamide (but not trimethoprim) allergy.<br />¶¶ Cephalexin is not as well studied as the other beta-lactam options listed.<br />ΔΔ When possible, fluoroquinolones should be reserved for more serious infections than acute uncomplicated cystitis. If used, patients should be advised about the uncommon but potentially serious musculoskeletal and neurologic adverse effects associated with fluoroquinolones.</div><div id=\"graphicVersion\">Graphic 115993 Version 1.0</div></div></div>"},"115994":{"type":"graphic_algorithm","displayName":"Antimicrobial selection for complicated UTI in inpatient adults","title":"Empiric antimicrobial selection for acute complicated urinary tract infection in adults in the inpatient setting","html":"<div class=\"graphic\"><div style=\"width: 867px\" class=\"figure\"><div class=\"ttl\">Empiric antimicrobial selection for acute complicated urinary tract infection in adults in the inpatient setting</div><div class=\"cntnt\"><img style=\"width:847px; height:875px;\" src=\"images/ID/115994_EpcatmblslccpUTIinpad.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>This algorithm reflects our approach to the selection of empiric antimicrobial therapy for patients hospitalized (or expected to be hospitalized) with an acute complicated UTI (ie, cystitis with signs or symptoms of infection extending beyond the bladder or pyelonephritis). The decision to hospitalize a patient is usually clear in the setting of critical illness or sepsis. Otherwise, general indications for inpatient management include persistently high fever (eg, &gt;101°F/&gt;38.4°C) or pain, marked debility, inability to maintain oral hydration or take oral medications, suspected urinary tract obstruction, and concerns regarding adherence to therapy. If outpatient management is anticipated following therapy in the emergency department, refer to other UpToDate content on antimicrobial therapy selection for the outpatient setting.</LI>&#xD;&#xA;<LI>In addition to antimicrobial therapy, the possibility of urinary obstruction should be considered and managed, if identified. Patients who have anatomical or functional urinary tract abnormalities (including neurogenic bladder, indwelling bladder catheters, nephrostomy tubes, ureteral stents) may warrant additional management, such as more frequent catheterization to improve urinary flow, exchange of a catheter, and/or urologic or gynecologic consultation.</LI>&#xD;&#xA;<LI>Doses listed are for patients with normal renal function and may require adjustment in the setting of renal impairment.</LI></UL></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; MDR: multidrug-resistant; ESBL: extended-spectrum beta-lactamase; TMP-SMX: trimethoprim-sulfamethoxazole; MRSA: methicillin-resistant <em>Staphylococcus aureus</em>; IV: intravenous.<br />* Individuals who have typical cystitis symptoms only, without fever or other systemic symptoms, have acute uncomplicated cystitis and are managed differently. The temperature threshold used to determine whether to treat a patient as uncomplicated cystitis versus complicated UTI is not well defined and should take into account baseline temperature, other potential contributors to an elevated temperature, and the risk of poor outcomes should empiric antimicrobial therapy be inappropriate.<br />&para; The possibility of prostatitis should also be considered in men.<br />&Delta; Patients with suspected or documented sepsis typically present with hypotension, tachycardia, fever, and leukocytosis. As severity worsens, signs of shock (eg, cool skin and cyanosis) and organ dysfunction (eg, oliguria, acute kidney injury, altered mental status) develop.<br /><span class=\"lozenge\">&loz;</span> Features that should raise suspicion for urinary tract obstruction include a decline in the renal function below baseline or a decline in urine output.<br />&sect; This includes a single antimicrobial dose given for prophylaxis prior to prostate procedures.<br />&yen; Ceftazidime-avibactam and ceftolozane-tazobactam also have activity against some ESBL-producing and MDR <em>Pseudomonas aeruginosa</em> isolates but should only be used if a carbapenem cannot be used. If carbapenem resistance is suspected based on prior susceptibility testing results, an infectious diseases consult should be obtained.<br />&Dagger; The choice among these agents depends on susceptibility of prior urinary isolates, patient circumstances (allergy or expected tolerability, history of recent antimicrobial use), local community resistance prevalence (if known), drug toxicity and interactions, availability, and cost. If <em>Enterococcus</em> or <em>Staphyloccus</em> species are suspected (eg, because of prior urinary isolates or gram-positive cocci on a current urine Gram stain), piperacillin-tazobactam is preferred because it has activity against these organisms. If drug-resistant gram-positive organisms are suspected because of previous urinary isolates or other risk factors, vancomycin (for MRSA) or linezolid or daptomycin (for VRE) should be added. If there is a risk of <em>Pseudomonas aeruginosa</em> (eg, because of growth on a urine culture in the past six months or febrile neutropenia, the higher dose of piperacillin-tazobactam or a fluoroquinolone should be chosen. Other appropriate antipseudomonal agents include cefepime and ceftazidime.<br />&dagger; In many cases, broad-spectrum antimicrobial regimens can be replaced by a more narrow-spectrum agent. Appropriate oral agents to treat complicated UTI include levofloxacin, ciprofloxacin, and TMP-SMX. Beta-lactams are appropriate if susceptibility is documented and other agents are not feasible.</div><div id=\"graphicVersion\">Graphic 115994 Version 3.0</div></div></div>"}};